October 2019	
Volume 26 Number 2	Se
Editors:	36
Kaye Wilson & Doris Chong email: enquiry@pharmac.govt.nz	_
Telephone +64 4 460 4990	Se
Facsimile +64 4 460 4995 Level 9, 40 Mercer Street	
PO Box 10 254 Wellington	
Freephone Information Line	
0800 66 00 50 (9am – 5pm weekdays)	
Circulation	
Published each April, August and December. Changes to the contents are published in	
monthly updates.	
Accessible in an electronic format at	
no cost from the PHARMAC website www.pharmac.govt.nz.	
You can register to have an electronic	
version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated	
email address each month by subscribing at	
www.pharmac.govt.nz/subscriptions.	
Production	
Typeset automatically from XML and T _E X. XML version of the Schedule available from	
www.pharmac.govt.nz/pub/schedule/archive/	
Programmers	-
Anrik Drenth & John Geering	Se
email: texschedule@pharmac.govt.nz	
©Pharmaceutical Management Agency	Se
ISSN 1172-9376 print	
This work is licensed under the Creative	_
Commons Attribution 4.0 International licence. In essence, you are free to copy, distribute	Se
and adapt it, as long as you attribute the work	
to PHARMAC and abide by the other licence	

terms. To view a copy of this licence, visit: creativecommons.org/licenses/by/4.0/. Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences

arising there from.

Section A	General Rules	5
Section B	Alimentary Tract & Metabolism	6
	Blood & Blood Forming Organs	35
	Cardiovascular System	45
	Dermatologicals	59
	Genito Urinary System	70
	Hormone Preparations – Systemic	78
	Infections – Agents For Systemic Use	89
	Musculoskeletal System	110
	Nervous System	118
	Oncology Agents & Immunosuppressants	155
	Respiratory System & Allergies	220
	Sensory Organs	228
	Various	233
Section C	Extemporaneous Compounds (ECPs)	235
Section D	Special Foods	238
Section I	National Immunisation Schedule	257
	Index	267

Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC's role:

"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at http://www.pharmac.govt.nz/about.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each Community Pharmaceutical or to DHB Hospitals in purchasing each Pharmaceutical, since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for Pharmaceuticals used in DHB Hospitals, on any logistics arrangements put in place.

This book contains sections A to D and Section I of the Pharmaceutical Schedule and lists the Pharmaceuticals funded for use in the community, including vaccines, as well as haemophilia and cancer treatments given in DHB hospitals. Section H lists the Pharmaceuticals that that can be used in DHB hospitals and is a separate publication.


The Pharmaceuticals in this book are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. The listings are displayed alphabetically under each heading.

The index lists both chemical entities and product brand names.

Explaining pharmaceutical entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the subsidy, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gram g	
kilogram kg	
international unit iu	

Abbreviations

Capsule Cream Device Dispersible Effervescent Emulsion	Amp Cap Crm Dev Disp Eff Emul EC
Enteric Coated	EC

microgram me	cg
milligramn	ng
millilitreı	ml

millimole	mmol
unit	u

Gelatinous	Gel	SolutionSoln
Granules	Gran	SuppositorySupp
Infusion	Inf	TabletTab
Injection	Inj	Tincture Tinc
Liquid	Liq	Trans Dermal Delivery
Long Acting	LA	SystemTDDS
Ointment	Oint	-
Sachet	Sach	

General Rules for the Pharmaceutical Schedule are located on the PHARMAC website.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
	\$	Per		Manufacturer
Antacids and Antiflatulents				
Antacids and Reflux Barrier Agents				
ALGINIC ACID Sodium alginate 225 mg and magnesium alginate 87.5 mg p sachet SODIUM ALGINATE		30	v	Gaviscon Infant
* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1.80 (8.60)	60		Gaviscon Double Strength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calciul carbonate 160 mg per 10 ml		500 m		Acidex
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE * Tab 600 mg CALCIUM CARBONATE Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement Only when prescribed for patients unable to swallow ca inappropriate and the prescription is endorsed accordin		100 500 m ts or v	ıl 🗸	Alu-Tab Roxane um carbonate tablets are
Antidiarrhoeals				
Agents Which Reduce Motility				
LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on * Tab 2 mg * Cap 2 mg	10.75	400 400		Nodia Diamide Relief
Rectal and Colonic Anti-inflammatories				
BUDESONIDE Cap 3 mg – Special Authority see SA1155 below – Retail pharmacy		90 ralid fo		Entocort CIR for applications meeting
the following criteria: Both:				
 Mild to moderate ileal, ileocaecal or proximal Crohn's disc Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fractional fractional content of the second se				
				continued.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

2.4 Severe acne following treatment with conventional corticosteroid therapy; or

2.5 History of severe psychiatric problems associated with corticosteroid treatment; or

- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an unapproved indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstr	ated no imp	provement in r	elapse rate.
HYDROCORTISONE ACETATE			
Rectal foam 10%, CFC-Free (14 applications)2	26.55	21.1 g OP	 Colifoam
HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORID	E		
Topical aerosol foam, 1% with pramoxine hydrochloride 1%	26.55	10 g OP	 Proctofoam S29
MESALAZINE			
Tab 400 mg	49.50	100	Asacol
Tab EC 500 mg		100	Asamax
Tab long-acting 500 mg		100	 Pentasa
Tab 800 mg	35.50	90	 Asacol
Modified release granules, 1 g14	41.72	120 OP	 Pentasa
Enema 1 g per 100 ml	41.30	7	 Pentasa
Suppos 500 mg2	22.80	20	 Asacol
Suppos 1 g	54.60	30	 Pentasa
OLSALAZINE			
Tab 500 mg	93.37	100	 Dipentum
Cap 250 mg		100	 Dipentum
SODIUM CROMOGLICATE			
Cap 100 mg	92.91	100	 Nalcrom
SULFASALAZINE			
* Tab 500 mg	14.00	100	 Salazopyrin
* Tab EC 500 mg		100	✓ Salazopyrin EN
Salazopyrin EN to be Sole Supply on 1 December 2019	0.00	100	
Local preparations for Anal and Rectal Disorders			

Local preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVAL Oint 950 mcg, with fluocortolone pivalate 920 mcg, and	LATE AND CI	NCHOCAINE	
cinchocaine hydrochloride 5 mg per g	6.35	30 g OP	 Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg	2.66	12	 Ultraproct
HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g Suppos 5 mg with cinchocaine hydrochloride 5 mg per g		30 g OP 12	✓ Proctosedyl✓ Proctosedyl

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$		Fully Brand or lised Generic Manufacturer
Management of Anal Fissures			
GLYCERYL TRINITRATE – Special Authority see SA1329 below * Oint 0.2% SA1329 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals vali chronic anal fissure that has persisted for longer than three week	d without further rene	30 g OP ewal unless r	Rectogesic notified where the patient has a
Antispasmodics and Other Agents Altering Gut	Motility		
GLYCOPYRRONIUM BROMIDE Inj 200 mcg per ml, 1 ml ampoule – Up to 10 inj available or PSO		10	 Max Health
HYOSCINE BUTYLBROMIDE * Tab 10 mg * Inj 20 mg, 1 ml – Up to 5 inj available on a PSO MEBEVERINE HYDROCHLORIDE * Tab 135 mg	9.57	100 5 90	 ✓ <u>Buscopan</u> ✓ Buscopan ✓ Colofac
Antiulcerants			
Antisecretory and Cytoprotective			
MISOPROSTOL			
* Tab 200 mcg	41.50	120	✓ Cytotec
Helicobacter Pylori Eradication			
CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement a) Maximum of 14 tab per prescription b) Subsidised only if prescribed for helicobacter pylori e Note: the prescription is considered endorsed if clar inhibitor and either amoxicillin or metronidazole.	eradication and presc		
H2 Antagonists			
RANITIDINE – Only on a prescription * Tab 150 mg * Tab 300 mg * Oral liq 150 mg per 10 ml * Inj 25 mg per ml, 2 ml		500 500 300 ml 5	 <u>Ranitidine Relief</u> <u>Ranitidine Relief</u> <u>Peptisoothe</u> Zantac
Proton Pump Inhibitors			
LANSOPRAZOLE * Cap 15 mg * Cap 30 mg		100 100	✓ Lanzol Relief ✓ Lanzol Relief

Xifaxan

56

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
OMEPRAZOLE				
For omeprazole suspension refer Standard Formulae, pa	ige 235			
* Cap 10 mg	1.98	90		<u>neprazole actavis</u> 10
* Cap 20 mg	1.96	90		<u>meprazole actavis</u> 20
* Cap 40 mg	3.12	90		neprazole actavis 40
* Powder – Only in combination		5 g		dwest
Only in extemporaneously compounded omeprazole * Inj 40 mg ampoule with diluent		5		<u>Reddy's</u> Omeprazole
PANTOPRAZOLE				
* Tab EC 20 mg * Tab EC 40 mg		100 100		inzop Relief inzop Relief
Site Protective Agents				
COLLOIDAL BISMUTH SUBCITRATE				
Tab 120 mg	14.51	50	🗸 Ga	astrodenol S29
SUCRALFATE				
Tab 1 g	35.50 (48.28)	120	Ca	arafate

RIFAXIMIN – Special Authority see SA1461 below – Retail pharmacy	
Tab 550 mg	00

➡SA1461 Special Authority for Subsidy

Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Diabetes

Hyperglycaemic Agents

armacy		
	100	 Proglicem S29
	100	 Proglicem S29
620.00	30 ml OP	 Proglycem S29
id for 12 months	where used for	the treatment of confirmed
t further renewal	unless notified	where the treatment remains
	1	 Glucagen Hypokit

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Pr \$	ice) Subs Per	Fully idised	Brand or Generic Manufacturer
Insulin - Short-acting Preparations				
NSULIN NEUTRAL ▲ Inj human 100 u per ml	25.26	10 ml OP		ctrapid
▲ Inj human 100 u per ml, 3 ml	42.66	5	🗸 A	umulin R ctrapid Penfill umulin R
Insulin - Intermediate-acting Preparations				
NSULIN ASPART WITH INSULIN ASPART PROTAMINE		5	🗸 N	ovoMix 30 FlexPen
NSULIN ISOPHANE ▲ Inj human 100 u per ml		10 ml OP		umulin NPH
Inj human 100 u per ml, 3 ml	29.86	5	🗸 Н	rotaphane umulin NPH rotaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL Inj human with neutral insulin 100 u per ml	25.26	10 ml OP		umulin 30/70 lixtard 30
Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓ H ✓ P ✓ P	umulin 30/70 enMix 30 enMix 40 enMix 50
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE Inj lispro 25% with insulin lispro protamine 75% 100 u per ml,			• •	enività 50
3 ml Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml		5 5		umalog Mix 25
		5	• п	umalog Mix 50
Insulin - Long-acting Preparations				
Inj 100 u per ml, 10 ml	63.00 94.50	1 5		antus antus
Inj 100 u per ml, 3 ml disposable pen		5		antus SoloStar
Insulin - Rapid Acting Preparations				
NSULIN ASPART Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml Inj 100 u per ml, 3 ml syringe	51.19	1 5 5	🗸 N	ovoRapid ovoRapid Penfill ovoRapid FlexPen
NSULIN GLULISINE Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml		1 5		pidra pidra
Inj 100 u per ml, 3 ml disposable pen NSULIN LISPRO		5		pidra SoloStar
 Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml 		10 ml OP 5		umalog umalog

10

ALIMENTARY	TRACT	AND N	METABOLIS	М
------------	-------	-------	------------------	---

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
Alpha Glucosidase Inhibitors				
ACARBOSE				
* Tab 50 mg		90		Glucobay
	10.47	~~		Accarb
* Tab 100 mg		90		Glucobay
	11.24	50	~	Acarbose Mylan S29
	20.23	90	1	Accarb
(Acarbose Mylan S29) Tab 100 mg to be delisted 1 January 202				
Oral Hypoglycaemic Agents				
GLIBENCLAMIDE				
* Tab 5 mg	6.00	100	~	Daonil
GLICLAZIDE				
* Tab 80 mg		500	1	Glizide
GLIPIZIDE				
* Tab 5 mg		100	1	Minidiab
METFORMIN HYDROCHLORIDE				
* Tab immediate-release 500 mg	8.63	1.000	1	Apotex
* Tab immediate-release 850 mg.		500		Apotex
PIOGLITAZONE				
* Tab 15 mg		90	1	Vexazone
* Tab 30 mg		90		Vexazone
* Tab 45 mg	7.10	90	~	Vexazone
VILDAGLIPTIN				
Tab 50 mg	40.00	60	✓	Galvus
VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE				
Tab 50 mg with 1,000 mg metformin hydrochloride	40.00	60	~	Galvumet
Tab 50 mg with 850 mg metformin hydrochloride	40.00	60	✓	Galvumet

Diabetes Management

Ketone Testing

BLOOD KETONE DIAGNOSTIC TEST STRIP - Subsidy by endorsement

- a) Not on a BSO
- b) Maximum of 20 strip per prescription
- c) Up to 10 strip available on a PSO
- d) Patient has any of the following:
 - 1) type 1 diabetes; or
 - 2) permanent neonatal diabetes; or
 - 3) undergone a pancreatectomy; or
 - 4) cystic fibrosis-related diabetes; or

metabolic disease or epilep	sy under the care of a paediatriciar	n, neurologist or metabolic specialist
The prescription must be endorse	ed accordingly	

i ne prescription must be endorsed accordingly.	
Test strips15.5	0

.... 15.50 10 strip OP

KetoSens

Dual Blood Glucose and Blood Ketone Testing DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A dual blood glucose and blood ketone diagnostic test meter is subsidised for a patient who has: 1) type 1 diabetes; or 2) permanent neonatal diabetes; or 3) undergone a pancreatectomy; or 4) cystic fibrosis-related diabetes; or 5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist. The prescription must be endorsed accordingly. Only 1 meter per patient will be subsidised (no repeat prescriptions). The avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter. Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A diagnostic blood glucose test meter is subsidised for a patient who: 1) is receiving insulin or sulphonylurea therapy; or 2) is pregnant with diabetes; or 3) is on home TPN at risk of hypoglycaemia or hyperglycaemia; or 4) has a genetic or an acquired disorder of glucose homeostasis, excluding type 1 or type 2 diab		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A dual blood glucose and blood ketone diagnostic test meter is subsidised for a patient who has: 1) type 1 diabetes; or 2) permanent neonatal diabetes; or 3) undergone a pancreatectomy; or 4) cystic fibrosis-related diabetes; or 5) metabolic disease or epilepsy under the care of a paediatrician, neurologist or metabolic specialist. The prescription must be endorsed accordingly. Only 1 meter per patient will be subsidised (no repeat prescriptions). I the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for a funded CareSens meter. Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips	Dual Blood Glucose and Blood Ketone Testing				
Meter with 50 lancets, a lancing device and 10 blood glucose diagnostic test strips	 DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A dual blood glucose and blood ketone diagnostic test m 1) type 1 diabetes; or 2) permanent neonatal diabetes; or 3) undergone a pancreatectomy; or 4) cystic fibrosis-related diabetes; or 5) metabolic disease or epilepsy under the care of a participation must be endorsed accordingly. Only 1 	C TEST METER – Su neter is subsidised for paediatrician, neurolog meter per patient will	a pati gist or be su	ient who has metabolic sj bsidised (no	: pecialist. repeat prescriptions). Fc
 diagnostic test strips	funded CareSens meter. Meter with 50 lancets, a lancing device and 10 blood glucos	Se .			
 BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by endorsement Maximum of 1 pack per prescription Up to 1 pack available on a PSO A diagnostic blood glucose test meter is subsidised for a patient who: is receiving insulin or sulphonylurea therapy; or is pregnant with diabetes; or is on home TPN at risk of hypoglycaemia or hyperglycaemia; or has a genetic or an acquired disorder of glucose homeostasis, excluding type 1 or type 2 diabetes and metabolic syndrome. The prescription must be endorsed accordingly. Only one CareSens meter per patient will be subsidised (no repeat prescriptions). Patients already using the CareSens N POP meter and CareSens N meter are not eligible for a new meter, unless they have: type 1 diabetes; or undergone a pancreatectomy; or cystic fibrosis-related diabetes. For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for funded CareSens meter. Meter with 50 lancets, a lancing device and 10 diagnostic test strips			1 OP	✓ <u>c</u>	areSens Dual
 a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A diagnostic blood glucose test meter is subsidised for a patient who: is receiving insulin or sulphonylurea therapy; or is pregnant with diabetes; or is on home TPN at risk of hypoglycaemia or hyperglycaemia; or has a genetic or an acquired disorder of glucose homeostasis, excluding type 1 or type 2 diabetes and metabolic syndrome. The prescription must be endorsed accordingly. Only one CareSens meter per patient will be subsidised (no repeat prescriptions). Patients already using the CareSens N POP meter and CareSens N meter are not eligible for a new meter, unless they have: type 1 diabetes; or permanent neonatal diabetes; or undergone a pancreatectomy; or cystic fibrosis-related diabetes. For the avoidance of doubt patients who have previously received a funded meter, other than CareSens, are eligible for funded CareSens meter. Meter with 50 lancets, a lancing device and 10 diagnostic test strips	Blood Glucose Testing				
	 a) Maximum of 1 pack per prescription b) Up to 1 pack available on a PSO c) A diagnostic blood glucose test meter is subsidised for a is receiving insulin or sulphonylurea therapy; or is pregnant with diabetes; or is on home TPN at risk of hypoglycaemia or hyperg has a genetic or an acquired disorder of glucose he syndrome. The prescription must be endorsed accordingly. Only or prescriptions). Patients already using the CareSens N F meter, unless they have: type 1 diabetes; or permanent neonatal diabetes; or undergone a pancreatectomy; or cystic fibrosis-related diabetes. For the avoidance of doubt patients who have previously funded CareSens meter. 	a patient who: glycaemia; or omeostasis, excluding ne CareSens meter pe POP meter and CareS y received a funded m	er pati ens N eter, c	ent will be su I meter are n other than Ca	ubsidised (no repeat lot eligible for a new areSens, are eligible for a lareSens N
	Note: Only 1 meter available per PSO	20.00			

	Subsidy		Fully	Brand or
	(Manufacturer's Price		sidised	Generic
	\$	Per		Manufacturer
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP - Up to 50) test available on a PSC)		
The number of test strips available on a prescription is	restricted to 50 unless:			
1) Prescribed for a patient on insulin or a sulphonylu	irea and endorsed accoi	dingly. Phar	macists	may annotate the
prescription as endorsed where there exists a rec	ord of prior dispensing o	of insulin or si	ulphony	lurea; or
2) Prescribed on the same prescription as insulin or	a sulphonylurea in whic	h case the pr	escripti	on is deemed to be
endorsed; or	and a surple second as a surplus of			
3) Prescribed for a pregnant woman with diabetes a	0.	· ·		and a second sector and
4) Prescribed for a patient on home TPN at risk of h	, , , , , , , , , , , , , , , , , , , ,	,		0,77
5) Prescribed for a patient with a genetic or an acqu		nomeostasis	exclual	ng type 1 or type
2 diabetes and metabolic syndrome and endorse	a accordingly.			
Test strips	10.56	50 test OP	v c	areSens N
		00 1001 01	_	areSens PRO
BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)			-	
The number of test strips available on a prescription is				
 Prescribed for a patient on insulin or a sulphonylu 		dinaly Dhor	magiata	may appatata tha
prescription as endorsed where there exists a rec				
 Prescribed on the same prescription as insulin or 	1 1 0			,
endorsed; or	a sulpriorigitiea in whic	ii case iiie pi	escriptio	
 Prescribed for a pregnant woman with diabetes a 	nd endorsed accordingly	/: or		
4) Prescribed for a patient on home TPN at risk of h			lendors	ed accordingly: or
5) Prescribed for a patient with a genetic or an acqu				0.7
2 diabetes and metabolic syndrome and endorse			enter a a	
······, ·····,	5,			
Blood glucose test strips		50 test OP	✓ S	ensoCard
Insulin Syringes and Needles				
Nakaiska in particula for sline particula particular second	a and non-mandles if you	بالاحد أدحيا أبر		farmer an the area
subsidy is available for disposable insulin syringes, needles				
ne supply of insulin or when prescribed for an insulin patien nnotate the prescription as endorsed where there exists a			coruing	iy. Fharmacisis may
NSULIN PEN NEEDLES – Maximum of 200 dev per preso	cription			
€ 29 g × 12.7 mm	•	100	✓ В	-D Micro-Fine
¥ 21 a ∨ 5 mm		100	./ D	D Miero Eine

*	31 g × 5 mm	100
	31 g × 6 mm	100
	31 g × 8 mm	100
	32 g × 4 mm	100
	5	

•	B-D Micro-Fine
1	B-D Micro-Fine
✓	Berpu

- ✓ B-D Micro-Fine
- B-D Micro-Fine

		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
INS	SULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE	E – Maximum of 200	dev p	per prescri	ption
*	Syringe 0.3 ml with 29 g × 12.7 mm needle		100	1	B-D Ultra Fine
		1.30	10		
		(1.99)			B-D Ultra Fine
*	Syringe 0.3 ml with 31 g × 8 mm needle		100	✓	B-D Ultra Fine II
		1.30	10		
		(1.99)			B-D Ultra Fine II
*	Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	✓	B-D Ultra Fine
		1.30	10		
		(1.99)			B-D Ultra Fine
*	Syringe 0.5 ml with 31 g × 8 mm needle		100	1	B-D Ultra Fine II
		1.30	10		
		(1.99)			B-D Ultra Fine II
*	Syringe 1 ml with 29 g × 12.7 mm needle		100	1	B-D Ultra Fine
		1.30	10		
		(1.99)			B-D Ultra Fine
*	Syringe 1 ml with 31 g × 8 mm needle		100	✓	B-D Ultra Fine II
		1.30	10		
		(1.99)			B-D Ultra Fine II

Insulin Pumps

INSULIN PUMP - Special Authority see SA1603 below - Retail pharmacy

- a) Maximum of 1 dev per prescription
- b) Only on a prescription
- c) Maximum of 1 insulin pump per patient each four year period.

Min basal rate 0.025 U/h		1	 MiniMed 640G
Min basal rate 0.1 U/h	4,500.00	1	 Tandem t:slim X2

⇒SA1603 Special Authority for Subsidy

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has permanent neonatal diabetes; and
- 2 A MDI regimen trial is inappropriate; and
- 3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 6 Either:
 - 6.1 Applicant is a relevant specialist; or
 - 6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
- 2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
- 3 It has been at least 4 years since the last insulin pump received by the patient or, in the case of patients qualifying under previous pump therapy for the initial application; the pump is due for replacement; and
- 4 Either:

14

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsi	dised	Generic	
\$	Per	1	Manufacturer	

continued...

- 4.1 Applicant is a relevant specialist; or
- 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person); and
- 6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol; and
- 7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 8 Either:
 - 8.1 Applicant is a relevant specialist; or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events; and
- 2 HbA1c has not increased by more than 5 mmol/mol from baseline; and
- 3 Either:
 - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 3.2 The pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1; and
- 6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
- 7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
- 8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	9	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
- 2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
- 3 Either:
 - 3.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 3.2 The pump is due for replacement; and
- 4 Either:
 - 4.1 Applicant is a relevant specialist; or
 - 4.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
- 3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
- 4 The patient is continuing to derive benefit from pump therapy; and
- 5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
- 6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
- 7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and

8 Either:

- 8.1 It has been at least 4 years since the last insulin pump was received by the patient; or
- 8.2 The pump is due for replacement; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less than 80 mmol/mol; and
- 2 The patient's HbA1c has not deteriorated more than 5 mmol/mol from the time of commencing pump treatment; and
- 3 The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline; and
- 4 Either:
 - 4.1 It has been at least 4 years since the last insulin pump was received by the patient; or
 - 4.2 The pump is due for replacement; and
- 5 Either:
 - 5.1 Applicant is a relevant specialist; or
 - 5.2 Applicant is a nurse practitioner working within their vocational scope.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufact

ic Manufacturer

Insulin Pump Consumables

⇒SA1604 Special Authority for Subsidy

Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has permanent neonatal diabetes: and
- 2 A MDI regimen trial is inappropriate; and
- 3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 6 Fither:
 - 6.1 Applicant is a relevant specialist; or
 - 6.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the followina:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and
- 2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and
- 3 Either:
 - 3.1 Applicant is a relevant specialist; or
 - 3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application - (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person): and
- 6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol: and
- 7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 8 Fither:
 - 8.1 Applicant is a relevant specialist: or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 2 vears for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from baseline in hypoglycaemic events: and
- 2 HbA1c has not increased by more than 5 mmol/mol from baseline; and
- 3 Fither:
 - 3.1 Applicant is a relevant specialist; or

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	idised	Generic	
\$	Per	1	Manufacturer	

continued...

3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and
- 3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
- 4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
- 5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to reduce HbA1; and
- 6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
- 7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than 90 mmol/mol; and
- 8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
- 9 Either:
 - 9.1 Applicant is a relevant specialist; or
 - 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a reduction in HbA1c from baseline of 10 mmol/mol; and
- 2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
- 3 Either:
 - 3.1 Applicant is a relevant specialist; or
 - 3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
- 2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump treatment; and
- 3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating pump therapy; and
- 4 The patient is continuing to derive benefit from pump therapy; and
- 5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and
- 6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and
- 7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and
- 8 Either:
 - 8.1 Applicant is a relevant specialist; or
 - 8.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

18

1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less

continued...

	Subsidy (Manufacturer's Pric	(a) Cuit	Fully Brand or osidised Generic
	(Manulacturers i no	Per	Manufacturer
ontinued			
than 80 mmol/mol; and			
2 The patient's HbA1c has not deteriorated more than 5 r			
3 The patient has not had an increase in severe unexplai	ned hypoglycaemic e	pisodes fro	m baseline; and
4 Either:			
4.1 Applicant is a relevant specialist; or4.2 Applicant is a nurse practitioner working within the second secon	heir vocational scope		
ISULIN PUMP CARTRIDGE - Special Authority see SA1604	4 on page 17 – Retail	pharmacy	
 Maximum of 3 sets per prescription 			
 b) Only on a prescription 			
c) Maximum of 13 packs of cartridge sets will be funded p			
Cartridge 300 U, t:lock × 10	50.00	1 OP	Tandem Cartridge
ISULIN PUMP INFUSION SET (STEEL CANNULA) – Specia	al Authority see SA16	04 on page	e 17 – Retail pharmacy
a) Maximum of 3 sets per prescription			
b) Only on a prescription			
c) Maximum of 13 infusion sets will be funded per year.			
10 mm steel needle; 29 G; manual insertion; 60 cm tubing	x		
10 with 10 needles		1 OP	Paradigm Sure-T
			MMT-884
10 mm steel needle; 29 G; manual insertion; 60 cm tubing	x		
10 with 10 needles; luer lock		1 OP	 Sure-T MMT-883
10 mm steel needle; 29 G; manual insertion; 80 cm tubing	x		
10 with 10 needles		1 OP	 Paradigm Sure-T
			MMT-886
10 mm steel needle; 29 G; manual insertion; 80 cm tubing	х		
10 with 10 needles; luer lock	130.00	1 OP	 Sure-T MMT-885
6 mm steel needle; 29 G; manual insertion; 60 cm tubing >	<		
10 with 10 needles	130.00	1 OP	Paradigm Sure-T
			MMT-864
6 mm steel needle; 29 G; manual insertion; 60 cm tubing >			_
10 with 10 needles; luer lock		1 OP	 Sure-T MMT-863
6 mm steel needle; 29 G; manual insertion; 80 cm tubing >			
10 with 10 needles	130.00	1 OP	Paradigm Sure-T
			MMT-866
6 mm steel needle; 29 G; manual insertion; 80 cm tubing >			_
10 with 10 needles; luer lock		1 OP	 Sure-T MMT-865
8 mm steel needle; 29 G; manual insertion; 60 cm tubing >			
10 with 10 needles	130.00	1 OP	Paradigm Sure-T
			MMT-874
8 mm steel needle; 29 G; manual insertion; 60 cm tubing >			_
10 with 10 needles; luer lock		1 OP	 Sure-T MMT-873
8 mm steel needle; 29 G; manual insertion; 80 cm tubing >			_
10 with 10 needles	130.00	1 OP	 Paradigm Sure-T
			MMT-876
8 mm steel needle; 29 G; manual insertion; 80 cm tubing >			
10 with 10 needles; luer lock	120.00	1 OP	Sure-T MMT-875

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (STEEL CANNULA, STRAIGHT	INSERTION) - Spe	ecial Author	rity see	SA1604 on page 17 -
Retail pharmacy				
 a) Maximum of 3 sets per prescription b) Only on a processing income 				
b) Only on a prescriptionc) Maximum of 13 infusion sets will be funded per year.				
6 mm steel cannula; straight insertion; 60 cm line × 10 with				
10 needles	130.00	1 OP	🖌 Ti	ruSteel
6 mm steel cannula; straight insertion; 81 cm line \times 10 with		1 01	• •	
10 needles		1 OP	🗸 Ti	ruSteel
8 mm steel cannula; straight insertion; 60 cm line × 10 with		-		
10 needles	130.00	1 OP	🗸 Ti	ruSteel
8 mm steel cannula; straight insertion; 81 cm line \times 10 with				
10 needles	130.00	1 OP	🗸 Ti	ruSteel
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN	SERTION WITH IN	SERTION	DEVICE	E) – Special Authority see
SA1604 on page 17 – Retail pharmacy				, , ,
 Maximum of 3 sets per prescription 				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
13 mm teflon cannula; angle insertion; insertion device; 110 d				
line × 10 with 10 needles		1 OP	✓ A	utoSoft 30
13 mm teflon cannula; angle insertion; insertion device; 60 cr		1.00		utoCoff 20
line × 10 with 10 needles	140.00	1 OP	♥ A	utoSoft 30

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Su Per	bsidised ✓	Generic Manufacturer
	T			
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE II	NSERTION) – Speci	al Autho	rity see S	A1604 on page 17 –
Retail pharmacy				
a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
13 mm teflon cannula; angle insertion; 120 cm line × 10 with	400.00	4.00		
10 needles		1 OP	• •	aradigm Silhouette MMT-382
40 mm toffen annuale angle in article 45 mm line - 40 millio				IVIIVI I -302
13 mm teflon cannula; angle insertion; 45 cm line × 10 with	100.00	1 00		anadiana Cilla susta
10 needles		1 OP	• •	aradigm Silhouette MMT-368
40 mm toffen annuale angle in article .00 mm line .40 milli				IVIIVI I -300
13 mm teflon cannula; angle insertion; 60 cm line × 10 with	100.00	1 00		anadiana Cilla susta
10 needles		1 OP	• •	aradigm Silhouette MMT-381
10 mm toffen commules engle incentions 00 cm lines s 10 with				101101 1-301
13 mm teflon cannula; angle insertion; 80 cm line × 10 with 10 needles	100.00	1 OP	./ D	erediem Cilheuette
TO needles		TUP	• •	aradigm Silhouette MMT-383
17 mm taflan cannulai angla incartiani 110 cm lina 10 with				101011-303
17 mm teflon cannula; angle insertion; 110 cm line × 10 with 10 needles	120.00	1 OP	. – –	aradigm Silhouette
TO fieldles		TOP	• •	MMT-377
17 mm teflon cannula; angle insertion; 110 cm line \times 10 with				WIWIT-377
10 needles; luer lock	120.00	1 OP	10	ilhouette MMT-371
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with		TOF	• 3	
10 needles	120.00	1 OP	. D	aradigm Silhouette
To needles		TOF	• •	MMT-378
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with				WIWIT-570
10 needles; luer lock	130.00	1 OP	.	ilhouette MMT-373
17 mm teflon cannula; angle insertion; 80 cm line × 10 with		1 01	- 3	
10 needles	130.00	1 OP	~ ¤	aradigm Silhouette
		I UF	• F	MMT-384

	Subsidy (Manufacturer's Pric \$	ce) Sub Per	Fully Brand osidised Generi ✓ Manufa	C
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAI see SA1604 on page 17 – Retail pharmacy a) Maximum of 3 sets per prescription	GHT INSERTION WI	TH INSERT	TION DEVICE) -	- Special Authority
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
6 mm teflon cannula; straight insertion; insertion device; 45	5 cm			
blue tubing × 10 with 10 needles	130.00	1 OP	 Paradign MMT-9 	
6 mm teflon cannula; straight insertion; insertion device; 45	5 cm			
pink tubing × 10 with 10 needles	130.00	1 OP	 Paradign MMT-9 	
6 mm teflon cannula; straight insertion; insertion device; 60) cm			
blue tubing × 10 with 10 needles	130.00	1 OP	 Paradign MMT-9 	
6 mm teflon cannula; straight insertion; insertion device; 60) cm			
pink tubing × 10 with 10 needles	130.00	1 OP	 Paradign MMT-9 	
6 mm teflon cannula; straight insertion; insertion device; 80) cm			
blue tubing × 10 with 10 needles	130.00	1 OP	 Paradign MMT-9 	
6 mm teflon cannula; straight insertion; insertion device; 80				
clear tubing × 10 with 10 needles	130.00	1 OP	 Paradign MMT-9 	
6 mm teflon cannula; straight insertion; insertion device; 80				
pink tubing x 10 with 10 needles		1 OP	 Paradign MMT-9 	
9 mm teflon cannula; straight insertion; insertion device; 80			_	
clear tubing × 10 with 10 needles	130.00	1 OP	 Paradign MMT-9 	
6 mm teflon cannula; straight insertion; insertion device;			_	
110 cm line × 10 with 10 needles		1 OP	 AutoSoft 	: 90
6 mm teflon cannula; straight insertion; insertion device; 60 line × 10 with 10 needles) cm 140.00	1 OP	✓ AutoSoft	: 90
9 mm teflon cannula; straight insertion; insertion device; 110 cm line × 10 with 10 needles	140.00	1 OP	✓ AutoSoft	: 90
9 mm teflon cannula; straight insertion; insertion device; 60) cm			
line × 10 with 10 needles		1 OP	 AutoSoft 	90

	Subsidy (Manufacturer's F	Price)	Fully Subsidised	Brand or Generic
	\$	Per	1	Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH	IT INSERTION)	 Special 	Authority s	ee SA1604 on page 17 -
Retail pharmacy a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
6 mm teflon cannula; straight insertion; 110 cm tubing × 10 w	ith			
10 needles	130.00	1 OP	✓ I	Paradigm Quick-Set
				MMT-398
6 mm teflon cannula; straight insertion; 110 cm tubing × 10 w		4.00		• · · • • • • • • • • • • • • • • • • •
10 needles; luer lock		1 OP	v (Quick-Set MMT-391
6 mm teflon cannula; straight insertion; 60 cm tubing × 10 with 10 needles		1 OP		Devedian Quiek Cat
TO needles	130.00	TUP	• 1	Paradigm Quick-Set MMT-399
6 mm teflon cannula; straight insertion; 60 cm tubing × 10 wit	h			WW 1-000
10 needles; luer lock		1 OP	✓ (Quick-Set MMT-393
6 mm teflon cannula; straight insertion; 80 cm tubing \times 10 wit				
10 needles		1 OP	✓ 1	Paradigm Quick-Set
				MMT-387
9 mm teflon cannula; straight insertion; 106 cm tubing \times 10 w				
10 needles	130.00	1 OP	✓ I	Paradigm Quick-Set
				MMT-396
9 mm teflon cannula; straight insertion; 110 cm tubing × 10 w		1.00		Outob Cat MNT 000
10 needles; luer lock 9 mm teflon cannula; straight insertion; 60 cm tubing × 10 wit		1 OP	•	Quick-Set MMT-390
9 mm tellon cannula; straight insention; 60 cm tubing × 10 with 10 needles		1 OP		Paradigm Quick-Set
To needles		TOF	• 1	MMT-397
9 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 10 wit	h			
10 needles; luer lock	130.00	1 OP	✓ (Quick-Set MMT-392
9 mm teflon cannula; straight insertion; 80 cm tubing × 10 wit				
10 needles		1 OP	🗸 I	Paradigm Quick-Set
				MMT-386
INSULIN PUMP RESERVOIR - Special Authority see SA1604 or	n page 17 – Ret	ail pharma	су	
 Maximum of 3 sets per prescription 				
b) Only on a prescription				
c) Maximum of 13 packs of reservoir sets will be funded per 10 when half setup and for participant of the		1 00		ADD Carterial and 1 0
10 × luer lock conversion cartridges 1.8 ml for Paradigm pum Cartridge for 5 and 7 series pump; 1.8 ml × 10		1 OP 1 OP		ADR Cartridge 1.8 Paradigm
		101	• •	1.8 Reservoir
Cartridge for 7 series pump; 3.0 ml × 10		1 OP	✓	Paradigm
				3.0 Reservoir
Digestives Including Enzymes				
PANCREATIC ENZYME				
Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase				
10,000 Ph Eur U, total protease 600 Ph Eur U)		100	1	Creon 10000
Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase,			-	
1,250 U protease))	,	100	✓	Panzytrat
Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase				-
25,000 Ph Eur U, total protease 1,000 Ph Eur U)	94.38	100	✓ (Creon 25000

A Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	Brand or
	(Manufacturer's Price)		Subsidised	Generic
	\$	Per		Manufacturer
URSODEOXYCHOLIC ACID - Special Authority see SA1739 be	low – Retail pharmad	су		
Cap 250 mg		100	✓ <u>U</u> I	rsosan
SA1739 Special Authority for Subsidy				
Initial application — (Alagille syndrome or progressive famili				relevant practitioner.
Approvals valid without further renewal unless notified for applica	tions meeting the foll	owing	g criteria:	

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Primary biliary cholangitis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure -- doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

	Subsidy (Manufacturer's Pr \$	ice) Subs Per	Fully Brand idised Generie Manufa	0
Laxatives				
Bulk-forming Agents				
ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription * Powder for oral soln	6.05	500 g OP	✓ Konsyl-D	2
MUCILAGINOUS LAXATIVES WITH STIMULANTS * Dry	6.02 (17.32)	500 g OP	Normacol	Dlue
	2.41 (8.72)	200 g OP	Normacol	
Faecal Softeners				
DOCUSATE SODIUM – Only on a prescription * Tab 50 mg	2.31	100	✓ <u>Coloxyl</u>	
* Tab 120 mg DOCUSATE SODIUM WITH SENNOSIDES		100	✓ Coloxyl	
 Tab 50 mg with sennosides 8 mg POLOXAMER – Only on a prescription 	3.10	200	✓ <u>Laxsol</u>	
Not funded for use in the ear. * Oral drops 10%	3.78	30 ml OP	✓ <u>Coloxyl</u>	
Opioid Receptor Antagonists - Peripheral				
METHYLNALTREXONE BROMIDE – Special Authority see SA Inj 12 mg per 0.6 ml vial		il pharmacy 1 7	✓ Relistor✓ Relistor	
 SA1691 Special Authority for Subsidy Initial application — (Opioid induced constipation) from any unless notified for applications meeting the following criteria: Both: The patient is receiving palliative care; and 	relevant practition	er. Approvals	s valid without fi	urther renewal
2 Either:2.1 Oral and rectal treatments for opioid induced cons2.2 Oral and rectal treatments for opioid induced cons			ed.	
Osmotic Laxatives				
GLYCEROL * Suppos 3.6 g – Only on a prescription	9.25	20	✓ <u>PSM</u>	
LACTULOSE – Only on a prescription * Oral liq 10 g per 15 ml Laevolac to be Sole Supply on 1 November 2019	3.33	500 ml	 Laevolac 	
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM B		D SODIUM C	HLORIDE	
Powder for oral soln 13.125 g with potassium chloride 46.6 r sodium bicarbonate 178.5 mg and sodium chloride 350.		30	✓ Molaxole	1
SODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8%	2.50	1	 Fleet Pho Enema 	•

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE	- Only on a prescrip	otion		
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Micolette to be Sole Supply on 1 November 2019	29.98	50	~ I	Aicolette
Stimulant Laxatives				
BISACODYL – Only on a prescription				
* Tab 5 mg	5.99	200	✓ L	<u>ax-Tab</u>
* Suppos 10 mg	3.74	10	✓ L	ax-Suppositories
SENNA – Only on a prescription				
* Tab, standardised	2.17	100		
	(6.84)		5	Senokot
	0.43	20		
	(1.72)		9	Senokot
Metabolic Disorder Agents				
Metabolic Disorder Agents ALGLUCOSIDASE ALFA – Special Authority see SA1622 below				

Myozyme

1

⇒SA1622 Special Authority for Subsidy

Initial application only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
- 2 Any of the following:
 - 2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
 - 2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
 - 2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
 - 2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
- 3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
- 4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
- 5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

Renewal only from a metabolic physician. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
- 2 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
- 3 Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- 4 Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
- 5 Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 6 There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
- 7 There is no evidence of new or progressive cardiomyopathy.

26

	Subsidy	a) 0: '	Fully	Brand or
	(Manufacturer's Pric \$	e) Sub: Per	sidised ✓	Generic Manufacturer
BETAINE - Special Authority see SA1727 below - Retail pha	rmacy			
Powder for oral soln		180 g OP	✓ C	ystadane
► SA1727 Special Authority for Subsidy		·		
Initial application only from a metabolic physician. Approvals	s valid for 12 months f	or applicatio	ns meet	ing the following criteria:
All of the following:				
 The patient has a confirmed diagnosis of homocystinur Any of the following: 	ia; and			
2.1 A cystathionine beta-synthase (CBS) deficiency	or			
2.2 A 5,10-methylene-tetrahydrofolate reductase (M 2.3 A disorder of intracellular cobalamin metabolism	THFR) deficiency; or			
3 An appropriate homocysteine level has not been achiev		nt trial of app	ropriate	vitamin supplementation
Renewal only from a metabolic physician. Approvals valid for patient is benefiting from treatment.			•	
GALSULFASE – Special Authority see SA1593 below – Retai	l pharmacy			
Inj 1 mg per ml, 5 ml vial		1	🗸 Na	aglazyme
► SA1593 Special Authority for Subsidy				
Initial application only from a metabolic physician. Approvals Both:	s valid for 12 months f	or applicatio	ns meet	ing the following criteria:
 The patient has been diagnosed with mucopolysacchar Either: 	idosis VI; and			
2.1 Diagnosis confirmed by demonstration of N-ace	tyl-galactosamine-4-s	ulfatase (ary	lsulfatas	e B) deficiency by either
enzyme activity assay in leukocytes or skin fibro				,
2.2 Detection of two disease causing mutations and VI.	patient has a sibling	who is know	n to hav	e mucopolysaccharidosis
Renewal only from a metabolic physician. Approvals valid for All of the following:			0	0
1 The treatment remains appropriate for the patient and t				
2 Patient has not had severe infusion-related adverse rea and/or adjustment of infusion rates; and	actions which were no	t preventabl	e by app	propriate pre-medication
3 Patient has not developed another life threatening or se	evere disease where t	he lona terr	noano	sis is unlikely to be
influenced by Enzyme Replacement Therapy (ERT); ar		ine long tern	rprogrio	
4 Patient has not developed another medical condition th		e expected	to comp	romise a response to
ERT.				
IDURSULFASE – Special Authority see SA1623 below – Reta		1	./ 5	
Inj 2 mg per ml, 3 ml vial	4,608.30	I	¥ EI	aprase
SA1623 Special Authority for Subsidy Initial application only from a metabolic physician. Approvals	valid for 24 weeks fo	r application	ne maatii	na the following criteria:
All of the following:		n application	is meen	ig the following enterna.
1 The patient has been diagnosed with Hunter Syndrome	(mucopolysaccharid	osis II); and		
2 Either:		,,		
 Diagnosis confirmed by demonstration of iduron assay in cultured skin fibroblasts; or 	ate 2-sulfatase deficie	ency in white	e blood c	ells by either enzyme
2.2 Detection of a disease causing mutation in the id	duronate 2-sulfatase o	gene; and		
3 Patient is going to proceed with a haematopoietic stem		-	next 3 m	onths and treatment with
idursulfase would be bridging treatment to transplant; a		,		
4 Patient has not required long-term invasive ventilation f (ERT); and	or respiratory failure p	orior to starti	ng Enzy	me Replacement Therap
5 Idursulfase to be administered for a total of 24 weeks (e	equivalent to 12 week	s pre- and 1	2 weeks	post-HSCT) at doses no

5 Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price)		Fully	Brand or Generic
	\$	Per	1	Manufacturer
LARONIDASE – Special Authority see SA1695 below – Retail Inj 100 U per ml, 5 ml vial		1	🗸 A	Idurazyme
SA1695 Special Authority for Subsidy		·		
Initial application only from a metabolic physician. Approvals	valid for 24 weeks for a	application	s meeti	ng the following criteria:
All of the following:				
1 The patient has been diagnosed with Hurler Syndrome 2 Either:		,		
 Diagnosis confirmed by demonstration of alpha- assay in cultured skin fibroblasts; or 				
2.2 Detection of two disease causing mutations in th to have Hurler syndrome; and	e alpha-L-iduronidase (gene and p	atient h	nas a sibling who is known
3 Patient is going to proceed with a haematopoietic stem laronidase would be bridging treatment to transplant; ar		within the r	next 3 n	nonths and treatment with
4 Patient has not required long-term invasive ventilation for (ERT); and	or respiratory failure pri-	or to startir	ig Enzy	me Replacement Therapy
5 Laronidase to be administered for a total of 24 weeks (e than 100 units/kg every week.	equivalent to 12 weeks p	ore- and 12	2 post-H	ISCT) at doses no greater
SAPROPTERIN DIHYDROCHLORIDE – Special Authority see Tab soluble 100 mg		il pharmac 30 OP	,	uvan
SA1757 Special Authority for Subsidy		10.01	• 1	uvan
Initial application only from a metabolic physician. Approvals	valid for 1 month for an	oplications	meetin	a the following criteria:
All of the following:				g
1 Patient has phenylketonuria (PKU) and is pregnant or a				I
2 Treatment with sapropterin is required to support mana				
 3 Sapropterin to be administered at doses no greater than 4 Sapropterin to be used alone or in combination with PK 			Ia	
5 Total treatment duration with sapropterin will not exceed			ncludes	s time for planning and
becoming pregnant) and treatment will be stopped after		- 5 5 (5
Renewal only from a metabolic physician or any relevant pract Approvals valid for 12 months for applications meeting the follo		ndation of	a metal	bolic physician.
All of the following:	wing chiena.			
1 Either:				
1.1 Following the initial one-month approval, the pat of sapropterin with a clinically appropriate reduct				

- pregnancy; or
 1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and
- 2 Any of the following:
 - 2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or
 - 2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or
 - 2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and
- 3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and
- 4 Sapropterin to be used alone or in combination with PKU dietary management; and
- 5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE - Special Authority see SA1599 on the next page - Retail pharmacy

Soln 100 mg per ml	CBS	100 ml	 Amzoate S29
--------------------	-----	--------	---------------------------------

28

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per ✓	Brand or Generic Manufacturer
 SA1599 Special Authority for Subsidy Initial application only from a metabolic physicial cycle disorder. Renewal only from a metabolic physician. Appre patient is benefiting from treatment. SODIUM PHENYLBUTYRATE – Special Author Grans 483 mg per g	ity see SA1598 below – Retail pharma 	eatment remains acy '4 g OP ✓ P ere the patient ha carbamylase or a	appropriate and the heburane Is a diagnosis of a urea rgininosuccinate
Gaucher's Disease			
 TALIGLUCERASE ALFA – Special Authority see Inj 200 unit vial	1,072.00	-	<u>lelyso</u>
The Co-ordinator, Gaucher Treatment Panel PHARMAC PO Box 10 254	Phone: 04 460 4990 Facsimile: 04 916 7571		

Completed application forms must be sent to the coordinator for the Gaucher Treatment Panel and will be considered by the Gaucher Treatment Panel at the next practicable opportunity.

Email: gaucherpanel@pharmac.govt.nz

Notification of the Gaucher Treatment Panel's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Access Criteria

Wellington

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- The patient has a diagnosis of symptomatic type 1 or type 3* Gaucher disease confirmed by the demonstration of specific deficiency of glucocerebrosidase in leukocytes or cultured skin fibroblasts, and genotypic analysis; and
- 2) Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by taliglucerase alfa or might be reasonably expected to compromise a response to therapy with taliglucerase alfa; and
- Taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units), unless otherwise agreed by PHARMAC; and
- 4) Supporting clinical information including test reports, MRI whole body STIR, serum glucosylsphingosine, haematological data, and other relevant investigations, are submitted to the Gaucher Panel for assessment; and
- 5) Any of the following:6) 1) Patient has had a second second
 - Patient has haematological complications such as haemoglobin less than 95 g/l, symptomatic anaemia, thrombocytopenia; at least two episodes of severely symptomatic splenic infarcts confirmed with imagery; or massive symptomatic splenomegaly; or
 - 2) Patient has skeletal complications such as acute bone crisis requiring hospitalisation or major pain management strategies; radiological MRI Evidence of incipient destruction of any major joint (e.g. hips or shoulder); spontaneous fractures or vertebral collapse; chronic bone pain not controlled by other pharmaceuticals; or
 - 3) Patient has significant liver dysfunction or hepatomegaly attributable to Gaucher disease; or

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subs	idised	Generic
\$	Per	~	Manufacturer

continued...

- 4) Patient has reduced vital capacity from clinically significant or progressive pulmonary disease due to Gaucher disease; or
- 5) Patient is a child and has experienced growth failure with significant decrease in percentile linear growth over a 6-12 month period.

*Unapproved indication

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1) Patient has demonstrated a symptomatic improvement or no deterioration in the main symptom for which therapy was initiated; and
- 2) Patient has demonstrated a clinically objective improvement or no deterioration in haemoglobin levels, platelet counts and liver and spleen size; and
- 3) Radiological (MRI) signs of bone activity performed at one year and two years since initiation of treatment begins, and two to three yearly thereafter, demonstrate no deterioration shown by the MRI, compared with MRI taken immediately prior to commencement of therapy or adjusted dose; and
- 4) Serum glucosylsphingosine levels taken at least 6 to 12 monthly show a decrease compared with baseline; and
- 5) Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
- Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
- 7) Patient is compliant with regular treatment and taliglucerase alfa is to be administered at a dose no greater than 30 unit/kg every other week rounded to the nearest whole vial (200 units), unless otherwise agreed by PHARMAC; and
- Supporting clinical information including test reports, MRI whole body STIR, serum glucosylsphingosine, haematological data, and other relevant investigations are submitted to the Gaucher Panel for assessment as required.

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE			
Soln 0.15% – Higher subsidy of \$20.31 per 500 ml with			
Endorsement	9.00	500 ml	
	(20.31)		Difflam
Additional subsidy by endorsement for a patient who has prescription is endorsed accordingly.	s oral mucositis a	as a result of tre	eatment for cancer, and the
CARMELLOSE SODIUM WITH GELATIN AND PECTIN			
Paste	17.20	56 g OP	 Stomahesive
	4.55	15 g OP	
	(7.90)		Orabase
	1.52	5 g OP	
	(3.60)		Orabase
Powder		28 g OP	.
	(10.95)		Stomahesive
CHLORHEXIDINE GLUCONATE			
Mouthwash 0.2%	2.57	200 ml OP	 healthE
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE			
* Adhesive gel 8.7% with cetalkonium chloride 0.01%	2.06	15 g OP	
	(6.00)	-	Bonjela
TRIAMCINOLONE ACETONIDE			
Paste 0.1%	5.33	5 g OP	 Kenalog in Orabase

30

	Subsidy (Manufacturer's Pri	co) Subc	Fully Brand or idised Generic
	(Manulacturer's Fill	Per	Manufacturer
Oropharyngeal Anti-infectives			
AMPHOTERICIN B Lozenges 10 mg	5.86	20	✓ Fungilin
/ICONAZOLE Oral gel 20 mg per g	4.74	40 g OP	✓ <u>Decozol</u>
NYSTATIN Oral liq 100,000 u per ml	1.95	24 ml OP	✓ <u>Nilstat</u>
Other Oral Agents			
For folinic mouthwash, pilocarpine oral liquid or saliva substitute	formula refer Stan	dard Formula	e, page 235
Soln 3% (10 vol) – Maximum of 200 ml per prescription Pharmacy Health Soln 3% (10 vol) to be delisted 1 July 2020) THYMOL GLYCERIN	1.40	100 ml	 Pharmacy Health
Compound, BPC	9.15	500 ml	✓ PSM
Vitamins			
Vitamin A			
/ITAMIN A WITH VITAMINS D AND C ★ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg p 10 drops		10 ml OP	✓ Vitadol C
Vitadol C Soln 1000 u with Vitamin D 400 u and ascorbic acid 3			
Vitamin B			
 HYDROXOCOBALAMIN Inj 1 mg per ml, 1 ml ampoule – Up to 6 inj available on a PapyRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription 	SO 1.89	3	✓ <u>Neo-B12</u>
 Fab 25 mg - No patient co-payment payable Fab 50 mg 		90 500	 ✓ <u>Vitamin B6 25</u> ✓ <u>Apo-Pyridoxine</u>
HIAMINE HYDROCHLORIDE – Only on a prescription K Tab 50 mg	4.89	100	✓ Max Health
ITAMIN B COMPLEX ≰ Tab, strong, BPC	7.15	500	✓ Bplex
Vitamin C			
SCORBIC ACID			
a) No more than 100 mg per doseb) Only on a prescription			
 b) Only on a prescription k Tab 100 mg 	8.10	500	✓ Cvite
-			

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Pri \$	ce) Subs Per	Fully Brand or idised Generic ✓ Manufacturer
Vitamin D			
ALFACALCIDOL * Cap 0.25 mcg	87.98 60.68 7.95	100 100 20 ml OP 100 100	 ✓ <u>One-Alpha</u> ✓ <u>One-Alpha</u> ✓ <u>One-Alpha</u> ✓ <u>Calcitriol-AFT</u> ✓ <u>Calcitriol-AFT</u>
 Cap 1.25 mg (50,000 iu) – Maximum of 12 cap per prescrip Oral liq 188 mcg per ml (7,500 iu per ml) 		12 4.8 ml OP	 ✓ <u>Vit.D3</u> ✓ Puria
Multivitamin Preparations			
MULTIVITAMIN RENAL – Special Authority see SA1546 below * Cap	6.49	30	Clinicians Renal Vit notified for applications meeting
 The patient has chronic kidney disease and is receiving of 2 The patient has chronic kidney disease grade 5, defined 15 ml/min/1.73 m² body surface area (BSA). 			
MULTIVITAMINS – Special Authority see SA1036 below – Reta		200 g OP	✓ Paediatric Seravit
 SA1036 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valinborn errors of metabolism. Renewal from any relevant practitioner. Approvals valid withou approval for multivitamins. 			
VITAMINS * Tab (BPC cap strength) * Cap (fat soluble vitamins A, D, E, K) – Special Authority se		1,000	✓ Mvite
SA1720 below – Retail pharmacy		60	 Vitabdeck
► SA1720 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals val the following criteria:	lid without further re	enewal unless	notified for applications meeting

Any of the following:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome; or
- 3 Patient has severe malabsorption syndrome.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Minerals				
Calcium				
CALCIUM CARBONATE * Tab eff 1.75 g (1 g elemental)		20	1	Calcium Sandoz S29
* Tab 1.25 g (500 mg elemental) CALCIUM GLUCONATE * Inj 10%, 10 ml ampoule		250 20		<u>Arrow-Calcium</u> Max Health ^{\$29}
Fluoride				
SODIUM FLUORIDE * Tab 1.1 mg (0.5 mg elemental)	5.75	100	1	PSM
lodine				
POTASSIUM IODATE * Tab 253 mcg (150 mcg elemental iodine)	4.69	90	1	<u>NeuroTabs</u>
Iron				
FERRIC CARBOXYMALTOSE – Special Authority see SA1840 Inj 50 mg per ml, 10 ml		acy 1	1	Ferinject
SA1840 Special Authority for Subsidy Initial application — (serum ferritin less than or equal to 20 months for applications meeting the following criteria: Both:	mcg/L) from any relev	vant p	practitioner	. Approvals valid for 3
 Patient has been diagnosed with iron-deficiency anaemi Any of the following: 	a with a serum ferritin I	evel o	of less thar	n or equal to 20 mcg/L; and
2.1 Patient has been compliant with oral iron treatme2.2 Treatment with oral iron has resulted in dose-limi2.3 Rapid correction of anaemia is required.		rover	n ineffective	e; or
Renewal — (serum ferritin less than or equal to 20 mcg/L) applications meeting the following criteria: Both:	from any relevant pract	itione	er. Approv	als valid for 3 months for
 Patient continues to have iron-deficiency anaemia with a A re-trial with oral iron is clinically inappropriate. 	serum ferritin level of	less t	han or equ	al to 20 mcg/L; and
Initial application — (iron deficiency anaemia) only from an	internal medicine nhvs	ician	obstetricia	in avnaecologist

Initial application — (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or medical practitioner on the recommendation of a internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has been diagnosed with iron-deficiency anaemia; and
- 2 Any of the following:
 - 2.1 Patient has been compliant with oral iron treatment and treatment has proven ineffective; or
 - 2.2 Treatment with oral iron has resulted in dose-limiting intolerance; or
 - 2.3 Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price)	Subsi		Brand or Generic
continued and a trial of oral iron is unlikely to be effective; or 2.4 Rapid correction of anaemia is required.	\$	Per	<u> </u>	Manufacturer
 Renewal — (iron deficiency anaemia) only from an internal memodical practitioner on the recommendation of a internal medicin Approvals valid for 3 months for applications meeting the followin Both: 1 Patient continues to have iron-deficiency anaemia; and 2 A re-trial with oral iron is clinically inappropriate. 	e physician, obstetri			
FERROUS FUMARATE * Tab 200 mg (65 mg elemental)	3.09	100	✓ F	erro-tab
FERROUS FUMARATE WITH FOLIC ACID	0.00	100	• 1	
* Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.68	60	✓ <u>F</u>	erro-F-Tabs
FERROUS SULFATE * Oral liq 30 mg (6 mg elemental) per 1 ml Ferodan to be Sole Supply on 1 November 2019	12.08	500 ml	✓ F	erodan
FERROUS SULPHATE * Tab long-acting 325 mg (105 mg elemental)		30	✓ F	errograd
IRON POLYMALTOSE			_	
* Inj 50 mg per ml, 2 ml ampoule	15.22 34.50	5	-	errum H errosig
Magnesium				
For magnesium hydroxide mixture refer Standard Formulae, page MAGNESIUM HYDROXIDE	e 235			
Suspension 8%	72.20	500 ml	✓ Т	&R \$29
MAGNESIUM SULPHATE * Inj 2 mmol per ml, 5 ml ampoule	10.21	10	✓ <u>D</u> ✓ D	<u>BL</u> BL S29 ^{S29}
Zinc				
ZINC SULPHATE * Cap 137.4 mg (50 mg elemental) Zincaps to be Sole Supply on 1 December 2019	11.00	100	✓ Z	incaps

BLOOD AND BLOOD FORMING ORGANS

Subsidised

Per

Fully

Subsidy (Manufacturer's Price) \$ Brand or Generic Manufacturer

Antianaemics

Hypoplastic and Haemolytic

➡SA1775 Special Authority for Subsidy

Initial application — (chronic renal failure) from any specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin is less than or equal to 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or

3.2 Both:

- 3.2.1 Patient has diabetes mellitus; and
- 3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; or
- 3.3 Patient is on haemodialysis or peritoneal dialysis.

Note: Epoetin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following

criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum epoetin level of < 500 IU/L; and
- 6 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

Renewal — (chronic renal failure) from any specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Epoetin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an unapproved indication

BLOOD AND BLOOD FORMING ORGANS

()	Subsidy /anufacturer's Price) \$	Per	Fully Subsidised	
EPOETIN ALFA – Special Authority see SA1775 on the previous p	age – Retail pharm	acy		
Wastage claimable				
Inj 1,000 iu in 0.5 ml, syringe	250.00	6	✓	Binocrit
Inj 2,000 iu in 1 ml, syringe	100.00	6	✓	Binocrit
Inj 3,000 iu in 0.3 ml, syringe	150.00	6	✓	Binocrit
Inj 4,000 iu in 0.4 ml, syringe	96.50	6	✓	Binocrit
Inj 5,000 iu in 0.5 ml, syringe	125.00	6	✓	Binocrit
Inj 6,000 iu in 0.6 ml, syringe	145.00	6	✓	Binocrit
Inj 8,000 iu in 0.8 ml, syringe		6	1	Binocrit
Inj 10,000 iu in 1 ml, syringe		6	✓	Binocrit
Inj 40,000 iu in 1 ml, syringe		1	1	Binocrit
Megaloblastic				
FOLIC ACID				
* Tab 0.8 mg	21.84	1.000) 🗸	Apo-Folic Acid
* Tab 5 mg		500	-	Apo-Folic Acid

Oral liq 50 mcg per ml26.00 25 ml OP

Antifibrinolytics, Haemostatics and Local Sclerosants

EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] - [Xpharm]

For patients with haemophilia B receiving prophylaxis treatment. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management group.

Inj 250 iu vial	612.50	່ 1	Alprolix
Inj 500 iu vial		1	Alprolix
Inj 1,000 iu vial		1	Alprolix
Inj 2,000 iu vial		1	 Alprolix
Inj 3,000 iu vial		1	🗸 Alprolix
ELTROMBOPAG - Special Authority see SA1743 b	elow – Retail pharmacy		
Wastage claimable			
Tab 25 mg		28	Revolade
Tab 50 mg	-	28	Revolade
J	-,		

⇒SA1743 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist. Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Initial application - (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist.

continued...

36

Biomed

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Either:
 - 3.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microliter; or
 - 3.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Initial application — (severe aplastic anaemia) only from a haematologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and

2 Either:

- 2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microliter; or
- 2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.

Renewal — (idiopathic thrombocytopenic purpura contraindicated to splenectomy) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's significant contraindication to splenectomy remains; and
- 2 The patient has obtained a response from treatment during the initial approval period; and
- 3 Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
- 4 Further treatment with eltrombopag is required to maintain response.

Renewal — (severe aplastic anaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
- 2 Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] - [Xpharm]

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Inj 1 mg syringe	1,178.30	1	NovoSeven RT
Inj 2 mg syringe	2,356.60	1	NovoSeven RT
Inj 5 mg syringe	5,891.50	1	NovoSeven RT
Inj 8 mg syringe	9,426.40	1	NovoSeven RT
, , , ,			

FACTOR EIGHT INHIBITOR BYPASSING FRACTION - [Xpharm]

For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Inj 500 U	1,315.00	1	FEIBA NF
Inj 1,000 U	2,630.00	1	🖌 FEIBA NF
Inj 2,500 U	6,575.00	1	🖌 FEIBA NF

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	I Generic
OROCTOCOG ALFA [RECOMBINANT FACTOR VIII] -				
For patients with haemophilia. Access to funded treat	tment is managed by the Ha	emop	hilia Trea	ters Group in conjunction
with the National Haemophilia Management Group.				
Inj 250 iu prefilled syringe		1		Xyntha
Inj 500 iu prefilled syringe		1		Xyntha
Inj 1,000 iu prefilled syringe		1		Xyntha
Inj 2,000 iu prefilled syringe		1		Xyntha
Inj 3,000 iu prefilled syringe	2,520.00	1	<i>•</i>	Xyntha
DNACOG ALFA [RECOMBINANT FACTOR IX] – [Xpha				
For patients with haemophilia, whose funded treatment	nt is managed by the Haemo	philia	Treaters	Group in conjunction with
the National Haemophilia Management Group.				
Inj 250 iu vial		1		BeneFIX
Inj 500 iu vial		1		BeneFIX
Inj 1,000 iu vial	,	1		BeneFIX
Inj 2,000 iu vial	·	1		BeneFIX
Inj 3,000 iu vial		1	-	BeneFIX
eneFIX Inj 2,000 iu vial to be delisted 1 November 2019,	ý			
eneFIX Inj 2,000 iu vial to be delisted 1 November 2019 eneFIX Inj 3,000 iu vial to be delisted 1 November 2019 DNACOG GAMMA, [RECOMBINANT FACTOR IX] – [X For patients with haemophilia. Access to funded treat with the National Haemophilia Management Group. Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial) pharm] iment is managed by the Ha 435.00 	1 1 1	\ \ \	RIXUBIS RIXUBIS RIXUBIS
eneFIX Inj 2,000 iu vial to be delisted 1 November 2019 eneFIX Inj 3,000 iu vial to be delisted 1 November 2019 DNACOG GAMMA, [RECOMBINANT FACTOR IX] – [X For patients with haemophilia. Access to funded treat with the National Haemophilia Management Group. Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial Inj 3,000 iu vial) pharm] Iment is managed by the Ha 435.00 870.00 1,740.00 2,610.00	1 1	\ \ \	RIXUBIS RIXUBIS
with the National Haemophilia Management Group. Inj 500 iu vial Inj 1,000 iu vial Inj 2,000 iu vial Inj 3,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVA For patients with haemophilia. Access to funded treat with the National Haemophilia Management Group. Inj 250 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,000 iu vial) pharm] iment is managed by the Ha 435.00 	' 1 1 1	hilia Trea	Rixubis Rixubis Rixubis Rixubis
eneFIX Inj 2,000 iu vial to be delisted 1 November 2019 eneFIX Inj 3,000 iu vial to be delisted 1 November 2019 DNACOG GAMMA, [RECOMBINANT FACTOR IX] – [X] For patients with haemophilia. Access to funded treat with the National Haemophilia Management Group. Inj 500 iu vial Inj 1,000 iu vial Inj 3,000 iu vial CTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVA For patients with haemophilia. Access to funded treat with the National Haemophilia. Access to funded treat with the National Haemophilia. Access to funded treat in 500 iu vial Inj 500 iu vial Inj 500 iu vial Inj 1,000 iu vial Inj 1,000 iu vial Inj 1,000 iu vial Inj 1,000 iu vial Inj 3,000 iu vial Inj 3,000 iu vial) pharm] iment is managed by the Ha 435.00 	1 1 1 emop 1 1 1	hilia Trea	RIXUBIS RIXUBIS RIXUBIS RIXUBIS ters Group in conjunction Advate Advate Advate Advate Advate
eneFIX Inj 2,000 iu vial to be delisted 1 November 2019 eneFIX Inj 3,000 iu vial to be delisted 1 November 2019 DNACOG GAMMA, [RECOMBINANT FACTOR IX] – [X] For patients with haemophilia. Access to funded treat with the National Haemophilia Management Group. Inj 500 iu vial. Inj 1,000 iu vial. Inj 2,000 iu vial. CTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVA For patients with haemophilia. Access to funded treat with the National Haemophilia. Access to funded treat with the National Haemophilia. Access to funded treat in j 2,000 iu vial. Inj 2,000 iu vial. Inj 2,000 iu vial. Inj 500 iu vial. Inj 1,500 iu vial. Inj 1,500 iu vial.) pharm] iment is managed by the Ha 	1 1 1 1 emop 1 1 1 1 1 1	hilia Trea	RIXUBIS RIXUBIS RIXUBIS RIXUBIS ters Group in conjunction Advate Advate Advate Advate Advate Advate Advate Advate Advate

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer
	•	rei	•	Manulaclurer
RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] For patients with haemophilia A receiving prophylaxis treatm		d trea	atment is m	anaged by the Haemonhilia
Treaters Group in conjunction with the National Haemophilia				anagoa by the Haemophina
Inj 250 iu vial	0 0 1	1	✓ ,	Adynovate
Inj 500 iu vial	600.00	1	✓ ,	Adynovate
Inj 1,000 iu vial	'	1		Adynovate
Inj 2,000 iu vial	2,400.00	1		Adynovate
SODIUM TETRADECYL SULPHATE				
* Inj 3% 2 ml		5		
	(73.00)			Fibro-vein
TRANEXAMIC ACID				
Tab 500 mg	20.67	100	√	Cyklokapron
Vitamin K				
PHYTOMENADIONE				
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO	8 00	5	1	Konakion MM
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO		5		Konakion MM
		Ŭ	-	
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN				
* Tab 100 mg		990	✓	Ethics Aspirin EC
Ethics Aspirin EC to be Sole Supply on 1 November 20	9			
CLOPIDOGREL				
* Tab 75 mg	5.44	84	✓ .	Arrow - Clopid
DIPYRIDAMOLE				
* Tab long-acting 150 mg		60	✓	Pytazen SR
PRASUGREL – Special Authority see SA1201 below – Retail ph	armacy			
Tab 5 mg		28	✓	Effient
Tab 10 mg		28		Effient
► SA1201 Special Authority for Subsidy				
Initial application — (coronary angioplasty and bare metal si	tent) from any releva	nt pra	actitioner. A	Approvals valid for 6
months where the patient has undergone coronary angioplasty ir				
Initial application - (drug eluting stent) from any relevant pra				ths where the patient has
had a drug-eluting cardiac stent inserted in the previous 4 weeks				
Initial application — (stent thromobosis) from any relevant pr		valid	without fur	ther renewal unless notified
where patient has experienced cardiac stent thrombosis whilst of			A	undial face Concernition where
Renewal — (coronary angioplasty and bare metal stent) from	n any relevant practiti	oner.	Approvals	valid for 6 months where

the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

TIC	CAGRELOR – Special Authority see SA1382 on the next page – Retail pharmac	;y	
*	Tab 90 mg90.00	56	🗸 Brilinta

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price) \$	Subsi Per	Fully idised	Brand or Generic Manufacturer	
---	--------------	-----------------	-------------------------------------	--

⇒SA1382 Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Heparin and Antagonist Preparations

DALTEPARIN SODIUM - Special Authority see SA1270 below - Retail pharmacy

Inj 2,500 iu per 0.2 ml prefilled syringe		10	 Fragmin
Inj 5,000 iu per 0.2 ml prefilled syringe		10	 Fragmin
Inj 7,500 iu per 0.75 ml graduated syringe	60.03	10	 Fragmin
Inj 10,000 iu per 1 ml graduated syringe		10	 Fragmin
Inj 12,500 iu per 0.5 ml prefilled syringe		10	 Fragmin
Inj 15,000 iu per 0.6 ml prefilled syringe		10	 Fragmin
Inj 18,000 iu per 0.72 ml prefilled syringe		10	 Fragmin
(Fragmin Inj 2,500 iu per 0.2 ml prefilled syringe to be delisted			
(Fragmin Ini 5.000 iu per 0.2 ml prefilled syringe to be delisted	. ,		

(Fragmin Inj 7,500 iu per 0.75 ml graduated syringe to be delisted 1 April 2020)

(Fragmin Inj 10,000 iu per 1 ml graduated syringe to be delisted 1 April 2020)

(Fragmin Inj 12,500 iu per 0.5 ml prefilled syringe to be delisted 1 January 2020)

(Fragmin Inj 15,000 iu per 0.6 ml prefilled syringe to be delisted 1 January 2020)

(Fragmin Inj 18,000 iu per 0.72 ml prefilled syringe to be delisted 1 January 2020)

⇒SA1270 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

40

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal - (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	<u> </u>	Manufacturer	

continued...

following criteria:

Either:

1 Low molecular weight heparin treatment is required during a patient's pregnancy; or

2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM - Special Authority see SA1646 below - Retail pharmacy

Inj 20 mg in 0.2 ml syringe	27.93	10	 Clexane
Inj 40 mg in 0.4 ml syringe		10	Clexane
Inj 60 mg in 0.6 ml syringe		10	 Clexane
Inj 80 mg in 0.8 ml syringe		10	 Clexane
Inj 100 mg in 1 ml syringe		10	Clexane
Inj 120 mg in 0.8 ml syringe		10	 Clexane
Inj 150 mg in 1 ml syringe		10	 Clexane

⇒SA1646 Special Authority for Subsidy

Initial application — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy, Malignancy or Haemodialysis) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy; or
- 3 For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml ampoule		50	 ✓ <u>Pfizer</u> ✓ Hospira
Inj 5,000 iu per ml, 1 ml	28.40	5	 ✓ Pfizer
Inj 5,000 iu per ml, 5 ml ampoule	203.68	50	 Pfizer
Inj 25,000 iu per ml, 0.2 ml	19.00	5	 Hospira
	122.00	10	Wockhardt S29
	190.00	50	 Pfizer S29

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
HEPARINISED SALINE	50.04	50		D(
Inj 10 iu per ml, 5 ml		50	•	Pfizer
Oral Anticoagulants				
DABIGATRAN				
Cap 75 mg – No more than 2 cap per day	76.36	60	1	Pradaxa
Cap 110 mg	76.36	60	✓	Pradaxa
Cap 150 mg	76.36	60	✓	Pradaxa
RIVAROXABAN				
Tab 10 mg – No more than 1 tab per day		30	1	Xarelto
Tab 15 mg – Up to 14 tab available on a PSO	77.56	28	1	Xarelto
Tab 20 mg	77.56	28	✓	Xarelto
WARFARIN SODIUM				
Note: Marevan and Coumadin are not interchangeable.				
* Tab 1 mg	3.46	50	1	Coumadin
-	7.60	100	1	Marevan
* Tab 2 mg	4.31	50	1	Coumadin
* Tab 3 mg		100	✓	Marevan
* Tab 5 mg	5.93	50	✓	Coumadin
-	13.50	100	1	Marevan

Blood Colony-stimulating Factors

FILGRASTIM - Special Authority see SA1259 below - Retail pha	rmacy		
Inj 300 mcg per 0.5 ml prefilled syringe		10	✓ <u>Nivestim</u>
Inj 480 mcg per 0.5 ml prefilled syringe	161.50	10	✓ <u>Nivestim</u>

► SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%*); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < $0.5 \times 10^{9}/L$); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^9 /L).

Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM – Special Authority see SA1384 below – Retail pharmacy

Inj 6 mg per 0.6 ml syringe	1,080.00	1	 Neulastim
-----------------------------	----------	---	-------------------------------

⇒SA1384 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%*). Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Fluids and Electrolytes				
Intravenous Administration				
GLUCOSE [DEXTROSE]	20.50	5	1	Piomod
 Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO 		5 1		Biomed Biomed
POTASSIUM CHLORIDE				
* Inj 75 mg per ml, 10 ml		50	1	AstraZeneca
SODIUM BICARBONATE	10.05			.
Inj 8.4%, 50 mla) Up to 5 inj available on a PSO		1	~	Biomed
b) Not in combination				
Inj 8.4%, 100 ml	20.50	1	✓	Biomed
a) Up to 5 inj available on a PSOb) Not in combination				
SODIUM CHLORIDE				
Not funded for use as a nasal drop. Not funded for nebuliser	use except when u	used in o	conjunction	n with an antibiotic intended
for nebuliser use. Inj 0.9%, bag – Up to 2000 ml available on a PSO	1 23	500 m		Baxter
	1.26	1,000 m		Baxter
Only if prescribed on a prescription for renal dialysis, main	ternity or post-nata	l care in	the home	of the patient, or on a PSO
for emergency use. (500 ml and 1,000 ml packs) Inj 23.4% (4 mmol/ml), 20 ml ampoule	22.00	5		Biomed
For Sodium chloride oral liquid formulation refer Standard			•	biomea
Inj 0.9%, 5 ml ampoule – Up to 5 inj available on a PSO		20	1	Fresenius Kabi
	7.00	50		InterPharma
Europeire Kabite to Oals Operations 4 December 2010			~	Multichem
Fresenius Kabi to be Sole Supply on 1 December 2019 Inj 0.9%, 10 ml ampoule – Up to 5 inj available on a PSO	5.40	50	1	Fresenius Kabi
	6.63	00		Pfizer
Fresenius Kabi to be Sole Supply on 1 December 2019				
Inj 0.9%, 20 ml ampoule	5.00	20		Fresenius Kabi
	7.50	30		Multichem InterPharma
Fresenius Kabi to be Sole Supply on 1 December 2019	7.00	00		
(InterPharma Inj 0.9%, 5 ml ampoule to be delisted 1 December 2	2019)			
(Multichem Inj 0.9%, 5 ml ampoule to be delisted 1 December 20	,			
(Pfizer Inj 0.9%, 10 ml ampoule to be delisted 1 December 2019)				
(Multichem Inj 0.9%, 20 ml ampoule to be delisted 1 December 2 (InterPharma Inj 0.9%, 20 ml ampoule to be delisted 1 December	,			
TOTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Sp	,			
Infusion		1 OP	1	TPN

	Subsidy (Manufacturer's F \$	Price) Subsi Per	idised G	Brand or Generic Nanufacturer
WATER				
 On a prescription or Practitioner's Supply Order only where Schedule requiring a solvent or diluent; or On a bulk supply order; or When used in the extemporaneous compounding of eyet When used for the dilution of sodium chloride soln 7% for 	e drops; or		ection liste	d in the Pharmaceutical
Inj 5 ml ampoule – Up to 5 inj available on a PSO	7.00	50	🗸 Inter	rPharma
Inj 10 ml ampoule – Up to 5 inj available on a PSO		50	 Pfize 	
Inj 20 ml ampoule – Up to 5 inj available on a PSO	5.00	20	✓ Fres	enius Kabi
	7.50	30		rPharma
Oral Administration				
CALCIUM POLYSTYRENE SULPHONATE Powder		300 g OP	🗸 Calc	ium Resonium
COMPOUND ELECTROLYTES				
Powder for oral soln – Up to 10 sach available on a PSO	2.30	10	🗸 Ener	rlyte
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] Soln with electrolytes (2 × 500 ml)	6.55	1,000 ml OP	✓ <u>Pedi</u> <u>Bu</u>	<u>ialyte -</u> Jbblegum
PHOSPHORUS				
Tab eff 500 mg (16 mmol)		100	Pho	sphate Phebra
POTASSIUM CHLORIDE	F 00	<u></u>		
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26 (11.85)	60	Chlo	rvescent
* Tab long-acting 600 mg (8 mmol)		200	✓ Spar	
SODIUM BICARBONATE				
Cap 840 mg	8.52	100	✓ Sodi✓ Sodi	
SODIUM POLYSTYRENE SULPHONATE				
Powder		454 g OP	✓ Reserved	onium-A

_					
		Subsidy		Fully	Brand or
		(Manufacturer's Price)		Subsidised	Generic
		\$	Per	1	Manufacturer
A	Ipha-Adrenoceptor Blockers				
A	Ipha Adrenoceptor Blockers				
DO	XAZOSIN				
*	Tab 2 mg	6 75	500	1	Apo-Doxazosin
*	Tab 4 mg		500		Apo-Doxazosin
	-		000	•	Apo Doxuzoom
РН	ENOXYBENZAMINE HYDROCHLORIDE				
*	Cap 10 mg	65.00	30	✓	BNM S29
		216.67	100	✓	Dibenzyline S29
PR	AZOSIN				
*	Tab 1 mg		100	1	Apo-Prazosin
*	Tab 2 mg		100		Apo-Prazosin
*	Tab 5 mg		100		Apo-Prazosin
	C C		100	-	/lpo i lazoom
	RAZOSIN				
*	Tab 1 mg		28		Actavis
*	Tab 2 mg		500		Apo-Terazosin
*	Tab 5 mg		500	✓	Apo-Terazosin

Agents Affecting the Renin-Angiotensin System

ACE Inhibitors

CAPTOPRIL		
* Oral liq 5 mg per ml94.99	95 ml OP	 Capoten
Oral liquid restricted to children under 12 years of age.		
CILAZAPRIL		
* Tab 0.5 mg2.09	90	✓ Zapril
* Tab 2.5 mg4.80	90	 Zapril
7.20	200	Apo-Cilazapril
* Tab 5 mg8.35	90	 Zapril
12.00	200	Apo-Cilazapril
(Apo-Cilazapril Tab 2.5 mg to be delisted 1 February 2020)		
(Apo-Cilazapril Tab 5 mg to be delisted 1 February 2020)		
ENALAPRIL MALEATE		
* Tab 5 mg	100	 Ethics Enalapril
* Tab 10 mg4.96	100	 Ethics Enalapril
* Tab 20 mg7.12	100	 Ethics Enalapril
LISINOPRIL		
* Tab 5 mg2.07	90	 Ethics Lisinopril
* Tab 10 mg2.36	90	 Ethics Lisinopril
* Tab 20 mg	90	 Ethics Lisinopril
PERINDOPRIL		
* Tab 2 mg	30	Apo-Perindopril
* Tab 4 mg4.80	30	✓ Apo-Perindopril
QUINAPRIL		
* Tab 5 mg6.01	90	Arrow-Quinapril 5
* Tab 10 mg	90	✓ Arrow-Quinapril 10
* Tab 20 mg	90	✓ Arrow-Quinapril 20
v		

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
ACE Inhibitors with Diuretics				
CILAZAPRIL WITH HYDROCHLOROTHIAZIDE * Tab 5 mg with hydrochlorothiazide 12.5 mg	10.18	100	✓ A	po-Cilazapril/ Hydrochlorothiazide
QUINAPRIL WITH HYDROCHLOROTHIAZIDE * Tab 10 mg with hydrochlorothiazide 12.5 mg * Tab 20 mg with hydrochlorothiazide 12.5 mg		30 30	_	accuretic 10 accuretic 20
Angiotensin II Antagonists				
CANDESARTAN CILEXETIL * Tab 4 mg	2.28 	90 90 90 90 84 84 84 84	✓ 000 ✓ 000 ✓ 11 ✓ 11 ✓ 11	Candestar Candestar Candestar Candestar Candestar Osartan Actavis Osartan Actavis Osartan Actavis Osartan Actavis
Angiotensin II Antagonists with Diuretics				
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE Tab 50 mg with hydrochlorothiazide 12.5 mg	1.88	30	✓ <u>A</u>	rrow-Losartan & Hydrochlorothiazide

Angiotensin II Antagonists with Neprilysin Inhibitors

SACUBITRIL WITH VALSARTAN - Special Authority see SA1751 below - Retail pharmacy

Note: Due to the angiotensin II receptor blocking activity of sacubitril with valsartan it should not be co-administered with an ACE inhibitor or another ARB.

Tab 24.3 mg with valsartan 25.7 mg	190.00	56	 Entresto 24/26
Tab 48.6 mg with valsartan 51.4 mg	190.00	56	 Entresto 49/51
Tab 97.2 mg with valsartan 102.8 mg	190.00	56	 Entresto 97/103

⇒SA1751 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient has heart failure; and
- 2 Any of the following:
 - 2.1 Patient is in NYHA/WHO functional class II; or
 - 2.2 Patient is in NYHA/WHO functional class III; or
 - 2.3 Patient is in NYHA/WHO functional class IV; and
- 3 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; and
- 4 Patient is receiving concomitant optimal standard chronic heart failure treatments.

Renewal from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price \$	e) Sut Per	Fully Brand or osidised Generic Manufacture	er
Antiarrhythmics				
r lignocaine hydrochloride refer to NERVOUS SYSTEM, Anae	esthetics, Local, pag	e 118		
/IODARONE HYDROCHLORIDE				
Tab 100 mg – Retail pharmacy-Specialist	3.80	30	 Aratac 	
	4.66		 Cordarone-X 	
Aratac to be Sole Supply on 1 December 2019				
Tab 200 mg – Retail pharmacy-Specialist	5.25	30	 Aratac 	
	7.63		Cordarone-X	
Aratac to be Sole Supply on 1 December 2019				
Inj 50 mg per ml, 3 ml ampoule – Up to 6 inj available on a	PSO9.98	5	🗸 Lodi	
	11.98	6	Cordarone-X	
	16.37	10	🗸 Max Health	
ordarone-X Tab 100 mg to be delisted 1 December 2019)				
ordarone-X Tab 200 mg to be delisted 1 December 2019)				
odi Inj 50 mg per ml, 3 ml ampoule to be delisted 1 February 2	2020)			
ordarone-X Inj 50 mg per ml, 3 ml ampoule to be delisted 1 Fe	ebruary 2020)			
ROPINE SULPHATE	• ·			
Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available on	0			
PSO		10	 Martindale 	
	12.07	10		
GOXIN			4	
Tab 62.5 mcg – Up to 30 tab available on a PSO	7.00	240	 Lanoxin PG 	
Lanoxin PG to be Sole Supply on 1 November 2019			4	
Tab 250 mcg – Up to 30 tab available on a PSO	15.20	240	 Lanoxin 	
Lanoxin to be Sole Supply on 1 November 2019			.	
Oral liq 50 mcg per ml	16.60	60 ml	 Lanoxin 	
			Lanoxin S29	S29
SOPYRAMIDE PHOSPHATE				
Cap 100 mg	23.87	100	 Rythmodan 	
			.,	
ECAINIDE ACETATE – Retail pharmacy-Specialist	10.05	<u></u>		
Tab 50 mg		60	 Flecainide BN Tambocor 	NIVI
Con long acting 100 mg	38.95	30	 Tambocor Tambocor CF 	-
Cap long-acting 100 mg				1
	39.51	90	✓ Flecainide	
			Controlled	
			Release Te	va
Flecainide Controlled Release Teva to be Sole Supply			6	
Cap long-acting 200 mg	61.06	90	 Flecainide 	
			Controlled	
			Release Te	
	68.78	30	 Tambocor CF 	R
Flecainide Controlled Release Teva to be Sole Supply		9		
Inj 10 mg per ml, 15 ml ampoule	52.45	5	 Tambocor 	
ambocor Tab 50 mg to be delisted 1 February 2020)				
ambocor CR Cap long-acting 100 mg to be delisted 1 Deceml	per 2019)			

	Subsidy		Fully	Brand or
(Ma	anufacturer's Price)		Subsidised	I Generic
	\$	Per	1	Manufacturer
MEXILETINE HYDROCHLORIDE				
▲ Cap 150 mg	162.00	100	1	Mexiletine
				Hydrochloride
▲ Cop 250 mg	202.00	100		USP S29 Mexiletine
▲ Cap 250 mg	202.00	100	•	Hydrochloride
				USP S29
PROPAFENONE HYDROCHLORIDE - Retail pharmacy-Specialist				
▲ Tab 150 mg	40.90	50	1	Rytmonorm
Antihypotensives				
MIDODRINE - Special Authority see SA1474 below - Retail pharma	асу			
Tab 2.5 mg		100	✓	Gutron
Tab 5 mg	79.00	100	✓	Gutron

➡SA1474 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where patient has disabling orthostatic hypotension not due to drugs.

Note: Treatment should be started with small doses and titrated upwards as necessary. Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta-Adrenoceptor Blockers

Beta Adrenoceptor Blockers

ATENOLOL

ATERIO E O E			
* Tab 50 mg	4.26	500	 Mylan Atenolol
* Tab 100 mg	7.30	500	 Mylan Atenolol
* Oral lig 25 mg per 5 ml		300 ml OP	✓ Atenolol AFT
Restricted to children under 12 years of age.			
BISOPROLOL FUMARATE			
* Tab 2.5 mg	3.53	90	 Bosvate
* Tab 5 mg		90	✓ Bosvate
* Tab 10 mg		90	✓ Bosvate
CARVEDILOL			<u></u>
	0.04	<u> </u>	
* Tab 6.25 mg		60	 Carvedilol Sandoz
* Tab 12.5 mg	2.30	60	 <u>Carvedilol Sandoz</u>
* Tab 25 mg	2.95	60	 Carvedilol Sandoz
CELIPROLOL			
* Tab 200 mg		180	✓ Celol
LABETALOL			
-		100	A 11 1 1
Tab 100 mg		100	 Hybloc
			Presolol S29
Tab 200 mg		100	 Hybloc
			Presolol S29
* Inj 5 mg per ml, 20 ml ampoule		5	
,	(88.60)	2	Trandate
(Hybloc Tab 100 mg to be delisted 1 December 2019)	()		

(Hybloc Tab 100 mg to be delisted 1 December 2019) (Hybloc Tab 200 mg to be delisted 1 February 2020)

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	Per	Subsidised	Generic Manufacturer
	\$	Per	•	Manufacturer
METOPROLOL SUCCINATE				
* Tab long-acting 23.75 mg	1.03	30	✓	Betaloc CR
* Tab long-acting 47.5 mg		30	✓	Betaloc CR
* Tab long-acting 95 mg	1.99	30	✓	Betaloc CR
* Tab long-acting 190 mg	3.00	30	✓	Betaloc CR
METOPROLOL TARTRATE				
* Tab 50 mg	5.66	100	✓	Apo-Metoprolol
* Tab 100 mg		60	1	Apo-Metoprolol
* Tab long-acting 200 mg		28	✓	Slow-Lopresor
* Inj 1 mg per ml, 5 ml vial		5	✓	Metroprolol IV
				Mylan
NADOLOL				
* Tab 40 mg		100	✓	Apo-Nadolol
* Tab 80 mg		100	✓	Apo-Nadolol
PINDOLOL				
* Tab 5 mg	13 22	100	1	Apo-Pindolol
* Tab 10 mg		100		Apo-Pindolol
* Tab 15 mg		100		Apo-Pindolol
· · · · · · · · · · · · · · · · · · ·				
PROPRANOLOL	4.64	100		Ana Dransanalal
* Tab 10 mg		100		Apo-Propranolol
* Tab 40 mg * Cap long-acting 160 mg		100 100		Apo-Propranolol Cardinol LA
		100	v	
* Oral liq 4 mg per ml – Special Authority see SA1327 below -		-00		D
Retail pharmacy		500 m	ni ∢	Roxane S29

⇒SA1327 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or
- 2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

SOTALOL		
* Tab 80 mg	 500	🗸 Mylan
* Tab 160 mg	100	 Mylan
TIMOLOL		
* Tab 10 mg	 100	🗸 Apo-Timol

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AM	LODIPINE			
*	Tab 2.5 mg	1.72	100	Apo-Amlodipine
*	Tab 5 mg	3.33	250	 Apo-Amlodipine
	Tab 10 mg		250	✓ Apo-Amlodipine

	Subsidy		Fully Brand or
	(Manufacturer's Price)		Subsidised Generic
	\$	Per	
ELODIPINE			
 Tab long-acting 2.5 mg 	1.45	30	Plendil ER
Tab long-acting 5 mg		90	 Felo 5 ER
Tab long-acting 10 mg		90	 Felo 10 ER
FEDIPINE			
Tab long-acting 10 mg	10.63	60	✓ Adalat 10
		00	✓ Adefin S29
Tab long-acting 20 mg	9.59	100	
Tab long-acting 30 mg		30	✓ Adalat Oros
			✓ Adefin XL
Tab long-acting 60 mg	5.67	30	✓ Adalat Oros
			✓ Adefin XL
defin XL Tab long-acting 30 mg to be delisted 1 March 2020)			
Other Calcium Channel Blockers			
LTIAZEM HYDROCHLORIDE			
Tab 30 mg	4.60	100	
Tab 60 mg	8.50	100	 Dilzem
Cap long-acting 120 mg		500	
Cap long-acting 180 mg		500	
Cap long-acting 240 mg	66.76	500	Apo-Diltiazem CD
RHEXILINE MALEATE			
Tab 100 mg	62.90	100	✓ Pexsig
RAPAMIL HYDROCHLORIDE			
Tab 40 mg	7.01	100	✓ Isoptin
Tab 80 mg		100	✓ Isoptin
Tab long-acting 120 mg		250	 Verpamil SR
	36.02	100	 Isoptin SR
Tab long-acting 240 mg	25.00	250	 Verpamil SR
Inj 2.5 mg per ml, 2 ml ampoule - Up to 5 inj available on a	a		
PSO	25.00	5	✓ Isoptin
erpamil SR Tab long-acting 120 mg to be delisted 1 May 202	0)		
Centrally-Acting Agents			
ONIDINE			
Patch 2.5 mg, 100 mcg per day – Only on a prescription		4	✓ <u>Mylan</u>
Patch 5 mg, 200 mcg per day – Only on a prescription		4	✓ Mylan
Patch 7.5 mg, 300 mcg per day – Only on a prescription		4	✓ Mylan
ONIDINE HYDROCHLORIDE	-		
Tab 25 mcg	8 75	112	 Clonidine BNM
Tab 150 mcg		100	
Inj 150 mcg per ml, 1 ml ampoule		10	✓ Medsurge
THYLDOPA	20100		<u></u>
Tab 250 mg	15 10	100	🗸 Methyldopa Mylan
1 au 200 1119		500	
	JZ.00	500	S29 S29

 * Tab 1 mg					
s Per ✓ Manufacturer Diuretics BUMETANIDE * Tab 1 mg 16.36 100 ✓ Burinex * Inj Son ong per ml, 4 mi vial. 7.95 5 ✓ Burinex * UPOSEMIDE [FRUSEMIDE] Tab 40 mg - Up to 30 tab available on a PSO 7.24 1,000 ✓ Apo-Furosemide * Tab 500 mg 20.40 20.40 ✓ Urex Forte ✓ Diurin 40 * Tab 500 mg 20.40 20.40 ✓ Urex Forte ✓ Usin 40 ✓ Milan Laboratories ####################################			۵)		
Duretics BUMETANIDE * Tab 1 mg 16.36 100 ✓ Burinex * Inj 500 mog per ml, 4 ml vial. 7.95 5 ✓ Burinex UNOSEMIDE [FRUSEMIDE] Tab 40 mg - Up to 30 tab available on a PSO. 7.24 1,000 ✓ Apo-Furosemide 20.40 20.40 ✓ Urex Forte ✓ Diurin 40 ✓ Mitian Laboratories # Tab 500 mg 25.00 50 ✓ Urex Forte * Tab 500 mg					
SUMETANIDE * Tab 1 mg	Diuretics				
 * Tab 1 mg	Loop Diuretics				
 * Tab 1 mg	BUMETANIDE				
UPOSEMIDE [FRUSEMIDE] 7.24 1,000 ✓ Apo-Furosemide Note: Wastage may only be claimed once on Milan Laboratories. ✓ Diurin 40 * Tab 500 mg 20.40 ✓ Milan Laboratories 50 50 ✓ Urex Forte * Crail iq 10 mg per ml. 11.20 30 ml OP ✓ Lasix * Inj 10 mg per ml. annuary 2020 € / Lasix Lasix * Inj 10 mg per ml. annuary 2020 € / Lasix Lasix Lasix * Inj 10 mg per ml. annuary 2020 € / Lasix Lasix Lasix * Inj 10 mg per ml. annuary 2020 € / Lasix Lasix Lasix * Inj 10 mg per ml. 2ml ampoule -Up to 5 inj available on a PSO 1.15 5 ✓ Frusemide-Claris Milan Laboratories Tab 40 mg to be delisted 1 November 2019) * Biomed Potassium Sparing Diuretics * Millan Laboratories * Inspra * SA1728 Special Authority for Subsidy * Inspra * Spifescina Authorit	-		100	1	Burinex
Tab 40 mg - Up to 30 tab available on a PSO	 Inj 500 mcg per ml, 4 ml vial 	7.95	5	1	Burinex
8.00 Diurin 40 Milan Laboratories \$\$ * Tab 500 mg 25.00 50 Urex Forte Lasix to be Sole Supply on 1 January 2020 In 10 mg per ml. 25 ml ampoule Lasix to be Sole Supply on 1 January 2020 In 10 mg per ml. 25 ml ampoule Lasix to be Sole Supply on 1 January 2020 In 10 mg per ml. 25 ml ampoule – Up to 5 inj available on a PSO 1.15 Frusemide-Claris Milan Laboratories \$\$ Tab 40 mg to be delisted 1 November 2019) Potassium Sparing Diuretics MullCRIDE HYDROCHLORIDE Oral liq 1 mg per ml. 30.00 25 ml OP Biomed PIPLERENONE - Special Authority see SA1728 below – Retail pharmacy Tab 25 mg SA1728) Special Authority for Subsidy Tab 25 mg Tab 25 mg SA1728 Special Authority for Subsidy Tab 25 mg SA1728 Special Authority for Subsidy Tab 25 mg Tab 25 mg SA1728 Special Authority for Subsidy Tab 25 mg SA1728 Special Authority for Subsidy Solitian failure with ejection fraction less than 40%; and 	FUROSEMIDE [FRUSEMIDE]				
20.40 ✓ Milan Laboratories Implicit Milan Laboratories. * Tab 500 mg 25.00 50 * Oral liq 10 mg per ml 11.20 30 ml OP Lasix to be Sole Supply on 1 January 2020 60.65 6 ✓ Lasix * Inj 10 mg per ml 2ml ampoule 60.65 6 ✓ Lasix Lasix to be Sole Supply on 1 January 2020 60.65 6 ✓ Lasix * Inj 10 mg per ml 2ml ampoule 00.65 6 ✓ Lasix Lasix to be Sole Supply on 1 January 2020 60.65 6 ✓ Lasix * Inj 10 mg per ml 2ml ampoule 00.65 6 ✓ Lasix Milan Laboratories Impoule 00.05 6 ✓ Lasix Milan Laboratories Impoule 00.05 6 ✓ Lasix Milan Laboratories Impoule 10 mg per ml 30.00 25 ml OP ✓ Biomed CPLERENONE - Special Authority see SA1728 below - Retail pharmacy 17.00 30 ✓ Inspra Tab 25 mg 11.87 30 ✓ Inspra *SA1728 Special Authority for Subsidy 11.87 30 ✓ Inspra *Solitial application from any relevant practitioner. Approvals valid without fu	Tab 40 mg – Up to 30 tab available on a PSO	7.24	1,000		
Note: Wastage may only be claimed once on Milan Laboratories. * Tab 500 mg. 25.00 50 ✓ Urex Forte Oral liq 10 mg per ml 11.20 30 ml OP ✓ Lasix Lasix to be Sole Supply on 1 January 2020 60.65 6 ✓ Lasix Lasix to be Sole Supply on 1 January 2020 60.65 6 ✓ Lasix K Inj 10 mg per ml. 2 ml ampoule – Up to 5 inj available on a PSO115 5 ✓ Frusemide-Claris Milan Laboratories SSS Tab 40 mg to be delisted 1 November 2019) POtassium Sparing Diuretics MMILORIDE HYDROCHLORIDE Oral liq 1 mg per ml 30.00 25 ml OP ✓ Biomed SPLEERNNE - Special Authority see SA1728 below - Retail pharmacy 17.00 30 ✓ Inspra Tab 25 mg 11.87 30 ✓ Inspra • SA1728 Special Authority for Subsidy 11.87 30 ✓ Inspra • Falteint has heart failure with ejection fraction less than 40%; and 2 Either: 2.1 Patient has heart failure with ejection fraction less than 40%; and 2 Either: 2.1 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone. AETOLAZONE Spiractin <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
Note: Wastage may only be claimed once on Milan Laboratories. 50 ✓ Urex Forte * Tab 500 mg per ml. 25.00 30 ml OP ✓ Lasix * Inj 10 mg per ml. 25 ml ampoule 60.65 6 ✓ Lasix Lasix to be Sole Supply on 1 January 2020 * Inj 10 mg per ml. 25 ml ampoule 60.65 6 ✓ Lasix * Inj 10 mg per ml. 21 manpoule – Up to 5 inj available on a PSO 5 ✓ Frusemide-Claris Milan Laboratories **** Tab 40 mg to be delisted 1 November 2019) ✓ Biomed Potassium Sparing Diuretics MILORIDE HYDROCHLORIDE 30.00 25 ml OP ✓ Biomed CPLERENONE - Special Authority see SA1728 below - Retail pharmacy Tab 50 mg 1 nspra Tab 25 mg 1728 Special Authority for Subsidy 111.87 30 ✓ Inspra *SA1728 Special Authority for Subsidy 11.187 30 ✓ Inspra *SA1728 Special Authority for Subsidy 11.187 30 ✓ Inspra *SA1728 Special Authority for Subsidy 11.187 30 ✓ Inspra *SA1728 Special Authority for Subsidy 11.187 30 ✓ Inspra *SA1728 <t< td=""><td></td><td>20.40</td><td></td><td>•</td><td></td></t<>		20.40		•	
* Tab 500 mg 25.00 50 ✓ Urex Forte * Oral liq 10 mg per ml 11.20 30 ml OP ✓ Lasix Lasix to be Sole Supply on 1 January 2020 60.65 6 ✓ Lasix * Inj 10 mg per ml, 25 ml ampoule - Up to 5 inj available on a PSO115 5 ✓ Frusemide-Claris Milan Laboratories @@ Tab 40 mg to be delisted 1 November 2019) 5 ✓ Inspra Potassium Sparing Diuretics MILORIDE HYDROCHLORIDE 30.00 25 ml OP ✓ Biomed Oral liq 1 mg per ml	Nata Mastana may ask ha slaimad anas as Milan Laka				Laboratories \$29
Oral liq 10 mg per ml			50	1	Urey Forte
Lasix to be Sole Supply on 1 January 2020 I not ong per ml, 25 ml ampoule	-				
 Inj 10 mg per ml, 25 ml ampoule					
 k inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO1.15 <i>Milan Laboratories Tab 40 mg to be delisted 1 November 2019</i>) Potassium Sparing Diuretics MMILORIDE HYDROCHLORIDE Oral liq 1 mg per ml	 Inj 10 mg per ml, 25 ml ampoule 	60.65	6	✓	Lasix
Milan Laboratories Tab 40 mg to be delisted 1 November 2019) Potassium Sparing Diuretics WILORIDE HYDROCHLORIDE Oral liq 1 mg per ml		00 445	-		Employed Obrida
Potassium Sparing Diuretics MILORIDE HYDROCHLORIDE Oral liq 1 mg per ml			5	•	Frusemide-Claris
MILORIDE HYDROCHLORIDE Oral liq 1 mg per ml	(Milan Laboratories \$29) Tab 40 mg to be delisted T November 2	019)			
Oral liq 1 mg per ml 30.00 25 ml OP ✓ Biomed EPLERENONE – Special Authority see SA1728 below – Retail pharmacy 17.00 30 ✓ Inspra Tab 50 mg 11.87 30 ✓ Inspra SA1728 Special Authority for Subsidy 11.87 30 ✓ Inspra SA1728 Special Authority for Subsidy 11.87 30 ✓ Inspra Soft Patient has heart failure with ejection fraction less than 40%; and 2 Either: 2.1 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone. METOLAZONE Tab 5 mg CBS 1 ✓ Metolazone sate Tab 5 mg	Potassium Sparing Diuretics				
EPLERENONE - Special Authority see SA1728 below - Retail pharmacy Tab 50 mg 17.00 30 Inspra Tab 25 mg 11.87 30 Inspra SA1728 Special Authority for Subsidy 11.87 30 Inspra Solowing criteria: 30 Inspra 11.87 30 Inspra Solt: 1 Patient has heart failure with ejection fraction less than 40%; and 2 Either: 2.1 Patient has heart failure with ejection fraction less than 40%; and 2 Either: 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone. METOLAZONE CBS 1 Metolazone see 50 Zaroxolyn see SPIRONOLACTONE 4.38 100 Spiractin Spiractin * Tab 25 mg 4.38 100 Spiractin Spiractin * Tab 100 mg 11.80 100 Spiractin Spiractin * Tab 100 mg 30.60 25 ml OP Biomed Biomed Biomed to be Sole Supply on 1 November 2019 30.60 25 ml OP Biomed	AMILORIDE HYDROCHLORIDE				
Tab 50 mg 17.00 30 Inspra Tab 25 mg 11.87 30 Inspra SA1728 Special Authority for Subsidy 11.87 30 Inspra mitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meetir he following criteria: 1 Patient has heart failure with ejection fraction less than 40%; and 2 Either: 2.1 Patient is intolerant to optimal dosing of spironolactone; or 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone. METOLAZONE Tab 5 mg CBS 1 ✓ Metolazone \$20 SPIRONOLACTONE 4.38 100 ✓ Spiractin * Tab 25 mg 4.38 100 ✓ Spiractin * Tab 100 mg 30.60 25 ml OP ✓ Biomed Biomed to be Sole Supply on 1 November 2019 30.60 25 ml OP ✓ Biomed MILORIDE HYDROCHLORIDE WITH FUROSEMIDE WILORIDE HYDROCHLORIDE WITH FUROSEMIDE 4.38 100 ✓ Spiractin	Oral liq 1 mg per ml		25 ml C	P 🗸	Biomed
Tab 25 mg					
 SA1728 Special Authority for Subsidy mitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meetir he following criteria: 				-	
nitial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meetir he following criteria: Both: 1 Patient has heart failure with ejection fraction less than 40%; and 2 Either: 2.1 Patient is intolerant to optimal dosing of spironolactone; or 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone. METOLAZONE Tab 5 mg		11.87	30	•	inspra
1 Patient has heart failure with ejection fraction less than 40%; and 2 Either: 2.1 Patient is intolerant to optimal dosing of spironolactone; or 2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone. METOLAZONE Tab 5 mg 1		l without further rer	newal u	nless notif	ied for applications meeting
2.2 Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone. METOLAZONE Tab 5 mg	1 Patient has heart failure with ejection fraction less than 40°	%; and			
Tab 5 mg CBS 1 ✓ Metolazone \$29 50 ✓ Zaroxolyn \$29 SPIRONOLACTONE 4.38 100 ✓ Spiractin ★ Tab 25 mg 1.80 100 ✓ Spiractin ★ Tab 100 mg 11.80 100 ✓ Spiractin Oral liq 5 mg per ml 30.60 25 ml OP ✓ Biomed Biomed to be Sole Supply on 1 November 2019 ✓ Spiractin ✓ Spiractin MULORIDE HYDROCHLORIDE WITH FUROSEMIDE ✓ ✓			n optima	l dosing o	f spironolactone.
Tab 5 mg CBS 1 ✓ Metolazone \$29 50 ✓ Zaroxolyn \$29 SPIRONOLACTONE 4.38 100 ✓ Spiractin ★ Tab 25 mg 1.80 100 ✓ Spiractin ★ Tab 100 mg 11.80 100 ✓ Spiractin Oral liq 5 mg per ml 30.60 25 ml OP ✓ Biomed Biomed to be Sole Supply on 1 November 2019 ✓ Spiractin ✓ Spiractin MULORIDE HYDROCHLORIDE WITH FUROSEMIDE ✓ ✓	METOLAZONE				
50 ✓ Zaroxolyn 529 SPIRONOLACTONE ★ Tab 25 mg		CBS	1	1	Metolazone S29
 * Tab 25 mg			50	1	Zaroxolyn S29
 * Tab 25 mg	SPIRONOLACTONE				-
 Tab 100 mg		4.38	100		
Biomed to be Sole Supply on 1 November 2019 Potassium Sparing Combination Diuretics MILORIDE HYDROCHLORIDE WITH FUROSEMIDE	* Tab 100 mg	11.80			
Potassium Sparing Combination Diuretics			25 ml C)P 🗸	Biomed
MILORIDE HYDROCHLORIDE WITH FUROSEMIDE					
	rolassium sparing combination Diuretics				
I ab 5 mg with turosemide 40 mg		0.00	~~		F
	 nau o mg with turosemide 40 mg 	ช.63	28	•	rumii

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	
AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZID * Tab 5 mg with hydrochlorothiazide 50 mg		50	1	Moduretic
Thiazide and Related Diuretics				
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE] * Tab 2.5 mg – Up to 150 tab available on a PSO		500	•	Arrow- Bendrofluazide
May be supplied on a PSO for reasons other than emerge * Tab 5 mg		500	1	<u>Arrow-</u> Bendrofluazide
CHLOROTHIAZIDE Oral liq 50 mg per ml CHLORTALIDONE [CHLORTHALIDONE]		25 ml O	P 🗸	Biomed
* Tab 25 mg Hygroton to be Sole Supply on 1 December 2019	6.50	50	1	Hygroton
INDAPAMIDE * Tab 2.5 mg	2.60	90	1	Dapa-Tabs
Lipid-Modifying Agents				
Fibrates				
BEZAFIBRATE * Tab 200 mg * Tab long-acting 400 mg GEMFIBROZIL * Tab 600 mg	12.89	90 30 60	1	<u>Bezalip</u> Bezalip Retard Lipazil
Other Lipid-Modifying Agents				
ACIPIMOX * Cap 250 mg NICOTINIC ACID * Tab 50 mg * Tab 500 mg	4.12	30 100 100	1	Olbetam <u>Apo-Nicotinic Acid</u> <u>Apo-Nicotinic Acid</u>
Resins				
COLESTIPOL HYDROCHLORIDE Grans for oral liq 5 g		30	1	Colestid
HMG CoA Reductase Inhibitors (Statins)				

Prescribing Guidelines

52

Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.

Ezetimibe Sandoz

	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
	\$	Per		Manufacturer
ATORVASTATIN – See prescribing guideline on the previous page	ge			
* Tab 10 mg	6.96	500	✓	Lorstat
* Tab 20 mg	9.99	500	✓	Lorstat
* Tab 40 mg		500	✓	Lorstat
* Tab 80 mg	27.19	500	1	Lorstat
PRAVASTATIN – See prescribing guideline on the previous page)			
* Tab 20 mg	4.72	100	✓	Apo-Pravastatin
* Tab 40 mg		100	✓	Apo-Pravastatin
SIMVASTATIN - See prescribing guideline on the previous page				
* Tab 10 mg	0.95	90	✓	Simvastatin Mylan
* Tab 20 mg	1.52	90	1	Simvastatin Mylan
* Tab 40 mg	2.63	90	1	Simvastatin Mylan
* Tab 80 mg	6.00	90	✓	Simvastatin Mylan

EZETIMIBE – Special Authority see SA1045 below – Retail pharmacy

*	Tab 10 mg		
---	-----------	--	--

► SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

30

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg5.15	30	 Zimybe
Tab 10 mg with simvastatin 20 mg6.15	30	 Zimybe
Tab 10 mg with simvastatin 40 mg7.15	30	 Zimybe
Tab 10 mg with simvastatin 80 mg8.15	30	 Zimybe

⇒SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of

continued...

Subsidy	· F	ully Brand o	r
(Manufacturer's	s Price) Subsidi	sed Generic	
\$	Per	 Manufac 	cturer

continued...

atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to less than or equal to 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy. If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

N	trates		
GL	CERYL TRINITRATE		
*	Oral pump spray, 400 mcg per dose – Up to 250 dose		
	available on a PSO4.45	250 dose OP	 Nitrolingual Pump Spray
*	Oral spray, 400 mcg per dose – Up to 200 dose available on a PSO4.45	200 dose OP	✓ Glytrin
*	Patch 25 mg, 5 mg per day15.73	30	✓ Nitroderm TTS
	Patch 50 mg, 10 mg per day	30	✓ Nitroderm TTS
	rtrin Oral spray, 400 mcg per dose to be delisted 1 May 2020)		
	SORBIDE MONONITRATE		
	Tab 20 mg	100	✓ Ismo 20
	Tab long-acting 40 mg7.50	30	✓ Ismo 40 Retard
	Tab long-acting 60 mg	90	✓ Duride
S	ympathomimetics		
AD	RENALINE		_
	Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO4.98	5	 Aspen Adrenaline
	5.25	_	 Hospira
	Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a PSO27.00	5	✓ Hospira
	49.00	10	 Aspen Adrenaline
ISO	PRENALINE [ISOPROTERENOL]		
*	Inj 200 mcg per ml, 1 ml ampoule	25	
	(164.20)		Isuprel
Vá	asodilators		
HY	DRALAZINE HYDROCHLORIDE		
*	Tab 25 mg - Special Authority see SA1321 on the next page -		
	Retail pharmacyCBS	1	 Hydralazine
		56	✓ Onelink S29
		84	AMDIPHARM \$29
		100	✓ Onelink S29
*	Inj 20 mg ampoule	5	✓ Apresoline

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Sub: Per	sidised ✓	Generic Manufacturer
SA1321 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals va the following criteria: Either:	alid without further rene	wal unles	s notifie	d for applications meeting
 For the treatment of refractory hypertension; or For the treatment of heart failure in combination with a r inhibitors and/or angiotensin receptor blockers. 	nitrate, in patients who a	are intoler	ant or ha	ave not responded to ACI
MINOXIDIL ▲ Tab 10 mg	70.00	100	✓ L	oniten
NICORANDIL ▲ Tab 10 mg Ikorel to be Sole Supply on 1 December 2019	25.57	60	✓ Ik	corel
▲ Tab 20 mg Ikorel to be Sole Supply on 1 December 2019		60	✓ Ik	corel
PAPAVERINE HYDROCHLORIDE * Inj 12 mg per ml, 10 ml ampoule	217.90	5	✔ Н	ospira
PENTOXIFYLLINE [OXPENTIFYLLINE] Tab 400 mg	42.26	50	🗸 Т	rental 400
Endothelin Receptor Antagonists				
AMBRISENTAN – Special Authority see SA1702 below – Reta Tab 5 mg Tab 10 mg	4,585.00	30 30	-	olibris olibris
→ SA1702 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hyperten Notes: Application details may be obtained from PHARMAC's The Coardinator BALLBasel		rmac.gov	. <u>nz</u> or:	
The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7561, Fax: (04) 974 4858, Email: <u>PAH@pharm</u>	ac.govt.nz			
BOSENTAN – Special Authority see SA1712 below – Retail pl Tab 62.5 mg	•	60	✓ <u>B</u>	osentan Dr
Tab 125 mg	141.00	60	✓ <u>B</u>	<u>Reddy's</u> osentan Dr Reddy's
				-

► SA1712 Special Authority for Subsidy

Initial application only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory physician or cardiologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
- 3 PAH is at NYHA/WHO functional class II, III, or IV; and
- 4 Any of the following:
 - 4.1 Both:
 - 4.1.1 Bosentan is to be used as PAH monotherapy; and
 - 4.1.2 Either:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
- 4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or
- 4.2 Both:
 - 4.2.1 Bosentan is to be used as PAH dual therapy; and
 - 4.2.2 Either:
 - 4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
 - 4.2.2.2 Patient deteriorated while on a PAH monotherapy; or

4.3 Both:

- 4.3.1 Bosentan is to be used as PAH triple therapy; and
- 4.3.2 Any of the following:
 - 4.3.2.1 Patient is on the lung transplant list; or
 - 4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Renewal only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory physician or cardiologist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following:

- 1 Both:
 - 1.1 Bosentan is to be used as PAH monotherapy; and
 - 1.2 Patient is stable or has improved while on bosentan; or
- 2 Both:
 - 2.1 Bosentan is to be used as PAH dual therapy; and
 - 2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or
- 3 Both:
 - 3.1 Bosentan is to be used as PAH triple therapy; and
 - 3.2 Any of the following:
 - 3.2.1 Patient is on the lung transplant list; or
 - 3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
 - 3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
 - 3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL - Special Authority see SA1825 below - Retail pharma	асу		
Tab 25 mg	0.64	4	 Vedafil
Tab 50 mg	0.64	4	✓ Vedafil
Tab 100 mg	6.60	12	✓ Vedafil

⇒SA1825 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon*) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Pri	ico)	Fully Subsidised	Brand or	
\$	Per		Generic Manufacturer	

continued...

All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Initial application — (Pulmonary arterial hypertension*) only from a respiratory specialist, cardiologist or medical practitioner on the recommendation of a respiratory specialist or cardiologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has pulmonary arterial hypertension (PAH)*; and
- 2 Any of the following:
 - 2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
 - 2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
 - 2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
- 3 Any of the following:
 - 3.1 PAH is in NYHA/WHO functional class II; or
 - 3.2 PAH is in NYHA/WHO functional class III; or
 - 3.3 PAH is in NYHA/WHO functional class IV; and

4 Either:

4.1 All of the following:

4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and

4.1.2 Either:

- 4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
- 4.1.2.2 Patient is peri Fontan repair; and
- 4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm-5); or
- 4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient's young age.

Note: Indications marked with * are unapproved indications.

Initial application — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has a documented history of traumatic or non-traumatic spinal cord injury; and
- 2 Patient has erectile dysfunction secondary to spinal cord injury requiring pharmacological treatment.

Renewal — (erectile dysfunction due to spinal cord injury) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Prostacyclin Analogues

EPOPROSTENOL - Special Authority see SA1696 below - F	Retail pharmacy		
Inj 500 mcg vial		1	🗸 Veletri
Inj 1.5 mg vial	73.21	1	🗸 Veletri

⇒SA1696 Special Authority for Subsidy

Special Authority approved by the Pulmonary Arterial Hypertension Panel

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The Coordinator, PAH Panel

PHARMAC, PO Box 10-254, WELLINGTON

Tel: (04) 916 7561, Fax: (04) 974 4858, Email: PAH@pharmac.govt.nz

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
ILOPROST – Special Authority see SA1705 below – Retail phar Nebuliser soln 10 mcg per ml, 2 ml Ventavis to be Sole Supply on 1 January 2020	,	30	✓ V	entavis
► SA1705 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensi Notes: Application details may be obtained from PHARMAC's w The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7561, Fax: (04) 974 4858, Email: <u>PAH@pharmac</u>	ebsite <u>http://www.pha</u>	armac.g	<u>ovt.nz</u> or:	

	Subsidy		Fully	Brand or
	(Manufacturer's Price	,	sidised	Generic
	\$	Per		Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterials, p	bage 89			
ADAPALENE				
a) Maximum of 30 g per prescription				
b) Only on a prescription				
Crm 0.1%		30 g OP	🗸 D	Differin
Gel 0.1%		30 g OP	🗸 D	Differin
ISOTRETINOIN - Special Authority see SA1475 below - Retail ph	narmacy			
Cap 5 mg		60	✓ 0	Iratane
Cap 10 mg		120	✓ 0	Iratane
Cap 20 mg		120	✓ 0	Iratane

⇒SA1475 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 3.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
- 2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN Crm 0.5 mg per g – Maximum of 50 g per prescription	50 g OP	✓ <u>ReTrieve</u>	
Antibacterials Topical			
For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 89			
HYDROGEN PEROXIDE * Crm 1%	10 g OP	 Crystaderm 	
	15 g OP	✓ Crystaderm	

DERMATOLOGICALS

	Subsidy (Manufacturer's F	Price) Subs	Fully Brand or sidised Generic
	\$	Per	 Manufacturer
<i>I</i> UPIROCIN			
Oint 2%	6.60 (9.26)	15 g OP	Bactroban
a) Only on a prescriptionb) Not in combination			
SODIUM FUSIDATE [FUSIDIC ACID]	4 50	5 0.0	
Crm 2%a) Maximum of 5 g per prescription	1.59	5 g OP	 Foban
b) Only on a prescription			
c) Not in combination			
Oint 2%	1.59	5 g OP	 Foban
a) Maximum of 5 g per prescription			
b) Only on a prescription			
c) Not in combination			
SULFADIAZINE SILVER	10.00		
Crm 1% a) Up to 250 g available on a PSO	10.80	50 g OP	Flamazine
 b) Not in combination 			
.,			
For systemic antifungals, refer to INFECTIONS, Antifungals,	page 96		
MOROLFINE	page 96		
, , , , , , , , , , , , , , , , , , , ,	page 96		
MOROLFINE a) Only on a prescription		5 ml OP	✓ <u>MycoNail</u>
MOROLFINE a) Only on a prescription b) Not in combination		5 ml OP	✓ <u>MycoNail</u>
AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription		5 ml OP	✓ <u>MycoNail</u>
AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination			
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8%		5 ml OP 7 ml OP	✓ <u>MycoNail</u> ✓ <u>Apo-Ciclopirox</u>
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE		7 ml OP	✓ <u>Apo-Ciclopirox</u>
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1%			
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1% a) Only on a prescription		7 ml OP	✓ <u>Apo-Ciclopirox</u>
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1%		7 ml OP	✓ <u>Apo-Ciclopirox</u>
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1% a) Only on a prescription b) Not in combination		7 ml OP 20 g OP	✓ <u>Apo-Ciclopirox</u>
MOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1% a) Only on a prescription b) Not in combination		7 ml OP 20 g OP	 ✓ <u>Apo-Ciclopirox</u> ✓ <u>Clomazol</u>
AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1% a) Only on a prescription b) Not in combination ¥ Soln 1%		7 ml OP 20 g OP	 ✓ <u>Apo-Ciclopirox</u> ✓ <u>Clomazol</u>
AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1% a) Only on a prescription b) Not in combination ≰ Soln 1% a) Only on a prescription b) Not in combination €CONAZOLE NITRATE		7 ml OP 20 g OP 20 ml OP	 ✓ <u>Apo-Ciclopirox</u> ✓ <u>Clomazol</u>
AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1% a) Only on a prescription b) Not in combination ≴ Soln 1% a) Only on a prescription b) Not in combination		7 ml OP 20 g OP	 <u>Apo-Ciclopirox</u> <u>Clomazol</u> Canesten
AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ≰ Crm 1% a) Only on a prescription b) Not in combination ≰ Soln 1% a) Only on a prescription b) Not in combination ECONAZOLE NITRATE Crm 1%		7 ml OP 20 g OP 20 ml OP	 ✓ <u>Apo-Ciclopirox</u> ✓ <u>Clomazol</u>
AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ★ Crm 1% a) Only on a prescription b) Not in combination ★ Soln 1% a) Only on a prescription b) Not in combination ECONAZOLE NITRATE Crm 1% a) Only on a prescription b) Not in combination		7 ml OP 20 g OP 20 ml OP	 <u>Apo-Ciclopirox</u> <u>Clomazol</u> Canesten
 AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ★ Crm 1% a) Only on a prescription b) Not in combination ★ Soln 1% a) Only on a prescription b) Not in combination ★ Soln 1% a) Only on a prescription b) Not in combination ECONAZOLE NITRATE Crm 1% a) Only on a prescription b) Not in combination 		7 ml OP 20 g OP 20 ml OP 20 g OP	 <u>Apo-Ciclopirox</u> <u>Clomazol</u> Canesten
AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ★ Crm 1% a) Only on a prescription b) Not in combination ★ Soln 1% a) Only on a prescription b) Not in combination ECONAZOLE NITRATE Crm 1% a) Only on a prescription b) Not in combination		7 ml OP 20 g OP 20 ml OP	 <u>Apo-Ciclopirox</u> <u>Clomazol</u> Canesten Pevaryl
 AMOROLFINE a) Only on a prescription b) Not in combination Nail soln 5% CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination Nail-soln 8% CLOTRIMAZOLE ★ Crm 1% a) Only on a prescription b) Not in combination ★ Soln 1% a) Only on a prescription b) Not in combination ★ Soln 1% a) Only on a prescription b) Not in combination ECONAZOLE NITRATE Crm 1% a) Only on a prescription b) Not in combination 		7 ml OP 20 g OP 20 ml OP 20 g OP	 <u>Apo-Ciclopirox</u> <u>Clomazol</u> Canesten

DERMATOLOGICALS

	Subsidy (Manufacturer's P \$	rice) Subs Per	Fully Brand or sidised Generic ✓ Manufacturer
MICONAZOLE NITRATE * Crm 2%	0.74	15 g OP	✓ Multichem
a) Only on a prescription	0.74	15 9 01	• <u>Multichem</u>
b) Not in combination	4.00	00 ml OD	
* Lotn 2%	4.36 (10.03)	30 ml OP	Daktarin
a) Only on a prescription	(*****)		
b) Not in combination	1.00	00 ml OD	
* Tinct 2%	4.36 (12.10)	30 ml OP	Daktarin
a) Only on a prescriptionb) Not in combination	(12.10)		Duntum
NYSTATIN			
Crm 100,000 u per g	1.00 (7.90)	15 g OP	Mycostatin
a) Only on a prescriptionb) Not in combination	(7.90)		wycostain
Antipruritic Preparations			
CALAMINE			
a) Only on a prescription			
b) Not in combination Crm, aqueous, BP	1 26	100 g	✓ healthE Calamine
		100 g	Aqueous Cream BP
Lotn, BP (PSM Lotn, BP to be delisted 1 July 2020)		2,000 ml	✓ PSM
CROTAMITON			
a) Only on a prescriptionb) Not in combination			
Crm 10%	3.29	20 g OP	✓ Itch-Soothe
MENTHOL – Only in combination			
 Only in combination with a dermatological base or pr With or without other dermatological galenicals. 	oprietary Topical C	orticosteriod –	Plain
Crystals	6.92 29.60	25 g 100 g	 ✓ MidWest ✓ MidWest

	Subsidy		Fully	Brand or
	(Manufacturer's Pr	ice) Subs	idised	Generic
	\$	Per	1	Manufacturer
Continentary ida Taniaal				
Corticosteroids Topical				
For systemic corticosteroids, refer to CORTICOSTEROIDS AND	RELATED AGEN	ITS, page 79		
Corticosteroids - Plain				
BETAMETHASONE DIPROPIONATE				
Crm 0.05%	2.96	15 g OP	🗸 D	Diprosone
	8.97	50 g OP	🗸 D	Diprosone
Crm 0.05% in propylene glycol base		30 g OP	🗸 D	Diprosone OV
Oint 0.05%	2.96	15 g OP	🗸 D	Diprosone
	8.97	50 g OP	🗸 D	Diprosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	🗸 D	Diprosone OV
(Diprosone OV Crm 0.05% in propylene glycol base to be delisted		Ũ		•
BETAMETHASONE VALERATE	- /			
* Crm 0.1%	3 45	50 g OP	/ F	Beta Cream
* Oint 0.1%		50 g OP 50 g OP		Beta Ointment
* Lotn 0.1%		50 g Ol 50 ml OP		Betnovate
		JUINUE	• •	Jeniovale
CLOBETASOL PROPIONATE				
* Crm 0.05%	2.18	30 g OP	✓ [Dermol
Dermol to be Sole Supply on 1 November 2019				
* Oint 0.05%	2.12	30 g OP	✓ C	Dermol
Dermol to be Sole Supply on 1 November 2019				
CLOBETASONE BUTYRATE				
Crm 0.05%		30 g OP		
	(7.09)		E	Eumovate
DIFLUCORTOLONE VALERATE	()			
	0.07			
Crm 0.1%		50 g OP		Indenne
	(15.86)		N	Verisone
Fatty oint 0.1%		50 g OP		La de casa
	(15.86)		N	lerisone
HYDROCORTISONE				
* Crm 1% – Only on a prescription	1.11	30 g OP	🗸 D	DermAssist
	16.25	500 g		harmacy Health
* Powder – Only in combination		25 g	✓ <u>A</u>	ABM
Up to 5% in a dermatological base (not proprietary Topic		- Plain) with c		
galenicals		,		č
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN				
Lotn 1% with paraffin liquid 15.9% and Ianolin 0.6% – Only of	'n			
		250 ml	. / г	OP Lotn HC
a prescription	10.37	200 111	ΨĽ	
HYDROCORTISONE BUTYRATE				
Lipocream 0.1%		30 g OP		ocoid Lipocream
	6.85	100 g OP		ocoid Lipocream
Oint 0.1%		100 g OP	_	.ocoid
Milky emul 0.1%		100 ml OP	✓ L	ocoid Crelo
METHYLPREDNISOLONE ACEPONATE				
Crm 0.1%		15 g OP	🗸 A	Advantan
Oint 0.1%		15 g OP		Advantan
		10 9 01		

DERMATOLOGICALS

	Subsidy		Fully Brand or
	(Manufacturer's P \$	rice) Subs Per	idised Generic Manufacturer
MOMETASONE FUROATE			
Crm 0.1%	1.51	15 g OP	 Elocon Alcohol Free
	2.50	50 g OP	 Elocon Alcohol Free
Oint 0.1%	1.51	15 g OP	 Elocon
	2.90	50 g OP	 <u>Elocon</u>
Lotn 0.1%	6.30	30 ml OP	 Elocon
TRIAMCINOLONE ACETONIDE			
Crm 0.02%		100 g OP	 Aristocort
Oint 0.02%	6.35	100 g OP	✓ <u>Aristocort</u>
Corticosteroids - Combination			
BETAMETHASONE VALERATE WITH CLIOQUINOL - Only on	a prescription		
Crm 0.1% with clioquinol 3%		15 g OP	
,	(4.90)	0	Betnovate-C
BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUS	SIDIC ACID		
Crm 0.1% with sodium fusidate (fusidic acid) 2%		15 g OP	
	(10.45)	•	Fucicort
 a) Maximum of 15 g per prescription 			
 b) Only on a prescription 			
HYDROCORTISONE WITH MICONAZOLE - Only on a prescript	tion		
* Crm 1% with miconazole nitrate 2%	2.00	15 g OP	✓ Micreme H
HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN - O	nly on a prescrip	tion	
Crm 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP	 Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	3.35	15 g OP	 Pimafucort
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCI	N AND NYSTAT	ΊN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg			
and gramicidin 250 mcg per g – Only on a prescription		15 g OP	
	(6.60)		Viaderm KC
Disinfecting and Cleansing Agents			
CHLORHEXIDINE GLUCONATE – Subsidy by endorsement			
a) No more than 500 ml per month			
b) Only if prescribed for a dialysis patient and the prescriptio	n is endorsed ac	cordingly.	
* Handrub 1% with ethanol 70%	4.29	500 ml	 healthE
* Soln 4% wash	3.98	500 ml	 healthE
TRICLOSAN – Subsidy by endorsement			
 a) Maximum of 500 ml per prescription b) 			
a) Only if prescribed for a patient identified with Methic	illin-resistant Sta	phylococcus a	ureus (MRSA) prior to elective
surgery in hospital and the prescription is endorsed			
b) Only if prescribed for a patient with recurrent Staphy		s infection and t	he prescription is endorsed
accordingly			• · · · · -
Soln 1%	5.90	500 ml OP	 healthE

	Subsidy		Fully Brand or
	(Manufacturer's		idised Generic
	\$	Per	 Manufacturer
Barrier Creams and Emollients			
Barrier Creams			
DIMETHICONE			6 -
* Crm 5% pump bottle	4.48	500 ml OP	✓ <u>healthE</u>
			Dimethicone 5%
* Crm 10% pump bottle	4.52	500 ml OP	✓ <u>healthE</u>
			Dimethicone 10%
ZINC AND CASTOR OIL			
* Oint	4.25	500 g	✓ Boucher
Emollients			
AQUEOUS CREAM			
* Crm		500 g	✓ Boucher
CETOMACROGOL			
* Crm BP	0.49	500 g	✓ healthE
	2.40	500 g	
CETOMACROGOL WITH GLYCEROL		500 100	
Crm 90% with glycerol 10%		500 ml OP	 Boucher Blackber
	2.82		 Pharmacy Health Control on a with
			Sorbolene with
	0.40	1 000	Glycerin
	3.10	1,000 ml OP	 Boucher Blackber
	3.87		 Pharmacy Health Control on a with
			Sorbolene with
			Glycerin
(Pharmacy Health Sorbolene with Glycerin Crm 90% with glyce			
(Pharmacy Health Sorbolene with Glycerin Crm 90% with glyce	rol 10% to be del	isted i March 20)20)
EMULSIFYING OINTMENT			•
* Oint BP	3.59	500 g	✓ <u>AFT</u>
OIL IN WATER EMULSION			
* Crm	2.19	500 g	 O/W Fatty Emulsion
			Cream
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50%	5.35	500 ml OP	✓ healthE
UREA		-	
* Crm 10%	1.37	100 g OP	✓ healthE Urea Cream
		100 g 01	
WOOL FAT WITH MINERAL OIL – Only on a prescription	E 60	1 000	
* Lotn hydrous 3% with mineral oil		1,000 ml	DD Lation
	(11.95)	250 ml OP	DP Lotion
	1.40	250 III UP	DP Lotion
	(4.53) 5.60	1,000 ml	
	5.60 (20.53)	1,000 111	Alpha-Keri Lotion
	(20.53) (23.91)		BK Lotion
	(23.91) 1.40	250 ml OP	DI LUUUI
	(7.73)	200 mi OP	BK Lotion
	(1.13)		DIX LOUOT

DERMATOLOGICALS

	Subsidy (Manufacturer's Pri \$	ice) Subs Per	Fully Brand or idised Generic ✓ Manufacturer
Other Dermatological Bases			
ARAFFIN White soft – Only in combination	20.20 3.58 (7.78) (8.69)	2,500 g 500 g	✓ IPW IPW PSM
Only in combination with a dermatological galenical or a PSM White soft to be delisted 1 May 2020)	is a diluent for a pr	oprietary Topi	cal Corticosteroid – Plain.
Minor Skin Infections			
OVIDONE IODINE			
Oint 10% a) Maximum of 100 g per prescription b) Only on a prescription	3.27	25 g OP	 Betadine
b) Only on a prescription Antiseptic soln 10%	2.55	100 ml	✓ Riodine
	3.83	15 ml	✓ Riodine
	5.40	500 ml	✓ Riodine
	6.20		 Betadine
	1.28	100 ml	
	(13.27)		Betadine
	0.19	15 ml	
	(7.41)		Betadine
Skin preparation, povidone iodine 10% with 30% alcohol	10.00	500 ml	 Betadine Skin Prep
	1.63	100 ml	
	(3.48)		Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol	1.63	100 ml	
	(6.64)		Pfizer
Betadine Antiseptic soln 10% to be delisted 1 February 2020) Betadine Antiseptic soln 10% to be delisted 1 February 2020) Betadine Antiseptic soln 10% to be delisted 1 February 2020)			
Parasiticidal Preparations			
IMETHICONE			
Eotn 4%		200 ml OP	✓ <u>healthE</u> <u>Dimethicone 4%</u> <u>Lotion</u>
/ERMECTIN – Special Authority see SA1225 on the next page			6 a b b b b b b b b b b
Tab 3 mg – Up to 100 tab available on a PSO		4	 Stromectol
 PSO for institutional use only. Must be endorsed a valid Special Authority for patient of that institution Ivermectin available on BSO provided the BSO indications For the purposes of subsidy of ivermectin, institution 	on. cludes a valid Spec	cial Authority f	or a patient of the institution.

 For the purposes of subsidy of ivermectin, institution means age related residential care facilities, disability care facilities or prisons.

(Subsidy Manufacturer's Price)	F	ully	Brand or Generic
(\$	Per	✓	Manufacturer

⇒SA1225 Special Authority for Subsidy

Initial application — (Scables) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Initial application — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:

continued...

Subsidy (Manufacturer's Price)	Ful Subsidise	,	
\$	Per •	Manufacturer	

continued...

- 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
- 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
- 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.
- Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria: Any of the following:

- 1 Filaricides; or
- Cutopoous longer
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

PERMETHRIN

Crm 5% Lotn 5%		30 g OP 30 ml OP	 ✓ <u>Lyderm</u> ✓ <u>A-Scabies</u>
PHENOTHRIN Shampoo 0.5%	11.36	200 ml OP	✓ Parasidose

Psoriasis and Eczema Preparations

ACITRETIN - Special Authority see SA1476 below - Retail pha	armacy		
Cap 10 mg		60	 Novatretin
Cap 25 mg	41.36	60	✓ Novatretin

⇒SA1476 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the safety issues around acitretin and is competent to prescribe acitretin; and 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
- 2 Patient is male.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Gel 500 mcg with calcipotriol 50 mcg per g52.24 Oint 500 mcg with calcipotriol 50 mcg per g19.95	60 g OP 30 g OP	 ✓ <u>Daivobet</u> ✓ <u>Daivobet</u>
CALCIPOTRIOL Oint 50 mcg per g45.00	100 g OP	✓ Daivonex

*Three months or six months, as applicable, dispensed all-at-once

DERMATOLOGICALS

	Subsidy (Manufacturer's P \$	rice) Subs Per	Fully Brand or sidised Generic ✓ Manufacturer
COAL TAR			
Soln BP – Only in combination		200 ml	 Midwest
a)			
 Up to 10% only in combination with a dermatol With or without other dermatological galenicals 		oprietary Topic	al Corticosteriod – Plain
 b) Midwest to be Sole Supply on 1 November 2019 	•		
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SUL	PHIIR		
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and			
allantoin crm 2.5%		75 g OP	
	(8.00)		Egopsoryl TA
	3.43	30 g OP	
	(4.35)		Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Soln 12% with salicylic acid 2% and sulphur 4% oint		25 g OP	✓ Coco-Scalp
	7.95	40 g OP	 Coco-Scalp
PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORE			
* Soln 2.3% with trolamine laurilsulfate and fluorescein sodium	13.86	500 ml	Pinetarsol
SALICYLIC ACID	10.00	050	/ Mildurent
Powder – Only in combination		250 g	 ✓ Midwest ✓ PSM
 Only in combination with a dermatological base or With or without other dermatological galenicals. 	proprietary Topic	cal Corticosterc	id – Plain or collodion flexible
SULPHUR			
Precipitated – Only in combination	6.35	100 g	 Midwest
1) Only in combination with a dermatological base or	proprietary Topic	al Corticostero	oid – Plain
2) With or without other dermatological galenicals.			
Seela Drenerations			
Scalp Preparations			
BETAMETHASONE VALERATE			
* Scalp app 0.1%	7.75	100 ml OP	 Beta Scalp
CLOBETASOL PROPIONATE			
* Scalp app 0.05%	5.69	30 ml OP	 Dermol
Dermol to be Sole Supply on 1 November 2019			

KETOCONAZOLE

68

Shampoo 2%.....2.99 a) Maximum of 100 ml per prescription

b) Only on a prescription

HYDROCORTISONE BUTYRATE

100 ml OP

100 ml OP

Locoid

✓ Sebizole

UNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly. Crm					
\$ Per ✓ Manufacturer SunscreenS UNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly. Crm				. ,	
Sunscreens UNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly. Crm		· ·		sidised	
UNSCREENS, PROPRIETARY – Subsidy by endorsement Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly. Crm		\$	Per		Manufacturer
Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly. Crm	Sunscreens				
endorsed accordingly. Crm	SUNSCREENS, PROPRIETARY – Subsidy by endorsement				
(5.89) Hamilton Sunscreen Lotn,		secondary to a defir	ned clinical co	ondition	and the prescription is
Lotn,	Crm	3.30	100 g OP		
Hamilton Sunscreen Crm to be delisted 1 March 2020) Wart Preparations or salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 67 MIQUIMOD Crm 5%, 250 mg sachet 21.72 24 Perrigo ODOPHYLLOTOXIN Soln 0.5% Anximum of 3.5 ml per prescription b) Only on a prescription b) Only on a prescription b) Other Skin Preparations Antineoplastics LUOROURACIL SODIUM		()			
Hamilton Sunscreen Crm to be delisted 1 March 2020) Wart Preparations or salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 67 MIQUIMOD Crm 5%, 250 mg sachet	Lotn,	5.10	200 g OP		
Wart Preparations or salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 67 MIQUIMOD Crm 5%, 250 mg sachet DODPHYLLOTOXIN Soln 0.5% Aliximum of 3.5 ml per prescription b) Only on a prescription Cother Skin Preparations Antineoplastics LUOROURACIL SODIUM					SPF 50+
or salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 67 MIQUIMOD Crm 5%, 250 mg sachet	Hamilton Sunscreen Crm to be delisted 1 March 2020)				
or salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 67 MIQUIMOD Crm 5%, 250 mg sachet					
MIQUIMOD Cm 5%, 250 mg sachet	Wart Preparations				
MIQUIMOD Cm 5%, 250 mg sachet			2		
Crm 5%, 250 mg sachet		MA PREPARATION	5, page 67		
ODOPHYLLOTOXIN Soln 0.5%		04 70			
Soln 0.5%	6	21./2	24	✓ Pe	errigo
a) Maximum of 3.5 ml per prescription b) Only on a prescription Other Skin Preparations Antineoplastics LUOROURACIL SODIUM					
b) Only on a prescription Other Skin Preparations Antineoplastics LUOROURACIL SODIUM			3.5 ml OP	✓ C	ondyline
Other Skin Preparations Antineoplastics LUOROURACIL SODIUM					
Antineoplastics	b) Only on a prescription				
Antineoplastics					
LUOROURACIL SODIUM	Other Skin Preparations				
LUOROURACIL SODIUM	Antinoonlactics				
	Anuneopiasues				
Crm 5%7.95 20 g OP 🖌 <u>Efudix</u>	FLUOROURACIL SODIUM				
	Crm 5%	7.95	20 g OP	✓ El	iudix

DERMATOLOGICALS

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
 \$	Per	1	Manufacturer

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic \$ Per Manufacturer **Contraceptives - Non-hormonal** Condoms CONDOMS * 49 mm - Up to 144 dev available on a PSO 11.42 ✓ Moments 144 ✓ Shield 49 13.36 ✓ Moments 10 Gold Knight 12 1.11 11.64 144 ✓ Moments ✓ Shield Blue 13.36 a) Maximum of 60 dev per prescription b) Up to 60 dev available on a PSO 144 Gold Knight a) Maximum of 60 dev per prescription b) Up to 60 dev available on a PSO * 53 mm (strawberry) 13.36 144 Gold Knight a) Maximum of 60 dev per prescription b) Up to 60 dev available on a PSO * 53 mm. 0.05 mm thickness......0.95 10 ✓ Moments Moments 11.42 144 a) Up to 60 dev available on a PSO b) Maximum of 60 dev per prescription 53 mm, chocolate, brown0.95 10 ✓ Moments * 11.64 144 ✓ Moments a) Up to 60 dev available on a PSO b) Maximum of 60 dev per prescription * 53 mm, strawberry, red.....0.95 ✓ Moments 10 11.64 144 ✓ Moments a) Up to 60 dev available on a PSO b) Maximum of 60 dev per prescription ✓ Moments 10 ✓ Moments 11.64 144 ✓ Durex Extra Safe 13.36 Gold Knight a) Maximum of 60 dev per prescription b) Up to 60 dev available on a PSO * 56 mm, 0.05 mm thickness.....1.30 12 Gold Knight 144 Gold Knight 15.57 a) Up to 60 dev available on a PSO b) Maximum of 60 dev per prescription * 56 mm. 0.08 mm thickness......0.97 10 ✓ Moments 11.64 144 Moments a) Up to 60 dev available on a PSO b) Maximum of 60 dev per prescription * 56 mm, 0.08 mm thickness, red0.97 Moments 10 11.64 ✓ Moments 144 a) Up to 60 dev available on a PSO b) Maximum of 60 dev per prescription 12 Gold Knight Gold Knight 15.57 144

a) Up to 60 dev available on a PSO

A Three Hontrasinppy maged and the second se

 $\ensuremath{\boldsymbol{\star}}$ Three months or six months, as applicable, dispensed all-at-once

GENITO-URINARY SYSTEM

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
* 56 mm, shaped	13.36 (16.08)	144		Durex Confidence
a) Maximum of 60 dev per prescription				
b) Up to 60 dev available on a PSO	1.00	10		Cold Knight
* 56 mm, strawberry	1.30 15.57	12 144		Gold Knight Gold Knight
a) Up to 60 dev available on a PSOb) Maximum of 60 dev per prescription	13.57	144	·	dold Knight
# 60 mm – Up to 144 dev available on a PSO	13.36	144	1	Shield XL
(Shield 49 49 mm to be delisted 1 March 2020) (Gold Knight 53 mm to be delisted 1 March 2020) (Shield Blue 53 mm to be delisted 1 March 2020) (Gold Knight 53 mm (chocolate) to be delisted 1 March 2020) (Gold Knight 53 mm (strawberry) to be delisted 1 March 2020) (Durex Extra Safe 56 mm to be delisted 1 March 2020) (Gold Knight 56 mm to be delisted 1 March 2020) (Durex Confidence 56 mm, shaped to be delisted 1 March 2020)				
Contraceptive Devices				
INTRA-UTERINE DEVICE a) Up to 40 dev available on a PSO b) Only on a PSO				
# IUD 29.1 mm length × 23.2 mm width Choice TT380 Short to be Sole Supply on 1 November 2		1	1	Choice TT380 Short
# IUD 33.6 mm length × 29.9 mm width	18.45	1	1	Choice TT380 Standard
Choice TT380 Standard to be Sole Supply on 1 November # IUD 35.5 mm length × 19.6 mm width Choice Load 375 to be Sole Supply on 1 November 2019		1	1	Choice Load 375

Contraceptives - Hormonal

Combined Oral Contraceptives

⇒SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

continued...

Subsidy Fully Brand or (Manufacturer's Price) Subsidised Generic Per Manufacturer \$ continued... The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999. Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either: · on a Social Welfare benefit; or • have an income no greater than the benefit. The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED ETHINYI OESTBADIOL WITH DESOGESTBEL 84 Mercilon 28 (19.80)a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 on the previous page b) Up to 84 tab available on a PSO * Tab 30 mcg with desogestrel 150 mcg and 7 inert tab......6.62 84 Marvelon 28 (19.80)a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 on the previous page b) Up to 84 tab available on a PSO ETHINYLOESTRADIOL WITH LEVONORGESTREL * Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets -Up to 112 tab available on a PSO2.18 84 Microgynon 20 ED ✓ Femme-Tab ED 6.45 112 Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab - Up * 84 Microaynon 50 ED to 84 tab available on a PSO......9.45 * Tab 30 mcg with levonorgestrel 150 mcg......6.62 63 (16.50)Microgynon 30 a) Higher subsidy of \$15.00 per 63 tab with Special Authority see SA0500 on the previous page b) Up to 63 tab available on a PSO * Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets - Levlen ED 84 ✓ Femme-Tab ED 112 6.45 ETHINYI OESTBADIOL WITH NOBETHISTEBONE Tab 35 mcg with norethisterone 1 mg – Up to 63 tab available ✓ Brevinor 1/21 63 * Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO......6.95 Brevinor 1/28 84 Tab 35 mcg with norethisterone 500 mcg – Up to 63 tab * available on a PSO......6.62 63 Brevinor 21 * Tab 35 mcg with norethisterone 500 mcg and 7 inert tab - Up to 84 tab available on a PSO......6.62 84 Norimin (Brevinor 1/21 Tab 35 mcg with norethisterone 1 mg to be delisted 1 July 2020)

GENITO-URINARY SYSTEM

(Brevinor 21 Tab 35 mcg with norethisterone 500 mcg to be delisted 1 July 2020)

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

Progestogen-only Contraceptives

⇒SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

1.1 Patient is on a Social Welfare benefit; or

1.2 Patient has an income no greater than the benefit; and

2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient is on a Social Welfare benefit; or

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

• on a Social Welfare benefit; or

• have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

* Tab 30 mcg	6.62	84
	(16.50)	
a) Higher subsidy of \$13.80 per 84 tab with Special Aub) Up to 84 tab available on a PSO	thority see SA0500) above
✤ Subdermal implant (2 × 75 mg rods) - Up to 3 pack available	ble	
on a PSO		1
MEDROXYPROGESTERONE ACETATE		
Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a Depo-Provera to be Sole Supply on 1 December 2019	PSO7.98	1
NORETHISTERONE		
* Tab 350 mcg – Up to 84 tab available on a PSO	6.25	84

Emergency Contraceptives

LEVONORGESTREL

- * Tab 1.5 mg4.95
 - a) Maximum of 2 tab per prescription
 - b) Up to 5 tab available on a PSO

c) Note: Direct Provision by a pharmacist permitted under the provisions in Part I of Section A.

1

Microlut

Jadelle

Depo-Provera

Noriday 28

✓ Postinor-1

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's P \$	rice) Subs Per	Fully Brand or idised Generic Manufacturer
Antiandrogen Oral Contraceptives			
 Prescribers may code prescriptions "contraceptive" (code "O") wh and prescription charge will be as per other contraceptives, as fol \$5.00 prescription charge (patient co-payment) will apply. prescriptions coded in any other way are subject to the non contr of supply. ie. Prescriptions may be written for up to three month CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL * Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs - U to 168 tab available on a PSO. 	llows: aceptive prescrip s supply. p		
Gynaecological Anti-infectives			
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC . Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphat 0.025%, glycerol 5% and ricinoleic acid 0.75% with appli	e	100 g OP	Aci-Jel
CLOTRIMAZOLE * Vaginal crm 1% with applicators	2.50	35 g OP	 Clomazol
Clomazol to be Sole Supply on 1 January 2020 * Vaginal crm 2% with applicators Clomazol to be Sole Supply on 1 January 2020		20 g OP	 Clomazol
MICONAZOLE NITRATE * Vaginal crm 2% with applicator		40 g OP	✓ <u>Micreme</u>
NYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s)	4.45	75 g OP	✓ <u>Nilstat</u>
Myometrial and Vaginal Hormone Preparations			
ERGOMETRINE MALEATE			
Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a PSO		5	✓ DBL Ergometrine
OESTRIOL * Crm 1 mg per g with applicator * Pessaries 500 mcg		15 g OP 15	✓ <u>Ovestin</u> ✓ <u>Ovestin</u>
OXYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml ampoule Inj 10 iu per ml, 1 ml ampoule		5 5	 ✓ <u>Oxytocin BNM</u> ✓ Oxytocin BNM
OXYTOCIN WITH ERGOMETRINE MALEATE – Up to 5 inj avai Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml	lable on a PSO	5	✓ Syntometrine
Pregnancy Tests - hCG Urine			
PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO			
Cassette	12.00	40 test OP	 <u>Smith BioMed Rapid</u> <u>Pregnancy Test</u>

	Subsidy cturer's Price) \$	Sub Per	Fully osidised	Brand or Generic Manufacturer
Urinary Agents				
For urinary tract Infections refer to INFECTIONS, Antibacterials, page 10	7			
5-Alpha Reductase Inhibitors				
INASTERIDE – Special Authority see SA0928 below – Retail pharmacy ★ Tab 5 mg	4.81	100 val unles	✓ <u>F</u> ss notifie	
 Patient has symptomatic benign prostatic hyperplasia; and Either: The patient is intolerant of non-selective alpha blockers or Symptoms are not adequately controlled with non-selective Idea: Patients with enlarged prostates are the appropriate candidates for 	e alpha blocke	rs.		
Alpha-1A Adrenoreceptor Blockers				
AMSULOSIN HYDROCHLORIDE – Special Authority see SA1032 belo ★ Cap 400 mcg	7.73 t further renew	100 val unles		amsulosin-Rex
Other Urinary Agents				
OXYBUTYNIN		500 73 ml		po-Oxybutynin po-Oxybutynin
Retail pharmacy	1.80 200	ml OP	✓ <u>B</u>	liomed
 SA1083 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid for 12 Both: The patient has recurrent calcium oxalate urolithiasis; and The patient has had more than two renal calculi in the two years p Renewal from any relevant practitioner. Approvals valid for 2 years when enefitting from the treatment.	rior to the app	lication.		
SODIUM CITRO-TARTRATE ₭ Grans eff 4 g sachets	2.34	28	√ U	Iral
OLIFENACIN SUCCINATE Tab 5 mg Tab 10 mg	3.00	30 30	✓ <u>s</u>	olifenacin Mylan olifenacin Mylan
76 Solo Subsidised S2	Unapproved	medicine	supplied	under Section 29

GENITO-URINARY SYSTEM

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's Price) \$		Fully Subsidised	
TOLTERODINE - Special Authority see SA1272 below - Retai	l pharmacy			
Tab 1 mg	14.56	56	✓	Arrow-Tolterodine
Tab 2 mg	14.56	56	✓	Arrow-Tolterodine
(Arrow-Tolterodine Tab 1 mg to be delisted 1 March 2020)				

► SA1272 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where patient has overactive bladder and a documented intolerance of, or is non-responsive to oxybutynin.

Detection of Substances in Urine

ORTHO-TOLIDINE

* Compound diagnostic sticks	7.50	50 test OP	
	(8.25)		Hemastix
TETRABROMOPHENOL			
* Blue diagnostic strips	7.02	100 test OP	
	(13.92)		Albustix

	Subsidy (Manufacturer's Price) \$	Sub: Per	Fully sidised	Brand or Generic Manufacturer
Calcium Homeostasis				
CALCITONIN				
* Inj 100 iu per ml, 1 ml ampoule		5	🗸 N	liacalcic
CINACALCET – Special Authority see SA1618 below – Retail Tab 30 mg – Wastage claimable		28	✓ <u>s</u>	ensipar
▶ SA1618 Special Authority for Subsidy Initial application only from a nephrologist or endocrinologist. following criteria: Either:	Approvals valid for 6 n	nonths for	applica	tions meeting the
1 All of the following:				
 1.1 The patient has been diagnosed with a parathyr 1.2 The patient has persistent hypercalcaemia (seru first-line treatments including sodium thiosulfate 1.3 The patient is symptomatic; or 2 All of the following: 	m calcium greater than	or equal t		/ ! !
 2.1 The patient has been diagnosed with calciphylax 2.2 The patient has symptomatic (e.g. painful skin u 3 mmol/L); and 2.3 The patient's condition has not responded to pre thiosulfate. 	ulcers) hypercalcaemia	(serum ca	lcium g	
Renewal only from a nephrologist or endocrinologist. Approva meeting the following criteria: Both:	Is valid without further r	renewal u	nless no	tified for applications
 The patient's serum calcium level has fallen to < 3mmo The patient has experienced clinically significant symptomic 				
Note: This does not include parathyroid adenomas unless the	se have become malign	ant.		
ZOLEDRONIC ACID				
Inj 4 mg per 5 ml, vial – Special Authority see SA1687 bel Retail pharmacy		1	✓ <u>Z</u>	<u>oledronic acid</u> <u>Mylan</u>
► SA1687 Special Authority for Subsidy Initial application — (bone metastases) only from an oncolo without further renewal unless notified for applications meeting Any of the following:	gist, haematologist or p the following criteria:	alliative c	are spe	cialist. Approvals valid
 Patient has hypercalcaemia of malignancy; or Both: 				
2.1 Patient has bone metastases or involvement; an2.2 Patient has severe bone pain resistant to standa		or		
3 Both:				
3.1 Patient has bone metastases or involvement; an3.2 Patient is at risk of skeletal-related events patho surgery to bone.		ord comp	ression,	, radiation to bone or

Initial application — (early breast cancer) only from an oncologist or medical practitioner on the recommendation of a oncologist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

 Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
 \$	Per 🗸	Manufacturer

continued...

- 1 Treatment to be used as adjuvant therapy for early breast cancer; and
- 2 Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
- 3 Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

Corticosteroids and Related Agents for System	nic Use		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETH	ASONE ACETA	ſF	
Ini 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml		5	
	(36.96)	Ũ	Celestone
	(00.00)		Chronodose
			Onionodobo
EXAMETHASONE			
Tab 0.5 mg – Retail pharmacy-Specialist	0.99	30	 Dexmethsone
Up to 60 tab available on a PSO			
 Tab 4 mg – Retail pharmacy-Specialist 	1.90	30	 Dexmethsone
Up to 30 tab available on a PSO			
Oral liq 1 mg per ml – Retail pharmacy-Specialist	45.00	25 ml OP	 Biomed
Oral liq prescriptions:			
1) Must be written by a Paediatrician or Paediatric C	ardiologist; or		
2) On the recommendation of a Paediatrician or Pae	diatric Cardiologi	st.	
,			
EXAMETHASONE PHOSPHATE			
Dexamethasone phosphate injection will not be funded for o		10	
Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a F		10	 Max Health
Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a F	PSO25.18	10	 Max Health
LUDROCORTISONE ACETATE			
F Tab 100 mcg		100	 Florinef
YDROCORTISONE			
← Tab 5 mg	0.10	100	Develop
5			✓ <u>Douglas</u>
Tab 20 mg		100	✓ <u>Douglas</u>
Inj 100 mg vial	5.30	1	 Solu-Cortef
a) Up to 5 inj available on a PSO			
b) Only on a PSO			
ETHYLPREDNISOLONE – Retail pharmacy-Specialist			
F Tab 4 mg		100	 Medrol
F Tab 100 mg		20	✓ Medrol
ETHYLPREDNISOLONE (AS SODIUM SUCCINATE) – Reta			<u></u>
			Colu Modrol Ast
Inj 40 mg vial		1	Solu-Medrol-Act-
			<u>O-Vial</u>
Ini 105 ma vial	00.00	4	Colu Modrol Ast
Inj 125 mg vial	28.90	1	✓ <u>Solu-Medrol-Act-</u>
			<u>O-Vial</u>
Ini 500 ma vial	00.70	1	Colu Modrol Act
Inj 500 mg vial		I	✓ <u>Solu-Medrol-Act-</u>
			<u>O-Vial</u>
	07 00	4	Colu Modrol
Inj 1 g vial	27.83	1	Solu-Medrol
ETHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml vial		5	Depo-Medrol
	UF.FFV	Ū	- Bopo mouloi

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully Brand or sidised Generic Manufacturer
PREDNISOLONE ★ Oral liq 5 mg per mI – Up to 30 ml available on a PSO Restricted to children under 12 years of age.	6.00	30 ml OP	✓ <u>Redipred</u>
PREDNISONE			* • • • • •
₭ Tab 1 mg		500	Apo-Prednisone
Tab 2.5 mg		500	Apo-Prednisone
Tab 5 mg – Up to 30 tab available on a PSO		500	✓ <u>Apo-Prednisone</u>
 Tab 20 mg 		500	 <u>Apo-Prednisone</u>
ETRACOSACTRIN			
 Inj 250 mcg per ml, 1 ml ampoule 	75.00	1	 AU Synacthen
			 Synacthen
			 Synacthen S29 S29
Inj 1 mg per ml, 1 ml ampoule		1	 Synacthen Depot
			 Synacthene
			Retard S29
Inj 40 mg per ml, 1 ml ampoule Sex Hormones Non Contraceptive	51.10	5	✓ Kenacort-A 40
Androgen Agonists and Antagonists			
••••			
••••	13.17	50	✓ Siterone
YPROTERONE ACETATE – Retail pharmacy-Specialist		50 50	 ✓ <u>Siterone</u> ✓ <u>Siterone</u>
YPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg			
YPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg ESTOSTERONE		50	✓ <u>Siterone</u>
YPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg ESTOSTERONE Patch 5 mg per day			
YPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg ESTOSTERONE Patch 5 mg per day ESTOSTERONE CIPIONATE – Retail pharmacy-Specialist		50 30	 ✓ <u>Siterone</u> ✓ Androderm
YPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg ESTOSTERONE Patch 5 mg per day ESTOSTERONE CIPIONATE – Retail pharmacy-Specialist Inj 100 mg per ml, 10 ml vial.		50	✓ <u>Siterone</u>
YPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg ESTOSTERONE Patch 5 mg per day ESTOSTERONE CIPIONATE – Retail pharmacy-Specialist Inj 100 mg per ml, 10 ml vial ESTOSTERONE ESTERS – Retail pharmacy-Specialist	26.75 90.00 76.50	50 30	 ✓ <u>Siterone</u> ✓ Androderm ✓ <u>Depo-Testosterone</u>
YPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg ESTOSTERONE Patch 5 mg per day ESTOSTERONE CIPIONATE – Retail pharmacy-Specialist Inj 100 mg per ml, 10 ml vial	26.75 90.00 76.50	50 30	 ✓ <u>Siterone</u> ✓ Androderm
YPROTERONE ACETATE – Retail pharmacy-Specialist Tab 50 mg Tab 100 mg ESTOSTERONE Patch 5 mg per day ESTOSTERONE CIPIONATE – Retail pharmacy-Specialist Inj 100 mg per ml, 10 ml vial ESTOSTERONE ESTERS – Retail pharmacy-Specialist Inj 250 mg per ml, 1 ml		50 30 1	 ✓ <u>Siterone</u> ✓ Androderm ✓ <u>Depo-Testosterone</u>
Tab 100 mg ESTOSTERONE Patch 5 mg per day ESTOSTERONE CIPIONATE – Retail pharmacy-Specialist Inj 100 mg per ml, 10 ml vial ESTOSTERONE ESTERS – Retail pharmacy-Specialist		50 30 1	 ✓ <u>Siterone</u> ✓ Androderm ✓ <u>Depo-Testosterone</u>

Hormone Replacement Therapy - Systemic

Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

80

	Subsidy		Fully	Brand or
	(Manufacturer's Price	e) Sul	bsidised	Generic
	\$	Per	1	Manufacturer
Oestrogens				
DESTRADIOL – See prescribing guideline on the previous page				
* Tab 1 mg		28 OP		
	(11.10)		E	Estrofem
* Tab 2 mg	4.12	28 OP		
	(11.10)		E	Estrofem
Patch 25 mcg per day	6.12	8	🗸 E	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
Patch 50 mcg per day	7.04	8	✓ E	Estradot 50 mcg
a) No more than 2 patch per week				
b) Only on a prescription				
Patch 75 mcg per day	7.91	8	✓ 1	Estradot
a) No more than 2 patch per week				
b) Only on a prescription	7.04	0		
Patch 100 mcg per day		8	•	Estradot
a) No more than 2 patch per week				
b) Only on a prescription				
DESTRADIOL VALERATE – See prescribing guideline on the pr				_
₭ Tab 1 mg		84		Progynova
₭ Tab 2 mg		84	✓ [Progynova
DESTROGENS – See prescribing guideline on the previous pag				
Conjugated, equine tab 300 mcg		28		
	(13.50)		F	Premarin
 Conjugated, equine tab 625 mcg 		28)
	(13.50)		ł	Premarin
Progestogens				
IEDROXYPROGESTERONE ACETATE - See prescribing guid	deline on the previo	us page		
₭ Tab 2.5 mg		30	✓ F	Provera
* Tab 5 mg		100		Provera
🖌 Tab 10 mg	7.15	30	🗸 F	Provera
Progestogen and Oestrogen Combined Prepara	tions			
DESTRADIOL WITH NORETHISTERONE – See prescribing gu				
* Tab 1 mg with 0.5 mg norethisterone acetate	5.40 (18.10)	28 OP	L	liovanaa
* Tab 2 mg with 1 mg norethisterone acetate	()	28 OP	r	Kliovance
► Tab 2 mg with t mg notethisterone acetate	(18.10)	20 01	L	Kliogest
★ Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg	(10.10)			lingest
oestradiol tab (12) and 1 mg oestradiol tab (6)	5 40	28 OP		
	(18.10)	20 01	٦	Frisequens
	()			
Other Oestrogen Preparations				
ETHINYLOESTRADIOL	17.00	100		17 Madiaal cond
* Tab 10 mcg	17.60	100	√ [NZ Medical and
				<u>Scientific</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Su Per	Ibsidised	Generic Manufacturer
OESTRIOL				
* Tab 2 mg	7.00	30	✓ (Ovestin
Other Progestogen Preparations				
LEVONORGESTREL				
Intra-uterine system 20 mcg per day – Special Authority see SA1608 below – Retail pharmacy	269.50	1	√	Mirena
■ SA1608 Special Authority for Subsidy Initial application — (No previous use) only from a relevant special applications meeting the following criteria:	ecialist or general pra	actitione	r. Appro	ovals valid for 6 months for
 All of the following: 1 The patient has a clinical diagnosis of heavy menstrual ble 2 The patient has failed to respond to or is unable to tolerate Menstrual Bleeding Guidelines; and 3 Either: 		armace	eutical the	erapies as per the Heavy
3.1 serum ferritin level $<$ 16 mcg/l (within the last 12 m 3.2 haemoglobin level $<$ 120 g/l.	onths); or			
Note: Applications are not to be made for use in patients as contr Renewal only from a relevant specialist or general practitioner. A following criteria: Both:				
 Either: Patient demonstrated clinical improvement of heavy Previous insertion was removed or expelled within 3 Applicant to state date of the previous insertion. 	0.			
MEDROXYPROGESTERONE ACETATE				
Tab 100 mg – Retail pharmacy-Specialist	101.00	100	✓	Provera HD
NORETHISTERONE	19.00	100		Primolut N
* Tab 5 mg – Up to 30 tab available on a PSO Primolut N to be Sole Supply on 1 January 2020		100	v	Primolul N
PROGESTERONE				
Cap 100 mg – Special Authority see SA1609 below – Retail				
pharmacy		30	v (Utrogestan
SA1609 Special Authority for Subsidy Initial application only from an obstetrician or gynaecologist. App following criteria: Both:	provals valid for 12 m	nonths f	or applic	ations meeting the
1 For the prevention of pre-term labour*; and 2 Either:				
2.1 The patient has a short cervix on ultrasound (define 2.2 The patient has a history of pre-term birth at less the		to 28 we	eeks); or	
Renewal only from an obstetrician or gynaecologist. Approvals va All of the following:		applica	ations me	eeting the following criteria:
 For the prevention of pre-term labour*; and Treatment is required for second or subsequent pregnancy 	; and			

- 3 Either:
 - 3.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
- 3.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are unapproved indications.

	Subsidv		Fully	Brand or
	(Manufacturer's Price)		Subsidised	
	(Wahalactarer 3 1 nee) \$	Per		Manufacturer
Thyroid and Antithyroid Agents				
CARBIMAZOLE				
* Tab 5 mg		100	1	AFT
5				Carbimazole S29
			1	Neo-Mercazole
LEVOTHYROXINE				
* Tab 25 mcg		90	1	Synthroid
* Tab 50 mcg		28		Mercury Pharma
5	4.05	90		Synthroid
	64.28	1,000	1	Eltroxin
* Tab 100 mcg	1.78	28	✓	Mercury Pharma
	4.21	90	1	Synthroid
	66.78	1,000	1	Eltroxin
PROPYLTHIOURACIL – Special Authority see SA1199 below	v – Retail pharmacy			
Propylthiouracil is not recommended for patients under th treatments are contraindicated.	e age of 18 years unles	s the p	atient is p	regnant and other
Tab 50 mg		100	1	PTU S29
SA1199 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals	alid for 2 years for appl	ication	s meeting	the following criteria:
Both:				5
1 The patient has hyperthyroidism; and				
2. The patient is intelerant of earhimazele or earhimazele	in contraindicated			

2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones

Growth Hormones

SO	MATROPIN (OMNITROPE) - Special Authority see SA1629 below	- Retail pharma	acy	
*	Inj 5 mg cartridge	34.88	1	 Omnitrope
*	Inj 10 mg cartridge	69.75	1	 Omnitrope
*	Inj 15 mg cartridge	104.63	1	 Omnitrope

► SA1629 Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria: Either:

1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

2 All of the following:

- Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
- 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

children who are 5 years or older, GH testing with sex steroid priming is required; and

- 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
- 2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and
- 3 A current bone age is 14 years or under ; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application - (short stature without growth hormone deficiency) only from a paediatric endocrinologist or

endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years or under (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and

continued...

84

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and</p>
- 3 A current bone age is to 14 years or under (female patients) or to 16 years or under (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and

6 Either:

- 6.1 The patient has a GFR less than or equal to 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l) × 40 = corrected GFR (ml/min/1.73m² in a child who may or may not be receiving dialysis; or
- 6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient is aged six months or older; and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 5 Either:

5.1 Both:

Subsidy (Manufacturer's Price)	Sul	Fully bsidised	Brand or Generic
 \$	Per	1	Manufacturer

continued...

- 5.1.1 The patient is aged two years or older; and
- 5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
- 5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
- 3 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type I diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

86

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within ±1SD of the mean of the normal range for age and sex; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
 \$	Per 🗸	

continued...

1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or 2 All of the following:

- 2.1 The patient has been treated with somatropin for more than 12 months; and
- 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
- 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
- 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

GnRH Analogues

OSERELIN			
Implant 3.6 mg, syringe		1	 Zoladex
Implant 10.8 mg, syringe	177.50	1	 Zoladex

LEUPRORELIN

G

Additional subsidy by endorsement where the patient is a child or adolescent and is unable to tolerate administration of goserelin and the prescription is endorsed accordingly.

Inj 3.75 mg prefilled dual chamber syringe - Higher subsidy of			
\$221.60 per 1 inj with Endorsement	66.48	1	
	(221.60)		Lucrin Depot 1-month
Inj 11.25 mg prefilled dual chamber syringe – Higher subsidy			
of \$591.68 per 1 inj with Endorsement	177.50	1	
	(591.68)		Lucrin Depot 3-month

Vasopressin Agonists

DESMOPRESSIN ACETATE			
Tab 100 mcg – Special Authority see SA1401 below – Retail pharmacy	25.00	30	✓ Minirin
 Tab 200 mcg – Special Authority see SA1401 below – Retail pharmacy ▲ Nasal drops 100 mcg per ml – Retail pharmacy-Specialist ▲ Nasal spray 10 mcg per dose – Retail pharmacy-Specialist 	39.03	30 2.5 ml OP 6 ml OP	 ✓ Minirin ✓ Minirin ✓ <u>Desmopressin-</u> <u>PH&T</u>
Inj 4 mcg per ml, 1 ml – Special Authority see SA1401 below – Retail pharmacy	67.18	10	✓ Minirin

■SA1401 Special Authority for Subsidy

Initial application — (Desmopressin tablets for Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary nocturnal enuresis; and
- 2 The nasal forms of desmopressin are contraindicated; and
- 3 An enuresis alarm is contraindicated.

Initial application — (Desmopressin tablets for Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

continued...

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	1	Manufacturer	

continued...

1 The patient has cranial diabetes insipidus; and

2 The nasal forms of desmopressin are contraindicated.

Renewal — (Desmopressin tablets) from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from the treatment.

Initial application — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

Renewal — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Other Endocrine Agents

CABERGOLINE

		an be	ab 0.5 mg - Maximum of 2 tab per prescription; can be
 Dostinex 	2	3.75	waived by Special Authority see SA1370 below
 Dostinex 	8	15.20	

⇒SA1370 Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 pathological hyperprolactinemia; or

2 acromegaly*.

Renewal — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment. Note: Indication marked with * is an unapproved indication.

CLOMIFENE CITRATE

Tab 50 mg	29.84	10	 Mylan Clomiphen S29
DANAZOL	00.00	100	•
Cap 100 mg Cap 200 mg		100 100	✓ Azol ✓ Azol
METYRAPONE Cap 250 mg – Retail pharmacy-Specialist		50	 Metopirone

	0 1 1	-	
	Subsidy		ully Brand or
	(Manufacturer's Price) \$	Subsidis Per	sed Generic Manufacturer
	Ψ	1 61	• Manulacturer
Anthelmintics			
ALBENDAZOLE - Special Authority see SA1318 below - Retail	pharmacy		
Tab 400 mg		60	Eskazole S29
► SA1318 Special Authority for Subsidy			
Initial application only from an infectious disease specialist or of	clinical microbiologist.	Approvals v	alid for 6 months where the
patient has hydatids.			
Renewal only from an infectious disease specialist or clinical mir remains appropriate and the patient is benefitting from the treatm		ils valid for 6	months where the treatment
MEBENDAZOLE – Only on a prescription			
Tab 100 mg	24 10	24	✓ De-Worm
Oral lig 100 mg per 5 ml		15 ml	- De-Wollin
	(7.17)	10 11	Vermox
	(7.17)		Verniex
PRAZIQUANTEL	69.00	8	✓ Biltricide
Tab 600 mg		0	Bitricide
Antibacterials			
a) For topical antibacterials, refer to DERMATOLOGICALS, page	ue 59		
b) For anti-infective eye preparations, refer to SENSORY ORG			
Cephalosporins and Cephamycins			
CEFACLOR MONOHYDRATE Cap 250 mg	04.70	100	- Danhavy Cafaelar
1 5			 ✓ <u>Ranbaxy-Cefaclor</u> ✓ Ranbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml – Wastage claimable	4.33		✓ <u>Ranbaxy-Celacior</u>
	4.00		 Kelloi
CEFALEXIN			
Cap 250 mg		20	 Cephalexin ABM
Cephalexin ABM to be Sole Supply on 1 November 201		00	
Cap 500 mg			 Cephalexin ABM Contained and a second s
Grans for oral liq 25 mg per ml – Wastage claimable			✓ <u>Cefalexin Sandoz</u>
Note: Cefalexin grans for oral liq will not be funded in a			
Grans for oral liq 50 mg per ml – Wastage claimable			✓ <u>Cefalexin Sandoz</u>
Note: Cefalexin grans for oral liq will not be funded in a	mounts more than 14	uays treatme	ent per dispensing.
CEFAZOLIN – Subsidy by endorsement			
Only if prescribed for dialysis or cellulitis in accordance with	a DHB approved pro	tocol and the	prescription is endorsed
accordingly.		-	<pre>/</pre>
Inj 500 mg vial		5	✓ <u>AFT</u>
Inj 1 g vial		5	✓ <u>AFT</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
CEFTRIAXONE – Subsidy by endorsement				
 a) Up to 10 inj available on a PSO 				
b) Subsidised only if prescribed for a dialysis or cystic fibros				
pelvic inflammatory disease, or the treatment of suspecte	d meningococcal dise	ease	, and the p	rescription or PSO is
endorsed accordingly.	0.00			Ceftriaxone-AFT
Inj 500 mg vial	0.89 1.20	1		DEVA
Ceftriaxone-AFT to be Sole Supply on 1 January 2020	1.20		v	DEVA
Inj 1 g vial	0.84	1	1	DEVA
III) I Y VIAI	3.99	5		Ceftriaxone-AFT
Ceftriaxone-AFT to be Sole Supply on 1 January 2020	0.00	5	•	
(DEVA Inj 500 mg vial to be delisted 1 January 2020)				
(DEVA Inj 1 q vial to be delisted 1 January 2020)				
CEFUROXIME AXETIL – Subsidy by endorsement Only if prescribed for prophylaxis of endocarditis and the pre-	corintian is andorsad	2000	rdinaly	
Tab 250 mg		50		Zinnat
1 ab 230 mg		50	•	Zinnat
Macrolides				
AZITHROMYCIN – Maximum of 5 days treatment per prescriptio A maximum of 24 months of azithromycin treatment for non-or Authority.				
Tab 250 mg	8.19	30	1	Apo-Azithromycin
Tab 500 mg – Up to 8 tab available on a PSO	0.93	2	1	Apo-Azithromycin
Grans for oral liq 200 mg per 5 ml (40 mg per ml) - Wastage	9			
claimable	14.38	15 m	nl 🖌	Zithromax
► SA1683 Special Authority for Waiver of Rule				
Initial application — (bronchiolitis obliterans syndrome, cyst	ic fibrosis and atypi	cal I	Mycobacte	erium infections) only from
a relevant specialist. Approvals valid without further renewal unle				
Any of the following:			Ū	-
1 Patient has received a lung transplant, stem cell transplan bronchiolitis obliterans syndrome*; or	t, or bone marrow tra	nspla	ant and re	quires treatment for

- 2 Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
- 3 Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas-related gram negative organisms*; or
- 4 Patient has an atypical Mycobacterium infection.

Note: Indications marked with * are unapproved indications.

Initial application — (non-cystic fibrosis bronchiectasis*) only from a respiratory specialist or paediatrician. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
- 2 Patient is aged 18 and under; and
- 3 Either:

90

- 3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
- 3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications.

Subsidy		Fully	Brand or	
(Manufacturer's	Price) Sub	sidised	Generic	
\$	Per	1	Manufacturer	

continued...

months for applications meeting the following criteria:

All of the following:

- 1 The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
- 2 Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and
- 3 The patient will not receive more than a total of 24 months' azithromycin cumulative treatment (see note).

The patient must not have had more than 1 prior approval.

Note: No further renewals will be subsidised. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis bronchiectasis will be subsidised. Indications marked with * are unapproved indications

CLARITHROMYCIN - Maximum of 500 mg per prescription; can be waived by Special Authority see SA1131 below

Tab 250 mg		14	✓ <u>Apo-Clarithromycin</u>
Grans for oral liq 250 mg per 5 ml - Wastage claimab	le192.00	50 ml	 Klacid

⇒SA1131 Special Authority for Waiver of Rule

Initial application — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Atypical mycobacterial infection; or

2 Mycobacterium tuberculosis infection where there is drug-resistance or intolerance to standard pharmaceutical agents.

Renewal — (Mycobacterial infections) only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	1	 Erythrocin IV
	100	 E-Mycin
		,
5.00	100 ml	 E-Mycin
	100 111	
6 77	100 ml	 E-Mycin
0.77	100 111	
14.95	100	
(22.29)		ERA
	100	
(44.58)		ERA
8.29	10	Rulide D
8.28	50	Arrow-
		Roxithromycin
16.33	50	✓ Arrow-
		Roxithromycin

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$	e) : Per	Fully Subsidised	
Penicillins	Ψ	I CI		Wandlacturei
AMOXICILLIN				
Cap 250 mg		500	1	Apo-Amoxi
a) Up to 30 cap available on a PSO				•
b) Up to 10 x the maximum PSO guantity for RFPP				
Cap 500 mg		500	1	Apo-Amoxi
a) Up to 30 cap available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml	1.20	100 ml	✓	Alphamox 125
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq 250 mg per 5 ml	1.31	100 ml	✓	Alphamox 250
a) Up to 300 ml available on a PSO				
b) Up to 10 x the maximum PSO quantity for RFPP				
c) Wastage claimable				
Inj 250 mg vial		10		Ibiamox
Inj 500 mg vial		10		Ibiamox
Inj 1 g vial – Up to 5 inj available on a PSO	17.29	10	v	Ibiamox
AMOXICILLIN WITH CLAVULANIC ACID				
Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab				
available on a PSO		20	✓	Augmentin
Grans for oral liq amoxicillin 25 mg with clavulanic acid 6.25	mg			
per ml		100 ml	✓	Augmentin
a) Up to 200 ml available on a PSO				
b) Wastage claimable				
Grans for oral liq amoxicillin 50 mg with clavulanic acid 12.5				
per ml – Up to 200 ml available on a PSO	2.20 1	00 ml C	P 🗸	Curam
BENZATHINE BENZYLPENICILLIN				
Inj 900 mg (1.2 million units) in 2.3 ml syringe – Up to 5 inj				
available on a PSO		10	✓	Bicillin LA
BENZYLPENICILLIN SODIUM [PENICILLIN G]				
Inj 600 mg (1 million units) vial – Up to 5 inj available on a F	2SO 10.35	10	1	Sandoz
		10		<u>oundor</u>
Cap 250 mg – Up to 30 cap available on a PSO	16.83	250	1	Staphlex
Cap 500 mg		500		Staphlex
Grans for oral liq 25 mg per ml		100 ml		AFT
a) Up to 200 ml available on a PSO			-	<u> </u>
b) Wastage claimable				
Grans for oral liq 50 mg per ml		100 ml	1	AFT
a) Up to 200 ml available on a PSO			-	<u> </u>
b) Wastage claimable				
Inj 250 mg vial	9.00	10	1	Flucloxin
Inj 500 mg vial		10		Flucloxin
Inj 1 g vial – Up to 5 inj available on a PSO		5		Flucil

	Subsidy (Manufacturer's Price \$	e) Su Per	Fully bsidised	Brand or Generic Manufacturer
PHENOXYMETHYLPENICILLIN (PENICILLIN V) Cap 250 mg – Up to 30 cap available on a PSO	2.59	50	✓ c	ilicaine VK
Cap 500 mg	4.26	50	✓ C	ilicaine VK
a) Up to 20 cap available on a PSOb) Up to 2 x the maximum PSO quantity for RFPP				
Grans for oral liq 125 mg per 5 ml	2.99	100 ml	🗸 A	FT
 a) Up to 200 ml available on a PSO b) Wastage claimable c) AFT to be 2016 grant to be a set of the set of				
c) AFT to be Sole Supply on 1 January 2020	2.00	100 ml	🗸 A	
Grans for oral liq 250 mg per 5 ml	3.99	100 mi	✓ A	FI
a) Up to 300 ml available on a PSOb) Up to 2 x the maximum PSO quantity for RFPPc) Wastage claimable				
 d) AFT to be Sole Supply on 1 January 2020 				
PROCAINE PENICILLIN Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO.	123.50	5	✓ <u>c</u>	ilicaine
Tetracyclines				
DOXYCYCLINE				
* Tab 50 mg – Up to 30 tab available on a PSO		30		
3 1	(6.00)		D	oxy-50
* Tab 100 mg - Up to 30 tab available on a PSO	64.43	500	🗸 D	oxine
(Doxy-50 Tab 50 mg to be delisted 1 January 2020)				
MINOCYCLINE HYDROCHLORIDE				
* Tab 50 mg – Additional subsidy by Special Authority see				
SA1355 below – Retail pharmacy		60		
- ····································	(12.05)		N	lino-tabs
* Cap 100 mg		100		
	(52.04)		N	linomycin
➡SA1355 Special Authority for Manufacturers Price				
Initial application from any relevant practitioner. Approvals va	lid without further ren	ewal unle	ss notifie	d where the patient has
rosacea.				

► SA1332 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

1 For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy; and

2 For use only in combination with bismuth as part of a quadruple therapy regimen.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Other Antibiotics				
For topical antibiotics, refer to DERMATOLOGICALS, page 59				
CIPROFLOXACIN Recommended for patients with any of the following: i) microbiologically confirmed and clinically significant pse ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea.	eudomonas infection;	or		
Tab 250 mg – Up to 5 tab available on a PSO	1.45	28	1	Cipflox
Tab 500 mg – Up to 5 tab available on a PSO		28		Cipflox
Tab 750 mg	3.15	28	•	Cipflox
CLINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement - Retail				
pharmacy - Specialist	4.10	16		Clindamycin ABM
	4.61	24	~	Dalacin C
Inj phosphate 150 mg per ml, 4 ml ampoule – Retail pharmacy-Specialist	39.00	10	1	Dalacin C
COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – S			•	Dalacin O
Only if prescribed for dialysis or cystic fibrosis patient and the			according	V.
Inj 150 mg		1	,	Colistin-Link
GENTAMICIN SULPHATE				
Inj 10 mg per ml, 1 ml ampoule – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient of endorsed accordingly.		5 / tract		DBL Gentamicin and the prescription is
Inj 40 mg per ml, 2 ml ampoule – Subsidy by endorsement	17.50	10	1	Pfizer
	30.00	50		Pfizer
Only if prescribed for a dialysis or cystic fibrosis patient of endorsed accordingly.	or complicated urinary	/ trac	t infection	and the prescription is
MOXIFLOXACIN – Special Authority see SA1740 below – Retai	Inharmaoy			
No patient co-payment payable	i priarriacy			
Tab 400 mg		5	1	Avelox
SA1740 Special Authority for Subsidy Initial application — (Tuberculosis) only from a respiratory sp for applications meeting the following criteria: Any of the following:	ecialist or infectious d	iseas	e specialis	st. Approvals valid for 1 yea
1 Both:				
1.1 Active tuberculosis*; and1.2 Any of the following:				
 1.2.1 Documented resistance to one or more firs 1.2.2 Suspected resistance to one or more first-liarea with known resistance), as part of regi 1.2.3 Impaired visual acuity (considered to precision) 	ne medications (tube imen containing other	seco		

- 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
- 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or

continued...

94

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; ٥r

- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*; or
- 3 Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.
- Note: Indications marked with * are unapproved indications.

Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application - (Mycoplasma genitalium) only from a sexual health specialist or Practitioner on the recommendation of a sexual health specialist. Approvals valid for 1 month for applications meeting the following criteria: All of the followina:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium* and is symptomatic; and
- 2 Either:
 - 2.1 Has tried and failed to clear infection using azithromycin; or
 - 2.2 Has laboratory confirmed azithromycin resistance; and
- 3 Treatment is only for 7 days.

Initial application — (Penetrating eve iniury) only from an ophthalmologist. Approvals valid for 1 month where the patient requires prophylaxis following a penetrating eye injury and treatment is for 5 days only.

Note: Indications marked with * are unapproved indications.

PAROMOMYCIN - Special Authority see SA1689 below - Retail pharmacy

16 ✓ Humatin S29

➡SA1689 Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Fither:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolyica carriage.

Renewal only from an infectious disease specialist, clinical microbiologist or gastroenterologist. Approvals valid for 1 month for applications meeting the following criteria:

Either:

- 1 Patient has confirmed cryptosporidium infection; or
- 2 For the eradication of Entamoeba histolvica carriage.

PYRIMETHAMINE - Special Authority see SA1328 below - Retail pharmacy

➡SA1328 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

30

Daraprim S29

Any of the following:

- 1 For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; or
- 2 For pregnant patients for the term of the pregnancy: or
- 3 For infants with congenital toxoplasmosis until 12 months of age.

SODIUM FUSIDATE [FUSIDIC ACID]

 Fucidin 12 Prescriptions must be written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist

SULFADIAZINE SODIUM	- Special Authority see SA1331 on the next page -	Retail pharmacy		
Tab 500 mg		56	✓	Wockhardt S29

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy	-) 0.1	Fully Brand or	
	(Manufacturer's Pric \$	e) Sub Per	sidised Generic ✓ Manufact	urer
SA1331 Special Authority for Subsidy				
itial application from any relevant practitioner. Approvals valid e following criteria:	without further re	newal unles	s notified for appli	cations meeti
by of the following:				
1 For the treatment of toxoplasmosis in patients with HIV for	a period of 3 mon	ths: or		
2 For pregnant patients for the term of the pregnancy; or		, -		
3 For infants with congenital toxoplasmosis until 12 months of	of age.			
OBRAMYCIN				
Inj 40 mg per ml, 2 ml vial – Subsidy by endorsement		5	 Tobramyci 	n Mylan
Only if prescribed for dialysis or cystic fibrosis patient and	the prescription i	s endorsed	accordingly.	
Solution for inhalation 60 mg per ml, 5 ml – Subsidy by	0.000.00			
endorsement	2,200.00	56 dose	 TOBI 	
a) Wastage claimableb) Only if prescribed for a cystic fibrosis patient and the prescribed for a cystic fibrosis patient.	prescription is end	orsed accor	dinaly	
BIMETHOPRIM			angry.	
Tab 300 mg – Up to 30 tab available on a PSO	16.50	50	🖌 ТМР	
RIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXA			<u></u>	
Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – U	-			
to 30 tab available on a PSO		500	🗸 Trisul	
Oral liq 8 mg sulphamethoxazole 40 mg per ml - Up to 200 n				
available on a PSO	2.97	100 ml	 Deprim 	
ANCOMYCIN – Subsidy by endorsement				
Only if prescribed for a dialysis or cystic fibrosis patient or for			for treatment of C	lostridium
difficile following metronidazole failure and the prescription is		0,	Malan	
Inj 500 mg vial	2.37	1	✓ Mylan	
Antifungals				
For topical antifungals refer to DERMATOLOGICALS, page 60				
For topical antifungals refer to GENITO URINARY, page 75				
UCONAZOLE				
Cap 50 mg – Retail pharmacy-Specialist	2.09	28	 Mylan 	
Cap 150 mg - Subsidy by endorsement	0.33	1	🗸 Mylan	
a) Maximum of 1 cap per prescription; can be waived by				
b) Patient has vaginal candida albicans and the practition				
not recommended and the prescription is endorsed ac Specialist.	cordingly; can be	waived by e	endorsement - Hei	all pharmacy
Cap 200 mg – Retail pharmacy-Specialist		28	🗸 Mylan	
Powder for oral suspension 10 mg per ml – Special Authority				
see SA1359 below – Retail pharmacy		35 ml	🗸 Diflucan S	29 S29
	98.50		 Diflucan 	
Wastage claimable				
SA1359 Special Authority for Subsidy				
tial application — (Systemic candidiasis) from any relevant	practitioner. Appr	ovals valid f	or 6 weeks for ap	plications
eting the following criteria:				

Both:

96

	Subsidy (Manufacturer's Pi		Fully	Brand or Generic
	\$	Per	/	Manufacturer
 continued 1 Patient requires prophylaxis for, or treatment of systemi 	a condidicaio: and			
2 Patient is unable to swallow capsules.	c canululasis, anu			
Initial application — (Immunocompromised) from any relevant	ant practitioner. Ap	provals valid f	or 6 mc	onths for applications
meeting the following criteria: All of the following:				
 Patient is immunocompromised; and Patient is at moderate to high risk of invasive fungal infe Patient is unable to swallow capsules. 	ection; and			
Renewal — (Systemic candidiasis) from any relevant practiti following criteria: Both:	ioner. Approvals va	alid for 6 week	s for ap	plications meeting the
 Patient requires prophylaxis for, or treatment of systemi 2 Patient is unable to swallow capsules. 	c candidiasis; and			
Renewal — (Immunocompromised) from any relevant practi following criteria: All of the following:	tioner. Approvals v	alid for 6 mont	hs for a	pplications meeting the
1 Patient remains immunocompromised; and				
 Patient remains at moderate to high risk of invasive func Patient is unable to swallow capsules. 	gal infection; and			
ITRACONAZOLE				
 Cap 100 mg – Subsidy by endorsement a) Funded for tinea vesicolor where topical treatment mycology, or for tinea unguium where terbinafine h terbinafine and diagnosis has been confirmed by m waived by endorsement - Retail pharmacy - Specia microbiologist, clinical immunologist or dermatologi b) Itrazole to be Sole Supply on 1 November 2019 Oral liq 10 mg per ml – Special Authority see SA1322 below 	has not been succe as not been succes hycology and the pr alist Specialist must ist.	ssful in eradica	nosis h tion or t idorsed	the patient is intolerant to accordingly. Can be
Retail pharmacy		150 ml OP	✓ s	poranox
► SA1322 Special Authority for Subsidy				
Initial application only from an infectious disease specialist, cl	linical microbiologis	t, clinical immu	inologis	
practitioner on the recommendation of a infectious disease phy valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE	sician, clinical micro deficiency. months where the ti	obiologist or cli		munologist. Approvals
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE Tab 200 mg - PCT - Retail pharmacy-Specialist - Subsid	sician, clinical micro deficiency. months where the tr	obiologist or cli reatment rema	ns app	nmunologist. Approvals
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE	sician, clinical micro deficiency. months where the tr	obiologist or cli	ins app	nmunologist. Approvals ropriate and the patient is ink Healthcare 529
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE Tab 200 mg - PCT - Retail pharmacy-Specialist - Subsid	sician, clinical micr deficiency. nonths where the tr y by CBS	obiologist or cli reatment rema 30	ins app	nmunologist. Approvals
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsid endorsement. Prescriptions must be written by, or on the recommend	sician, clinical micr deficiency. nonths where the tr y by CBS	obiologist or cli reatment rema 30	ins app	nmunologist. Approvals ropriate and the patient is ink Healthcare 529
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsid endorsement. Prescriptions must be written by, or on the recommend	sician, clinical micro deficiency. months where the tr y by CBS dation of an oncolog 	obiologist or cli reatment rema 30	ins app ✓ Li ✓ N	inmunologist. Approvals ropriate and the patient is ink Healthcare s29 izoral s29
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsid endorsement Prescriptions must be written by, or on the recommend NYSTATIN Tab 500,000 u	sician, clinical micro deficiency. months where the tr y by CBS dation of an oncolog 	obiologist or cli reatment rema 30 gist 50	ins app ✓ Li ✓ N	nmunologist. Approvals ropriate and the patient is ink Healthcare 529
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsid endorsement Prescriptions must be written by, or on the recommend NYSTATIN	sician, clinical micro deficiency. months where the tr y by CBS dation of an oncolog 	obiologist or cli reatment rema 30 gist	ins app ✓ Li ✓ N N	inmunologist. Approvals ropriate and the patient is ink Healthcare s29 izoral s29
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsid endorsement Prescriptions must be written by, or on the recommend NYSTATIN Tab 500,000 u Cap 500,000 u POSACONAZOLE – Special Authority see SA1285 on the nex	sician, clinical micro deficiency. nonths where the tr y by CBS dation of an oncolog 14.16 (17.09) 12.81 (15.47) tt page – Retail pha	obiologist or cli reatment rema 30 gist 50 50 rmacy	ins app ✓ Li ✓ N N N	Inmunologist. Approvals ropriate and the patient is ink Healthcare (229) izoral (529) ilstat
valid for 6 months where the patient has a congenital immune of Renewal from any relevant practitioner. Approvals valid for 6 r benefitting from the treatment. KETOCONAZOLE Tab 200 mg – PCT – Retail pharmacy-Specialist – Subsid endorsement Prescriptions must be written by, or on the recommend NYSTATIN Tab 500,000 u Cap 500,000 u	sician, clinical micro deficiency. nonths where the tr y by CBS dation of an oncolog 14.16 (17.09) 12.81 (15.47) tt page – Retail pha 	obiologist or cli reatment rema 30 gist 50 50	ins app Li N N N N N	Inmunologist. Approvals ropriate and the patient is ink Healthcare (\$29) izoral (\$29)

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	~	Manufacturer

⇒SA1285 Special Authority for Subsidy

Initial application only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

* Tab 250 mg1.33	14	 Deolate
VORICONAZOLE – Special Authority see SA1273 below – Retail pharmacy		
Tab 50 mg	56	 Vttack
Tab 200 mg	56	✓ Vttack
Powder for oral suspension 40 mg per ml – Wastage		
claimable1,437.00	70 ml	✓ Vfend

⇒SA1273 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

Il of the following.

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient continues to require treatment for proven or probable invasive aspergillus infection; or
 - 3.2 Patient continues to require treatment for possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

98

	Subsidy (Manufacturer's Priv \$	ce) Sub Per	Fully Brand or osidised Generic Manufacturer	
Antimalarials	•			
PRIMAQUINE PHOSPHATE – Special Authority see SA1684 b	elow – Retail pharn	nacy		
Tab 7.5 mg		56	Primacin S29	
→SA1684 Special Authority for Subsidy Initial application only from an infectious disease specialist or of meeting the following criteria: Both:	clinical microbiologi	st. Approva	lls valid for 1 month for ap	plication
1 The patient has vivax or ovale malaria; and 2 Primaquine is to be given for a maximum of 21 days.				
Renewal only from an infectious disease specialist or clinical mi the following criteria:	crobiologist. Appro	ovals valid fo	or 1 month for applications	s meeting
Both: 1 The patient has relapsed vivax or ovale malaria; and 2 Primaquine is to be given for a maximum of 21 days.				
Antiparasitics				
Antiprotozoals				
QUININE SULPHATE				
* Tab 300 mg	61.91	500	🗸 Q 300	
Antitrichomonal Agents				
METRONIDAZOLE				
Tab 200 mg – Up to 30 tab available on a PSO		100	 Trichozole 	
Tab 400 mg – Up to 15 tab available on a PSO		100	 Trichozole 	
Oral liq benzoate 200 mg per 5 ml		100 ml	 FlagyI-S 	
Suppos 500 mg	24.48	10	Flagyl	
ORNIDAZOLE				
Tab 500 mg	23.00	10	 Arrow-Ornidazol 	9
Antituberculotics and Antileprotics				
Note: There is no co-payment charge for all pharmaceuticals lis immigration status.	ted in the Antituber	culotics and	I Antileprotics group rega	dless of
CLOFAZIMINE – Retail pharmacy-Specialist				
a) No patient co-payment payable				
 b) Prescriptions must be written by, or on the recommenda dermatologist. 	tion of, an infectiou	s disease pl	nysician, clinical microbiol	ogist or
* Cap 50 mg		100	 Lamprene S29 	
CYCLOSERINE – Retail pharmacy-Specialist				
a) No patient co-payment payableb) Prescriptions must be written by, or on the recommendation	tion of, an infectiou	s disease pl	nysician, clinical microbiol	ogist or
respiratory physician. Cap 250 mg	344 00	60	 Cyclorin S29 	
	1,294.50	100	✓ King S29	
(King 🐲 Cap 250 mg to be delisted 1 November 2019)	,		y —	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
DAPSONE – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendat dermatologist 	ion of, an infectious d	iseas	e physicia	n, clinical microbiologist or
Tab 25 mg		100	1	Dapsone
Tab 100 mg		100	1	Dapsone
ETHAMBUTOL HYDROCHLORIDE - Retail pharmacy-Specialis	st			
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendat respiratory physician 		iseas	e physicia	n, clinical microbiologist or
Tab 100 mg		100	1	EMB Fatol S29
Tab 400 mg		56	1	Myambutol S29
ISONIAZID – Retail pharmacy-Specialist				
 a) No patient co-payment payable 				
 b) Prescriptions must be written by, or on the recommendat microbiologist, dermatologist or public health physician 				
* Tab 100 mg		100	~	<u>PSM</u>
ISONIAZID WITH RIFAMPICIN – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendat microbiologist, dermatologist or public health physician 	ion of, an internal me	dicine	physician	, paediatrician, clinical
* Tab 100 mg with rifampicin 150 mg		100		Rifinah
* Tab 150 mg with rifampicin 300 mg		100	✓	Rifinah
PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist a) No patient co-payment payable				
 b) Prescriptions must be written by, or on the recommendat respiratory physician 	ion of, an infectious d	iseas	e specialis	t, clinical microbiologist or
Grans for oral liq 4 g sachet		30	1	Paser S29
PROTIONAMIDE – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendat respiratory physician 	ion of, an infectious d	iseas	e specialis	t, clinical microbiologist or
Tab 250 mg		100	1	Peteha S29
PYRAZINAMIDE – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendat respiratory physician 	ion of, an infectious d	iseas	e physicia	n, clinical microbiologist or
* Tab 500 mg		100	1	AFT-Pyrazinamide
RIFABUTIN – Retail pharmacy-Specialist				-
a) No patient co-payment payableb) Prescriptions must be written by, or on the recommendat	ion of, an infectious d	iseas	e physicia	n, respiratory physician or
gastroenterologist * Cap 150 mg		30	1	Mycobutin

	Subsidy Manufacturer's Price		Fully Brand ised Gene	
	\$	Per	 Manu 	facturer
RIFAMPICIN – Subsidy by endorsement				
 a) No patient co-payment payable b) For confirmed recurrent Staphylococcus aureus infection ir antimicrobial based on susceptibilities and the prescription Retail pharmacy - Specialist. Specialist must be an interna paediatrician, or public health physician. 	is endorsed accord al medicine physicia	dingly; can be an, clinical mi	e waived by icrobiologist,	endorsement -
₭ Cap 150 mg		100	✓ <u>Rifadin</u>	
 K Cap 300 mg K Oral liq 100 mg per 5 ml 		100 60 ml	 ✓ <u>Rifadin</u> ✓ Rifadin 	
	12.00	00 111	• <u>niiauiii</u>	
Antivirals				
For eye preparations refer to Eye Preparations, Anti-Infective Prep	arations, page 228			
Hepatitis B Treatment				
ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – F Tab 10 mg		30	✓ Hepsera	1
SA0829 Special Authority for Subsidy				-
nitial application only from a gastroenterologist or infectious dise	ase specialist. Ap	provals valid	for 1 year fo	r applications
neeting the following criteria:				
All of the following:				
1 Patient has confirmed Hepatitis B infection (HBsAg+); and				
Documented resistance to lamivudine, defined as: 2 Patient has raised serum ALT (> 1 × ULN); and				
3 Patient has HBV DNA greater than 100,000 copies per mL,	or viral load 10 fol	d or higher ov	ver nadir: an	h
4 Detection of M204I or M204V mutation; and		a or riighter of	vor naun, an	
5 Either:				
5.1 Both:				
5.1.1 Patient is cirrhotic; and				
5.1.2 adefovir dipivoxil to be used in combination v	vith lamivudine; or			
5.2 Both:				
5.2.1 Patient is not cirrhotic; and				
5.2.2 adefovir dipivoxil to be used as monotherapy				
Renewal only from a gastroenterologist or infectious disease spec reating physician, treatment remains appropriate and patient is be lotes: Lamivudine should be added to adefovir dipivoxil if a patier lefined as:	nefiting from treatn	nent.		
i) raised serum ALT (> 1 × ULN); and				
 ii) HBV DNA greater than 100,000 copies per mL, or viral load iii) Detection of N236T or A181T/V mutation. 	10 fold or higher o	over nadir; an	ıd	
Adefovir dipivoxil should be stopped 6 months following HBeAg se	roconversion for pa	itients who w	ere HReA∩₊	prior to
commencing adefovir dipivoxil.			5.5 H Bong+	P.101 10
The recommended dose of adefovir dipivoxil is no more than 10mg				
n patients with renal insufficiency adefovir dipivoxil dose should be		lance with the	e datasheet	guidelines.
Adefovir dipivoxil should be avoided in pregnant women and childr	en.			
INTECAVIR	50.00			
₭ Tab 0.5 mg		30	 Entecav 	vir Sandoz
AMIVUDINE – Special Authority see SA1685 on the next page –		00	/ 7 . ··	
Tab 100 mg		28	✓ <u>Zetlam</u>	
Oral lig 5 mg per ml	270.00 24	10 ml OP	Zeffix	

*Three months or six months, as applicable, dispensed all-at-once

(1	Subsidy Manufacturer's Price) \$	Subsi Per	Fully dised	Brand or Generic Manufacturer
➡SA1685 Special Authority for Subsidy				
Initial application only from a relevant specialist or medical practiti		nendation	of a rel	levant specialist.
Approvals valid for 1 year where used for the treatment or prevention Renewal from any relevant practitioner. Approvals valid for 2 years		a traatman	t or pro	wantion of honotitic R
TENOFOVIR DISOPROXIL				evenuori or nepaulus D.
Tenofovir disoproxil prescribed under endorsement for the treat antiretrovirals for the purposes of Special Authority SA1651., pr		uded in the	count	of up to 4 subsidised
* Tab 245 mg (300.6 mg as a succinate)		30	✓ <u>T</u>	<u>enofovir Disoproxil</u> <u>Teva</u>
Herpesvirus Treatments				
ACICLOVIR				
* Tab dispersible 200 mg		25	✓ <u>L</u>	
* Tab dispersible 400 mg		56	✓ L	
* Tab dispersible 800 mg	5.98	35	✓ L	ovir
VALACICLOVIR				
Tab 500 mg		30	✓ V	aclovir
Tab 1,000 mg	11.35	30	✓ V	aclovir
VALGANCICLOVIR – Special Authority see SA1404 below – Retai	l pharmacy			
Tab 450 mg	225.00	60	✓ V	alganciclovir
				<u>Mylan</u>

⇒SA1404 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive.

Initial application - (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for

Subsidy	Full	/ Brand or	
(Manufacturer's Price)	Subsidise	d Generic	Generic
\$	Per 🖌	Manufacturer	

continued...

3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis C Treatment

GLECAPREVIR WITH PIBRENTASVIR - [Xpharm] Note the supply of treatment is via PHARMAC's approved direct distribution supply. Further details can be found on PHARMAC's website https://www.pharmac.govt.nz/hepatitis-c-treatments 84 OP ✓ Maviret LEDIPASVIR WITH SOFOSBUVIR - [Xpharm] - Special Authority see SA1605 below No patient co-payment payable Tab 90 mg with sofosbuvir 400 mg......24,363.46 28 Harvoni ■SA1605 Special Authority for Subsidy Special Authority approved by the Hepatitis C Treatment Panel (HepCTP) Notes: By application to the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP and approved subject to confirmation of eligibility. Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz/hepatitis-c-treatments or: The Coordinator, Hepatitis C Treatment Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 460 4990.

Email: <u>hepcpanel@pharmac.govt.nz</u>

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Subsidy by endorsement; can be waived by Special Authority see SA1842 on the next page

- a) Brand switch fee payable (Pharmacode 2573865) see page 233 for details
- b) Endorsement for treatment of HIV: Prescription is deemed to be endorsed if emtricitabine with tenofovir disoproxil is co-prescribed with another antiretroviral subsidised under Special Authority SA1651 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Emtricitabine with tenofovir disoproxil prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals, and counts as two antiretroviral medications, for the purposes of Special Authority SA1651, page 105 There is an approval process to become a named specialist to prescribe antiretroviral therapy in New Zealand. Further information is available on the PHARMAC website.

i ab 200 mg with tenofovir disoproxii 245 mg (300.6 mg	g as a		
succinate)	61.15	30	✓ Teva

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	✓	Manufacturer

⇒SA1842 Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
- 2 Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 3 months and is not contraindicated for treatment; and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
- 6 Either:
 - 6.1 All of the following:
 - 6.1.1 Patient is male or transgender; and
 - 6.1.2 Patient has sex with men; and
 - 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
 - 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or
 - 6.2 All of the following:
 - 6.2.1 Patient has a regular partner who has HIV infection; and
 - 6.2.2 Partner is either not on treatment or has a detectable viral load; and
 - 6.2.3 Condoms have not been consistently used.

Renewal from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
- 2 Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
- 3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months and is not contraindicated for treatment; and
- 4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
- 5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
- 6 Either:
 - 6.1 All of the following:
 - 6.1.1 Patient is male or transgender; and
 - 6.1.2 Patient has sex with men; and
 - 6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
 - 6.1.4 Any of the following:
 - 6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
 - 6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
 - 6.1.4.3 Patient has used methamphetamine in the last three months; or
 - 6.2 All of the following:
 - 6.2.1 Patient has a regular partner who has HIV infection; and
 - 6.2.2 Partner is either not on treatment or has a detectable viral load; and
 - 6.2.3 Condoms have not been consistently used.

Per

Fully

Subsidised

Subsidy (Manufacturer's Price)

\$

Brand or Generic Manufacturer

Antiretrovirals

⇒SA1651 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the patient has confirmed HIV infection.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Subsidy	Fi	ully	Brand or
(Manufacturer's Price)	Subsidis	ed	Generic
\$	Per	✓	Manufacturer

continued...

Notes: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

Tab 50 mg Tab 200 mg Tab 600 mg Oral liq 30 mg per ml (Stocrin 529 Tab 50 mg to be delisted 1 April 2020) (Stocrin 529 Oral lig 30 mg per ml to be delisted 1 August 2020)	190.15 63.38	rmacy 30 90 30 180 ml OP	 ✓ Stocrin \$29 ✓ Stocrin ✓ Stocrin ✓ Stocrin \$29
ETRAVIRINE – Special Authority see SA1651 on the previous pag Tab 200 mg		armacy 60	✓ Intelence

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE – Special Authority see SA1651 on the pr Tab 300 mg Oral liq 20 mg per ml	180.00	- Retail pharmacy 60 240 ml OP	✓ <u>Ziagen</u> ✓ Ziagen
ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority s Note: abacavir with lamivudine (combination tablets) counts as anti-retroviral Special Authority.	s two anti-retr	oviral medication	s for the purposes of the
Tab 600 mg with lamivudine 300 mg	63.00	30	 Kivexa
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPRO	XIL – Specia	al Authority see S	A1651 on the previous page -
Retail pharmacy			
a) Brand switch fee payable (Pharmacode 2573873) - see page	e 233 for det	ails	
b) Note: Efavirenz with emtricitabine and tenofovir disoproxil	·		nedications for the purposes of
the anti-retroviral Special Authority			
Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil			
245 mg (300 mg as a maleate)	106.88	30	🗸 <u>Mylan</u>
EMTRICITABINE - Special Authority see SA1651 on the previous	page – Retail	pharmacy	
Cap 200 mg		30	 Emtriva
LAMIVUDINE - Special Authority see SA1651 on the previous page		armaov	
Tab 150 mg		60	 Lamivudine
Tab 150 mg		00	Alphapharm
Oral liq 10 mg per ml	102 50	240 ml OP	✓ 3TC
			- 010
ZIDOVUDINE [AZT] – Special Authority see SA1651 on the previo			
Cap 100 mg		100	✓ Retrovir
Oral liq 10 mg per ml		200 ml OP	Retrovir

ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see SA1651 on page 105 – Retail pharmacy Note: zidovudine [AZT] with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority. Tab 300 mg with lamivudine 150 mg		Subsidy (Manufacturer's Price \$		Fully dised	Brand or Generic Manufacturer		
Protease Inhibitors ATAZANAVIR SULPHATE - Special Authority see SA1651 on page 105 - Retail pharmacy Brand switch fee payable (Pharmacode 2573857) - see page 233 for details Cap 150 mg							
ATAZANAVIR SULPHATE – Special Authority see SA1651 on page 105 – Retail pharmacy Brand switch fee payable (Pharmacode 2573857) - see page 233 for details Cap 150 mg	Tab 300 mg with lamivudine 150 mg		60	✓ <u>A</u>	lphapharm		
Brand switch fee payable (Pharmacode 2573857) - see page 233 for details Cap 150 mg	Protease Inhibitors						
Cap 150 mg		•	armacy				
Cap 200 mg			<u></u>				
DARUNAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy Tab 400 mg							
Tab 400 mg			00	• 10	<u>eva</u>		
Tab 600 mg 476.00 60 ✓ Prezista LOPINAVIR WITH RITONAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy 183.75 60 ✓ Kaletra Tab 200 mg with ritonavir 25 mg 183.75 60 ✓ Kaletra Oral liq 80 mg with ritonavir 50 mg 463.00 120 ✓ Kaletra Oral liq 80 mg with ritonavir 20 mg per ml 735.00 300 ml OP ✓ Kaletra RITONAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy 7ab 100 mg Morvir ✓ Strand Transfer Inhibitors 1,090.00 30 ✓ Tivicay RALTEGRAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy 1,090.00 60 ✓ RALTEGRAVIR POTASSIUM – Special Authority see SA1651 on page 105 – Retail pharmacy 1,090.00 60 ✓			60	. D	raziata		
LOPINAVIR WITH RITONAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy Tab 100 mg with ritonavir 25 mg	5			. —			
Tab 100 mg with ritonavir 25 mg 183.75 60 Kaletra Tab 200 mg with ritonavir 50 mg 463.00 120 Kaletra Oral liq 80 mg with ritonavir 20 mg per ml 735.00 300 ml OP Kaletra RITONAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy 30 Morvir Strand Transfer Inhibitors 43.31 30 Morvir DOLUTEGRAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy 1,090.00 30 Tivicay RALTEGRAVIR POTASSIUM – Special Authority see SA1651 on page 105 – Retail pharmacy 1,090.00 60 Isentress	0			• 😐			
Tab 200 mg with ritonavir 50 mg 463.00 120 ✓ Kaletra Oral liq 80 mg with ritonavir 20 mg per ml 735.00 300 ml OP ✓ Kaletra RITONAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy 30 ✓ Norvir Strand Transfer Inhibitors 0 ✓ Norvir DOLUTEGRAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy 30 ✓ Norvir RALTEGRAVIR – Special Authority see SA1651 on page 105 – Retail pharmacy 1,090.00 30 ✓ Tivicay RALTEGRAVIR POTASSIUM – Special Authority see SA1651 on page 105 – Retail pharmacy 1,090.00 60 ✓ Isentress				✓ K	aletra		
Oral liq 80 mg with ritonavir 20 mg per ml	5						
RITONAVIR - Special Authority see SA1651 on page 105 - Retail pharmacy Tab 100 mg	5			_			
Tab 100 mg							
DOLUTEGRAVIR - Special Authority see SA1651 on page 105 - Retail pharmacy Tab 50 mg 1,090.00 30 ✓ Tivicay RALTEGRAVIR POTASSIUM - Special Authority see SA1651 on page 105 - Retail pharmacy Tab 400 mg 1,090.00 60 ✓ Isentress			30	🗸 N	orvir		
DOLUTEGRAVIR - Special Authority see SA1651 on page 105 - Retail pharmacy Tab 50 mg 1,090.00 30 ✓ Tivicay RALTEGRAVIR POTASSIUM - Special Authority see SA1651 on page 105 - Retail pharmacy Tab 400 mg 1,090.00 60 ✓ Isentress							
Tab 50 mg 30 ✓ Tivicay RALTEGRAVIR POTASSIUM – Special Authority see SA1651 on page 105 – Retail pharmacy Tab 400 mg 60 ✓ Isentress	Strand Transfer Inhibitors						
RALTEGRAVIR POTASSIUM – Special Authority see SA1651 on page 105 – Retail pharmacy Tab 400 mg	DOLUTEGRAVIR – Special Authority see SA1651 on page 105	- Retail pharmacy					
Tab 400 mg 1,090.00 60 🗸 Isentress	Tab 50 mg	1,090.00	30	🗸 Ti	ivicay		
· ··· · · · · · · · · · · · · · · · ·	RALTEGRAVIR POTASSIUM – Special Authority see SA1651 o	n page 105 – Retai	l pharmacy				
Tab 600 mg	Tab 400 mg	1,090.00	60	🗸 Is	entress		
	Tab 600 mg	1,090.00	60	🗸 Is	entress HD		

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects. Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

1) Diagnosis

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
- · PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.

Exclusion Criteria

- 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- 2) Pregnancy.
- 3) Neutropenia (< 2.0×10^9) and/or thrombocytopenia.

continued...

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Sub	osidy Fu	Ily Brand or
(Manufactu	urer's Price) Subsidise	ed Generic
	\$ Per	 Manufacturer

continued...

4) Continuing alcohol abuse and/or continuing intravenous drug users.

Dosage

The current recommended dosage is 3 million units of interferon alfa-2a or interferon alfa-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

INTERFERON ALFA-2A - PCT - Retail pharmacy-Specialist

- a) See prescribing guideline on the previous page
- b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician or ophthalmologist

PEGYLATED INTERFERON ALFA-2A - Special Authority see SA1400 below - Retail pharmacy

- a) See prescribing guideline on the previous page

► SA1400 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- 2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and

INFECTIONS - AGENTS FOR SYSTEMIC USE

Sub	sidy	Fully	Brand or
(Manufactu	urer's Price) Sub	sidised	Generic
	\$ Per	1	Manufacturer

continued...

- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alfa 2a is not approved for use in children.

Urinary Tract Infections

HEXAMINE HIPPURATE

* Tab 1 g		100	
J.	(40.01)		Hiprex
NITROFURANTOIN			
* Tab 50 mg		100	 Nifuran
* Tab 100 mg		100	 Nifuran
NORFLOXACIN			
Tab 400 mg - Subsidy by endorsement		100	Arrow-Norfloxacin
Out of an end to defend and the to defend on the second back	and a state of a state of the for each	and the state of the second	

Only if prescribed for a patient with an uncomplicated urinary tract infection that is unresponsive to a first line agent or with proven resistance to first line agents and the prescription is endorsed accordingly.

	Subsidy		Fully Brand or
	(Manufacturer's Price)		Subsidised Generic
	\$	Per	Manufacturer
Anticholinesterases			
NEOSTIGMINE METILSULFATE			
Inj 2.5 mg per ml, 1 ml ampoule		50	✓ AstraZeneca
PYRIDOSTIGMINE BROMIDE			
▲ Tab 60 mg	45.79	100	 Mestinon
Mestinon to be Sole Supply on 1 November 2019			
Non-Steroidal Anti-Inflammatory Drugs			
DICLOFENAC SODIUM	1.00	50	Dielofongo Condo-
Tab EC 25 mg Tab 50 mg dispersible		50 20	 ✓ <u>Diclofenac Sandoz</u> ✓ Voltaren D
* Tab 50 mg dispersible		20 50	 ✓ Voltaren D ✓ Diclofenac Sandoz
* Tab long-acting 75 mg		500	✓ Apo-Diclo SR
* Tab long-acting 100 mg		500	✓ Apo-Diclo SR
 Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a P 		5	✓ Voltaren
* Suppos 12.5 mg		10	✓ Voltaren
* Suppos 25 mg		10	✓ Voltaren
 Suppos 50 mg – Up to 10 supp available on a PSO 		10	✓ Voltaren
* Suppos 100 mg		10	✓ Voltaren
IBUPROFEN			
* Tab 200 mg	11 71	1.000) ✓ Relieve
* Tab long-acting 800 mg		30	✓ Brufen SR
* Oral lig 20 mg per ml		200 m	
KETOPROFEN			
* Cap long-acting 200 mg	12.07	28	 Oruvail SR
	12.07	20	
MEFENAMIC ACID			
* Cap 250 mg		50	
	(9.16)	~~	Ponstan
	0.50	20	Deneter
	(5.60)		Ponstan
NAPROXEN			6 · · · · · · · · · · ·
* Tab 250 mg		500	✓ Noflam 250
* Tab 500 mg		250	
* Tab long-acting 750 mg		28	✓ Naprosyn SR 750
* Tab long-acting 1 g	8.21	28	Naprosyn SR 1000
SULINDAC			
* Tab 100 mg		50	✓ Aclin
* Tab 200 mg		50	 Aclin
-	15.10	50	• Acim
TENOXICAM		50	
TENOXICAM * Tab 20 mg		100	✓ <u>Tilcotil</u>

	Subsidy		Fully Brand or
	(Manufacturer's Price \$) Per	Subsidised Generic Manufacturer
NSAIDs Other			
ELECOXIB			
Cap 100 mg	3.63	60	Celebrex
Cap 200 mg	2.30	30	✓ <u>Celecoxib Pfizer</u> ✓ Celebrex
Celebrex Cap 100 mg to be delisted 1 January 2020)			 <u>Celecoxib Pfizer</u>
Topical Products for Joint and Muscular Pain			
APSAICIN			
Crm 0.025% - Special Authority see SA1289 below - Retail			
pharmacy		25 g Ol	
SA1289 Special Authority for Subsidy	9.95	45 g Ol	P ✓ Zostrix
itial application from any relevant practitioner. Approvals valic steoarthritis that is not responsive to paracetamol and oral non-s			
Antirheumatoid Agents			
YDROXYCHLOROQUINE			
✤ Tab 200 mg	7.98	100	Plaquenil
EFLUNOMIDE			
Tab 10 mg Tab 20 mg		30 30	 ✓ <u>Apo-Leflunomide</u> ✓ Apo-Leflunomide
5	2.90	30	• Apo-Lenunonnue
ENICILLAMINE Tab 125 mg	67 23	100	D-Penamine
Tab 250 mg		100	✓ D-Penamine
ODIUM AUROTHIOMALATE			
Inj 10 mg in 0.5 ml ampoule		10	✓ Myocrisin
Inj 20 mg in 0.5 ml ampoule	113.17	10	 Myocrisin
Inj 50 mg in 0.5 ml ampoule		10	 Myocrisin
Myocrisin Inj 10 mg in 0.5 ml ampoule to be delisted 1 March 202	,		
Myocrisin Inj 20 mg in 0.5 ml ampoule to be delisted 1 March 202 Myocrisin Inj 50 mg in 0.5 ml ampoule to be delisted 1 March 202	/		
Drugs Affecting Bone Metabolism	20)		
Alendronate for Osteoporosis			
LENDRONATE SODIUM			
🗧 Tab 70 mg	2.44	4	 Fosamax
LENDRONATE SODIUM WITH COLECALCIFEROL			·
LENDHONATE SODIUM WITH COLECALCIFEROL Tab 70 mg with colecalciferol 5,600 iu	1.51	4	✓ Fosamax Plus

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy Fully Brand	lor
(Manufacturer's Price) Subsidised Gener	ric
\$ Per 🖌 Manuf	facturer

⇒SA1777 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 Either:
 - 2.1 The patient is female and postmenopausal; or
 - 2.2 The patient is male or non-binary; and
- 3 Any of the following:
 - 3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
 - 3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 3.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 3.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 4 Zoledronic acid is contraindicated because the patient's creatinine clearance is less than 35 mL/min; and
- 5 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes); and
- 6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or teriparatide.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with denosumab
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body
- e) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy

PAMIDRONATE DISODIUM

	Inj 3 mg per ml, 10 ml vial	5.98	1	 Pamisol
	Inj 6 mg per ml, 10 ml vial	15.02	1	 Pamisol
	Inj 9 mg per ml, 10 ml vial		1	 Pamisol
RAL	OXIFENE HYDROCHLORIDE – Special Authority see SA1779 or	n the next page -	- Retail pha	armacy
*	Tab 60 mg	53.76	28	 Evista
	-			

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	1	Manufacturer	

⇒SA1779 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score less than or equal to -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg3.10	4	Risedronate Sandoz
TERIPARATIDE – Special Authority see SA1139 below – Retail pharmacy		
Inj 250 mcg per ml, 2.4 ml	1	 Forteo

⇒SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsidi	sed	Generic
\$	Per	1	

continued...

during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID

0.00 100 ml OP

Aclasta

SA1780 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
 - 2 Any of the following:
 - 2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or

Subsidy	F	ully	Brand or	
(Manufacturer's Price)	Subsidi	sed	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
- 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteriod therapy (greater than or equal to 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score less than or equal to -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 The patient has had a Special Authority approval for alendronate (Underlying was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

-2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOPURINOL

* Tab 100 mg * Tab 300 mg		DP-Allopurinol DP-Allopurinol
BENZBROMARONE - Special Authority see SA1537 below		
Tab 100 mg	 0 🗸	Benzbromaron AL
		100 S29

⇒SA1537 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 Both:
 - 2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Notes); and
 - 2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 2.4 All of the following:
 - 2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 2.4.2 Allopurinol is contraindicated; and
 - 2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- 3 The patient is receiving monthly liver function tests.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefitting from the treatment; and
- 2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.
- Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity.

In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/home/resources-2/

COLCHICINE

*	Tab 500 mcg9.	.58 100	 Colgout
---	---------------	---------	-----------------------------

	Subsidy (Manufacturer's Price) \$	Su Per	Fully ubsidised	Brand or Generic Manufacturer	
FEBUXOSTAT – Special Authority see SA1538 below – Retail pl	harmacy				_
Tab 80 mg		28	🗸 A	denuric	
Tab 120 mg		28	🗸 🗸	denuric	

► SA1538 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

* Tab 500 mg	55.00	100	Probenecid-AFT
Muscle Relaxants			
BACLOFEN			
* Tab 10 mg	4.20	100	 Pacifen
Inj 0.05 mg per ml, 1 ml ampoule - Subsidy by endorsement	11.55	1	 Lioresal Intrathecal
Subsidised only for use in a programmable pump in patier caused intolerable side effects and the prescription is end		1 0	nts have been ineffective or have
Inj 2 mg per ml, 5 ml ampoule – Subsidy by endorsement		5	✓ <u>Medsurge</u>
Subsidised only for use in a programmable pump in patier caused intolerable side effects and the prescription is end			nts have been ineffective or have
DANTROLENE			
Cap 25 mg	65.00	100	 Dantrium
			 Dantrium S29 S29
Cap 50 mg	77.00	100	 Dantrium
ORPHENADRINE CITRATE			
Tab 100 mg	18.54	100	✓ <u>Norflex</u>

	Subsidy		Fully Brand or
	(Manufacturer's Price) \$	Per	Subsidised Generic Manufacturer
Agents for Parkinsonism and Related Disorder	S		
Dopamine Agonists and Related Agents			
AMANTADINE HYDROCHLORIDE			
▲ Cap 100 mg		60	 Symmetrel
APOMORPHINE HYDROCHLORIDE		_	<i></i>
▲ Inj 10 mg per ml, 2 ml ampoule		5	 Movapo
BROMOCRIPTINE MESYLATE			
* Tab 2.5 mg		100	Apo-Bromocriptine
	00.00	400	
▲ Tab 200 mg		100	Entapone
LEVODOPA WITH BENSERAZIDE	10.05	400	
* Tab dispersible 50 mg with benserazide 12.5 mg		100	
* Cap 50 mg with benserazide 12.5 mg		100	
* Cap 100 mg with benserazide 25 mg		100	
* Cap long-acting 100 mg with benserazide 25 mg		100 100	
* Cap 200 mg with benserazide 50 mg	20.25	100	 Madopar 250
LEVODOPA WITH CARBIDOPA			4
* Tab 100 mg with carbidopa 25 mg	17.97	100	
			 ✓ Sinemet
* Tab long-acting 100 mg with carbidopa 25 mg		100	
* Tab long-acting 200 mg with carbidopa 50 mg		100	
	46.73		✓ Mylan S29
* Tab 250 mg with carbidopa 25 mg		100	✓ Sinemet
PRAMIPEXOLE HYDROCHLORIDE			
▲ Tab 0.25 mg		100	Ramipex
▲ Tab 1 mg	20.73	100	Ramipex
ROPINIROLE HYDROCHLORIDE			
▲ Tab 0.25 mg	2.78	100	Apo-Ropinirole
-	2.85	84	✓ Ropin
▲ Tab 1 mg	3.95	84	 Ropin
	5.00	100	Apo-Ropinirole
▲ Tab 2 mg	5.48	84	🗸 Ropin
	7.72	100	
▲ Tab 5 mg		84	 Ropin
	16.51	100	Apo-Ropinirole
(Apo-Ropinirole Tab 0.25 mg to be delisted 1 March 2020)			
(Apo-Ropinirole Tab 1 mg to be delisted 1 March 2020)			
(Apo-Ropinirole Tab 2 mg to be delisted 1 March 2020)			
(Apo-Ropinirole Tab 5 mg to be delisted 1 March 2020)			
SELEGILINE HYDROCHLORIDE			
* Tab 5 mg	22.00	100	 Apo-Selegiline
			S29 S29
TOLCAPONE			
▲ Tab 100 mg		100	 Tasmar

NERVOUS S	SYSTEM
-----------	--------

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Per	Subsidised	
Anticholinergics				
BENZATROPINE MESYLATE				
Tab 2 mg	7.99	60	1	Benztrop
Inj 1 mg per ml, 2 ml		5		Cogentin
	190.00	10	~	Omega
a) Up to 10 inj available on a PSOb) Only on a PSO				
PROCYCLIDINE HYDROCHLORIDE				
Tab 5 mg	7.40	100	~	Kemadrin
Agents for Essential Tremor, Chorea and Relate	ed Disorders			
RILUZOLE – Special Authority see SA1403 below – Retail phan	macv			
Wastage claimable	,			
Tab 50 mg	130.00	56	~	Rilutek
SA1403 Special Authority for Subsidy				
Initial application only from a neurologist or respiratory speciali	st. Approvals valid fo	r 6 m	onths for a	pplications meeting the
following criteria:				
All of the following:				
1 The patient has amyotrophic lateral sclerosis with disease				
2 The patient has at least 60 percent of predicted forced vit	tal capacity within 2 m	onths	s prior to th	e initial application; and
3 The patient has not undergone a tracheostomy; and				
4 The patient has not experienced respiratory failure; and				
5 Any of the following:				
5.1 The patient is ambulatory; or				
5.2 The patient is able to use upper limbs; or				
5.3 The patient is able to swallow.				
Renewal from any relevant practitioner. Approvals valid for 18 r All of the following:	months for application	s mee	eting the fo	llowing criteria:
1 The patient has not undergone a tracheostomy; and				
2 The patient has not experienced respiratory failure; and				
3 Any of the following:				
3.1 The patient is ambulatory; or				
0.0 The action the shirt to see a more allocked and				
3.2 The patient is able to use upper limbs; or				
3.2 The patient is able to use upper limbs; or3.3 The patient is able to swallow.				

	Subsidy (Manufacturer's Price) \$	Full Subsidise Per ✔	d Generic
Anaesthetics			
Local			
LIDOCAINE [LIGNOCAINE] Gel 2%, tube – Subsidy by endorsement a) Up to 150 ml available on a PSO			Xylocaine 2% Jelly
 b) Subsidised only if prescribed for urethral or cervical a 			
Gel 2%, 10 ml urethral syringe – Subsidy by endorsement			Pfizer
a) Up to 5 each available on a PSO	105.00	25 🗸	Cathejell
 c) Cathejell to be Sole Supply on 1 November 2019 (Pfizer Gel 2%, 10 ml urethral syringe to be delisted 1 November LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Oral (gel) soln 2% 	,	200 ml 🗸	Mucosoothe
Inj 1%, 5 ml ampoule – Up to 25 inj available on a PSO			Lidocaine-Claris
	17.50	50	Elaocanic-olaris
	(35.00)		Xylocaine
Inj 2%, 5 ml ampoule – Up to 5 inj available on a PSO	· · ·	25 🖌	Lidocaine-Claris
Lidocaine-Claris to be Sole Supply on 1 November 2019			
Inj 1%, 20 ml ampoule – Up to 5 inj available on a PSO		5	Xylocaine
Inj 1%, 20 ml vial – Up to 5 inj available on a PSO	6.20	5 🖌	Lidocaine-Claris
Inj 2%, 20 ml vial – Up to 5 inj available on a PSO	6.45	5 🖌	Lidocaine-Claris
LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes -			
Subsidy by endorsement a) Up to 5 each available on a PSO	81.50	10 🗸	Pfizer

b) Subsidised only if prescribed for urethral or cervical administration and the prescription is endorsed accordingly.

Topical Local Anaesthetics

► SA0906 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

LIDOCAINE [LIGNOCAINE] - Special Authority see SA0906 a	bove – Retail pharr	nacy	
Crm 4%		5 g OP	🖌 LMX4
	27.00	30 g OP	🖌 LMX4
LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE - Special Au	thority see SA0906	above - Reta	il pharmacy
Crm 2.5% with prilocaine 2.5%		30 g OP	🖌 EMLA
Crm 2.5% with prilocaine 2.5% (5 g tubes)	45.00	5	🖌 EMLA

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	
Analgesics				
For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, pa	ge 110			
Non-opioid Analgesics				
For aspirin & chloroform application refer Standard Formulae, pag	je 235			
\SPIRIN ₭ Tab dispersible 300 mg – Up to 30 tab available on a PSO CAPSAICIN – Subsidy by endorsement	4.50	100	1	Ethics Aspirin
Subsidised only if prescribed for post-herpetic neuralgia or dia accordingly.	abetic peripheral ne	uropat	hy and the	e prescription is endorsed
Crm 0.075%		45 g O	P 🗸	Zostrix HP
VEFOPAM HYDROCHLORIDE Tab 30 mg	23.40	90	1	Acupan
ARACETAMOL				
Tab 500 mg - blister pack – Up to 30 tab available on a PSO.	7.12	1,000		Paracetamol Pharmacare Pharmacare
	6.00	1.000		Pharmacy Health Pharmacare
 K Tab 500 mg - bottle pack K Oral liq 120 mg per 5 ml 		1,000 r		Paracare
a) Up to 200 ml available on a PSO				
b) Not in combination ₭ Oral liq 250 mg per 5 ml	5.81	1,000 r	nl 🗸	Paracare Double Strength
a) Up to 100 ml available on a PSOb) Not in combination				
 Suppos 125 mg Suppos 250 mg 		10 10		<u>Gacet</u> Gacet
 Suppos 250 mg Suppos 500 mg Pharmacy Health Tab 500 mg - blister pack to be delisted 1 Janu 	12.40	50		Gacet
Opioid Analgesics				
CODEINE PHOSPHATE – Safety medicine; prescriber may deter Tab 15 mg Tab 30 mg Tab 60 mg	5.75 6.80	equeno 100 100 100		PSM PSM PSM

Tab long-acting 60 mg......8.60

DIHYDROCODEINE TARTRATE

✓ DHC Continus

60

NERVOUS SYSTEM

	Subsidy		Full	Brand or
	(Manufacturer's Price)		Subsidised	
	(Manulacialer 3 1 100) \$	Per		
FENTANYL				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing fi	requency			
Inj 50 mcg per ml, 2 ml ampoule		10	✓	Boucher and Muir
Inj 50 mcg per ml, 10 ml ampoule	9.41	10	~	Boucher and Muir
Patch 12.5 mcg per hour	2.95	5	~	Fentanyl Sandoz
Patch 25 mcg per hour	3.66	5		Fentanyl Sandoz
Patch 50 mcg per hour	6.65	5		Fentanyl Sandoz
Patch 75 mcg per hour		5		Fentanyl Sandoz
Patch 100 mcg per hour	11.40	5	~	Fentanyl Sandoz
METHADONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable	eanency			
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fi 		e of th	ne cheape	st form available
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be 		e of th	ne cheape	st form available
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fi 	reimbursed at the rat	e of th	ne cheape	st form available
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fi d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). 	reimbursed at the rat	e of th 10		st form available Methatabs
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fi d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard f 	reimbursed at the rat Formulae, page 235 1.40			
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fid) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard fi Tab 5 mg 	reimbursed at the rat Formulae, page 235 	10		Methatabs
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard f Tab 5 mg Tab 5 mg - bottle pack 	reimbursed at the rat Formulae, page 235 1.40 1.40 5.79	10 10	- - - -	<u>Methatabs</u> Methatabs
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard fr Tab 5 mg Tab 5 mg - bottle pack Oral liq 2 mg per ml 	reimbursed at the rat Formulae, page 235 	10 10 200 m		<u>Methatabs</u> Methatabs Biodone
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard F Tab 5 mg Tab 5 mg - bottle pack	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m	- - - - - - - - - - - - - -	<u>Methatabs</u> Methatabs <u>Biodone</u> Biodone Forte
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard F Tab 5 mg Tab 5 mg - bottle pack Oral liq 2 mg per ml Oral liq 1 mg per ml 	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 200 m	- - - - - - - - - - - - - -	<u>Methatabs</u> Methatabs <u>Biodone</u> Biodone Forte Biodone Extra Forte
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard f Tab 5 mg Tab 5 mg - bottle pack Oral liq 2 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml <i>Methatabs Tab 5 mg - bottle pack to be delisted 1 December 20</i> 	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 200 m	- - - - - - - - - - - - - -	<u>Methatabs</u> Methatabs <u>Biodone</u> Biodone Forte Biodone Extra Forte
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard f Tab 5 mg Tab 5 mg - bottle pack Oral liq 2 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml <i>Methatabs Tab 5 mg - bottle pack to be delisted 1 December 20</i> MORPHINE HYDROCHLORIDE 	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 200 m	- - - - - - - - - - - - - -	<u>Methatabs</u> Methatabs <u>Biodone</u> Biodone Forte Biodone Extra Forte
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard f Tab 5 mg Tab 5 mg - bottle pack Oral liq 2 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml <i>Methatabs Tab 5 mg - bottle pack to be delisted 1 December 2t</i> MORPHINE HYDROCHLORIDE a) Only on a controlled drug form 	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 200 m	- - - - - - - - - - - - - -	<u>Methatabs</u> Methatabs <u>Biodone</u> Biodone Forte Biodone Extra Forte
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard F Tab 5 mg Tab 5 mg - bottle pack. Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml, 1 ml Methatabs Tab 5 mg - bottle pack to be delisted 1 December 20 MORPHINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable 	reimbursed at the rat Formulae, page 235 1.40 1.40 5.79 5.79 6.79 61.00 019)	10 10 200 m 200 m 200 m	- - - - - - - - - - - - - -	<u>Methatabs</u> Methatabs <u>Biodone</u> Biodone Forte Biodone Extra Forte
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard F Tab 5 mg Tab 5 mg - bottle pack Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml, 1 ml Methatabs Tab 5 mg - bottle pack to be delisted 1 December 20 MORPHINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr 	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 200 m 10	י י ו י י י י י י י י י י י י י י י י י	Methatabs Methatabs Biodone Biodone Forte Biodone Extra Forte AFT
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard ff Tab 5 mg Tab 5 mg - bottle pack Oral liq 2 mg per ml Oral liq 10 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml, 1 ml Methatabs Tab 5 mg - bottle pack to be delisted 1 December 20 MORPHINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr Oral liq 1 mg per ml 	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 10	י שי או שי או שי או שי	Methatabs Methatabs Biodone Biodone Forte Biodone Extra Forte AFT RA-Morph
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard F Tab 5 mg Tab 5 mg - bottle pack	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 10 200 m 200 m 200 m	11 ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	Methatabs Methatabs Biodone Biodone Forte Biodone Extra Forte AFT RA-Morph RA-Morph
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard ff Tab 5 mg Tab 5 mg - bottle pack Oral liq 2 mg per ml Oral liq 10 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml, 1 ml Methatabs Tab 5 mg - bottle pack to be delisted 1 December 20 MORPHINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr Oral liq 1 mg per ml 	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 10	י או י או י או י או י או י או י	Methatabs Methatabs Biodone Biodone Forte Biodone Extra Forte AFT RA-Morph RA-Morph Ordine \$239
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard ff Tab 5 mg Tab 5 mg - bottle pack. Oral liq 2 mg per ml Oral liq 5 mg per ml Inj 10 mg per ml, 1 ml Methatabs Tab 5 mg - bottle pack to be delisted 1 December 20 MORPHINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr Oral liq 2 mg per ml Oral liq 3 mg per ml Oral liq 5 mg per ml 	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 200 m 10 200 m 200 m	1)	Methatabs Methatabs Biodone Biodone Forte Biodone Extra Forte AFT RA-Morph RA-Morph Ordine \$29 RA-Morph
 b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fr d) Extemporaneously compounded methadone will only be (methadone powder, not methadone tablets). e) For methadone hydrochloride oral liquid refer Standard F Tab 5 mg Tab 5 mg - bottle pack	reimbursed at the rat Formulae, page 235 	10 10 200 m 200 m 10 200 m 200 m 200 m		Methatabs Methatabs Biodone Biodone Forte Biodone Extra Forte AFT RA-Morph RA-Morph Ordine \$239

	Subsidy		Fully	
(N	anufacturer's Price	Per	Subsidised	I Generic Manufacturer
	φ	Fei	•	Manulaciurei
NORPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequ				• • •
Tab immediate-release 10 mg		10		Sevredol
Tab long-acting 10 mg		10		Arrow-Morphine LA
Tab immediate-release 20 mg		10		Sevredol
Tab long-acting 30 mg		10		Arrow-Morphine LA
Tab long-acting 60 mg		10		Arrow-Morphine LA
Tab long-acting 100 mg		10		Arrow-Morphine LA
Cap long-acting 10 mg	2.05	10	~	m-Eslon
m-Eslon to be Sole Supply on 1 January 2020				
Cap long-acting 30 mg	3.00	10	✓	m-Eslon
m-Eslon to be Sole Supply on 1 January 2020				
Cap long-acting 60 mg	6.12	10	1	m-Eslon
m-Eslon to be Sole Supply on 1 January 2020				
Cap long-acting 100 mg	7.13	10	1	m-Eslon
m-Eslon to be Sole Supply on 1 January 2020				
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	6.27	5	1	DBL Morphine
		Ũ		Sulphate
Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSC		5	1	DBL Morphine
nij to nig per mi, i mi ampoule – op to 5 nij avaliable on a F30	J4.47	5	•	
leide source of a strength of the test strength of the PO		-		Sulphate
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSC	J4.76	5	•	DBL Morphine
				Sulphate
Inj 30 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSC	D6.19	5	✓	DBL Morphine
				Sulphate 54
MORPHINE TARTRATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
 c) Safety medicine; prescriber may determine dispensing frequ 	IODOV			
Inj 80 mg per ml, 1.5 ml ampoule		5	1	DBL Morphine
	42.72	5	•	Tartrate
				Tartrate
DXYCODONE HYDROCHLORIDE				
 a) Only on a controlled drug form 				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing frequ	iency			
Tab controlled-release 5 mg	2.15	20	✓	Oxycodone Sandoz
Tab controlled-release 10 mg	2.15	20	1	Oxycodone Sandoz
Tab controlled-release 20 mg		20		Oxycodone Sandoz
Tab controlled-release 40 mg		20		Oxycodone Sandoz
Tab controlled-release 80 mg		20		Oxycodone Sandoz
Cap immediate-release 5 mg		20		OxyNorm
Cap immediate-release 10 mg		20		OxyNorm
Cap immediate-release 10 mg		20		OxyNorm
Oral lig 5 mg per 5 ml		250 m		OxyNorm
1 51			-	•
Inj 10 mg per ml, 1 ml ampoule		5		OxyNorm OxyNorm
Inj 10 mg per ml, 2 ml ampoule		5		OxyNorm OxyNorm
Inj 50 mg per ml, 1 ml ampoule		5		<u>OxyNorm</u>
PARACETAMOL WITH CODEINE – Safety medicine; prescriber ma				
* Tab paracetamol 500 mg with codeine phosphate 8 mg		1,000		Paracetamol +

Codeine (Relieve)

NERVOUS SYSTEM

A Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

123

	Subsidy		Fully	Brand or
	(Manufacturer's Price) \$	Per	Subsidised	
PETHIDINE HYDROCHLORIDE	Ŷ	1.01	•	Manufacturer
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing free				
Tab 50 mg		10	1	PSM
Inj 50 mg per ml, 1 ml ampoule $-$ Up to 5 inj available on a P	SO 4.98	5	1	DBL Pethidine
		_		Hydrochloride
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a P	SO5.12	5	~	DBL Pethidine
				Hydrochloride
TRAMADOL HYDROCHLORIDE	4.55	00		Transal CD 100
Tab sustained-release 100 mg Tab sustained-release 150 mg		20 20		Tramal SR 100 Tramal SR 150
Tab sustained-release 100 mg		20		Tramal SR 200
Cap 50 mg		100		Arrow-Tramadol
	-			
Antidepressants				
Cyclic and Related Agents				
AMITRIPTYLINE - Safety medicine; prescriber may determine di	spensing frequency			
Tab 10 mg		100		Arrow-Amitriptyline
Tab 25 mg		100		Arrow-Amitriptyline
Tab 50 mg		100		Arrow-Amitriptyline
CLOMIPRAMINE HYDROCHLORIDE - Safety medicine; prescrit		•		
Tab 10 mg		100		Apo-Clomipramine
Tab 25 mg	4.73 9.46	50 100		Apo-Clomipramine Apo-Clomipramine
DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE - Subsidy by end		100	•	Apo-ciompranine
a) Safety medicine; prescriber may determine dispensing free				
 b) Subsidy by endorsement – Subsidised for patients who we 		[dothi	enin] hvdr	ochloride prior to 1 June
2019 and the prescription is endorsed accordingly. Pharm				
exists a record of prior dispensing of dosulepin [dothiepin]				
Tab 75 mg		100	1	Dopress
Cap 25 mg	6.45	100	1	Dopress
(Dopress Tab 75 mg to be delisted 1 August 2020)				
(Dopress Cap 25 mg to be delisted 1 January 2020)				
DOXEPIN HYDROCHLORIDE – Subsidy by endorsement				
a) Safety medicine; prescriber may determine dispensing free	quency			
b) Subsidy by endorsement - Subsidised for patients who we				
prescription is endorsed accordingly. Pharmacists may an	notate the prescript	ion as	endorsed	d where there exists a recoi
of prior dispensing of doxepin hydrochloride.	6 20	100		Anton
Cap 10 mg Cap 25 mg		100 100	-	Anten Anten
Cap 50 mg		100	-	Anten
(Anten Cap 10 mg to be delisted 1 January 2020)			5	
(Anten Cap 25 mg to be delisted 1 April 2020)				
(Anten Cap 50 mg to be delisted 1 May 2020)				
IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber r	nay determine dispe	nsina	frequence	V
Tab 10 mg		50		Tofranil
-	10.96	100		Tofranil
Tab 25 mg	8.80	50	~	Tofranil

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	_	Subsidised	
	\$	Per		Manufacturer
MAPROTILINE HYDROCHLORIDE – Safety medicine; prescri	ber may determine dis	oensi	ing frequer	су
Tab 25 mg	7.52	30		Ludiomil
	12.53	50	✓	Ludiomil
	25.06	100		Ludiomil
Tab 75 mg	14.01	20	✓	Ludiomil
	21.01	30	✓	Ludiomil
NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; pres	criber may determine of	dispe	nsing freg	Jency
Tab 10 mg		100		Norpress
Tab 25 mg		180		Norpress
5				
Monoamine-Oxidase Inhibitors (MAOIs) - Non	Selective			
PHENELZINE SULPHATE				
* Tab 15 mg		60	1	Nardil S29 S29
· · · · · · · · · · · · · · · · · ·	118.00	100		Nardil
			-	
	40.05	~~		D
* Tab 10 mg		28		Parnate S29 S29
	22.94	50		Parnate
	96.00	100	1	Parnate S29 S29
Monoamine-Oxidase Type A Inhibitors				
MOCLOBEMIDE				
* Tab 150 mg	6.40	60	1	Aurorix
* Tab 150 mg		60		Aurorix
* Tab 500 mg		00	•	AUIOIIX
Selective Serotonin Reuptake Inhibitors				
CITALOPRAM HYDROBROMIDE				
* Tab 20 mg	1.52	84	1	PSM Citalopram
ESCITALOPRAM				
* Tab 10 mg	1 11	28	1	Escitalopram-
		20	-	Apotex
				<u>- potox</u>
* Tab 20 mg	1.90	28	1	Escitalopram-
-				Apotex
LUOXETINE HYDROCHLORIDE				
* Tab dispersible 20 mg, scored – Subsidy by endorsement.	2.47	30	~	Arrow-Fluoxetine
Subsidised by endorsement				
 When prescribed for a patient who cannot swallo accordingly; or 	w whole tablets or cape	sules	and the p	rescription is endorsed
2) When prescribed in a daily dose that is not a mul				
endorsed. Note: Tablets should be combined w	th capsules to facilitate	e incr	emental 10) mg doses.
₭ Cap 20 mg	1.99	90	1	Arrow-Fluoxetine
PAROXETINE				
* Tab 20 mg	3 61	90	./	Loxamine
τ τω 20 mg	4.02	90		Apo-Paroxetine
(Apo-Paroxetine Tab 20 mg to be delisted 1 March 2020)	4.02		•	Apo-raiozeune
קרי מוסגפוווופ דמט צט וווץ וט טפ טפווגופט ד ואמוטוו 2020)				

A Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	
	(Manufacturer's Price)		Subsidised	
	\$	Per		Manufacturer
SERTRALINE				
* Tab 50 mg	0.92	30	1	Setrona
	3.05	90	1	Arrow-Sertraline
* Tab 100 mg	1.61	30	1	Setrona
	5.25	90	✓	Arrow-Sertraline
(Arrow-Sertraline Tab 50 mg to be delisted 1 March 2020) (Arrow-Sertraline Tab 100 mg to be delisted 1 March 2020)				
Other Antidepressants				
MIRTAZAPINE				
Tab 30 mg	2.63	30	1	Apo-Mirtazapine
Tab 45 mg		30		Apo-Mirtazapine
C C		00	•	
/ENLAFAXINE	6.00	04		Enlofox VD
₭ Cap 37.5 mg ₭ Cap 75 mg		84 84		Enlafax XR Enlafax XR
₭ Cap 75 mg ₭ Cap 150 mg		84 84	-	Enlafax XR
к Сар 150 mg		04	•	
Antiepilepsy Drugs				
Agents for Control of Status Epilepticus				
CLONAZEPAM – Safety medicine; prescriber may determine dis	spensing frequency			
Inj 1 mg per ml, 1 ml		5	1	Rivotril
DIAZEPAM – Safety medicine; prescriber may determine disper	nsing frequency			
Inj 5 mg per ml, 2 ml ampoule – Subsidy by endorsement	0 1 2	5	1	Hospira
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
 c) PSO must be endorsed "not for anaesthetic procedu 	res".			
Rectal tubes 5 mg – Up to 5 tube available on a PSO		5	1	Stesolid
Rectal tubes 10 mg – Up to 5 tube available on a PSO		5		Stesolid
PARALDEHYDE				
k lnj 5 ml	1 500 00	5		AET COO
	1,500.00	5	v	AFT S29
PHENYTOIN SODIUM		_		
Inj 50 mg per ml, 2 ml ampoule – Up to 5 inj available on a F	SO88.63	5	~	Hospira
Inj 50 mg per ml, 5 ml ampoule − Up to 5 inj available on a		_		
PSO		5	<i>,</i>	Hospira
Control of Epilepsy				
CARBAMAZEPINE				
K Tab 200 mg	14 53	100	1	Tegretol
★ Tab 200 mg		100		Tegretol CR
K Tab long-acting 200 mg		100		Tegretol
K Tab long-acting 400 mg		100		Tegretol CR
 Tab long acting 400 mg. ★ Oral liq 20 mg per ml. 		250 n		Tegretol
CLOBAZAM – Safety medicine; prescriber may determine dispe Tab 10 mg		50		Frisium
-		50	•	i natulli
CLONAZEPAM – Safety medicine; prescriber may determine dis		0 1		Divertril
Oral drops 2.5 mg per ml		0 ml (Jr 🗸	Rivotril

126

	Subsidy (Manufacturer's Price \$		Fully dised	
ETHOSUXIMIDE				
Cap 250 mg		100	✓	Zarontin
Oral liq 250 mg per 5 ml		200 ml	✓	Zarontin
GABAPENTIN Note: Not subsidised in combination with subsidised pregaba	lin			
* Cap 100 mg		100	1	Apo-Gabapentin
* Cap 300 mg		100		Apo-Gabapentin
* Cap 400 mg		100	✓	Apo-Gabapentin
LACOSAMIDE - Special Authority see SA1125 below - Retail ph	armacy			
▲ Tab 50 mg		14	✓	Vimpat
▲ Tab 100 mg		14	✓	Vimpat
-	200.24	56	✓	Vimpat
▲ Tab 150 mg	75.10	14	✓	Vimpat
	300.40	56	✓	Vimpat
▲ Tab 200 mg	400.55	56	✓	Vimpat

■ SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

LAMOTRIGINE

▲ Tab dispersible 2 mg	6.74 3	30 🗸	Lamictal
▲ Tab dispersible 5 mg	9.64 3	30 🗸	Lamictal
1	5.00 5	56 🖌	Arrow-Lamotrigine
▲ Tab dispersible 25 mg – Brand switch fee payable			
(Pharmacode 2575949) - see page 233 for details	2.76	56 🖌	Logem
Tab dispersible 50 mg – Brand switch fee payable			
(Pharmacode 2575949) - see page 233 for details	3.31 5	56 🖌	Logem
▲ Tab dispersible 100 mg – Brand switch fee payable			
(Pharmacode 2575949) - see page 233 for details	4.40 5	56 🗸	Logem
LEVETIRACETAM			
Tab 250 mg	4.99 6	50 🗸	Everet
Tab 500 mg	8.79 6	50 🗸	Everet
Tab 750 mg1	4.39 6	50 🗸	Everet
Tab 1,000 mg1	8.59 6	50 🗸	Everet
Oral liq 100 mg per ml4	4.78 300	ml OP 🛛 🗸	Levetiracetam-AFT
PHENOBARBITONE			
For phenobarbitone oral liquid refer Standard Formulae, page 235			
* Tab 15 mg	0.00 5	00 🗸	PSM
* Tab 30 mg4		00 🗸	PSM

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		Fully	Brand or
()	Manufacturer's Price		Subsidised	
	\$	Per		Manufacturer
PHENYTOIN SODIUM				
* Tab 50 mg	75.00	200	1	Dilantin Infatab
Cap 30 mg	74.00	200	1	Dilantin
Cap 100 mg		200	✓	Dilantin
 Oral liq 30 mg per 5 ml 	22.03	500 ml	~	Dilantin
PREGABALIN				
Note: Not subsidised in combination with subsidised gabapent	in			
🖌 Cap 25 mg	2.25	56	1	Pregabalin Pfizer
🖌 Cap 75 mg	2.65	56	1	Pregabalin Pfizer
₭ Cap 150 mg	4.01	56	✓	Pregabalin Pfizer
₭ Cap 300 mg	7.38	56	1	Pregabalin Pfizer
PRIMIDONE				
🖌 Tab 250 mg	17.25	100	1	Apo-Primidone
	62.00	200	1	Mysoline S29 S29
ODIUM VALPROATE				•
Tab 100 mg	13.65	100	1	Epilim Crushable
Tab 200 mg EC		100		Epilim
Tab 500 mg EC		100		Epilim
♦ Oral liq 200 mg per 5 ml		300 ml	1	Epilim S/F Liquid
				Epilim Syrup
Inj 100 mg per ml, 4 ml	41.50	1		Epilim IV
TIRIPENTOL - Special Authority see SA1330 below - Retail pha				-
Cap 250 mg		60	1	Diacomit S29
Powder for oral lig 250 mg sachet		60		Diacomit S29
		00	•	Diaconnicaza

⇒SA1330 Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

Tab 25 mg	11.07	60	 Arrow-Topiramate
-			 Topiramate Actavis
	26.04		 Topamax
Tab 50 mg		60	 Arrow-Topiramate
J. J			 Topiramate Actavis
	44.26		 Topamax
Tab 100 mg		60	Arrow-Topiramate
C C			 Topiramate Actavis
	75.25		 Topamax
Tab 200 mg		60	 Arrow-Topiramate
C C			 Topiramate Actavis
	129.85		 Topamax
Sprinkle cap 15 mg	20.84	60	 Topamax
Sprinkle cap 25 mg		60	 Topamax
/IGABATRIN – Special Authority see SA1072 on the	next nage – Retail pharmac	v	
Tab 500 mg		y 100	✓ Sabril

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	1	Manufacturer	

⇒SA1072 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

- 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
- 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: ``Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. **Renewal** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 110

Acute Migraine Treatment

ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg31.00	100	 ✓ Cafergot ✓ Cafergot S29 \$29
RIZATRIPTAN		
Tab orodispersible 10 mg5.26	30	 <u>Rizamelt</u>
SUMATRIPTAN		
Tab 50 mg24.44	100	Apo-Sumatriptan
Tab 100 mg46.23	100	 Apo-Sumatriptan
Inj 12 mg per ml, 0.5 ml prefilled pen - Maximum of 10 inj per		
prescription	2 OP	Sun Pharma S29
81.15		 Clustran

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
Prophylaxis of Migraine				
or Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYS				
₭ Tab 500 mcg	23.21	100	✓	Sandomigran
Antinausea and Vertigo Agents				
or Antispasmodics refer to ALIMENTARY TRACT, page 8				
PREPITANT – Special Authority see SA0987 below – Retail pha Cap 2 × 80 mg and 1 × 125 mg		3 OP	1	Emend Tri-Pack
itial application from any relevant practitioner. Approvals valid metogenic chemotherapy and/or anthracycline-based chemother enewal from any relevant practitioner. Approvals valid for 12 mon nemotherapy and/or anthracycline-based chemotherapy for the tr ETAHISTINE DIHYDROCHLORIDE	apy for the treatme onths where the par reatment of maligna	nt of m tient is	alignancy.	0 0 0 7
€ Tab 16 mg	2.89	84	1	Vergo 16
YCLIZINE HYDROCHLORIDE Tab 50 mg	0.55	10	1	Nausicalm
YCLIZINE LACTATE Inj 50 mg per ml, 1 ml	14.95	5	1	Nausicalm
OMPERIDONE ← Tab 10 mg	2.25	100	1	Pharmacy Health
YOSCINE HYDROBROMIDE	10.50	_		
Inj 400 mcg per ml, 1 ml ampoule		5		Hospira Martindale S29
Patch 1.5 mg - Special Authority see SA1387 below - Retail	93.00	10	•	Martindale 529
pharmacy		2	✓	Scopoderm TTS
SA1387 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals valid	for 1 year for appli	cations	meeting tl	ne following criteria:
 Control of intractable nausea, vomiting, or inability to swall where the patient cannot tolerate or does not adequately re Control of clozapine-induced hypersalivation where trials of ineffective. 	espond to oral anti-	nausea	agents; o	r
Renewal from any relevant practitioner. Approvals valid for 1 yea enefiting from treatment.	r where the treatme	ent rem	ains appro	priate and the patient is
IETOCLOPRAMIDE HYDROCHLORIDE				
€ Tab 10 mg	1.30	100	1	Metoclopramide Actavis 10
Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PS	O9.50 13.56	10		Pfizer Link Healthcare \$29
Pfizer to be Sole Supply on 1 January 2020	13.00		•	
ink Healthcare [39] Ini 5 ma per ml 2 ml ampoule to be delister	d 1 January 2020)			

(Link Healthcare S29 Inj 5 mg per ml, 2 ml ampoule to be delisted 1 January 2020)

_		Subsidy		Fully	
		(Manufacturer's Price) \$	Per	Subsidised	
	IDANSETRON	· · · · · · · · · · · · · · · · · · ·			
-	Tab 4 mg	3.36	50	1	Apo-Ondansetron
	Tab disp 4 mg – Up to 10 tab available on a PSO		10		Ondansetron
					ODT-ORLA
*	Tab 8 mg	4.77	50	1	Apo-Ondansetron
*	Tab disp 8 mg – Up to 10 tab available on a PSO		10		Ondansetron
	· ···· ·······························				ODT-DRLA
DE	OCHLORPERAZINE				<u></u>
	Tab 3 mg buccal	5.07	50		
ጥ	Tab 5 mg bucca	(15.00)	50		Buccastem
*	Tab 5 mg – Up to 30 tab available on a PSO	()	250	1	Nausafix
	Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO		10		Stemetil
*		20.01	10	•	Stemetii
٨	Intipsychotics				
1	Intersycholog				
G	General				
AIV	ISULPRIDE – Safety medicine; prescriber may determine dis		20		Culmula
	Tab 100 mg		30	v	Sulprix
	Sulprix to be Sole Supply on 1 November 2019	14.06	60		Sulprix
	Tab 200 mg	14.90	00	•	Sulprix
	Sulprix to be Sole Supply on 1 November 2019 Tab 400 mg	27 70	60	1	Sulprix
	Oral lig 100 mg per ml		60 m		Solian
(ج	olian Oral liq 100 mg per ml to be delisted 1 July 2020)		00 11	•	Jonan
•		,			
٩F	RIPIPRAZOLE – Safety medicine; prescriber may determine d				
	Tab 5 mg		30		Aripiprazole Sandoz
	Tab 10 mg		30		Aripiprazole Sandoz
	Tab 15 mg		30		Aripiprazole Sandoz
	Tab 20 mg		30		Aripiprazole Sandoz
	Tab 30 mg		30		Aripiprazole Sandoz
CH	ILORPROMAZINE HYDROCHLORIDE – Safety medicine; pr	escriber may determin	ne dis	spensing fr	requency
	Tab 10 mg – Up to 30 tab available on a PSO	14.83	100	✓	Largactil
	Largactil to be Sole Supply on 1 January 2020				
	Tab 25 mg - Up to 30 tab available on a PSO	15.62	100	1	Largactil
	Largactil to be Sole Supply on 1 January 2020				
	Tab 100 mg - Up to 30 tab available on a PSO		100	✓	Largactil
	Largactil to be Sole Supply on 1 January 2020				-
	Inj 25 mg per ml, 2 ml - Up to 5 inj available on a PSO		10	✓	Largactil
	Largactil to be Sole Supply on 1 January 2020				

	Subsidy (Manufacturer's Price)		Fully Subsidised	
	(Manufacturer's Price)	Per	Subsidised	Manufacturer
	Ŧ			
LOZAPINE – Hospital pharmacy [HP4] Safety medicine; prescriber may determine dispensing frequ	0001			
, , , , , , , , , , , , , , , , , , , ,	•	50		Clozaril
Tab 25 mg		50		
	6.69	100		Clopine
	11.36	100		Clozaril
Tak 50 mm	13.37			Clopine
Tab 50 mg		50		Clopine
T 1 100	17.33	100		Clopine
Tab 100 mg		50		Clozaril
	17.33			Clopine
	29.45	100	-	Clozaril
	34.65			Clopine
Tab 200 mg		50	✓	Clopine
	69.30	100	✓	Clopine
Suspension 50 mg per ml	17.33	100 m	nl 🗸	Clopine
ALOPERIDOL – Safety medicine; prescriber may determine di	spensina frequency			
Tab 500 mcg – Up to 30 tab available on a PSO		100	1	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100		Serenace
Tab 5 mg – Up to 30 tab available on a PSO		100		Serenace
Oral liq 2 mg per ml – Up to 200 ml available on a PSO		100 m		Serenace
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PS		10		Serenace
EVOMEPROMAZINE HYDROCHLORIDE - Safety medicine; p				
Inj 25 mg per ml, 1 ml ampoule		10	v	Wockhardt
EVOMEPROMAZINE MALEATE – Safety medicine; prescriber	may determine disp	ensing	frequenc	y
Tab 25 mg		100	 Image: A set of the set of the	Nozinan
Tab 100 mg	41.75	100		Nozinan
THIUM CARBONATE – Safety medicine; prescriber may deter	mine disnensina frea	nuenci	u .	
Tab 250 mg	, ,	500		Lithicarb FC
Tab long-acting 400 mg		100		Priadel
Cap 250 mg		100		Douglas
		100	•	Douglas
ANZAPINE – Safety medicine; prescriber may determine disp	0 1 7			
Tab 2.5 mg		28		Zypine
Tab 5 mg		28		Zypine
Tab orodispersible 5 mg		28	-	Zypine ODT
Tab 10 mg		28		Zypine
Tab orodispersible 10 mg	2.05	28	1	Zypine ODT
ERICYAZINE - Safety medicine; prescriber may determine dis	pensing frequency			
Tab 2.5 mg		84	1	Neulactil
	12.49	100		Neulactil
Tab 10 mg		84		Neulactil
······································	44.45	100		Neulactil
UETIAPINE – Safety medicine; prescriber may determine disp				
	0 1 2	00		Quatanal
Tab 25 mg		90		Quetapel Quetapel
Tab 100 mg		90		Quetapel
Tab 200 mg		90		Quetapel
Tab 300 mg	9.60	90	✓	Quetapel

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	Sub Per	sidised	Generic
	\$	Per	1	Manufacturer
RISPERIDONE - Safety medicine; prescriber may determine	dispensing frequency			
Tab 0.5 mg		60	✓ <u>A</u>	ctavis
Tab 1 mg	2.06	60	🗸 A	ctavis
Tab 2 mg	2.29	60	🗸 🗸	ctavis
Tab 3 mg	2.50	60	🗸 🗸	ctavis
Tab 4 mg	3.43	60	🗸 🗸	ctavis
Oral lig 1 mg per ml	7.66	30 ml	🗸 🖌	lisperon
IPRASIDONE – Safety medicine; prescriber may determine	dispensing frequency		_	
Cap 20 mg		60	√ 7	usdone
Cap 40 mg		60	_	usdone
Cap 60 mg		60		usdone
Cap 80 mg		60	_	usdone
			_	
CUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; p	,		0 1	,
Tab 10 mg		100	• 0	lopixol
Denet Injections				
Depot Injections				
LUPENTHIXOL DECANOATE - Safety medicine; prescriber	r may determine dispen	sina freau	encv	
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO		5 5		luanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO		5		luanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	-	luanxol
		-	-	launixon
ALOPERIDOL DECANOATE – Safety medicine; prescriber		•		
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO		5		aldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		5		aldol Concentrate
			• H	aldol
				Decanoas S29
LANZAPINE – Special Authority see SA1428 below – Retail	pharmacy			
Safety medicine; prescriber may determine dispensing fre	quency			
Inj 210 mg vial		1	🗸 Z	yprexa Relprevv
Inj 300 mg vial		1	✓ Z	yprexa Relprevv
				vprexa Relprevv

➡SA1428 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

PALIPERIDONE - Special Authority see SA1429 on the next page - Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg syringe	1	Invega Sustenna
Inj 50 mg syringe	1	Invega Sustenna
Inj 75 mg syringe	1	Invega Sustenna
Inj 100 mg syringe	1	Invega Sustenna
Inj 150 mg syringe	1	 Invega Sustenna

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

SA1429 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Paliperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling paliperidone depot injection.

RISPERIDONE - Special Authority see SA1427 below - Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg vial	1	Risperdal Consta
Inj 37.5 mg vial	1	 Risperdal Consta
lnj 50 mg vial217.56	1	 Risperdal Consta

➡SA1427 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE – Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a	PSO19.80	5	 Clopixol
Anxiolytics			
BUSPIRONE HYDROCHLORIDE			
* Tab 5 mg	20.23	100	✓ <u>Orion</u>
* Tab 10 mg		100	✓ <u>Orion</u>
CLONAZEPAM - Safety medicine; prescriber may dete	rmine dispensing frequency		
Tab 500 mcg		100	✓ <u>Paxam</u>
Tab 2 mg	10.78	100	✓ Paxam
DIAZEPAM - Safety medicine; prescriber may determin	ne dispensing frequency		
Tab 2 mg		500	 <u>Arrow-Diazepam</u>
Tab 5 mg		500	 Arrow-Diazepam

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
LORAZEPAM – Safety medicine; prescriber may determine dispertine	0 1 2	250		Ativan
Tab 1 mg Tab 2.5 mg		250 100		Ativan
OXAZEPAM - Safety medicine; prescriber may determine disper	0 1 2			
Tab 10 mg Tab 15 mg		100 100		Ox-Pam Ox-Pam

Multiple Sclerosis Treatments

DIMETHYL FUMARATE - Special Authority see SA1559 below - Retail pharmacy

Wastage claimable

Cap 120 mg		14	 Tecfidera
Cap 240 mg	2,000.00	56	 Tecfidera

⇒SA1559 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: <u>mstaccoordinator@pharmac.govt.nz</u>

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- b) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- c) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the
 past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- d) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;

Subsidy	0.1	Fully	Brand or	
(Manufacturer's Price) \$	Per	osidised ✓	Generic Manufacturer	

- e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever (T> 37.5° C); and
- e) applications must be made by the patient's neurologist or general physician; and
- f) patients must have no previous history of lack of response to dimethyl fumarate; and
- g) patients must have not previously had intolerance to dimethyl fumarate; and
- h) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to dimethyl fumarate; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

FINGOLIMOD - Special Authority see SA1562 below - Retail pharmacy

Wastage claimable Cap 0.5 mg

ap 0.5 mg	2,200.00	28	🗸 Gilenya
-----------	----------	----	-----------

► SA1562 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified). Entry Criteria

S	Subsidy	Fully	Brand or
(Manufa	acturer's Price) Subsi	dised	Generic
	\$ Per	1	Manufacturer

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the
 past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T> 37.5°C); and
- 5) applications must be made by the patient's neurologist or general physician; and
- 6) patients must have no previous history of lack of response to fingolimod; and
- 7) patients must have not previously had intolerance to fingolimod; and
- 8) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to fingolimod; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If

Subsidy	Full	/ Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per 🖌	Manufacturer	

a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

NATALIZUMAB – Special Authority see SA1563 below – Retail pharmacy

Inj 20 mg per ml, 15 ml vial...... 1,750.00 1 🗸 Tysabri

⇒SA1563 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T> 37.5°C); and
- 5) applications must be made by the patient's neurologist or general physician; and
- 6) treatment must be initiated and supervised by a neurologist who is registered in the Tysabri Australasian Prescribing Programme operated by the supplier; and
- 7) patients must have no previous history of lack of response to natalizumab; and

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

- 8) patients must have not previously had intolerance to natalizumab; and
- 9) a) Patient is JC virus negative, or
 - b) Patient is JC virus positive and has given written informed consent acknowledging an understanding of the risk of progressive multifocal leucoencephalopathy (PML) associated with natalizumab
- 10) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to natalizumab; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier.

Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate.

Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur.

TERIFLUNOMIDE – Special Authority see SA1560 below – Retail pharmacy

Wastage claimable	•		
Tah 14 mg		1 582 62	28

lab	14 mg	1,582.62	28	Aubagio

⇒SA1560 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Entry Criteria

1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T> 37.5°C); and
- 5) applications must be made by the patient's neurologist or general physician; and
- 6) patients must have no previous history of lack of response to teriflunomide; and
- 7) patients must have not previously had intolerance to teriflunomide; and
- 8) patient must not be co-prescribed beta interferon or glatiramer acetate.

Stopping Criteria

Any of the following:

- 1) Confirmed progression of disability that is sustained for six months. Progression of disability is defined as progress by any of the following EDDSS points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to teriflunomide; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Switching between natalizumab, fingolimod, dimethyl fumarate and teriflunomide is permitted provided the EDSS stopping criteria are not met. Switching to interferon or glatiramer acetate is only permitted provided the EDSS stopping criteria are not met and both fingolimod and natalizumab are either not tolerated or treatment with both agents would be clinically inappropriate. Continued relapses on treatment would be expected to lead to a switch of treatment provided the stopping criteria are not met. If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully sidised	Brand or Generic Manufacturer
continued riteria, a period of 6 months is allowed from the start of t	he relapse for recovery to occ	cur.		
Other Multiple Sclerosis Treatments				
 GLATIRAMER ACETATE – Special Authority see SA180 Inj 40 mg prefilled syringe – No patient co-payment j SA1808 Special Authority for Subsidy Special Authority approved by the Multiple Sclerosis Treat Notes: Special Authority approved by the Multiple Sclerosis considered by MSTAC at its regular meetings and approvide bolow). Application details may be obtained from PHARMAC's weight of the second s	oayable2,275.00 tment Committee sis Treatment Assessment C red subject to eligibility accord	ling to the	(MSTA	
The coordinator Multiple Sclerosis Treatment Assessment Committee PHARMAC PO Box 10 254 Wellington	Phone: 04 460 4990 Facsimile: 04 916 7571 Email: <u>mstaccoordinator@</u>	pharmac	.govt.nz	
Completed application forms must be sent to the coordina portunity.	ator for MSTAC and will be co	nsidered	by MST	AC at the next practicab

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, 40 mg glatiramer acetate 3 times weekly will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. As a new Special Authority approval number is required the MSTAC coordinator should be notified of the change and a new prescription provided. **Entry Criteria**

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the
 past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;

continued...

NERVOUS SYSTEM

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

	Subsidy		ully	Brand or
()	Manufacturer's Price)	Subsidi	sed	Generic
	\$	Per	✓	Manufacturer

- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever (T> 37.5°C); and
- 5) applications must be made by the patient's neurologist; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and
- 7) patients must have either:
 - a) intolerance to both natalizumab and fingolimod; or
 - b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and
- 8) patient will not be co-prescribed natalizumab or fingolimod.

Stopping Criteria

Any of the following:

- Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as progress by any of the following EDDSS Points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

INTERFERON BETA-1-ALPHA - Special Authority see SA1809 below - Retail pharmacy

No patient co-payment payable

Inj 6 million iu prefilled syringe	4	Avonex
Injection 6 million iu per 0.5 ml pen injector1,170.00	4	 Avonex Pen

⇒SA1809 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

Subsidy	Subs	Fully	Brand or
(Manufacturer's Price)		dised	Generic
\$	Per	1	Manufacturer

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, 40 mg glatiramer acetate 3 times weekly will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. As a new Special Authority approval number is required the MSTAC coordinator should be notified of the change and a new prescription provided. **Entry Criteria**

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and
- 3) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T> 37.5°C); and
- 5) applications must be made by the patient's neurologist; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and
- 7) patients must have either:
 - a) intolerance to both natalizumab and fingolimod; or
 - b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and
- 8) patient will not be co-prescribed natalizumab or fingolimod.

Stopping Criteria

Any of the following:

1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as progress by any of the following EDDSS Points:

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price)	Sub	Fully sidised	Brand or Generic
 \$	Per	~	Manufacturer

a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or

- b) 1.0 to 3.0; or
- c) 1.5 to 3.5; or
- d) 2.0 to 4.0; or
- e) 2.5 to 4.5; or
- f) 3.0 to 4.5; or
- g) 3.5 to 4.5; or
- h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

INTERFERON BETA-1-BETA - Special Authority see SA1810 below - Retail pharmacy

No patient co-payment payable

Inj 8 million iu per 1 ml...... 1,322.89 15 🗸 Betaferon

⇒SA1810 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Special Authority approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, 40 mg glatiramer acetate 3 times weekly will be subsidised.

Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. As a new Special Authority approval number is required the MSTAC coordinator should be notified of the change and a new prescription provided. **Entry Criteria**

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis must include MRI confirmation; and
- 2) patients must have Clinically Definite Relapsing Remitting MS with or without underlying progression; and

	Subsidy		Fully	Brand or
(N	Ianufacturer's Price)	Subsi	dised	Generic
	\$	Per	1	Manufacturer

continued...

- 3) patients must have:
 - a) EDSS score 0 4.0 and:
 - Experienced at least 1 significant relapse of MS in the previous 12 months or 2 significant relapses in the past 24 months; and
 - Evidence of new inflammatory activity on an MR scan within the past 24 months, any of the following:
 - i) a gadolinium enhancing lesion; or
 - ii) a Diffusion Weighted Imaging positive lesion; or
 - iii) a T2 lesion with associated local swelling; or
 - iv) a prominent T2 lesion that clearly is responsible for the clinical features of a recent relapse; or
 - v) new T2 lesions compared with a previous MR scan; and
- 4) A significant relapse must:
 - a) be confirmed by the applying neurologist or general physician (the patient may not necessarily have been seen by them during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) start at least one month after the onset of a previous relapse;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke Functional System scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T> 37.5°C); and
- 5) applications must be made by the patient's neurologist; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate; and
- 7) patients must have either:
 - a) intolerance to both natalizumab and fingolimod; or
 - b) treatment with both natalizumab and fingolimod is considered clinically inappropriate; and
- 8) patient will not be co-prescribed natalizumab or fingolimod.

Stopping Criteria

Any of the following:

- Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as progress by any of the following EDDSS Points:
 - a) from starting at EDSS 0 increasing to (i.e. stopping on reaching) EDSS 3.0; or
 - b) 1.0 to 3.0; or
 - c) 1.5 to 3.5; or
 - d) 2.0 to 4.0; or
 - e) 2.5 to 4.5; or
 - f) 3.0 to 4.5; or
 - g) 3.5 to 4.5; or
 - h) 4.0 to 4.5.
- 2) increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 4) non-compliance with treatment, including refusal to undergo annual assessment.

Note: Treatment with interferon beta -1-beta, interferon beta-1-alpha and glatiramer acetate, is permitted only if treatment with both natalizumab and fingolimod is not tolerated or treatment with both would be clinically inappropriate. Beta-interferon or glatiramer acetate will not be funded as second line treatments if EDSS progression has occurred on treatment with natalizumab or fingolimod. Patients who have an increasing relapse rate over 12 months of treatment (compared with the relapse rate on

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

starting treatment) and who do not meet the EDSS Stopping Criteria at annual review may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa. Patients may switch from either of the beta-interferon's [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa for increased relapses only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to increasing relapse rate over 12 months of treatment). If a relapse has resulted in an increased EDSS score that potentially may lead to discontinuation of treatment according to stopping criteria, a period of 6 months is allowed from the start of the relapse for recovery to occur. In this setting anti-JCV antibody positive status may be accepted as a clinically inappropriate reason for treatment with natalizumab.

Sedatives and Hypnotics MELATONIN - Special Authority see SA1666 below - Retail pharmacy 30 Circadin SA1666 Special Authority for Subsidy Initial application only from a psychiatrist, paediatrician, neurologist, respiratory specialist or medical practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder)*; and 2 Behavioural and environmental approaches have been tried and were unsuccessful, or are inappropriate; and 3 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and 4 Patient is aged 18 years or under*. Renewal only from a psychiatrist, paediatrician, neurologist, respiratory specialist or medical practitioner on the recommendation of a psychiatrist, paediatrician, neurologist or respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following: 1 Patient is aged 18 years or under*; and 2 Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and 3 Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia: and 4 Funded modified-release melatonin is to be given at doses no greater than 10 mg per day. Note: Indications marked with * are unapproved indications. MIDAZOLAM - Safety medicine; prescriber may determine dispensing frequency Inj 1 mg per ml, 5 ml ampoule4.30 10 ✓ Midazolam-Claris Inj 1 mg per ml, 5 ml plastic ampoule - Up to 10 inj available 10 Pfizer on a PSO......14.90 On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only. ✓ Midazolam-Claris Inj 5 mg per ml, 3 ml ampoule2.50 5 Inj 5 mg per ml, 3 ml plastic ampoule - Up to 5 inj available on a PSO......11.90 5 Pfizer On a PSO for status epilepticus use only. PSO must be endorsed for status epilepticus use only. NITRAZEPAM - Subsidy by endorsement a) Safety medicine; prescriber may determine dispensing frequency b) Subsidy by endorsement - subsidised for patients who were taking nitrazepam prior to 1 August 2019 and the prescription is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of nitrazepam in the preceding 12 months. 100 ✓ Nitrados

(Nitrados Tab 5 mg to be delisted 1 January 2021)

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	Si	ubsidised	Generic
	`\$	Per	~	Manufacturer
PHENOBARBITONE SODIUM – Special Authority see SA138	36 below – Retail pharma	acy		
Inj 200 mg per ml, 1 ml ampoule		5	 Image: A second s	Aspen S29
SA1386 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals v	alid without further rene	wal unle	ess notifie	ed for applications meetin
he following criteria:				
Both:				
1 For the treatment of terminal agitation that is unrespon-	sive to other agents; and	1		
2 The applicant is part of a multidisciplinary team working	g in palliative care.			
TEMAZEPAM - Safety medicine; prescriber may determine d	ispensing frequency			
Tab 10 mg	1 0 1 ,	25	 I 	Normison
TRIAZOLAM – Safety medicine; prescriber may determine dis			-	
Tab 125 mcg		100		
105 120 mog	(9.85)	100	I	Hypam
Tab 250 mcg	· · /	100		.)pain
	(11.20)		H	Hypam
ZOPICLONE - Safety medicine; prescriber may determine di	spensing frequency			
Tab 7.5 mg		500	1	Zopiclone Actavis
Ũ			-	
Stimulants/ADHD Treatments				
ATOMOXETINE - Special Authority see SA1416 below - Ret	ail pharmacy			
Cap 10 mg		28	✓ :	Strattera
Cap 18 mg		28	✓ :	Strattera
Cap 25 mg		28	✓ :	Strattera
Cap 40 mg	107.03	28	✓ :	Strattera
Cap 60 mg	107.03	28		Strattera
Cap 80 mg		28		Strattera
Cap 100 mg	139.11	28	✓ :	Strattera

⇒SA1416 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
 - 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamfetamine sulphate tablets.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

NERVOUS SYSTEM

	Subsidy (Manufacturer's Prio \$	ce) Su Per	Fully bsidised	Brand or Generic Manufacturer
EXAMFETAMINE SULFATE – Special Authority see SA114	9 below – Retail phar	rmacy		
a) Only on a controlled drug form				
b) Safety medicine; prescriber may determine dispensing				
Tab 5 mg	20.00	100	✓ <u>P</u> :	SM
»SA1149 Special Authority for Subsidy itial application — (ADHD in patients 5 or over) only from				
ecommendation of a paediatrician or psychiatrist (in writing).	Approvals valid for 2	4 months fo	or applicat	ions meeting the followi
iteria:				
Il of the following:				
 ADHD (Attention Deficit and Hyperactivity Disorder) pa Diagnosed according to DSM-IV or ICD 10 criteria; and Either: 		r over; and		
3.1 Applicant is a paediatrician or psychiatrist; or				
3.2 Applicant is a medical practitioner and confirms last 2 years and has recommended treatment for			st has bee	en consulted within the
itial application — (ADHD in patients under 5) only from oplications meeting the following criteria: oth:	a paediatrician or psy	rchiatrist. A	Approvals	valid for 12 months for
1 ADHD (Attention Deficit and Hyperactivity Disorder) pa 2 Diagnosed according to DSM-IV or ICD 10 criteria.	tients under 5 years o	of age; and		
itial application — (Narcolepsy) only from a neurologist o	r respiratory specialis	t. Approva	ls valid fo	r 24 months where the
atient suffers from narcolepsy.				
enewal — (ADHD in patients 5 or over) only from a paedia				
i a paediatrician or psychiatrist (in writing). Approvals valid footh:	or 24 months for appl	ications me	eting the t	following criteria:
 The treatment remains appropriate and the patient is b Either: 	enefiting from treatme	ent; and		
2.1 Applicant is a paediatrician or psychiatrist; or2.2 Applicant is a medical practitioner and confirms last 2 years and has recommended treatment for			st has bee	en consulted within the
enewal — (ADHD in patients under 5) only from a paediat	•	-	volid for t	10 months whore the
eatment remains appropriate and the patient is benefiting fro		Appiovais	valiu iui	
enewal — (Narcolepsy) only from a neurologist or respirate		als valid fo	r 24 mont	hs where the treatment
mains appropriate and the patient is benefiting from treatme				
ETHYLPHENIDATE HYDROCHLORIDE - Special Authorit		– Retail pha	armacv	
a) Only on a controlled drug form			,	
b) Safety medicine; prescriber may determine dispensing	frequency			
Tab immediate-release 5 mg		30	🗸 R	ubifen
Tab immediate-release 10 mg	3.00	30	🗸 R	
				ubifen
Tab immediate-release 20 mg		30		ubifen
	10.05	30	✓ R	ubifen SR
Tab sustained-release 20 mg		100		italin SR

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

Subsidy	Ful	ly Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per •	 Manufacturer 	

continued...

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see SA1151 on the next page – Retail pharmacy

a) Only on a controlled drug form

 b) Safety medicine; prescriber may determine dispensir 	ig frequency		
Tab extended-release 18 mg		30	 Methylphenidate ER Teva
	58.96		 Concerta
Tab extended-release 27 mg		30	 Methylphenidate ER Teva
	65.44		 Concerta
Tab extended-release 36 mg		30	 Methylphenidate ER Teva
	71.93		 Concerta
Tab extended-release 54 mg		30	 Methylphenidate ER Teva
	86.24		 Concerta
Cap modified-release 10 mg		30	 Ritalin LA
Cap modified-release 20 mg		30	 Ritalin LA
Cap modified-release 30 mg		30	 Ritalin LA
Cap modified-release 40 mg		30	 Ritalin LA

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	✓	

⇒SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

MODAFINIL – Special Authority see SA1126 below – Retail pharmacy

⇒SA1126 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
 - 3.1 An effective dose of a subsidised formulation of methylphenidate or dexamfetamine has been trialled and discontinued because of intolerable side effects; or
 - 3.2 Methylphenidate and dexamfetamine are contraindicated.

Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

*	Tab 5 mg4.34	90	Donepezil-Rex
	Tab 10 mg6.64	90	 Donepezil-Rex

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
RIVASTIGMINE – Special Authority see SA1488 below – Retail	pharmacy				
Patch 4.6 mg per 24 hour		30	🖌 Ex	xelon	
Patch 9.5 mg per 24 hour		30	🖌 Ex	xelon	

► SA1488 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 The patient has been diagnosed with dementia; and
- 2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate; and
- 2 The patient has demonstrated a significant and sustained benefit from treatment.

Treatments for Substance Dependence

BUPRENORPHINE WITH NALOXONE - Special Authority see SA1203 below - Retail pharmacy

- a) No patient co-payment payable
- b) Safety medicine; prescriber may determine dispensing frequency

Tab sublingual	2 mg with n	aloxone 0.5 mg	 	57.40	28	 Suboxone
Tab sublingual	8 mg with n	aloxone 2 mg	 	.166.00	28	 Suboxone

⇒SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health..

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	 ✓ 	Manufacturer	

continued...

- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from

any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Tab modified-release 150 mg	11.00	30	✓ Zyban
DISULFIRAM Tab 200 mg		100	 Antabuse
NALTREXONE HYDROCHLORIDE - Special Authority see S			
Tab 50 mg	112.55	30	 Naltraccord

⇒SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised		
NICOTINE					
a) Nicotine will not be funded in amounts less than 4 weeks	of treatment.				
b) Note: Direct Provision by a pharmacist permitted under t	he provisions in Part	l of S	ection A.		
Patch 7 mg – Up to 28 patch available on a PSO		28	✓	Habitrol	
Patch 7 mg for direct distribution only - [Xpharm]	3.94	7	✓	Habitrol	
Patch 14 mg – Up to 28 patch available on a PSO		28	✓	Habitrol	
Patch 14 mg for direct distribution only - [Xpharm]	4.52	7	✓	Habitrol	
Patch 21 mg – Up to 28 patch available on a PSO	21.77	28	✓	Habitrol	
Patch 21 mg for direct distribution only - [Xpharm]	5.18	7	✓	Habitrol	
Lozenge 1 mg – Up to 216 loz available on a PSO		216	✓	Habitrol	
Lozenge 1 mg for direct distribution only - [Xpharm]	3.20	36	✓	Habitrol	
Lozenge 2 mg – Up to 216 loz available on a PSO		216	✓	<u>Habitrol</u>	
Lozenge 2 mg for direct distribution only - [Xpharm]	3.24	36	✓	Habitrol	
Gum 2 mg (Fruit) – Up to 384 piece available on a PSO		384	✓	Habitrol	
Gum 2 mg (Fruit) for direct distribution only - [Xpharm]	8.64	96	✓	Habitrol	
Gum 2 mg (Mint) – Up to 384 piece available on a PSO		384	✓	Habitrol	
Gum 2 mg (Mint) for direct distribution only - [Xpharm]	8.64	96	✓	Habitrol	
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO		384	✓	Habitrol	
Gum 4 mg (Fruit) for direct distribution only – [Xpharm]		96	✓	Habitrol	
Gum 4 mg (Mint) – Up to 384 piece available on a PSO		384	✓	Habitrol	
Gum 4 mg (Mint) for direct distribution only - [Xpharm]	10.01	96	1	Habitrol	

VARENICLINE TARTRATE - Special Authority see SA1845 below - Retail pharmacy

a) A maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval, including the starter pack

b) Varenicline will not be funded in amounts less than 4 weeks of treatment.

c) The 6-month time period in which a patient can receive a funded 12-week course of varenicline tartrate starts from the date the Special Authority is approved.

Tab 0.5 mg × 11 and 1 mg × 4225.64	53 OP	 Varenicline Pfizer
Tab 1 mg27.10	56	✓ Varenicline Pfizer

⇒SA1845 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not had a Special Authority for varenicline approved in the last 6 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking;

continued...

NERVOUS SYSTEM

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

and

- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 It has been 6 months since the patient's previous Special Authority was approved; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 12 weeks' funded varenicline (see note).

The patient must not have had an approval in the past 6 months.

Notes: a maximum of 12 weeks' varenicline will be subsidised on each Special Authority approval. This includes the 4-week 'starter' pack.

	Subsidy		Fully	Brand or
	(Manufacturer's Price)		Subsidised	Generic
	\$	Per	1	Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BENDAMUSTINE HYDROCHLORIDE – PCT only – Specialist – Inj 25 mg vial Inj 100 mg vial Inj 1 mg for ECP		e <mark>SA16</mark> 1 1 1 mg	✓ F ✓ F	libomustin libomustin Baxter
➡SA1667 Special Authority for Subsidy				
Initial application — (treatment naive CLL) only from a relevant				the recommendation of a
relevant specialist. Approvals valid for 12 months for applications All of the following:	s meeting the followin	ng crite	ria:	
5	A abrania lumphanitia		mia raqui	ing tractment, and
1 The patient has Binet stage B or C, or progressive stage A 2 The patient is chemotherapy treatment naive; and		leuka	emia requir	ing treatment, and
 3 The patient is unable to tolerate toxicity of full-dose FCR; a 4 Patient has ECOG performance status 0-2; and 	and			
5 Patient has a Cumulative Illness Rating Scale (CIRS) scor	re of < 6: and			
6 Bendamustine is to be administered at a maximum dose of		1 and	2 every 4	weeks for a maximum of
6 cycles.				
Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymp to comprise a known standard therapeutic chemotherapy regimer				py treatment is considered
Initial application - (Indolent, Low-grade lymphomas) only f	rom a relevant specia	alist or	medical pr	
recommendation of a relevant specialist. Approvals valid for 9 m	onths for applications	s meeti	ng the follo	wing criteria:
All of the following:	at and			
 The patient has indolent low grade NHL requiring treatment Patient has a WHO performance status of 0-2; and 	nt; and			
3 Either:				
3.1 Both:				
3.1.1 Patient is treatment naive; and				
3.1.2 Bendamustine is to be administered for a m CD20+); or	aximum of 6 cycles (in com	bination wi	th rituximab when
3.2 All of the following:				
3.2.1 Patient has relapsed refractory disease follo		rapy; a	ind	
3.2.2 The patient has not received prior bendamu	istine therapy; and			
3.2.3 Either:				
3.2.3.1 Both:				
3.2.3.1.1 Bendamustine is to be adminis combination with rituximab wh		n of 6 c	ycles in rel	apsed patients (in
3.2.3.1.2 Patient has had a rituximab tre	<i>,,</i>	of 12 m	onths or m	nore; or
3.2.3.2 Bendamustine is to be administered a refractory patients.				

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Both:

- 1 Patients have not received a bendamustine regimen within the last 12 months; and
- 2 Either:
 - 2.1 Both:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Pri \$	ce) Subs Per	Fully idised	Brand or Generic Manufacturer
ontinued				
2.1.1 Bendamustine is to be administered for a n	naximum of 6 cycle	es in relapsed	l patien	ts (in combination with
rituximab when CD20+); and				
2.1.2 Patient has had a rituximab treatment-free		-		
2.2 Bendamustine is to be administered as a monothe				
lote: 'indolent, low-grade lymphomas' includes follicular, mantle	cell, marginal zor	e and lympho	oplasm	acytic/ Waldenstrom's
nacroglobulinaemia.				
BUSULFAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg		100	✓ N	lyleran
ARBOPLATIN – PCT only – Specialist				
Inj 10 mg per ml, 45 ml vial		1		OBL Carboplatin
	45.20			Carboplatin Ebewe
	48.50			Carbaccord
Inj 1 mg for ECP	0.10	1 mg	✓ E	Baxter
ARMUSTINE – PCT only – Specialist				
Inj 100 mg vial	1,387.00	1	✓ E	BiCNU
				Bicnu Heritage S29
Inj 100 mg for ECP	1,387.00	100 mg OP	✓ E	Baxter
HLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg	29.06	25	🗸 I	.eukeran FC
SISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml vial		1	✓ [OBL Cisplatin
	15.00			Cisplatin Ebewe
Inj 1 mg per ml, 100 ml vial		1		OBL Cisplatin
	21.00			Cisplatin Ebewe
Inj 1 mg for ECP	0.25	1 mg	✓ E	Baxter
YCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist	79.00	50	✓ E	ndoxan S29
	158.00	100	🗸 F	Procytox S29
Wastage claimable			_	
Inj 1 g vial – PCT – Retail pharmacy-Specialist		1		Indoxan
	127.80	6		ytoxan
Inj 2 g vial – PCT only – Specialist		1		Indoxan
Inj 1 mg for ECP – PCT only – Specialist	0.04	1 mg	•	Baxter
OSFAMIDE – PCT only – Specialist				
lnj 1 g		1	-	loloxan
Inj 2 g		1	-	loloxan
Inj 1 mg for ECP	0.10	1 mg	v 1	Baxter
OMUSTINE – PCT – Retail pharmacy-Specialist	100 50	~~		
Cap 10 mg		20		CeeNU
Cap 40 mg		20	V (CeeNU
IELPHALAN			-	
Tab 2 mg – PCT – Retail pharmacy-Specialist		25	-	Alkeran
Inj 50 mg – PCT only – Specialist	67.80	1	✓ ↓	Alkeran

	Subsidy		Fully	
	(Manufacturer's Price) \$	Per	Subsidised	
OXALIPLATIN – PCT only – Specialist				
Inj 100 mg vial	25.01	1	~	Oxaliplatin Actavis 100
	110.00		1	Oxaliplatin Ebewe
Inj 5 mg per ml, 20 ml vial	46.32	1		Oxaliccord Oxaliplatin Accord
Inj 1 mg for ECP	0.48	1 mg	1	Baxter
(Oxaliccord Inj 5 mg per ml, 20 ml vial to be delisted 1 Februar	y 2020)	•		
THIOTEPA – PCT only – Specialist				
Inj 15 mg vial	CBS	1	1	Bedford S29
, ,			1	THIO-TEPA S29
			1	Tepadina S29
Inj 100 mg vial	CBS	1		Tepadina S29
Antimetabolites				
AZACITIDINE – PCT only – Specialist – Special Authority see	SA1467 below			
Inj 100 mg vial		1	1	Azacitidine Dr Reddy's
	605.00		1	Vidaza
Inj 1 mg for ECP		1 mg	1	Baxter

► SA1467 Special Authority for Subsidy

Initial application only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
 - 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
 - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- 2 The patient has performance status (WHO/ECOG) grade 0-2; and
- 3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
- 4 The patient has an estimated life expectancy of at least 3 months.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

	Subsidy acturer's Price)	Fu Subsidise	•
(Manu	acturer's Price) \$	Per	Manufacturer
ALCIUM FOLINATE			
Tab 15 mg - PCT - Retail pharmacy-Specialist1	04.26	10 •	 DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	17.10	5 •	 Hospira
Inj 10 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist	.7.28	1 •	Calcium Folinate Sandoz
Inj 50 mg - PCT - Retail pharmacy-Specialist	18.25	5 •	Calcium Folinate Ebewe
Inj 10 mg per ml, 10 ml vial – PCT only – Specialist	.9.49	1 •	 Calcium Folinate Sandoz
Inj 100 mg - PCT only - Specialist	.7.33	1 •	 Calcium Folinate Ebewe
Inj 300 mg - PCT only - Specialist	22.51	1 •	 Calcium Folinate Ebewe
Inj 10 mg per ml, 35 ml vial – PCT only – Specialist	25.14	1 •	 Calcium Folinate Sandoz
Inj 1 g – PCT only – Specialist	67.51	1 •	Calcium Folinate Ebewe
Inj 10 mg per ml, 100 ml vial – PCT only – Specialist	72.00	1 •	 Calcium Folinate Sandoz
Inj 1 mg for ECP – PCT only – Specialist alcium Folinate Ebewe Inj 50 mg to be delisted 1 March 2020)	.0.06	1 mg 🔹	Baxter
APECITABINE – Retail pharmacy-Specialist			
Tab 150 mg	11.15	60 •	Brinov
Tab 500 mg	62.28	120 •	Brinov
ADRIBINE – PCT only – Specialist			
Inj 1 mg per ml, 10 ml5,2		-	Leustatin
Inj 10 mg for ECP7	49.96 10	mg OP 🔹	Baxter
/TARABINE			
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist4 Inj 100 mg per ml, 20 ml vial – PCT – Retail		-	Pfizer
pharmacy-Specialist			Pfizer
Inj 1 mg for ECP – PCT only – Specialist		. 3	Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist		5 -	Baxter
Tab 10 mg – PCT – Retail pharmacy-Specialist4			Fludara Oral
Inj 50 mg vial – PCT only – Specialist			Fludarabine Ebewe
Inj 50 mg for ECP – PCT only – Specialist1 UOROURACIL	15.29 50	5 -	Baxter
Inj 50 mg per ml, 20 ml vial – PCT only – Specialist			Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml vial – PCT only – Specialist Inj 1 mg for ECP – PCT only – Specialist			 Fluorouracil Ebewe Baxter
EMCITABINE HYDROCHLORIDE - PCT only - Specialist			
Inj 1 g, 26.3 ml vial	62.50		DBL Gemcitabine
Inj 1 g	15.89	-	Gemcitabine Ebewe
	49.20		Gemzar
Inj 1 mg for ECP	.0.02	1 mg 🔹	Baxter

	Subsidy		Fully	Brand or
(1	Manufacturer's Price		ubsidised	Generic
	\$	Per	/	Manufacturer
IRINOTECAN HYDROCHLORIDE – PCT only – Specialist				
Inj 20 mg per ml, 5 ml vial	71.44	1	✓	rinotecan
				Accord S29
			✓ 1	rinotecan Actavis
				100
	100.00		✓ 1	rinotecan-Rex
Inj 1 mg for ECP	0.75	1 mg	 Image: A second s	Baxter
MERCAPTOPURINE		-		
Tab 50 mg – PCT – Retail pharmacy-Specialist		25	 Image: A second s	Puri-nethol
Oral suspension 20 mg per ml – Retail pharmacy-Specialist –			-	
Special Authority see SA1725 below	428.00 10	00 ml OF	1	Allmercap
- CA1725 Creation Authority for Cubaidy		-		

⇒SA1725 Special Authority for Subsidy

Initial application only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where the patient requires a total dose of less than one full 50 mg tablet per day.

Renewal only from a paediatric haematologist or paediatric oncologist. Approvals valid for 12 months where patient still requires a total dose of less than one full 50 mg tablet per day.

METHOTREXATE

*	Tab 2.5 mg – PCT – Retail pharmacy-Specialist8.05	90	✓ Trexate
*	Tab 10 mg – PCT – Retail pharmacy-Specialist	90	✓ Trexate
*	Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	 Hospira
*	Inj 7.5 mg prefilled syringe14.61	1	 Methotrexate
			Sandoz
*	Inj 10 mg prefilled syringe14.66	1	 Methotrexate
			Sandoz
*	Inj 15 mg prefilled syringe14.77	1	 Methotrexate
	1 - 31 3		Sandoz
*	Inj 20 mg prefilled syringe14.88	1	✓ Methotrexate
			Sandoz
*	Inj 25 mg prefilled syringe14.99	1	✓ Methotrexate
ጥ	Inj 25 mg premied synnige	1	Sandoz
*	Ini 20 ma profilled ouringe	1	✓ Methotrexate
*	Inj 30 mg prefilled syringe15.09	I	
		_	Sandoz
*	Inj 25 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist30.00	5	 DBL Methotrexate
			Onco-Vial
*	Inj 25 mg per ml, 20 ml vial – PCT – Retail pharmacy-Specialist45.00	1	 DBL Methotrexate
			Onco-Vial
*	Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist25.00	1	 Methotrexate Ebewe
*	Inj 100 mg per ml, 50 ml vial – PCT – Retail		
	pharmacy-Specialist	1	 Methotrexate Ebewe
*	Inj 1 mg for ECP – PCT only – Specialist0.06	1 mg	✓ Baxter
*	Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist	5 mg ÕP	 Baxter
PF	METREXED – PCT only – Specialist – Special Authority see SA1679 on the	0	
	Inj 100 mg vial	1	Juno Pemetrexed
	Inj 500 mg vial	1	 ✓ Juno Pemetrexed ✓ Juno Pemetrexed
		1 mg	✓ Baxter
	Inj 1 mg for ECP0.55	i ng	

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per ✓	Manufacturer

⇒SA1679 Special Authority for Subsidy

Initial application — (mesothelioma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 Patient has been diagnosed with mesothelioma; and
- 2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.

Renewal — (mesothelioma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment; and
- 3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.

Initial application — (non-small cell lung carcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

1 Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and

2 Either:

- 2.1 Both:
 - 2.1.1 Patient has chemotherapy-naïve disease; and
 - 2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
- 2.2 All of the following:
 - 2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
 - 2.2.2 Patient has not received prior funded treatment with pemetrexed; and
 - 2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

Renewal — (non-small cell lung carcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

- All of the following:
 - 1 No evidence of disease progression; and
 - 2 The treatment remains appropriate and the patient is benefitting from treatment; and
 - 3 Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

THIOGUANINE - PCT - Retail pharmacy-Specialist

Tab 40 mg126.31	25	 Lanvis
Other Cytotoxic Agents		
AMSACRINE – PCT only – Specialist Inj 50 mg per ml, 1.5 ml ampoule	6 5	 Amsidine S29 AmsaLyo S29
ANAGRELIDE HYDROCHLORIDE – PCT – Retail pharmacy-Specialist Cap 0.5 mgCBS	100	✓ Agrylin S23 ✓ Teva S29
ARSENIC TRIOXIDE – PCT only – Specialist Inj 1 mg per ml, 10 ml vial4,817.00 Inj 10 mg for ECP481.70	10 10 mg OP	✓ Phenasen✓ Baxter

	Subsidy (Manufacturer's Price \$) Sub Per	Fully sidised	Brand or Generic Manufacturer
BLEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu, vial	161.01	1	✓ D	BL Bleomycin Sulfate
Inj 1,000 iu for ECP	12.45	1,000 iu	🗸 В	axter
BORTEZOMIB – PCT only – Specialist – Special Authority see S/ Inj 3.5 mg vial Inj 1 mg for ECP	1,892.50	1 1 mg	•	elcade eaxter

➡SA1576 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
- 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.
- Note: Indications marked with * are unapproved indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 The patient has relapsed or refractory multiple myeloma; or
 - 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and

2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

- a) a known therapeutic chemotherapy regimen and supportive treatments; or
- b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

COLASPASE [L-ASPARAGINASE] - PCT only - Specialist

Inj 10,000 iu	102.32	1	 Leunase
Inj 10,000 iu for ECP	102.32	10,000 iu OP	 Baxter
DACARBAZINE – PCT only – Specialist			
Inj 200 mg vial	58.06	1	 DBL Dacarbazine
	580.60	10	 Dacarbazine
			APP S29
Inj 200 mg for ECP	58.06	200 mg OP	 Baxter
DACTINOMYCIN [ACTINOMYCIN D] - PCT only - Specialist			
Inj 0.5 mg vial	166.75	1	 Cosmegen
Inj 0.5 mg for ECP	166.75	0.5 mg OP	 Baxter

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy Manufacturor's P	rico)	Fully	
	(Manufacturer's P \$	rice) Per	Subsidised	Generic Manufacturer
AUNORUBICIN – PCT only – Specialist				
Inj 2 mg per ml, 10 ml		1	1	Pfizer
Inj 20 mg for ECP		20 mg (Baxter
OCETAXEL – PCT only – Specialist		5		
Inj 10 mg per ml, 2 ml vial	12/0	1	1	DBL Docetaxel
Inj 20 mg		1		Docetaxel Sandoz
Inj 10 mg per ml, 8 ml vial		1		DBL Docetaxel
Inj 20 mg per ml, 4 ml vial		1	-	Docetaxel
			•	Accord S29
Inj 80 mg	195.00	1	1	Docetaxel Sandoz
Inj to ing		1 mg		Baxter
	0.55	i iig	•	Daxlei
DXORUBICIN HYDROCHLORIDE – PCT only – Specialist	10.00			Devenuble in Etc.
Inj 2 mg per ml, 5 ml vial		1		Doxorubicin Ebewe
Inj 2 mg per ml, 25 ml vial		1	-	Doxorubicin Ebewe
	17.00			Arrow-Doxorubicin
Inj 2 mg per ml, 50 ml vial		1		Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial		1		Doxorubicin Ebewe
	65.00	4	-	Arrow-Doxorubicin
Inj 1 mg for ECP	0.29	1 mg	~	Baxter
PIRUBICIN HYDROCHLORIDE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml vial		1		Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial		1		Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial		1		Epirubicin Ebewe
Inj 1 mg for ECP	0.37	1 mg	1	Baxter
TOPOSIDE				
Cap 50 mg - PCT - Retail pharmacy-Specialist	340.73	20	✓	Vepesid
Cap 100 mg - PCT - Retail pharmacy-Specialist	340.73	10	✓	Vepesid
Inj 20 mg per ml, 5 ml vial - PCT - Retail pharmacy-Specialis	t7.90	1	✓	Rex Medical
Inj 1 mg for ECP – PCT only – Specialist	0.09	1 mg	1	Baxter
OPOSIDE PHOSPHATE – PCT only – Specialist				
Inj 100 mg (of etoposide base)		1	1	Etopophos
Inj 1 mg (of etoposide base) for ECP		1 mg	-	Baxter
DROXYUREA – PCT – Retail pharmacy-Specialist		0		
Cap 500 mg	31.76	100	1	Hydrea
		100	•	nyarea
	00.00			7
Inj 5 mg vial – PCT only – Specialist		1		Zavedos
Inj 10 mg vial – PCT only – Specialist			-	Zavedos
Inj 1 mg for ECP – PCT only – Specialist		1 mg	•	Baxter
NALIDOMIDE - Retail pharmacy-Specialist - Special Authority	see SA1468 be	elow		
Wastage claimable			-	
Cap 10 mg		21		Revlimid
Cap 15 mg		21		Revlimid
Cap 25 mg	7,627.00	21	1	Revlimid

➡SA1468 Special Authority for Subsidy

Initial application — (Relapsed/refractory disease) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

	Subsidy	F	ully	Brand or
(Ma	anufacturer's Price)	Subsidi	sed	Generic
	\$	Per	✓	Manufacturer

continued...

1 Patient has relapsed or refractory multiple myeloma with progressive disease; and

2 Either:

2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or

2.2 Both:

2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and

- 2.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 No evidence of disease progression; and

2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

MESNA

Tab 400 mg – PCT – Retail pharmacy-Specialist	50	 Uromitexan
Tab 600 mg – PCT – Retail pharmacy-Specialist	50	 Uromitexan
Inj 100 mg per ml, 4 ml ampoule – PCT only – Specialist 177.45	15	 Uromitexan
Inj 100 mg per ml, 10 ml ampoule - PCT only - Specialist	15	 Uromitexan
Inj 1 mg for ECP – PCT only – Specialist2.96	100 mg	 Baxter
MITOMYCIN C – PCT only – Specialist	-	
Inj 5 mg vial204.08	1	 Arrow
Inj 1 mg for ECP42.04	1 mg	 Baxter
MITOZANTRONE – PCT only – Specialist	•	
Inj 2 mg per ml, 10 ml vial	1	 Mitozantrone Ebewe
Inj 1 mg for ECP5.51	1 mg	 Baxter
PACLITAXEL – PCT only – Specialist	•	
Inj 30 mg47.30	5	Paclitaxel Ebewe
Inj 100 mg20.00	1	Paclitaxel Ebewe
91.67		Paclitaxel Actavis
lnj 150 mg26.69	1	Paclitaxel Ebewe
137.50		 Anzatax
		Paclitaxel Actavis
lnj 300 mg35.35	1	Paclitaxel Ebewe
275.00		 Anzatax
		Paclitaxel Actavis
Inj 1 mg for ECP0.19	1 mg	 Baxter
PEGASPARGASE - PCT only - Special Authority see SA1325 on the next page		
Inj 3,750 IU per 5 ml	1	 Oncaspar S29

	Subsidy Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
SA1325 Special Authority for Subsidy nitial application only from a relevant specialist or medical practiti pprovals valid for 12 months for applications meeting the following Il of the following:		nendatio	on of a re	levant specialist.
 The patient has newly diagnosed acute lymphoblastic leuka Pegaspargase to be used with a contemporary intensive mutility Treatment is with curative intent. 		rapy trea	atment pr	otocol; and
tenewal only from a relevant specialist or medical practitioner on t or 12 months for applications meeting the following criteria: Il of the following:	he recommendation	n of a re	levant spe	ecialist. Approvals valio
 The patient has relapsed acute lymphoblastic leukaemia; an Pegaspargase to be used with a contemporary intensive mu Treatment is with curative intent. 		rapy trea	atment pr	otocol; and
PENTOSTATIN [DEOXYCOFORMYCIN] - PCT only - Specialist				
Inj 10 mg		1	✓ N	ipent S29
ROCARBAZINE HYDROCHLORIDE – PCT – Retail pharmacy-S	•			
Cap 50 mg	980.00	50	🖌 N	atulan S29
1 0		00	• 14	alulali
EMOZOLOMIDE – Special Authority see SA1741 below – Retail				
		5		rion
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg	10.20	5	✓ 0	rion Temozolomide
EMOZOLOMIDE – Special Authority see SA1741 below – Retail	10.20		✓ 0 ✓ T	rion Temozolomide emaccord
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg	10.20	5	✓ 0 ✓ T ✓ A	rion Temozolomide emaccord po-Temozolomide
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg	10.20	5	✓ 0 ✓ T ✓ A	rion Temozolomide emaccord
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg	10.20	5	✓ 0 ✓ T ✓ A ✓ 0	rion Temozolomide emaccord po-Temozolomide rrion
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg	10.20 16.38 18.30	5	✓ 0 ✓ T ✓ A ✓ 0 ✓ T	rion Temozolomide emaccord po-Temozolomide irion Temozolomide
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg	10.20 16.38 18.30	5	✓ 0 ✓ T ✓ A ✓ 0 ✓ T ✓ T ✓ A	rion Temozolomide emaccord po-Temozolomide rion Temozolomide emizole 20 \$29 emaccord po-Temozolomide
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg	10.20 16.38 18.30 	5	✓ 0 ✓ T ✓ A ✓ 0 ✓ T ✓ T ✓ A	rion Temozolomide emaccord po-Temozolomide rion Temozolomide emizole 20 \$29 emaccord po-Temozolomide rion
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg Cap 20 mg	10.20 16.38 18.30 35.98 40.20	5 5 5	✓ 0 ✓ T ✓ A ✓ 0 ✓ T ✓ T ✓ A ✓ 0	rion Temozolomide emaccord po-Temozolomide rion Temozolomide emizole 20 \$29 emaccord po-Temozolomide rion Temozolomide
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg	10.20 16.38 18.30 35.98 40.20 50.12	5	✓ 0 ✓ T ✓ A ✓ 0 ✓ T ✓ T ✓ A ✓ 0 ✓ T	rion Temozolomide emaccord po-Temozolomide rion Temozolomide emizole 20 \$29 emaccord po-Temozolomide rion Temozolomide emaccord
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg Cap 20 mg	10.20 16.38 18.30 35.98 40.20	5 5 5	✓ 0 ✓ T ✓ A ✓ 0 ✓ T ✓ T ✓ A ✓ 0 ✓ T	rion Temozolomide emaccord po-Temozolomide rion Temozolomide emizole 20 \$29 emaccord po-Temozolomide rion Temozolomide emaccord rion
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg Cap 20 mg Cap 100 mg Cap 140 mg	10.20 16.38 18.30 35.98 40.20 50.12 56.00	5 5 5 5	 ✓ 0 ✓ T ✓ A ✓ 0 ✓ T ✓ A ✓ 0 ✓ T ✓ 0 ✓ T ✓ 0 ✓ T ✓ 0 ✓ T ✓ 0 ✓ 0	rrion Temozolomide emaccord po-Temozolomide rrion Temozolomide emizole 20 \$29 emaccord po-Temozolomide prion Temozolomide emaccord prion Temozolomide
EMOZOLOMIDE – Special Authority see SA1741 below – Retail Cap 5 mg Cap 20 mg	10.20 16.38 18.30 35.98 40.20 50.12 56.00	5 5 5	✓ 0 ✓ T ✓ A ✓ 0 ✓ T ✓ T ✓ A ✓ 0 ✓ T ✓ T ✓ 0 ✓ T ✓ 0 ✓ 0 ✓ 1 ✓ 1 ✓ 0 ✓ 1 ✓ 1 ✓ 1 ✓ 1 ✓ 1 ✓ 1 ✓ 1 ✓ 1 ✓ 1 ✓ 1	rion Temozolomide emaccord po-Temozolomide rion Temozolomide emizole 20 \$29 emaccord po-Temozolomide rion Temozolomide emaccord rion

⇒SA1741 Special Authority for Subsidy

Initial application — (high grade gliomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
 - 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
 - 3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle, at a maximum dose of 200 mg/m² per day.

Initial application - (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 9 months for applications

Subsidy		Fully	Brand or
(Manufacturer's P	rice)	Subsidised	Generic
\$	Per	 ✓ 	Manufacturer

continued...

meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
- 2 Temozolomide is to be given in combination with capecitabine; and
- 3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose of 200 mg/m² per day; and
- 4 Temozolomide to be discontinued at disease progression.

Initial application — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 9 months where the patient has relapsed/refractory Ewing's sarcoma.

Renewal — (high grade gliomas) only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Patient has glioblastoma multiforme; and
- 1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
- 2 All of the following:
 - 2.1 Patient has anaplastic astrocytoma*; and
 - 2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
 - 2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Renewal — (neuroendocrine tumours) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Renewal — (ewing's sarcoma) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not subsidised for the treatment of relapsed high grade glioma.

THALIDOMIDE - Retail pharmacy-Specialist - Special Authority see SA1124 below

Cap 50 mg		28	 Thalomid
Cap 100 mg	756.00	28	 Thalomid

■SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an unapproved indication.

TRETINOIN

	Subsidy Manufacturer's Price)	Sub	Fully sidised	Brand or Generic
	\$	Per	✓	Manufacturer
VINBLASTINE SULPHATE				
Inj 1 mg per ml, 10 ml vial – PCT – Retail pharmacy-Specialisi		5	🗸 Н	lospira
Inj 1 mg for ECP – PCT only – Specialist	4.14	1 mg	🗸 В	Baxter
VINCRISTINE SULPHATE				
Inj 1 mg per ml, 1 ml vial – PCT – Retail pharmacy-Specialist.	74.52	5	✓ D	BL Vincristine Sulfate
Inj 1 mg per ml, 2 ml vial – PCT – Retail pharmacy-Specialist.	85.61	5	✓ D	BL Vincristine Sulfate
Inj 1 mg for ECP – PCT only – Specialist	11.30	1 mg	🗸 В	laxter
VINORELBINE – PCT only – Specialist				
Inj 10 mg per ml, 1 ml vial	12.00	1	🖌 N	lavelbine
	42.00		🗸 V	inorelbine Ebewe
Inj 10 mg per ml, 5 ml vial	56.00	1	🗸 N	lavelbine
	210.00		-	inorelbine Ebewe
Inj 1 mg for ECP	1.25	1 mg	✓ В	Baxter

Protein-tyrosine Kinase Inhibitors

DASATINIB - Special Authority see SA1805 below - Retail pharmacy

Tab 20 mg	60	 Sprycel
Tab 50 mg	60	 Sprycel
Tab 70 mg	60	 Sprycel

⇒SA1805 Special Authority for Subsidy

Initial application only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

- Any of the following:
 - 1 Both:
 - 1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
 - 1.2 Maximum dose of 140 mg/day; or
 - 2 Both:
 - 2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
 - 2.2 Maximum dose of 140 mg/day; or
 - 3 All of the following:
 - 3.1 The patient has a diagnosis of CML in chronic phase; and
 - 3.2 Maximum dose of 100 mg/day; and
 - 3.3 Any of the following:
 - 3.3.1 Patient has documented treatment failure* with imatinib; or
 - 3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
 - 3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or
 - 3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

Renewal only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Lack of treatment failure while on dasatinib*; and
- 2 Dasatinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum dasatinib dose of 140 mg/day for accelerated or blast phase CML and Ph+ ALL, and 100 mg/day for chronic phase CML.

Note: *treatment failure for CML as defined by Leukaemia Net Guidelines. **Kinase-Inhibition Study with Sprycel Start-up https://www.cancertrialsnz.ac.nz/kiss/

	Subsidy (Manufacturer's Price) \$	Pe	Fully Subsidised	d Generic
ERLOTINIB – Retail pharmacy-Specialist – Special Authority se	ee SA1653 below			
Tab 100 mg		30		Tarceva
Tab 150 mg	1,146.00	30	v	Tarceva
 SA1653 Special Authority for Subsidy Initial application only from a relevant specialist or medical pra Approvals valid for 4 months for applications meeting the followid All of the following: 1 Patient has locally advanced or metastatic, unresectable 2 There is documentation confirming that the disease expr 3 Either: 3.1 Patient is treatment naive; or 3.2 Both: 3.2.1 The patient has discontinued gefitinib due 3.2.2 The cancer did not progress while on gefit 4 Erlotinib is to be given for a maximum of 3 months. Renewal only from a relevant specialist or medical practitioner of for 6 months where radiological assessment (preferably includint) 	ing criteria: , non-squamous Non s esses activating mutat to intolerance; and tinib; and on the recommendatio	Smal tions	I Cell Lung of EGFR t a relevant	Cancer (NSCLC); and yrosine kinase; and specialist. Approvals valid
GEFITINIB – Retail pharmacy-Specialist – Special Authority se		1001		piogressed.
Tab 250 mg		30	1	Iressa
SA1654 Special Authority for Subsidy Initial application only from a relevant specialist or medical pra Approvals valid for 4 months for applications meeting the followi All of the following: 1 Patient has locally advanced, or metastatic, unresectable 2 Either:	ing criteria:			
2 Eurier. 2.1 Patient is treatment naive; or				
2.2 Both:				
2.2.1 The patient has discontinued erlotinib due2.2.2 The cancer did not progress whilst on erlo				
3 There is documentation confirming that disease express4 Gefitinib is to be given for a maximum of 3 months.	0			
Renewal only from a relevant specialist or medical practitioner of for 6 months where radiological assessment (preferably includin				
IMATINIB MESILATE				
Note: Imatinib-AFT is not a registered for the treatment of 0 imatinib mesilate (supplied by Novartis) remains fully subsid metastatic malignant GIST, see SA1460 in Section B of the Total Course II and the interview of the subside the section B of the	dised under Special Au	uthor	ity for patie	
Tab 100 mg – [Xpharm] – Special Authority see SA1460 below	2 400 00	60	1	Glivec
* Cap 100 mg	,	60		Imatinib-AFT
* Cap 400 mg		30		Imatinib-AFT
Special Authority for Subsidy Special Authority by the CML/GIST Co-ordinator				
Notes: Application details may be obtained from PHARMAC's v sent to:	vebsite <u>http://www.pha</u>	irma	<u>c.govt.nz</u> , a	and prescriptions should be

Subsidy (Manufacturer's Price)	Fi Subsidis	ully	Brand or Generic
\$	Per	✓	Manufacturer

continued...

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: cmlgistcoordinator@pharmac.govt.nz
Wellington	

Special Authority criteria for GIST - access by application

Funded for patients:

- a) With a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST).
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

LAPATINIB DITOSYLATE - Special Authority see SA1191 below - Retail pharmacy

Tab 250 mg 1,899.00 70 🗸 Tykerb

⇒SA1191 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

NILOTINIB - Special Authority see SA1489 on the next page - Retail pharmacy

Wastage claimable		
Cap 150 mg4,680.0	0 120	🗸 Tasigna
Cap 200 mg6,532.0	0 120	🗸 Tasigna

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	1	Manufacturer	

⇒SA1489 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and 2 Either:

2.1 Patient has documented CML treatment failure* with imatinib; or

2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and

- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Renewal only from a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PAZOPANIB - Special Authority see SA1190 below - Retail pharmacy

Tab 200 mg1,334.70) 30	Votrient
Tab 400 mg2,669.40) 30	 Votrient

⇒SA1190 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of less than or equal to 70; or
 - 5.6 2 or more sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

	Subsidy (Manufacturer's Price) \$	Per		Brand or Generic Manufacturer
RUXOLITINIB – Special Authority see SA1753 below – Retail pha	armacy			
Wastage claimable				
Tab 5 mg	2,500.00	56	v ,	Jakavi
Tab 15 mg	5,000.00	56	✓,	Jakavi
Tab 20 mg	5,000.00	56	✓.	Jakavi
- CA17ED One sight Authority for Outpainty				

⇒SA1753 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
- 2 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
- 3 A maximum dose of 20 mg twice daily is to be given.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 A maximum dose of 20 mg twice daily is to be given.

SUNITINIB - Special Authority see SA1266 below - Retail pharmacy

Cap 12.5 mg	2,315.38	28	 Sutent
Cap 25 mg	4,630.77	28	 Sutent
Cap 50 mg	9,261.54	28	 Sutent

➡SA1266 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of less than or equal to 70; or
 - 5.6 2 or more sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application - (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant

Subsidy	Fully	/ Brand or	
(Manufacturer's Price)	Subsidised	d Generic	
\$	Per 🗸	Manufacturer	

continued...

specialist. Approvals valid for 3 months for applications meeting the following criteria:

- Both:
 - 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and

2 Either:

- 2.1 The patient's disease has progressed following treatment with imatinib; or
- 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria: Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Endocrine Therapy

For GnRH ANALOGUES - refer to HORMONE PREPARATIONS, Trophic Hormones, page 83

ABIRATERONE ACETATE - Retail pharmacy-Specialist - Special Authority see SA1767 below

Wastage claimable

➡SA1767 Special Authority for Subsidy

Initial application only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has prostate cancer; and
- 2 Patient has metastases; and
- 3 Patient's disease is castration resistant; and
- 4 Either:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 4.1 All of the following:
 - 4.1.1 Patient is symptomatic; and
 - 4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
 - 4.1.3 Patient has ECOG performance score of 0-1; and
 - 4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
- 4.2 All of the following:
 - 4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and
 - 4.2.2 Patient has ECOG performance score of 0-2; and
 - 4.2.3 Patient has not had prior treatment with abiraterone.

Renewal — (abiraterone acetate) only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Significant decrease in serum PSA from baseline; and
- 2 No evidence of clinical disease progression; and
- 3 No initiation of taxane chemotherapy with abiraterone; and
- 4 The treatment remains appropriate and the patient is benefiting from treatment.

BICALUTAMIDE

Tab 50 mg	3.80	28	 Binarex
FLUTAMIDE – Retail pharmacy-Specialist			
Tab 250 mg	100.38	84	✓ Flutamide
	119.50	100	Mylan S29 ✓ Flutamin
MEGESTROL ACETATE – Retail pharmacy-Specialist			
Tab 160 mg	63.53	30	Apo-Megestrol
OCTREOTIDE			
Inj 50 mcg per ml, 1 ml vial		5	DBL Octreotide
Inj 100 mcg per ml, 1 ml vial		5	 DBL Octreotide
Inj 500 mcg per ml, 1 ml vial	72.50	5	 DBL Octreotide
OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) - Spec	cial Authority see SA1	016 below -	Retail pharmacy
Inj LAR 10 mg prefilled syringe	1,772.50	1	 Sandostatin LAR
Inj LAR 20 mg prefilled syringe		1	 Sandostatin LAR
Inj LAR 30 mg prefilled syringe	2,951.25	1	 Sandostatin LAR

⇒SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application - (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant

Subsidy		Fully	Brand or	
(Manufacturer's Price	e) S	ubsidised	Generic	
\$	Per	1	Manufacturer	

continued...

specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

1 VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or

2 Both:

- 2.1 Gastrinoma; and
- 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or

3 Both:

- 3.1 Insulinomas; and
- 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or

5 Both:

- 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
- 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

TAMOXIFEN CITRATE

Tab 10 mg11.75 Tab 20 mg	60 60	 <u>Tamoxifen Sandoz</u> <u>Tamoxifen Sandoz</u>
ç		

Aromatase Inhibitors

ANASTROZOLE		
* Tab 1 mg5.04	30	 Rolin
EXEMESTANE		
EXEMISTANE		
* Tab 25 mg14.50	30	 Pfizer Exemestane

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
LETROZOLE * Tab 2.5 mg	4.68	30	1	Letrole
Immunosuppressants				
Cytotoxic Immunosuppressants				
AZATHIOPRINE – Retail pharmacy-Specialist				
* Tab 25 mg	7.35	60	1	Azamun
	9.66	100	1	Imuran
Azamun to be Sole Supply on 1 January 2020				
* Tab 50 mg	7.60	100	✓	Azamun
	10.58		1	Imuran
Azamun to be Sole Supply on 1 January 2020			-	
* Inj 50 mg vial		1	~	Imuran
(Imuran Tab 25 mg to be delisted 1 January 2020) (Imuran Tab 50 mg to be delisted 1 January 2020)				
MYCOPHENOLATE MOFETIL				
Tab 500 mg	25.00	50	✓	Cellcept
Cap 250 mg		100	✓	Cellcept
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement. Mycophenolate powder for oral liquid is subsidised only the prescription is endorsed accordingly.		65 ml o swal	-	Cellcept and capsules, and when
Fusion Proteins				
ETANERCEPT - Special Authority see SA1812 below - Retail	pharmacy			Faland

Inj 25 mg		4	 Enbrel
Inj 50 mg autoinjector		4	 Enbrel
Inj 50 mg prefilled syringe	1,599.96	4	 Enbrel

SA1812 Special Authority for Subsidy

Initial application - (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and 1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance: and
 - 2.2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
- 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and 1.2 Either:

Subsidy	Full	/ Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per 🖌	Manufacturer	

continued...

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm 65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

1 Both:

Fither:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

	Subsidy		Fully	Brand or
1)	Manufacturer's Price)	Subsid	dised	Generic
	\$	Per	~	Manufacturer

continued...

- 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
 - 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

Subsidy		Fully	Brand or
(Manufacturer's Price) (Subsidised	Generic
\$	Per	1	Manufacturer

continued...

- 1.1 Applicant is a dermatologist; or
- 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

2 Either:

2.1 Both:

2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

2.1.2 Either:

- 2.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
- 2.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

2.2 Both:

- 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Subsidy		Fully	Brand or
(Manufacturer's Price)	Sub	sidised	Generic
\$	Per	✓	Manufacturer

continued...

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 The patient has a sustained improvement in inflammatory markers and functional status.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist Inj 50 mg per ml, 5 ml2,351.25	5	🗸 ATGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE - PCT only - Specialist		
Subsidised only for bladder cancer.		
Inj 2-8 × 100 million CFU149.37	1	 OncoTICE
Inj 40 mg per ml, vial162.70	3	 SII-Onco-BCG §29
(SII-Onco-BCG S29 Inj 40 mg per ml, vial to be delisted 1 January 2020)		

Monoclonal Antibodies

ADALIMUMAB – Special Authority see SA1847 below – R	etail pharmacy		
Inj 20 mg per 0.4 ml prefilled syringe	1,599.96	2	🗸 Humira
Inj 40 mg per 0.8 ml prefilled pen	1,599.96	2	 HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe	1,599.96	2	🗸 Humira

⇒SA1847 Special Authority for Subsidy

Initial application — (Crohn's disease - adults) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids: and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (Crohn's disease - adults) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

Sub	bsidy	Fully	Brand or
(Manufactu	urer's Price) Subs	sidised	Generic
	\$ Per	1	Manufacturer

continued...

All of the following:

1 Either:

- 1.1 Applicant is a gastroenterologist; or
- 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (Crohn's disease - children) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (Crohn's disease - children) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Either:

- 2.1 Either:
 - 2.1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 PCDAI score is 15 or less; or
- 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that PCDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (adult-onset Still's disease) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Fither:

1 Both:

1.1 Fither:

continued...

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsid	ised	Generic
\$	Per	1	Manufacturer

continued...

- 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
- 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD: or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 The patient has a sustained improvement in inflammatory markers and functional status.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- Either:
 - 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
 - 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

continued...

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for chronic ocular inflammation; or

2 Both:

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 12 weeks' initial treatment; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < 1/2+ anterior chamber or vitreous cells, absence of active

Subsidy	Fu	lly Brand or	
(Manufacturer's Price)	Subsidise	ed Generic	
\$	Per	 Manufacturer 	

continued...

- vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Patient has confirmed Crohn's disease; and

2 Either:

- 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
- 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and
- 4 The patient will be assessed for response to treatment after 4 months' adalimumab treatment (see Note).

Note: A maximum of 4 months' adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn's disease.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or
- 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient diagnosed with JIA; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
- 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
- 2.5.2 Physician's global assessment indicating severe disease.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

	Subsidy		Fully	Brand or
(Man	ufacturer's Price)	Subsid	dised	Generic
	\$	Per	✓	Manufacturer

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Note: Indications marked with * are unapproved indications.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
- 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
- 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

- 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Initial application — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has severe Behcet's disease that is significantly impacting the patient's quality of life (see Notes); and
- 2 Either:
 - 2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or
 - 2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and
- 3 The patient is experiencing significant loss of quality of life; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: Behcet's disease diagnosed according to the International Study Group for Behcet's disease. Lancet

1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al, J Rheumatol. 2004;31:931-7.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

Renewal — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Renewal — (severe chronic plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Either:
 - 2.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or

Subsidy	F	ully	Brand or	
(Manufacturer's Price)	Subsidi	sed	Generic	
\$	Per	1	Manufacturer	

continued...

2.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline valuee; or

2.2 Both:

- 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Initial application — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from infliximab; or
 - 1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or
- 2 Both:
 - 2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
 - 2.2 Any of the following:
 - 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
 - 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
 - 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has had a good clinical response following 3 initial doses; or
 - 1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
 - 1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and</p>
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if adalimumab is withdrawn.

Initial application — (hidradenitis suppurativa) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

continued...

AThree months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or
(Manufacturer's Price)	5	Subsidised	Generic
\$	Per	1	Manufacturer

continued...

- 1 Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
- 2 Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
- 3 The patient has 3 or more active lesions (e.g. inflammatory nodules, abscesses, draining fistulae); and
- 4 The patient has a Dermatology Quality of Life Index of 10 or more and the assessment is no more than 1 month old at time of application; and
- 5 Following the initial loading doses, adalimumab is to be administered at doses no greater than 40mg every 7 days.

Renewal — (hidradenitis suppurativa) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
- 2 The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
- 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

🗸 Eylea

1

⇒SA1772 Special Authority for Subsidy

Initial application — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Any of the following:
 - 1.1.1 Wet age-related macular degeneration (wet AMD); or
 - 1.1.2 Polypoidal choroidal vasculopathy; or
 - 1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
 - 1.2 Either:
 - 1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
 - 1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
 - 1.3 There is no structural damage to the central fovea of the treated eye; and
 - 1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
- 2 Either:
 - 2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
 - 2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Initial application — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has centre involving diabetic macular oedema (DMO); and
- 2 Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
- 3 Patient has reduced visual acuity between 6/9 6/36 with functional awareness of reduction in vision; and
- 4 Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
- 5 There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Renewal — (wet age related macular degeneration) only from an ophthalmologist. Approvals valid for 12 months for

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

applications meeting the following criteria:

All of the following:

- 1 Documented benefit must be demonstrated to continue; and
- 2 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 3 There is no structural damage to the central fovea of the treated eye.

Renewal — (diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 There is stability or two lines of Snellen visual acuity gain; and
- 2 There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
- 3 Patient's vision is 6/36 or better on the Snellen visual acuity score; and
- 4 There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
- 5 After each consecutive 12 months treatment with (2nd line anti-VEGF agent), patient has retrialled with at least one injection of bevacizumab and had no response.

CETUXIMAB - PCT only - Specialist - Special Authority see SA1697 below

Inj 5 mg per ml, 20 ml vial	64.00	1	 Erbitux
Inj 5 mg per ml, 100 ml vial1,8	20.00	1	 Erbitux
Inj 1 mg for ECP	3.82	1 mg	 Baxter

► SA1697 Special Authority for Subsidy

Initial application only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
- 2 Patient is contraindicated to, or is intolerant of, cisplatin; and
- 3 Patient has good performance status; and
- 4 To be administered in combination with radiation therapy.

INFLIXIMAB - PCT only - Special Authority see SA1831 below

Inj 100 mg		1	Remicade
Inj 1 mg for ECP	8.29	1 mg	 Baxter

⇒SA1831 Special Authority for Subsidy

Initial application — (Crohn's disease (adults)) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Renewal - (Crohn's disease (adults)) only from a gastroenterologist or Practitioner on the recommendation of a

Subsidy		Fully	Brand or	
(Manufacturer's Price	e)	Subsidised	Generic	
\$	Per	1	Manufacturer	

gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 Any of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Crohn's disease (children)) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Either:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Renewal — (Crohn's disease (children)) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (Graft vs host disease) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has steroid-refractory acute graft vs. host disease of the gut.

Initial application — (Pulmonary sarcoidosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has life-threatening pulmonary sarcoidosis diagnosed by a multidisciplinary team that is refractory to other treatments.

Initial application — (acute severe fulminant ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 weeks for applications meeting the following criteria: Both:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful.

Initial application — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and

2 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
- 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initial application - (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Fither:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and 1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab: or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation: or

2 Both:

- 2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2.2 Any of the following:
 - 2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective: or
 - 2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or
 - 2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Renewal — (chronic ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has had a good clinical response following 3 initial doses; or
- 2 Following each 12 month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < 1/2+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12 month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability. unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initial application - (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 4 months for applications meeting the following criteria: Both:

1 Patient has confirmed Crohn's disease: and

2 Either:

2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

2.2 Patient has one or more rectovaginal fistula(e).

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application - (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist.

Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with neurosarcoiosis by a multidisciplinary team; and
- 2 Patient has CNS involvement; and
- 3 Patient has steroid-refractory disease; and
- 4 Either:
 - 4.1 IV cyclophosphamide has been tried; or
 - 4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Renewal — (neurosarcoidosis) only from a neurologist or Practitioner on the recommendation of a neurologist. Approvals valid for 18 months for applications meeting the following criteria:

Either:

- 1 A withdrawal period has been tried and the patient has relapsed; or
- 2 All of the following:
 - 2.1 A withdrawal period has been considered but would not be clinically appropriate; and
 - 2.2 There has been a marked reduction in prednisone dose; and
 - 2.3 Either:
 - 2.3.1 There has been an improvement in MRI appearances; or
 - 2.3.2 Marked improvement in other symptomology.

Initial application — (plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 3 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Renewal — (plaque psoriasis)** only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

1 Either:

- 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
- 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with infliximab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 Rheumatoid arthritis; or
 - 2.2 Ankylosing spondylitis; or
 - 2.3 Psoriatic arthritis; or
 - 2.4 Severe ocular inflammation; or
 - 2.5 Chronic ocular inflammation; or
 - 2.6 Crohn's disease (adults); or
 - 2.7 Crohn's disease (children); or
 - 2.8 Fistulising Crohn's disease; or
 - 2.9 Severe fulminant ulcerative colitis; or

continued...

Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	sidised	Generic	
\$	Per	1	Manufacturer	

continued...

- 2.10 Severe ulcerative colitis; or
- 2.11 Plaque psoriasis; or
- 2.12 Neurosarcoidosis; or
- 2.13 Severe Behcet's disease.

Initial application — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initial application — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and 2 Fither:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initial application — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

1 The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes); and

2 Either:

196

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
- 2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
- 3 The patient is experiencing significant loss of quality of life.

Notes: Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.

Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

Renewal — (severe Behcet's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Renewal — (severe fulminant ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

Initial application — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and

1.2 Either:

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or

2 Both:

2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and

2.2 Any of the following:

- 2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or
- 2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or
- 2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Renewal — (severe ocular inflammation) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

1 The patient has had a good clinical response following 3 initial doses; or

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2 Following each 12 month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
- 3 Following each 12 month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initial application — (severe ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
 - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Renewal — (severe ulcerative colitis) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
 - 2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle. Up to 10 mg/kg every 8 weeks (or equivalent) may be used for patients treated with this dose prior to 1 February 2019.

OBINUTUZUMAB - PCT only - Specialist - Special Authority see SA1627 below

Inj 25 mg per ml, 40 ml vial	5,910.00	1	🖌 Gazyva
Inj 1 mg for ECP	6.21	1 mg	 Baxter

⇒SA1627 Special Authority for Subsidy

Initial application — (chronic lymphocytic leukaemia) only from a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

198

- 1 The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
- 2 The patient is obinutuzumab treatment naive; and
- 3 The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and</p>
- 4 Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
- 5 Patient has good performance status; and

	Subsidy	Fully	Brand or
	acturer's Price) S	Subsidised	Generic
· · · · · · · · · · · · · · · · · · ·	\$ Per	✓	Manufacturer

continued...

6 Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

Notes: Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* Neutrophil greater than or equal to 1.5×10^9 /L and platelets greater than or equal to 75×10^9 /L.

OMALIZUMAB - Special Authority see SA1744 below - Retail pharmacy

Inj 150 mg prefilled syringe		1	🗸 Xolair
Inj 150 mg vial	450.00	1	🗸 Xolair

⇒SA1744 Special Authority for Subsidy

Initial application — (severe asthma) only from a respiratory specialist or clinical immunologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 6 years or older; and
- 2 Patient has a diagnosis of severe asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Either:
 - 6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
 - 6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
- 7 Patient has an Asthma Control Test (ACT) score of 10 or less; and
- 8 Baseline measurements of the patient's asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Initial application — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient must be aged 12 years or older; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
 - 2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; or
 - 2.2 Patient has a Urticaria Control Test (UCT) of 8 or less; and
- 3 Any of the following:
 - 3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
 - 3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
 - 3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and

4 Either:

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 4.1 Treatment to be stopped if inadequate response* following 4 doses; or
- 4.2 Complete response* to 6 doses of omalizumab.

Renewal — (severe asthma) only from a clinical immunologist or respiratory specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
- 2 A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Renewal — (severe chronic spontaneous urticaria) only from a clinical immunologist or dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Patient has previously adequately responded* to 6 doses of omalizumab; or

2 Both:

- 2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
- 2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB – PCT only – Specialist – Special Authority see SA1606 below

Inj 30 mg per ml, 14 ml vial	 1	 Perjeta
Inj 420 mg for ECP	 420 mg OP	 Baxter

⇒SA1606 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:

- 2.1 Patient is chemotherapy treatment naïve; or
- 2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
- 3 The patient has good performance status (ECOG grade 0-1); and
- 4 Pertuzumab to be administered in combination with trastuzumab; and
- 5 Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
- 6 Pertuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RITUXIMAB - PCT only - Specialist - Special Authority see SA1818 on the next page

Inj 100 mg per 10 ml vial		2	 Mabthera
Inj 500 mg per 50 ml vial	2,688.30	1	 Mabthera
Inj 1 mg for ECP	5.64	1 mg	 Baxter

	Subsidy	Fully	Brand or
(Manuf	facturer's Price) Subs	idised	Generic
	\$ Per	~	Manufacturer

⇒SA1818 Special Authority for Subsidy

Initial application — (ABO-incompatible renal transplant) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid without further renewal unless notified where patient is to undergo an ABO-incompatible renal transplant*.

Note: Indications marked with * are unapproved indications.

Initial application — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 3 Any of the following:
 - 3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
 - 3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
 - 3.3 Cyclophosphamide and methotrexate are contraindicated; or
 - 3.4 Patient is a female of child-bearing potential; or
 - 3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

Renewal — (ANCA associated vasculitis) from any relevant practitioner. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Antibody-mediated renal transplant rejection) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid without further renewal unless notified where patient has been diagnosed with antibody-mediated renal transplant rejection^{*}.

Note: Indications marked with * are unapproved indications.

Initial application — (Chronic lymphocytic leukaemia) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient does not have chromosome 17p deletion CLL; and
- 6 Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	✓	Manufacturer	

continued...

7 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2. **Renewal — (Chronic lymphocytic leukaemia)** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
- 2 The patient has had an interval of 36 months or more since commencement of initial rituximab treatment; and
- 3 The patient does not have chromosome 17p deletion CLL; and
- 4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
- 5 Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

Renewal — (Neuromyelitis Optica Spectrum Disorder) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

Initial application — (Neuromyelitis Optica Spectrum Disorder(NMOSD)) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m2 administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Initial application — (Post-transplant) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Renewal — (Post-transplant) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.
- Note: Indications marked with * are unapproved indications.

Initial application — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 Either:
 - 2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
 - 2.2 Both:
 - 2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
 - 2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Renewal — (Severe Refractory Myasthenia Gravis) only from a neurologist or medical practitioner on the recommendation of a neurologist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 One of the following dose regimens is to be used: 375 mg/m2 of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Either:
 - 3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
 - 3.2 Both:
 - 3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
 - 3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Initial application — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS))

only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient is a child with SDNS* or FRNS*; and
- 2 Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
- 3 Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
- 4 Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
- 5 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 4 weeks for applications meeting the following criteria: All of the following:

- 1 Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
- 2 Treatment with tacrolimus for at least 3 months has been ineffective; and
- 3 Genetic causes of nephrotic syndrome have been excluded; and
- 4 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Renewal — (Steroid resistant nephrotic syndrome (SRNS)) only from a nephrologist or Practitioner on the recommendation of a nephrologist. Approvals valid for 4 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
- 2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
- 3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

Initial application — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Renewal — (aggressive CD20 positive NHL) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria: Any of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Renewal — (haemophilia with inhibitors) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initial application — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 weeks for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
- 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

Note: Indications marked with * are unapproved indications.

Renewal — (immune thrombocytopenic purpura (ITP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 weeks for applications meeting the following criteria:

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria: Either:

1 Both:

- The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or

2 Both:

- The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Renewal — (indolent, low-grade lymphomas or hairy cell leukaemia*) from any relevant practitioner. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom

macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with rituximab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 haemophilia with inhibitors; or
 - 2.2 rheumatoid arthritis; or
 - 2.3 severe cold haemagglutinin disease (CHAD); or
 - 2.4 warm autoimmune haemolytic anaemia (warm AIHA); or
 - 2.5 immune thrombocytopenic purpura (ITP); or
 - 2.6 thrombotic thrombocytopenic purpura (TTP); or
 - 2.7 pure red cell aplasia (PRCA); or
 - 2.8 ANCA associated vasculitis; or
 - 2.9 treatment refractory systemic lupus erythematosus (SLE); or
 - 2.10 steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS).

Initial application — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

Renewal — (pure red cell aplasia (PRCA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 6 weeks where patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

Initial application — (rheumatoid arthritis - TNF inhibitors contraindicated) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of

Subsidy	Ful	y Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per •	Manufacturer	

leflunomide alone or in combination with oral or parenteral methotrexate; and

- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8 Either:

- 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initial application — (rheumatoid arthritis - prior TNF inhibitor use) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

1 Both:

- 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Renewal — (rheumatoid arthritis - re-treatment in 'partial responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

- 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	✓	Manufacturer	

Renewal — (rheumatoid arthritis - re-treatment in 'responders' to rituximab) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physiciann; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

- 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
- 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and 4 Maximum of two 1.000 mg infusions of rituximab given two weeks apart.
- **Initial application** (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 weeks for applications meeting the following criteria:
- Both:
 - 1 Patient has cold haemagglutinin disease*; and
 - 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with * are unapproved indications.

Renewal — (severe cold haemagglutinin disease (CHAD)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 weeks for applications meeting the following criteria: Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 weeks for applications meeting the following criteria: Either:

- 1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
- 2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

Renewal — (thrombotic thrombocytopenic purpura (TTP)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 weeks for applications meeting the following criteria: All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initial application — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 7 months for applications meeting

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

the following criteria:

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Renewal — (treatment refractory systemic lupus erythematosus (SLE)) only from a rheumatologist, nephrologist or Practitioner on the recommendation of a rheumatologist or nephrologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

Initial application — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 weeks for applications meeting the following criteria: Both:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are unapproved indications.

Renewal — (warm autoimmune haemolytic anaemia (warm AIHA)) only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 4 weeks for applications meeting the following criteria: Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

SECUKINUMAB - Special Authority see SA1754 below - Retail pharmacy

Inj 150 mg per ml, 1 ml prefilled syringe......1,599.00 2 Cosentyx

⇒SA1754 Special Authority for Subsidy

Initial application — (severe chronic plaque psoriasis – second-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
 - 2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
- 3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has

Subsidy		Fully	Brand or
(Manufacturer's Price) S	Subsidised	Generic
\$	Per	✓	Manufacturer

continued...

been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Initial application — (severe chronic plaque psoriasis – first-line biologic) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Renewal — (severe chronic plaque psoriasis – first and second-line biologic) only from a dermatologist or medical practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

1 Either:

- 1.1 Patient's PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
- 1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
- 2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

SILTUXIMAB - Special Authority see SA1596 below - Retail pharmacy

Note: Siltuximab is to be administered at doses no	greater than 11 mg/kg every	3 weeks.	
Inj 100 mg vial		1	 Sylvant
Inj 400 mg vial		1	 Sylvant

► SA1596 Special Authority for Subsidy

Initial application only from a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's Disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

Renewal only from a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

(Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
TOCILIZUMAB - PCT only - Special Authority see SA1781 below	1			
Inj 20 mg per ml, 4 ml vial		1	1	Actemra
Inj 20 mg per ml, 10 ml vial		1	1	Actemra
Inj 20 mg per ml, 20 ml vial		1	✓	Actemra
Inj 1 mg for ECP		1 mg	~	Baxter

➡SA1781 Special Authority for Subsidy

Initial application — (cytokine release syndrome) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient is enrolled in the Children's Oncology Group AALL1331 trial; and
 - 1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and
 - 1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses; or
- 2 All of the following:
 - 2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
 - 2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
 - 2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initial application — (previous use) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient was being treated with tocilizumab prior to 1 February 2019; and
- 2 Any of the following:
 - 2.1 rheumatoid arthritis; or
 - 2.2 systemic juvenile idiopathic arthritis; or
 - 2.3 adult-onset Still's disease; or
 - 2.4 polyarticular juvenile idiopathic arthritis; or
 - 2.5 idiopathic multicentric Castleman's disease.

Initial application — (Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
- 3 Either:
 - 3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
 - 3.2 Both:
 - 3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
 - 3.2.2 Either:
 - 3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
 - 3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subsid	dised	Generic	
\$	Per	1	Manufacturer	

Initial application — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
- 2 Tocilizumab is to be used as monotherapy; and
- 3 Either:
 - 3.1 Treatment with methotrexate is contraindicated; or
 - 3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
- 4 Either:
 - 4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
 - 4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and

5 Either:

- 5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
- 5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 6 Either:
 - 6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
- 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Initial application — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Initial application — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and
- 1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or
- 2 All of the following:
 - 2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and
 - 2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and
- 2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
- 3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

Renewal — (Rheumatoid Arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

Renewal — (systemic juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either:

- Either:
 - 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
 - 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Renewal — (adult-onset Still's disease) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months where the patient has a sustained improvement in inflammatory markers and functional status.

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subsi	dised	Generic
\$	Per	~	Manufacturer

Renewal — (polyarticular juvenile idiopathic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (idiopathic multicentric Castleman's disease) only from a haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist. Approvals valid for 12 months where the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – PCT only – Specialist – Special Authority see SA1632 below

Inj 150 mg vial		1	 Herceptin
Inj 440 mg vial		1	 Herceptin
Inj 1 mg for ECP	9.36	1 mg	 Baxter

► SA1632 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 2.2 Both:
 - 2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on lapatinib; and
- 3 Either:
 - 3.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 3.2 All of the following:
 - 3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 3.2.3 The patient has good performance status (ECOG grade 0-1); and
- 4 Trastuzumab not to be given in combination with lapatinib; and
- 5 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and

Subsidy (Manufacturer's Price)	Su	Fully bsidised	Brand or Generic
\$	Per	1	Manufacturer

continued...

4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
 - 3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
 - 3.2 Both:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; or
 - 3.3 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 4 Either:
 - 4.1 Trastuzumab will not be given in combination with pertuzumab; or
 - 4.2 All of the following:
 - 4.2.1 Trastuzumab to be administered in combination with pertuzumab; and
 - 4.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
 - 4.2.3 The patient has good performance status (ECOG grade 0-1); and
- 5 Trastuzumab not to be given in combination with lapatinib; and
- 6 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Programmed Cell Death-1 (PD-1) Inhibitors

		NIVOLUMAB – PCT only – Specialist – Special Authority see SA1656 below
🗸 Opdivo	1	Inj 10 mg per ml, 4 ml vial1,051.98
 Opdivo 	1	Inj 10 mg per ml, 10 ml vial2,629.96
 Baxter 	1 mg	Inj 1 mg for ECP

⇒SA1656 Special Authority for Subsidy

Initial application — (unresectable or metastatic melanoma) only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

Subsidy		ully	Brand or
(Manufacturer's	Price) Subsid	ised	Generic
\$	Per	✓	Manufacturer

continued...

All of the following:

- 1 Patient has metastatic or unresectable melanoma stage III or IV; and
- 2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded pembrolizumab; or

4.2 Both:

- 4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
- 4.2.2 The cancer did not progress while the patient was on pembrolizumab; and
- 5 Nivolumab is to be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles); and
- 6 Baseline measurement of overall tumour burden is documented (see Note); and
- 7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of nivolumab will not be continued beyond 12 weeks (6 cycles) if their disease progresses during this time.

Renewal — (unresectable or metastatic melanoma) only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note; or
 - 1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.3 Patient has stable disease according to RECIST criteria (see Note); and
- 2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and
- 3 No evidence of progressive disease according to RECIST criteria (see Note); and
- 4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
- 5 Nivolumab will be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB - PCT only - Specialist - Special Authority see SA1657 on the next page

Inj 25 mg per ml, 4 ml vial	 1	 Keytruda
Inj 1 mg for ECP	 1 mg	 Baxter

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subsid	dised	Generic
 \$	Per	1	Manufacturer

► SA1657 Special Authority for Subsidy

Initial application — (unresectable or metastatic melanoma) only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has metastatic or unresectable melanoma stage III or IV; and
- 2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and
- 3 The patient has ECOG performance score of 0-2; and
- 4 Either:
 - 4.1 Patient has not received funded nivolumab; or

4.2 Both:

- 4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance; and
- 4.2.2 The cancer did not progress while the patient was on nivolumab; and
- 5 Pembrolizumab is to be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles); and
- 6 Baseline measurement of overall tumour burden is documented (see Note); and
- 7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of pembrolizumab will not be continued beyond 12 weeks (4 cycles) if their disease progresses during this time.

Renewal — (unresectable or metastatic melanoma) only from a medical oncologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
 - 1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
 - 1.3 Patient has stable disease according to RECIST criteria (see Note); and
- 2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and
- 3 No evidence of progressive disease according to RECIST criteria (see Note); and
- 4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
- 5 Pembrolizumab will be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks. Response definitions as follows:

- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
Other Immunosuppressants				
CICLOSPORIN Cap 25 mg Cap 50 mg Cap 100 mg Oral liq 100 mg per ml	88.91 177.81	50 50 50 0 ml C	1 1	Neoral Neoral Neoral Neoral
EVEROLIMUS – Special Authority see SA1491 below – Retail pha Wastage claimable Tab 10 mg Tab 5 mg	6,512.29	30 30		Afinitor Afinitor

➡SA1491 Special Authority for Subsidy

Initial application only from a neurologist or oncologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has tuberous sclerosis; and
- 2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Renewal only from a neurologist or oncologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Documented evidence of SEGA reduction or stabilisation by MRI within the last 3 months; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

SIROLIMUS – Special Authority see SA0866 below – Retail pharmacy

Tab 1 mg	 100	 Rapamune
Tab 2 mg	 100	 Rapamune
Oral liq 1 mg per ml	 60 ml OP	 Rapamune

► SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR< 30 ml/min; or
- · Rapidly progressive transplant vasculopathy; or
- · Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- · Leukoencepthalopathy; or
- Significant malignant disease

TACROLIMUS – Special Authority see SA1745 below – Retail pharmacy

Cap 0.5 mg	 100	 Tacrolimus Sandoz
Cap 0.75 mg	 100	Tacrolimus Sandoz
Cap 1 mg	100	Tacrolimus Sandoz
Cap 5 mg	 50	 Tacrolimus Sandoz

⇒SA1745 Special Authority for Subsidy

Initial application - (organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified

continued...

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	1	Manufacturer	

continued...

where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

Initial application — (non-transplant indications*) only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient requires long-term systemic immunosuppression; and
- 2 Ciclosportin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

Note: Indications marked with * are unapproved indications

(N)	Subsidy lanufacturer's Price)	Subs	Fully idised	Brand or Generic
(iv	\$	Per		Manufacturer
Antiallergy Preparations				
Allergic Emergencies				
ICATIBANT – Special Authority see SA1558 below – Retail pharma Inj 10 mg per ml, 3 ml prefilled syringe SA1558 Special Authority for Subsidy Initial application only from a clinical immunologist or relevant spec the following criteria:	.2,668.00	1 valid for 12		razyr s for applications meeting
 Both: 1 Supply for anticipated emergency treatment of laryngeal/oro-angioedema (HAE) for patients with confirmed diagnosis of C 2 The patient has undergone product training and has agreed a Renewal from any relevant practitioner. Approvals valid for 12 mon is benefiting from treatment. 	1-esterase inhibite	or deficien n for self-a	cy; and dminist	ration.
Allergy Desensitisation				
Initial application only from a relevant specialist. Approvals valid for Both: 1 RAST or skin test positive; and 2 Patient has had severe generalised reaction to the sensitising Renewal only from a relevant specialist. Approvals valid for 2 years benefiting from treatment	g agent.		-	
benefiting from treatment. BEE VENOM ALLERGY TREATMENT – Special Authority see SA1	367 above – Reta	il pharmac	;y	
Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent	285.00	1 OP	🗸 V	enomil S29
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent	205.00	1 OP		lbov
9 ml, 3 diluent 1.8 ml Treatment kit - 1 vial 550 mcg freeze dried venom, with diluent .		1 OP 1 OP	✓ A ✓ H	idey ymenoptera S29
WASP VENOM ALLERGY TREATMENT – Special Authority see S. Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze		-		
dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze	305.00	1 OP	🗸 A	lbey
dried venom, with diluent Treatment kit (Paper wasp venom) - 6 vials 120 mcg freeze	305.00	1 OP	✔ H	ymenoptera S29
dried venom, with diluent Treatment kit (Yellow Jacket venom) - 1 vial 550 mcg freeze	305.00	1 OP	🗸 V	enomil S29
dried venom, with diluent Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze	305.00	1 OP	✓ Н	ymenoptera S29
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml	305.00	1 OP	🗸 A	lbey

✓ Venomil S29

Treatment kit (Yellow jacket venom) - 6 vials 120 mcg freeze

1 OP

_					
		Subsidy		Fully	Brand or
		(Manufacturer's F	Price) Subs	idised	Generic
		\$	Per	✓	Manufacturer
Α	ntihistamines				
CF	TIRIZINE HYDROCHLORIDE				
	Tab 10 mg	1 1 2	100	1	Zista
~	Zista to be Sole Supply on 1 November 2019		100	•	21310
*	11.5	0.00	000 ml		Histaclear
	Oral liq 1 mg per ml	2.99	200 ml	v	Histaclear
	ILORPHENIRAMINE MALEATE				
*	Oral liq 2 mg per 5 ml	9.37	500 ml	✓	Histafen
		0.00	10		
*	Tab 2 mg		40		
		(8.40)			Polaramine
		1.01	20		
		(5.99)			Polaramine
*	Oral liq 2 mg per 5 ml		100 ml		
		(10.29)			Polaramine
		(
	XOFENADINE HYDROCHLORIDE				
*	Tab 60 mg		20		
		(8.23)			Telfast
*	Tab 120 mg	4.74	10		
		(8.23)			Telfast
		14.22	30		
		(26.44)			Telfast
		(20.44)			rendet
	RATADINE				
*	Tab 10 mg	1.28	100		Lorafix
*	Oral liq 1 mg per ml	2.15	120 ml	-	Lorfast
PF	OMETHAZINE HYDROCHLORIDE				
*	Tab 10 mg	1.68	50	1	Allersoothe
	Tab 25 mg		50		Allersoothe
	•				
	Oral liq 1 mg per 1 ml		100 ml		Allersoothe
*	Inj 25 mg per ml, 2 ml ampoule - Up to 5 inj available on a F	PSO 15.54	5	•	Hospira
Ľ	nhaled Corticosteroids				
BE	CLOMETHASONE DIPROPIONATE				
	Aerosol inhaler, 50 mcg per dose		200 dose OP	1	Qvar
	Aerosol inhaler, 50 mcg per dose CFC-free		200 dose OP		Beclazone 50
	Aerosol inhaler, 100 mcg per dose		200 dose OP		Qvar
	Aerosol inhaler, 100 mcg per dose CFC-free		200 dose OP		Beclazone 100
	Aerosol inhaler, 250 mcg per dose CFC-free		200 dose OP	•	Beclazone 250
ΒL	DESONIDE				
	Powder for inhalation, 100 mcg per dose		200 dose OP	1	Pulmicort
	,				Turbuhaler
	Powder for inhalation, 200 mag par doca	10.00	200 dose OP	1	Pulmicort
	Powder for inhalation, 200 mcg per dose		200 UUSE OP	•	
					Turbuhaler
	Powder for inhalation, 400 mcg per dose		200 dose OP	~	Pulmicort
					Turbuhaler

Subsidy		Fully Brand or
		dised Generic Manufacturer
Ψ	1.01	· Manufacturer
4.00	100 1000 000	
		✓ Floair
		✓ Flixotide
		 Flixotide Accuhaler
		 Flixotide Accuhaler
		✓ Floair
		 ✓ Flixotide ✓ Floair
		 ✓ Flixotide
	60 dose OP	 Flixotide Accuhaler
sts		
evice20.64	60 dose	
(35.80)		Foradil
. ,		
se) 10.32	60 dose OP	
,		Oxis Turbuhaler
(10.00)		
C1 00		/ Onderen Dresenheler
		 Onbrez Breezhaler Onbrez Breezhaler
	30 00se OP	 Onbrez Breeznaler
		 Serevent
		✓ Meterol
25.00	60 dose OP	 Serevent Accuhaler
a-Adrenocept	or Agonists	
	120 dose OP	🗸 Vannair
	120 dose OP 120 dose OP	 ✓ Vannair ✓ Symbicort
18.23 6 mcg33.74		 ✓ Vannair ✓ Symbicort Turbuhaler 100/6
6 mcg33.74		 Symbicort
6 mcg33.74	120 dose OP 120 dose OP	 ✓ Symbicort Turbuhaler 100/6 ✓ Vannair
6 mcg33.74	120 dose OP	 Symbicort Turbuhaler 100/6
6 mcg33.74	120 dose OP 120 dose OP	 ✓ Symbicort Turbuhaler 100/6 ✓ Vannair ✓ Symbicort
3 mcg33.74 21.40 3 mcg44.08	120 dose OP 120 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6
6 mcg33.74	120 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort
3 mcg33.74 21.40 3 mcg44.08	120 dose OP 120 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12
3 mcg33.74 21.40 3 mcg44.08	120 dose OP 120 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP 30 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12 Breo Ellipta
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12 Breo Ellipta RexAir
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP 30 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12 Breo Ellipta RexAir Seretide
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP 30 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12 Breo Ellipta RexAir Seretide RexAir
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP 30 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12 Breo Ellipta RexAir Seretide
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP 30 dose OP 120 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12 Breo Ellipta RexAir Seretide RexAir Seretide
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP 30 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12 Breo Ellipta RexAir Seretide RexAir
3 mcg33.74 	120 dose OP 120 dose OP 120 dose OP 60 dose OP 30 dose OP 120 dose OP 120 dose OP	 Symbicort Turbuhaler 100/6 Vannair Symbicort Turbuhaler 200/6 Symbicort Turbuhaler 400/12 Breo Ellipta RexAir Seretide RexAir Seretide
	\$	4.68 120 dose OP 7.50 120 dose OP 7.50 60 dose OP 7.50 60 dose OP 7.50 60 dose OP 7.22 120 dose OP 13.60 120 dose OP 10.18 120 dose OP 27.20 120 dose OP 13.60 60 dose OP ists 60 dose OP sevice 20.64 60 dose OP (16.90) 60 dose OP 61.00 30 dose OP 25.00 120 dose OP 120 dose OP 120 dose OP

222

	Subsidy		Fully Brand or
	(Manufacturer's I		
	\$	Per	Manufacturer
Beta-Adrenoceptor Agonists			
SALBUTAMOL			
Oral liq 400 mcg per ml		150 ml	✓ <u>Ventolin</u>
Infusion 1 mg per ml, 5 ml		10	 Ventolin
Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO	53.00	5	 Ventolin
Inhaled Beta-Adrenoceptor Agonists			
SALBUTAMOL			
Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000			
dose available on a PSO	3.80	200 dose OP	 Respigen
			✓ SalAir
	(6.00)		Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml ampoule – Up to 30 neb		00	A sthe line
available on a PSO		20	 Asthalin
Nebuliser soln, 2 mg per ml, 2.5 ml ampoule – Up to 30 neb available on a PSO		20	 Asthalin
		20	• <u>Astriani</u>
TERBUTALINE SULPHATE Powder for inhalation, 250 mcg per dose, breath activated	27 30	200 dose OP	 Bricanyl Turbuhaler
		200 0030 01	
Anticholinergic Agents			
IPRATROPIUM BROMIDE			
Aerosol inhaler, 20 mcg per dose CFC-free – Up to 400 dos	0		
available on a PSO		200 dose OP	 Atrovent
Nebuliser soln, 250 mcg per ml, 1 ml ampoule - Up to 40 ne			
available on a PSO		20	 Univent
Nebuliser soln, 250 mcg per ml, 2 ml ampoule – Up to 40 ne	эb		
available on a PSO	11.73	20	 Univent
Univent to be Sole Supply on 1 January 2020			
Inhaled Beta-Adrenoceptor Agonists with Antic	holinergic A	gents	
SALBUTAMOL WITH IPRATROPIUM BROMIDE			
Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg	ber		
dose CFC-free		200 dose OP	 Duolin HFA
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per			
vial, 2.5 ml ampoule – Up to 20 neb available on a PSO	5.20	20	✓ <u>Duolin</u>
Long-Acting Muscarinic Antagonists			
GLYCOPYRRONIUM – Subsidy by endorsement			
a) Inhaled glycopyrronium treatment will not be subsidised in	f patient is also r	receiving treatme	ent with subsidised tiotropium of
umeclidinium.	cubeidicad anh	for patients wh	a hava boon diagnosod ca
b) Glycopyrronium powder for inhalation 50 mcg per dose is having COPD using spirometry, and the prescription is er	ndorsed accordi	nalv	o nave been ulaynosed as
Powder for inhalation 50 mcg per dose		30 dose OP	 Seebri Breezhaler

	Subsidy		Fully	Brand or
	(Manufacturer's Pri		Subsidised	Generic
	\$	Per	1	Manufacturer
TIOTROPIUM BROMIDE – Subsidy by endorsement				
 a) Tiotropium treatment will not be subsidised if patient is umeclidinium. 	also receiving treatr	nent with s	subsidised	inhaled glycopyrronium or
b) Tiotropium bromide is subsidised only for patients who prescription is endorsed accordingly. Patients who had Authority are deemed endorsed.				
Powder for inhalation, 18 mcg per dose	50.37	30 dose		Spiriva
Soln for inhalation 2.5 mcg per dose		60 dose C)P 🖌 S	Spiriva Respimat
UMECLIDINIUM – Subsidy by endorsement				
 a) Umeclidinium will not be subsidised if patient is also red tiotropium bromide. 	ceiving treatment wit	h subsidis	ed inhaled	d glycopyrronium or
b) Umeclidinium powder for inhalation 62.5 mcg per dose COPD using spirometry, and the prescription is endorse		or patients	who have	been diagnosed as having
Powder for inhalation 62.5 mcg per dose	61.50	30 dose C)P 🖌 I	ncruse Ellipta

Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

Combination long acting muscarinic antagonist and long acting beta-2 agonist will not be subsidised if patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

■SA1584 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Patient has been stabilised on a long acting muscarinic antagonist; and

2 The prescriber considers that the patient would receive additional benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Patient is compliant with the medication: and
- 2 Patient has experienced improved COPD symptom control (prescriber determined).

GLYCOPYRRONIUM WITH INDACATEROL - Special Authority see SA1584 above - Retail	pharmacy
Powder for Inhalation 50 mcg with indacaterol 110 mcg81.00 30 dose Ol	 Viltibro Breezhaler
TIOTROPIUM BROMIDE WITH OLODATEROL - Special Authority see SA1584 above - Ret	ail pharmacy
Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg81.00 60 dose Ol	Spiolto Respimat
UMECLIDINIUM WITH VILANTEROL - Special Authority see SA1584 above - Retail pharma	ICY

Powder for inhalation 62.5 mcg with vilanterol 25 mcg77.00 30 dose OP Anoro Ellipta

Antifibrotics

NINTEDANIB – Special Authority see SA1755 below – Retail pharmacy						
Note: Nintedanib not subsidised in combination with subs	sidised pirfenidone.					
Cap 100 mg		60 OP	 Ofev 			
Cap 150 mg		60 OP	 Ofev 			

■SA1755 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 2 Forced vital capacity is between 50% and 90% predicted; and
- 3 Nintedanib is to be discontinued at disease progression (See Note); and
- 4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with pirfenidone; or
 - 5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received pirfenidone, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
- 3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE - Retail pharmacy-Specialist - Special Authority see SA1748 below

Note: Pirfenidone is not subsidised in combination with subsidised nintedanib.

► SA1748 Special Authority for Subsidy

Initial application — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
- 2 Forced vital capacity is between 50% and 80% predicted; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note); and
- 4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 5 Any of the following:
 - 5.1 The patient has not previously received treatment with nintedanib; or
 - 5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
 - 5.3 Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Renewal — (idiopathic pulmonary fibrosis) only from a respiratory specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
- 2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
- 3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

	Subsidy		Fully Brand or
	(Manufacturer's Pric	ce) Subs Per	sidised Generic Manufacturer
	φ	Fel	
Leukotriene Receptor Antagonists			
MONTELUKAST			
* Tab 4 mg	4.25	28	 Montelukast Mylan
	5.25		 Apo-Montelukast
Montelukast Mylan to be Sole Supply on 1 January 2020		00	Mantalukaat Mulan
₭ Tab 5 mg	4.25 5.50	28	 Montelukast Mylan Apo-Montelukast
Montelukast Mylan to be Sole Supply on 1 January 2020			
₭ Tab 10 mg		28	 Montelukast Mylan
	5.65		Accord S29
			 Apo-Montelukast
Montelukast Mylan to be Sole Supply on 1 January 2020			
Apo-Montelukast Tab 4 mg to be delisted 1 January 2020) Apo-Montelukast Tab 5 mg to be delisted 1 January 2020)			
Accord S29 Tab 10 mg to be delisted 1 January 2020)			
Apo-Montelukast Tab 10 mg to be delisted 1 January 2020)			
Mast Cell Stabilisers			
IEDOCROMIL			
Aerosol inhaler, 2 mg per dose CFC-free		12 dose OP	✓ Tilade
ODIUM CROMOGLICATE			
Aerosol inhaler, 5 mg per dose CFC-free		12 dose OP	 Intal Forte CFC Free
Mathylyanthinas			
Methylxanthines			
MINOPHYLLINE			
Inj 25 mg per ml, 10 ml ampoule − Up to 5 inj available on a	404.07	_	
PSO		5	 DBL Aminophylline
	00.00	100	
 Tab long-acting 250 mg Nuelin-SR to be Sole Supply on 1 January 2020 	23.02	100	Nuelin-SR
 Oral lig 80 mg per 15 ml 	16.60	500 ml	✓ Nuelin
Nuelin to be Sole Supply on 1 January 2020			
Mucolytics			
ORNASE ALFA – Special Authority see SA0611 below – Retail	pharmacy		
Nebuliser soln, 2.5 mg per 2.5 ml ampoule		6	 Pulmozyme
SA0611 Special Authority for Subsidy			
Special Authority approved by the Cystic Fibrosis Advisory Panel			
lotes: Application details may be obtained from PHARMAC's we	ebsite http://www.p	harmac.govt	. <u>nz</u> or:
The Co-ordinator, Cystic Fibrosis Advisory Panel Phone: (0	4) 460 4990		
PHARMAC, PO Box 10 254 Facsimile:	(04) 916 7571		
Wellington Email: CF	Panel@pharmac.	govt.nz	
and the second			- Read at the second

Prescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.

	Subsidy (Manufacturer's \$	Price) Subsi Per	Fully Brand or idised Generic ✓ Manufacturer
ODIUM CHLORIDE	Ψ	1 61	• Manulacturer
Not funded for use as a nasal drop.			
Soln 7%	24.50	90 ml OP	 Biomed
Biomed to be Sole Supply on 1 November 2019			
Nasal Preparations			
Allergy Prophylactics			
BECLOMETHASONE DIPROPIONATE			
Metered aqueous nasal spray, 50 mcg per dose	2.35	200 dose OP	
	(5.26)		Alanase
Metered aqueous nasal spray, 100 mcg per dose		200 dose OP	Alemana
Alapage Metered aguague pagel aprov. 50 mag par dage to be a	(6.00) Ioliatad 1, Ianua	(m/ 2020)	Alanase
Alanase Metered aqueous nasal spray, 50 mcg per dose to be o Alanase Metered aqueous nasal spray, 100 mcg per dose to be			
Nanase Metered aqueous nasar spray, 100 micy per dose to be		ury 2020)	
Metered aqueous nasal spray, 50 mcg per dose	2.59	200 dose OP	✓ SteroClear
Metered aqueous nasal spray, 100 mcg per dose		200 dose OP	✓ SteroClear
LUTICASONE PROPIONATE			
Metered aqueous nasal spray, 50 mcg per dose	1.98	120 dose OP	 Flixonase Hayfever
			& Allergy
PRATROPIUM BROMIDE			
Aqueous nasal spray, 0.03%	4.61	15 ml OP	 Univent
Respiratory Devices			
MASK FOR SPACER DEVICE			
 a) Up to 50 dev available on a PSO b) Only on a PSO 			
c) Only for children aged six years and under			
Small	2.20	1	 e-chamber Mask
PEAK FLOW METER			
a) Up to 25 dev available on a PSO			
b) Only on a PSO			
Low range	9.54	1	 Mini-Wright AFS
			Low Range
Normal range	9.54	1	 Mini-Wright Standard
PACER DEVICE			Stanuaru
a) Up to 50 dev available on a PSO			
b) Only on a PSO			
220 ml (single patient)	2.95	1	🗸 e-chamber Turbo
510 ml (single patient)		1	 e-chamber La
			Grande
800 ml	6.50	1	 Volumatic
Respiratory Stimulants			
Oral liq 20 mg per ml (10 mg base per ml)	15 10	25 ml OP	 Biomed

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

			<u> </u>
	Subsidy (Manufacturer's F	Prico) Subo	Fully Brand or idised Generic
	(International Clutter S r	Per	✓ Manufacturer
	¥	-	
Ear Preparations			
ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BI	ENZETHONIUM		
For Vosol ear drops with hydrocortisone powder refer Stand		ige 235	
Ear drops 2% with 1, 2-Propanediol diacetate 3% and		-	
benzethonium chloride 0.02%	6.97	35 ml OP	✓ Vosol
FLUMETASONE PIVALATE			
Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	 Locacorten-Viaform ED's
			✓ Locorten-Vioform
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYC		ΓΙΝ	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate			
2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml OP	Kenacomb
Lio mg and gramoun Loo mog por g			- Rendoemb
Ear/Eye Preparations			
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and			
gramicidin 50 mcg per ml	4.50	8 ml OP	
	(9.27)		Sofradex
FRAMYCETIN SULPHATE			
Ear/Eye drops 0.5%	4.13	8 ml OP	
	(8.65)		Soframycin
Eye Preparations			
Eye preparations are only funded for use in the eye, unless expli	citly stated other	wise.	
Anti-Infective Preparations			
ACICLOVIR			
* Eye oint 3%	14.92	4.5 g OP	✓ ViruPOS
CHLORAMPHENICOL			
Eye oint 1%	2.48	4 g OP	 Chlorsig
Eye drops 0.5%		10 ml OP	 Chlorafast
 a) Funded for use in the ear*. Indications marked with b) Chlorafast to be Sole Supply on 1 November 2019 	* are unapprove	d indications.	
CIPROFLOXACIN			
Eye drops 0.3% – Subsidy by endorsement	9.99	5 ml OP	 Ciprofloxacin Teva
When prescribed for the treatment of bacterial keratitis		al conjunctivitis	
for the second line treatment of chronic suppurative otiti	s media (CSOM)		
Note: Indication marked with a * is an unapproved indic	auun.		
	11 40		- Conontio
Eye drops 0.3%	11.40	5 ml OP	 Genoptic
	0.07	10 - 00	
* Eye drops 0.1%		10 ml OP	Brolono
	(14.55)		Brolene
SODIUM FUSIDATE [FUSIDIC ACID]	E 00	E a OB	 Fucithalmic
Eye drops 1%		5 g OP	

()	Subsidy Vanufacturer's F	Price) Subs	Fully sidised	Brand or Generic
·	\$	Per	1	Manufacturer
TOBRAMYCIN				
Eye oint 0.3%	10.45	3.5 g OP	🗸 I	obrex
Eye drops 0.3%	11.48	5 ml OP	✓ Т	obrex
Corticosteroids and Other Anti-Inflammatory Pre	parations			
DEXAMETHASONE				
* Eye oint 0.1%	5.86	3.5 g OP	✓ N	laxidex
* Eye drops 0.1%	4.50	5 ml OP	✓ N	laxidex
Ocular implant 700 mcg - Special Authority see SA1680 below	v			
- Retail pharmacy		1	√ (zurdex

SENSORY ORGANS

■ SA1680 Special Authority for Subsidy

Initial application — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has diabetic macular oedema with pseudophakic lens; and
- 2 Patient has reduced visual acuity of between 6/9 6/48 with functional awareness of reduction in vision; and
- 3 Either:
 - 3.1 Patient's disease has progressed despite 3 injections with bevacizumab; or
 - 3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Renewal — (Diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Initial application — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient has diabetic macular oedema; and
- 2 Patient has reduced visual acuity of between 6/9 6/48 with functional awareness of reduction in vision; and
- 3 Patient is of child bearing potential and has not yet completed a family; and
- 4 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

Renewal — (Women of child bearing age with diabetic macular oedema) only from an ophthalmologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient's vision is stable or has improved (prescriber determined); and
- 2 Patient is of child bearing potential and has not yet completed a family; and
- 3 Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE

*	Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b			· · · · ·
	sulphate 6,000 u per g5.3	39 3	8.5 g OP	 Maxitrol
*	Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin			
	b sulphate 6,000 u per ml4.5	50 5	5 ml OP	 Maxitrol
DIC	CLOFENAC SODIUM			
	Eye drops 0.1%	30 5	5 ml OP	 Voltaren Ophtha
				-

[▲]Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

*Three months or six months, as applicable, dispensed all-at-once

SENSORY ORGANS

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully Brand or sidised Generic ✔ Manufacturer
FLUOROMETHOLONE			
* Eye drops 0.1%	3.09 5.20	5 ml OP	✓ FML✓ Flucon
LEVOCABASTINE			
Eye drops 0.5 mg per ml	8.71 (10.34)	4 ml OP	Livostin
LODOXAMIDE	0.74		
Eye drops 0.1%	8./1	10 ml OP	 Lomide
PREDNISOLONE ACETATE	0.00	10 ml OD	Prednisolone-AFT
Eye drops 1%		10 ml OP 5 ml OP	✓ Prednisolone-AFT ✓ Pred Forte
PREDNISOLONE SODIUM PHOSPHATE - Special Authority			
Eye drops 0.5%, single dose (preservative free)		20 dose	✓ Minims Prednisolone
■ SA1715 Special Authority for Subsidy Initial application only from an ophthalmologist or optometrist. following criteria: Both:	Approvals valid f	for 6 months for	r applications meeting the
1 Patient has severe inflammation; and			
2 Patient has a confirmed allergic reaction to preservative	in eye drops.		
Renewal from any relevant practitioner. Approvals valid for 6 n benefiting from treatment.	nonths where the	treatment rema	ins appropriate and the patient is
SODIUM CROMOGLICATE			
Eye drops 2%	1.79	5 ml OP	Cromal \$29
Rexacrom to be Sole Supply on 1 January 2020			Rexacrom
Glaucoma Preparations - Beta Blockers			
BETAXOLOL			
* Eye drops 0.25%		5 ml OP	 Betoptic S
* Eye drops 0.5%	7.50	5 ml OP	 Betoptic
TIMOLOL			4 - - - - - - - - - -
* Eye drops 0.25%		5 ml OP	 Arrow-Timolol Timontal VE
 * Eye drops 0.25%, gel forming * Eye drops 0.5% 		2.5 ml OP 5 ml OP	 Timoptol XE Arrow-Timolol
 * Eye drops 0.5%, gel forming 		2.5 ml OP	✓ Timoptol XE
(Timoptol XE Eye drops 0.25%, gel forming to be delisted 1 Jan			
Glaucoma Preparations - Carbonic Anhydrase	Inhibitors		
ACETAZOLAMIDE			
* Tab 250 mg	17.03	100	✓ Diamox
BRINZOLAMIDE			
* Eye drops 1%	9.77	5 ml OP	 Azopt
DORZOLAMIDE HYDROCHLORIDE			
* Eye drops 2%	9.77 (17.44)	5 ml OP	Trusopt
		5 ml OP	Trusopt

(\$29) Unapproved medicine supplied under Section 29

SENSORY ORGANS

	Subsidy (Manufacturer's Prie \$	ce) Subs Per	Fully Brand or sidised Generic ✓ Manufact	urer
Glaucoma Preparations - Prostaglandin Analog	jues			
BIMATOPROST				
* Eye drops 0.03%	3.30	3 ml OP	 Bimatopro Multiche 	
LATANOPROST				
* Eye drops 0.005%	1.57	2.5 ml OP	✓ Teva	
TRAVOPROST			<u> </u>	
* Eye drops 0.004%	7.30 19.50	5 ml OP 2.5 ml OP	 ✓ Travopt ✓ Travatan 	
	19.50	2.5 III OF	• ITavalali	
Glaucoma Preparations - Other				
BRIMONIDINE TARTRATE				
* Eye drops 0.2%	4.29	5 ml OP	✓ Arrow-Brin	nonidine
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE				
* Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	 Combigan 	
PILOCARPINE HYDROCHLORIDE				
* Eye drops 1%		15 ml OP	 Isopto Car 	
* Eye drops 2%		15 ml OP	 Isopto Car 	
* Eye drops 4%		15 ml OP	 Isopto Car 	pine
Subsidised for oral use pursuant to the Standard Formu	llae.			
* Eye drops 2% single dose – Special Authority see SA0895				
below – Retail pharmacy		20 dose	 Minims Pile 	ocarpine

SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE * Eye drops 1%	.36	15 ml OP	✓ <u>Atropt</u>
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%	.76	15 ml OP	 Cyclogyl
TROPICAMIDE * Eye drops 0.5% * Eye drops 1%		15 ml OP 15 ml OP	✓ Mydriacyl✓ Mydriacyl

Preparations for Tear Deficiency

For acetylcysteine eye drops refer Standard Formulae, page 235			
HYPROMELLOSE			
* Eye drops 0.5%	2.00	15 ml OP	
	(3.92)		Methopt

231

	Subsidy (Manufacturer's Pri	ce) Subs	Fully	Brand or Generic
	`\$	Per	1	Manufacturer
HYPROMELLOSE WITH DEXTRAN				
* Eye drops 0.3% with dextran 0.1%	2.30	15 ml OP	🗸 P	oly-Tears
POLYVINYL ALCOHOL				
* Eye drops 1.4%	2.62	15 ml OP	🗸 V	istil
* Eye drops 3%	3.68	15 ml OP	🗸 V	istil Forte
(Vistil Eye drops 1.4% to be delisted 1 January 2020)				
(Vistil Forte Eye drops 3% to be delisted 1 March 2020)				

Preservative Free Ocular Lubricants

⇒SA1388 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Confirmed diagnosis by slit lamp of severe secretory dry eye; and
- 2 Either:
 - 2.1 Patient is using eye drops more than four times daily on a regular basis; or
 - 2.2 Patient has had a confirmed allergic reaction to preservative in eye drop.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient continues to require lubricating eye drops and has benefited from treatment.

CARBOMER - Special Authority see SA1388 above - Retail pl	harmacy		
Ophthalmic gel 0.3%, 0.5 g	8.25	30	 Poly-Gel
MACROGOL 400 AND PROPYLENE GLYCOL - Special Author	ority see SA1388 ab	ove – Retail	pharmacy
Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml	4.30	24	 Systane Unit Dose
SODIUM HYALURONATE [HYALURONIC ACID] - Special Au	thority see SA1388	above – Reta	ail pharmacy
Fue drane 1 me ner mi	· 00.00	10 - 00	Ulula Freeh

Other Eye Preparations

NAPHAZOLINE HYDROCHLORIDE * Eye drops 0.1%	15 ml OP	 Naphcon Forte
OLOPATADINE Eye drops 0.1%	5 ml OP	 Patanol
PARAFFIN LIQUID WITH WOOL FAT * Eye oint 3% with wool fat 3%	3.5 g OP	 Poly-Visc
RETINOL PALMITATE Eye oint 138 mcg per g	5 g OP	✓ VitA-POS

	Subsidy (Manufacturer's Price) \$	Subsic Per	Fully dised	Brand or Generic Manufacturer
Various				
Various PHARMACY SERVICES May only be claimed once per patient. * Brand switch fee	4.50	1 fee	✓ B	SF Logem SF Mylan Efavirenz Emtricitbane Tenofov SF Teva Atazanavir Sulphate SF Teva Emtricitabine Tenofoir Disoprox
 a) The Pharmacode for BSF Teva Atazanavir Sulphate b) The Pharmacode for BSF Teva Emtricitabine Tenofoi c) The Pharmacode for BSF Mylan Efavirenz Emtricitbaa d) The Pharmacode for BSF Logem is 2575949 - see al (BSF Logem Brand switch fee to be delisted 1 January 2020) (BSF Mylan Efavirenz Emtricitbane Tenofov Brand switch fee to be (BSF Teva Atazanavir Sulphate Brand switch fee to be delisted 1 (BSF Teva Emtricitabine Tenofor Brand switch fee to be 	ir Disoprox is 257386 ne Tenofov is 25738 so page 127 De delisted 1 Deceml December 2019)	5 - see also 73 - see also ber 2019)		
Agents Used in the Treatment of Poisonings				
Antidotes				
ACETYLCYSTEINE – Retail pharmacy-Specialist Inj 200 mg per ml, 10 ml ampoule NALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO	58.76	10	✓ <u>D</u>	BL Acetylcysteine
 b) Only on a PSO * Inj 400 mcg per ml, 1 ml ampoule 	22.60	5	✓ <u>D</u>	BL Naloxone Hydrochloride
Removal and Elimination				
CHARCOAL * Oral liq 50 g per 250 ml a) Up to 250 ml available on a PSO b) Only on a PSO DEFERASIPOX		i0 ml OP	✓ C	arbosorb-X
DEFERASIROX – Special Authority see SA1492 on the next page Wastage claimable Tab 125 mg dispersible Tab 250 mg dispersible Tab 500 mg dispersible		28 28 28	🗸 E	xjade xjade xjade

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once VARIOUS

Subsidy (Manufacturer's Price)	5	Fully Subsidised	Brand or Generic
\$	Per	1	Manufacturer

⇒SA1492 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
- 2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
- 3 Any of the following:
 - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
 - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
 - 3.3 Treatment with deferiprone has resulted in arthritis; or
 - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per μL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 1.0 cells per μL).</p>

Renewal only from a haematologist. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE - Special Authority see SA1480 below - Retail pharmacy

Tab 500 mg		 100	 Ferriprox
Oral liq 100 mg per	1 ml	 250 ml OP	 Ferriprox

⇒SA1480 Special Authority for Subsidy

Initial application only from a haematologist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; or

2 The patient has been diagnosed with chronic iron overload due to acquired red cell aplasia.

DESFERRIOXAMINE MESILATE

* Inj 500 mg vial		10	✓ <u>DBL</u> <u>Desferrioxamine</u> <u>Mesylate for Inj</u> <u>BP</u>
SODIUM CALCIUM EDETATE			
* Inj 200 mg per ml, 5 ml		6	
	(156.71)		Calcium Disodium Versenate

Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs	PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
ASPIRIN AND CHLOROFORM APPLICATION Aspirin Soluble tabs 300 mg Chloroform	12 tabs to 100 ml	PHENOBARBITONE SODIUM PAEDIATRIC ORAL mg per ml) Phenobarbitone Sodium	LIQUID (10
CODEINE LINCTUS (3 mg per 5 ml) Codeine phosphate Glycerol Preservative	60 mg 40 ml	Glycerol BP Water PILOCARPINE ORAL LIQUID	400 mg 4 ml to 40 ml
Water CODEINE LINCTUS (15 mg per 5 ml)	qs to 100 ml	Pilocarpine 4% eye drops Preservative Water	qs qs to 500 ml
Codeine phosphate Glycerol Preservative	300 mg 40 ml qs	(Preservative should be used if quantity supplied is than 5 days.)	
Water FOLINIC MOUTHWASH	to 100 ml	SALIVA SUBSTITUTE FORMULA Methylcellulose Preservative	5 g qs
Calcium folinate 15 mg tab Preservative Water	1 tab qs to 500 ml	Water (Preservative should be used if quantity supplied is than 5 days. Maximum 500 ml per prescription.)	to 500 ml
(Preservative should be used if quantity supplied is than 5 days. Maximum 500 ml per prescription.)	for more	SODIUM CHLORIDE ORAL LIQUID Sodium chloride inj 23.4%, 20 ml	qs
MAGNESIUM HYDROXIDE 8% MIXTURE Magnesium hydroxide paste 29% Methyl hydroxybenzoate	275 g 1.5 g	Water (Only funded if prescribed for treatment of hyponatra	qs aemia)
	to 1,000 m	VANCOMYCIN ORAL SOLUTION (50 mg per ml) Vancomycin 500 mg injection	10 vials
METHADONE MIXTURE Methadone powder Glycerol Water	qs qs to 100 ml	Glycerol BP Water (Only funded if prescribed for treatment of Clostridiu following metronidazole failure)	40 ml to 100 ml ım difficile
METHYL HYDROXYBENZOATE 10% SOLUTION Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml of oral liqu	10 g to 100 ml iid mixture)	VOSOL EAR DROPS WITH HYDROCORTISONE POWDER 1% Hydrocortisone powder Vosol Ear Drops	1% to 35 ml
OMEPRAZOLE SUSPENSION Omeprazole capules or powder Sodium bicarbonate powder BP Water	qs 8.4 g to 100 ml		

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price \$	e) Sub Per	osidised G	rand or eneric anufacturer
Extemporaneously Compounded Preparations a	and Galenicals	;		
BENZOIN Tincture compound BP	24.42 (39.90)	500 ml	Phar	macy Health
 (Pharmacy Health Tincture compound BP to be delisted 1 March. CHLOROFORM a) Only in combination b) Maximum of 100 ml per prescription c) Only in aspirin and chloroform application. d) Note: This product is no longer being manufactured by th 	2020)`	he delisted		
determined. Chloroform BP		500 ml	✓ PSM	
CODEINE PHOSPHATE – Safety medicine; prescriber may dete Powder – Only in combination	rmine dispensing fi	requency 25 g	Doug	Jlas
Only in extemporaneously compounded codeine linctus. COLLODION FLEXIBLE Note: This product is no longer being manufactured by the se determined.				
Collodion flexible COMPOUND HYDROXYBENZOATE – Only in combination Only in extemporaneously compounded oral mixtures. Soln		100 ml 100 ml	✓ PSM	
GLYCERIN WITH SODIUM SACCHARIN – Only in combination Only in combination with Ora-Plus. Suspension		473 ml		Sweet SF
GLYCERIN WITH SUCROSE – Only in combination Only in combination with Ora-Plus. Suspension		473 ml	✓ Ora-	
GLYCEROL * Liquid – Only in combination Only in extemporaneously compounded oral liquid prepa	3.28	500 ml	✓ <u>heal</u>	thE Glycerol BP
MAGNESIUM HYDROXIDE Paste 29% (PSM Paste 29% to be delisted 1 July 2020)	22.61	500 g	✓ PSM	
METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing fre d) Extemporaneously compounded methadone will only be re (methadone powder, not methadone tablets). Powder	eimbursed at the ra	ate of the c	heapest forr	n available
METHYL HYDROXYBENZOATE Powder		25 g	✓ <u>Midv</u>	vest
METHYLCELLULOSE Powder Suspension – Only in combination		100 g 473 ml	✓ <u>Mid\</u> ✓ <u>Ora-</u>	

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Pric \$	ce) Per	Fully Subsidised	Generic	
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCH Suspension		mbinati 473 n		Ora-Blend SF	
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE - On Suspension		473 n	nl 🗸	Ora-Blend	
PHENOBARBITONE SODIUM Powder – Only in combination Only in children up to 12 years	52.50 325.00	10 g 100 g		MidWest MidWest	
PROPYLENE GLYCOL Only in extemporaneously compounded methyl hydroxybenz Lig		500 n	nl 🗸	Midwest	
SODIUM BICARBONATE Powder BP – Only in combination		500 (g 🗸	Midwest David Craig	
 a) Only in extemporaneously compounded omeprazole b) Midwest to be Sole Supply on 1 January 2020 (David Craig Powder BP to be delisted 1 January 2020) 	()	suspens	sion.		
SYRUP (PHARMACEUTICAL GRADE) – Only in combination Only in extemporaneously compounded oral liquid preparation Liq		500 n	nl 🗸	Midwest	
Midwest to be Sole Supply on 1 January 2020 WATER Tap – Only in combination	0.00	1 ml	1	Tap water	

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	1	Manufacturer

Nutrient Modules

Carbohydrate

⇒SA1522 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Fither:

- 1 cystic fibrosis; or
- 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 faltering growth in an infant/child; or
- 4 bronchopulmonary dysplasia; or
- 5 premature and post premature infant; or
- 6 inborn errors of metabolism; or
- 7 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal — (Cystic fibrosis or renal failure)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Carbohydrate And Fat

⇒SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SU	JPPLEMENT – Special Author	ity see SA1376 on t	he previous pag	e – Hosp	oital pharmacy [HP3]
Powder (neutral)	-		400 g OP	Duod	al Super
			-	So	uble Powder

Fat

⇒SA1523 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or

continued...

Subsidy (Manufacturer's Price)	Subsi	Fully dised	Brand or Generic
 \$	Per	1	Manufacturer

- 10 ascites; or
- 11 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal — (Inborn errors of metabolism)** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Patho

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT - Special Autho	ity see SA1523 on the previous	page – Hospital pharmacy [HP3]
--------------------------------	--------------------------------	--------------------------------

Emulsion (neutral)		200 ml OP	✓ Calogen
	30.75	500 ml OP	 Calogen
Emulsion (strawberry)		200 ml OP	 Calogen
Oil		500 ml OP	 MCT oil (Nutricia)
Oil, 250 ml		4 OP	 Liquigen

Protein

⇒SA1524 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see SA1524 above – Hospital	pharmacy [HP3]	
Powder	225 g OP	🗸 I
8.95	227 g OP	✓ I
	•	

 Protifar
 Resource Beneprotein

Subsidy (Manufacturer's Price)

\$

Per

Fully Subsidised

Generic Manufacturer

Brand or

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

⇒SA1094 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CORD ORAL FEED 1.5KCAL/ML - Special Author	rity see SA1094 above – Hosp	oital pharmacy [I	HP3]
Liquid	1.66	237 ml OP	 Pulmocare

Diabetic Products

⇒SA1095 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1095 above - Liquid	- Hospital pharm 1,000 ml OP	acy [HP3] ✓ Diason RTH ✓ Glucerna Select RTH
DIABETIC ORAL FEED 1KCAL/ML - Special Authority see SA1095 above - Ho	spital pharmacy	[HP3]
Liquid (strawberry)1.50	200 ml OP	✓ Diasip
Liquid (vanilla)1.50	200 ml OP	✓ Diasip
1.88	250 ml OP	 Glucerna Select
1.78	237 ml OP	
(2.10)		Resource Diabetic
(2.10)		Sustagen Diabetic

Subsid	y Full	Brand or
(Manufacturer	s Price) Subsidise	I Generic
\$	Per 🗸	Manufacturer

Fat Modified Products

⇒SA1525 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED	- Special Authority see SA152	5 above – Hospital phar	macy [HP3]		
Powder		60.48	400 g OP	~	Monogen

Paediatric Products For Children Awaiting Liver Transplant

⇒SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Paediatric Products For Children With Chronic Renal Failure

⇒SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

	Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
·	\$	Per 🗸	Manufacturer
ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see SA10		•	
Liquid		00 g OP 🛛 🗸	Kindergen

SPECIAL FOODS

Paediatric Products

⇒SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1379 Liquid	
PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1379 al Liquid2.68	bove – Hospital pharmacy [HP3] 500 ml OP ✓ Nutrini RTH ✓ Pediasure RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority Liquid	y see SA1379 above – Hospital pharmacy [HP3] 500 ml OP ✓ Nutrini Energy Multi Fibre
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA1379 abo Liquid (strawberry)1.60 Liquid (vanilla)1.60	ve – Hospital pharmacy [HP3] 200 ml OP ✓ Fortini 200 ml OP ✓ Fortini
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1379 above Liquid (chocolate)	e – Hospital pharmacy [HP3] 200 ml OP ✓ Pediasure 200 ml OP ✓ Pediasure 200 ml OP ✓ Pediasure 250 ml OP ✓ Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see Liquid (unflavoured) 1.60 Liquid (chocolate) 1.60 Liquid (strawberry) 1.60 Liquid (vanilla) 1.60	SA1379 above – Hospital pharmacy [HP3] 200 ml OP ✓ Fortini Multi Fibre 200 ml OP ✓ Fortini Multi Fibre
PEPTIDE-BASED ORAL FEED – Special Authority see SA1379 above – Hos Powder	pital pharmacy [HP3] 400 g OP ✓ Peptamen Junior

	Subsidy (Manufacturer's Pric \$	ce) Si Per	Fully ubsidised	Brand or Generic Manufacturer
Renal Products				
 SA1101 Special Authority for Subsidy nitial application only from a dietitian, relevant specialist or verse where the patient has acute or chronic kidney disease. Renewal only from a dietitian, relevant specialist, vocationally ecommendation of a dietitian, relevant specialist or vocational applications meeting the following criteria: Both: The treatment remains appropriate and the patient is be General Practitioners must include the name of the diet practitioner and date contacted. 	registered general pr ly registered general enefiting from treatme	actitioner practitione	or general er. Approv	practitioner on the vals valid for 3 years for
RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority se Liquid		ospital ph 500 ml OF		P3] I epro HP RTH
RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see SA Liquid		tal pharma 220 ml OF	P ✓N	· lepro HP (strawberry) lepro HP (vanilla)
RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA1		l pharmac 237 ml OF	y [HP3]	lovaSource Renal

Specialised And Elemental Products

⇒SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

SPECIAL FOODS

	Subsidy (Manufacturer's I \$	Price) Subsi Per	Fully idised	Brand or Generic Manufacturer
ENTERAL/ORAL SEMI-ELEMENTAL FEED 1.5KCAL/ML – Spi pharmacy [HP3] Liquid	,	e SA1377 on th 1,000 ml OP	e previ	
ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see Liquid (grapefruit), 250 ml carton Liquid (pineapple & orange), 250 ml carton Liquid (summer fruits), 250 ml carton	171.00 171.00	previous page - 18 OP 18 OP 18 OP 18 OP	✓ E	ital pharmacy [HP3] Elemental 028 Extra Elemental 028 Extra Elemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see S Powder (unflavoured)		r <mark>evious page</mark> – H 80 g OP		al pharmacy [HP3] /ivonex TEN
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Aut [HP3] Liquid	,	7 on the previou 1,000 ml OP		e – Hospital pharmacy Peptisorb

Paediatric Products For Children With Low Energy Requirements

⇒SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 Child aged one to eight years; and
 - 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML	- Special Authority	see SA1196	above -	- Hospital pharmacy [HP3]
Liquid	4.00	500 ml OP	✓	Nutrini Low Energy
				Multi Fibre

Standard Supplements

⇒SA1554 Special Authority for Subsidy

Initial application — (Children - indications other than exclusive enteral nutrition for Crohn's disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and

3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal - (Children - indications other than exclusive enteral nutrition for Crohn's disease) only from a dietitian, relevant

continued...

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic	
\$	Per 🗸	Manufacturer	

specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist or dietitian on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 Dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Renewal — (Children - exclusive enteral nutrition for Crohn's disease) only from a gastroenterologist, dietitian on the recommendation of a gastroenterologist or vocationally registered general practitioner on the recommendation of a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient is under 18 years of age; and
- 2 It is to be used as exclusive enteral nutrition for the treatment of Crohn's disease; and
- 3 General Practitioners and dietitians must include the name of the gastroenterologist recommending treatment and the date the gastroenterologist was contacted.

Initial application — (Adults) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

1 Any of the following:

Patient is Malnourished

- 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
- 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
- Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:
 - Patient is Malnourished
 - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m²; or
 - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 2.3 Patient has a BMI of less than 20 kg/m² and unintentional weight loss greater than 5% within the last 3-6 months.

Subsidy	F	ully	Brand or	
(Manufacturer's Price)	Subsidis	sed	Generic	
\$	Per	✓	Manufacturer	

Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

Is being fed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or

- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery or glossectomy; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (< 13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being met.

Initial application — (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or

continued...

Subsidy		Fully	Brand or
(Manufacturer's Price)	Subs	idised	Generic
\$	Per	1	Manufacturer

- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1554 on page 245 – Liquid	Hospital pharmacy [HP3] 1,000 ml OP ✓ Nutrison Energy
ENTERAL FEED 1KCAL/ML – Special Authority see SA1554 on page 245 – Ho Liquid	ospital pharmacy [HP3] 250 ml OP ✓ Isosource Standard 1,000 ml OP ✓ Nutrison Standard RTH ✓ Osmolite RTH
ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Special Authority see SA1554 Liquid	on page 245 – Hospital pharmacy [HP3] 1,000 ml OP ✓ Nutrison 800 Complete Multi Fibre
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1554 on Liquid	page 245 – Hospital pharmacy [HP3] 1,000 ml OP ✓ Jevity RTH ✓ Nutrison Multi Fibre
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1554 or Liquid	n page 245 – Hospital pharmacy [HP3] 250 ml OP ✓ Ensure Plus HN 1,000 ml OP ✓ Ensure Plus RTH ✓ Jevity HiCal RTH ✓ Nutrison Energy Multi Fibre

	Subsidy (Manufacturer's F \$		Fully Brand or lised Generic Manufacturer
ORAL FEED (POWDER) – Special Authority see SA1554 on pag Note: Higher subsidy for Sustagen Hospital Formula will only number and an appropriately endorsed prescription.	be reimbursed		
Powder (chocolate) – Higher subsidy of up to \$26.00 per 850 with Endorsement		850 g OP	✓ Ensure
	9.54 (26.00)	840 g OP	Sustagen Hospital
Additional subsidy by endorsement is available for patien	ts with fat mala	bsorption, fat into	Formula Active plerance or chyle leak. The
prescription must be endorsed accordingly. Powder (vanilla) – Higher subsidy of up to \$26.00 per 850 g			
with Endorsement	26.00	857 g OP 850 g OP	✓ Fortisip✓ Ensure
	9.54 (26.00)	840 g OP	Sustagen Hospital Formula Active
Additional subsidy by endorsement is available for patien prescription must be endorsed accordingly.	ts with fat malal	bsorption, fat into	
ORAL FEED 1.5KCAL/ML – Special Authority see SA1554 on pa Additional subsidy by endorsement is available for patients be epidermolysis bullosa, or as exclusive enteral nutrition in child disease. The prescription must be endorsed accordingly. Liquid (banana) – Higher subsidy of \$1.26 per 200 ml with Endorsement	eing bolus fed th dren under the a	nrough a feeding	tube, who have severe
Liquid (chocolate) - Higher subsidy of \$1.26 per 200 ml with	(1.26)		Fortisip
Endorsement		200 ml OP	Ensure Plus Fortisip
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 n with Endorsement		200 ml OP	Ensure Plus
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement	ı , ,	200 ml OP	
	(1.26) (1.26)		Ensure Plus Fortisip
Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml wi Endorsement	0.85	237 ml OP	
	(1.33) 0.72 (1.26)	200 ml OP	Ensure Plus Ensure Plus
	(1.26)		Fortisip

SPECIAL FOODS

	Subsidy (Manufacturer's F \$	Price) Subsi Per	Fully idised	Brand or Generic Manufacturer
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see Additional subsidy by endorsement is available for patients b epidermolysis bullosa. The prescription must be endorsed av Liguid (chocolate) – Higher subsidy of \$1.26 per 200 ml with	eing bolus fed th ccordingly.			
Endorsement		200 ml OP	F	ortisip Multi Fibre
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement		200 ml OP	F	ortisip Multi Fibre
Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with Endorsement	0.72 (1.26)	200 ml OP	F	ortisip Multi Fibre

High Calorie Products

⇒SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML – Special Authority see SA1195 abo	ve – Hospital	pharmacy [HP3]	
Liquid	5.50	500 ml OP	 Nutrison
			Concentrated
	11.00	1,000 ml OP	🗸 Two Cal HN RTH
		,	

	Subsidy (Manufacturer's Pri \$	ice) Subs Per	Fully idised	Brand or Generic Manufacturer	
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 on the Additional subsidy by endorsement is available for patients b epidermolysis bullosa. The prescription must be endorsed a Liquid (vanilla) – Higher subsidy of \$1.90 per 200 ml with	eing bolus fed thr				
Endorsement	0.96 (1.90)	200 ml OP	Τv	vo Cal HN	
Food Thickeners					
 SA1106 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder. Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: The treatment remains appropriate and the patient is benefiting from treatment; and General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted. 					
FOOD THICKENER – Special Authority see SA1106 above – Ho Powder		[HP3] 300 g OP 380 g OP		utilis eed Thickener Karicare Aptamil	
Gluten Free Foods					
The funding of gluten free foods is no longer being actively mana no longer considering the listing of new products, or making subs anticipate that the range of funded items will reduce over time.	sidy, or other chan	iges to the exis	sting list	ings. As a result we	

► SA1729 Special Authority for Subsidy

Initial application — (all patients) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

necessary for good outcomes. A range of gluten free options are available through retail outlets.

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

Initial application — (paediatric patients diagnosed by ESPGHAN criteria) only from a paediatric gastroenterologist. Approvals valid without further renewal unless notified where the paediatric patient fulfils ESPGHAN criteria for biopsy free diagnosis of coeliac disease.

GLUTEN FREE BAKING MIX – Special Authority see SA17	729 above – Hospital pharmacy [HP3]	
Powder	2.81 1,000 g OP	
	(5.15)	Healtheries Simple Baking Mix
GLUTEN FREE BREAD MIX - Special Authority see SA17	29 above – Hospital pharmacy [HP3]	
Powder		
	(7.32)	NZB Low Gluten Bread Mix
	3.51	
	(10.87)	Horleys Bread Mix

SPECIAL FOODS

	Subsidy (Manufacturer's Pr \$	ice) S Per	Fully ubsidised	Brand or Generic Manufacturer
GLUTEN FREE FLOUR - Special Authority see SA1729 on the				IP3]
Powder		2,000 g O		
	(18.10)		ł	Horleys Flour
GLUTEN FREE PASTA - Special Authority see SA1729 on the	previous page - H	lospital pha	armacy [H	IP3]
Buckwheat Spirals	2.00	250 g OP)	
	(3.11)		(Orgran
Corn and Vegetable Shells	2.00	250 g OP)	
	(2.92)			Orgran
Corn and Vegetable Spirals		250 g OP		
	(2.92)			Orgran
Rice and Corn Lasagne Sheets		200 g OP		_
	(3.82)			Orgran
Rice and Corn Macaroni		250 g OP		~
	(2.92)			Orgran
Rice and Corn Penne		250 g OP		^
Disc and Maine Deate Opinale	(2.92)	050		Orgran
Rice and Maize Pasta Spirals		250 g OP		O wenne w
Dice and Millet Chirole	(2.92)	050 ~ 00		Orgran
Rice and Millet Spirals		250 g OP)
Pice and corp apaghetti peedlee	(3.11)	275 a OB		Orgran
Rice and corn spaghetti noodles		375 g OP		Orgran
Vegetable and Rice Spirals	(2.92)	250 g OP		Jigian
vegetable and title opliato	(2.92)	200 Y OF		Orgran
Italian long style spaghetti		220 g OP		orgran
	(3.11)	220 y OI		Orgran

Foods And Supplements For Inborn Errors Of Metabolism

⇒SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE - Special Autho	rity see SA110	8 above – Hos	pital pharmacy [HP3]
Powder	461.94	500 g OP	 XMET Maxamum

Supplements For MSUD

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE - Sp	ecial Authority s	see SA1108 above – Hospital
pharmacy [HP3]	-	
Powder	500 g OP	MSUD Maxamum

	Subsidy (Manufacturer's Price) \$		Fully Brand or dised Generic ✔ Manufacturer
Supplements For PKU			
AMINOACID FORMULA WITHOUT PHENYLALANINE – Special pharmacy [HP3]	Authority see SA11	08 on the p	revious page – Hospital
Tabs		75 OP	 Phlexy 10
Powder (chocolate) 36 g sachet	393.00	30	 PKU Anamix Junior Chocolate
Powder (unflavoured) 27.8 g sachets	936.00	30	 PKU Lophlex Powder
Powder (unflavoured) 36 g sachets		30	PKU Anamix Junior
Powder (vanilla) 36 g sachet		30	 PKU Anamix Junior Vanilla
Infant formula	174.72 4	00 g OP	PKU Anamix Infant
Powder (orange)		00 g OP	✓ XP Maxamum
Powder (unflavoured)		00 g OP	✓ XP Maxamum
Liquid (berry)		25 ml OP	 PKU Anamix Junior LQ
Liquid (orange)		25 ml OP	 PKU Anamix Junior LQ
Liquid (unflavoured)		25 ml OP	 PKU Anamix Junior LQ
Liquid (forest berries), 250 ml carton		18 OP	 Easiphen Liquid
Liquid (juicy tropical) 125 ml		30 OP	PKU Lophlex LQ 20
Oral semi-solid (berries) 109 g		36 OP	 PKU Lophlex Sensation 20
Liquid (juicy berries) 62.5 ml	939.00	60 OP	PKU Lophlex LQ 10
Liquid (juicy citrus) 62.5 ml		60 OP	PKU Lophlex LQ 10
Liquid (juicy orange) 62.5 ml		60 OP	PKU Lophlex LQ 10
Liquid (juicy berries) 125 ml.		30 OP	PKU Lophlex LQ 20
Liquid (juicy orange) 125 ml		30 OP	 PKU Lophlex LQ 20

Foods

LOW PROTEIN BAKING MIX - Special Authority see SA1108 on	the previous pa	<mark>age</mark> – Hospital ı	oharmacy [HP3]
Powder	8.22	500 g OP	 Loprofin Mix
LOW PROTEIN PASTA - Special Authority see SA1108 on the pr	revious page -	Hospital pharm	acy [HP3]
Animal shapes	11.91	500 g OP	 Loprofin
Lasagne	5.95	250 g OP	 Loprofin
Low protein rice pasta	11.91	500 g OP	 Loprofin
Macaroni	5.95	250 g OP	 Loprofin
Penne	11.91	500 g OP	 Loprofin
Spaghetti	11.91	500 g OP	 Loprofin
Spirals	11.91	500 g OP	 Loprofin

SPECIAL FOODS

	Subsidy (Manufacturer's Prio \$	ce) Subs Per	Fully sidised	Brand or Generic Manufacturer
Infant Formulae				
For Williams Syndrome				
 SA1110 Special Authority for Subsidy itial application only from a dietitian, relevant specialist or ear where the patient is an infant suffering from Williams Syntemewal only from a dietitian, relevant specialist, vocationally ecommendation of a dietitian, relevant specialist or vocational pplications meeting the following criteria: ioth: The treatment remains appropriate and the patient is the gractitioner and date contacted. OW CALCIUM INFANT FORMULA – Special Authority see 	ndrome and associate y registered general pr ally registered general penefiting from treatme stitian, relevant specia	d hypercalca actitioner or practitioner. ent; and list or vocatio	emia. general Approv	practitioner on the vals valid for 1 year for egistered general
Powder		400 g OP		ocasol
Gastrointestinal and Other Malabsorptive Pro	oblems			
MINO ACID FORMULA – Special Authority see SA1219 be Powder Powder (unflavoured)	43.60	acy [HP3] 400 g OP 400 g OP	✓ E ✓ E ✓ N ✓ N	Ifamino Junior Elecare Elecare LCP Ieocate Gold Ieocate Junior Unflavoured Ieocate SYNEO
Powder (vanilla)	53.00	400 g OP	✓ E	leocate Junior Vanilla

⇒SA1219 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

	Subsidy (Manufacturer's Price) \$ F	Fully Subsidised Per ✓	Brand or Generic Manufacturer
EXTENSIVELY HYDROLYSED FORMULA – Special Authority Powder			y [HP3] µptamil Gold+ Pepti Junior
 SA1557 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vomonths for applications meeting the following criteria: Any of the following: Both: 	ocationally registered gen	eral practitione	r. Approvals valid for 6
 1.1 Cows milk formula is inappropriate due to severe 1.2 Either: 1.2.1 Soy milk formula has been reasonably triangle 	alled without resolution of	symptoms; or	ent; and
 1.2.2 Soy milk formula is considered clinically in 2 Severe malabsorption; or 3 Short bowel syndrome; or 4 Intractable diarrhoea; or 5 Biliary atresia; or 6 Cholestatic liver diseases causing malsorption; or 7 Cystic fibrosis; or 8 Proven fat malabsorption; or 9 Severe intestinal motility disorders causing significant m 10 Intestinal failure; or 11 All of the following: 		cated; or	
 11.1 For step down from Amino Acid Formula; and 11.2 The infant is currently receiving funded amino acid. 11.3 The infant is to be trialled on, or transitioned to, at 11.4 General Practitioners must include the name of the practitioner and the date contacted. Note: A reasonable trial is defined as a 2-4 week trial, or signs Renewal only from a dietitian, relevant specialist, vocationally applications meeting the following criteria: All of the following: 	an extensively hydrolysed the dietitian, relevant spec of an immediate IgE med registered general practitic	ialist or vocatio liated allergic re oner or general	eaction. practitioner on the
 An assessment as to whether the infant can be transitio undertaken; and The outcome of the assessment is that the infant contin 			

- The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general
- practitioner and the date contacted.

Fluid Restricted

PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Special Authority see SA1698 below – Hospital pharmacy [HP3] Liquid......2.35 125 ml OP ✓ Infatrini

► SA1698 Special Authority for Subsidy

Initial application only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient is fluid restricted or volume intolerant and has been diagnosed with faltering growth; and
- 2 Patient is under the care of a paediatrician or dietitian who has recommended treatment with a high energy infant formula;

continued...

SPECIAL FOODS

Subsidy (Manufacturer's Price)	Su	Fully Ibsidised	Brand or Generic
 \$	Per	1	Manufacturer

continued...

and

3 Patient is under 18 months of age or weighs less than 8 kg.

Note: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Renewal only from a paediatrician, dietitian or general practitioner on the recommendation of a paediatrician or dietitian. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient continues to be fluid restricted or volume intolerant and has faltering growth; and
- 2 Patient is under the care of a hospital paediatrician or dietitian who has recommended treatment with a high energy infant formula; and
- 3 Patient is under 18 months of age or weighs less than 8 kg.

Note: "Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

Ketogenic Diet

⇒SA1197 Special Authority for Subsidy

Initial application only from a metabolic physician or paediatric neurologist. Approvals valid for 3 months where the patient has intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

Renewal only from a metabolic physician or paediatric neurologist. Approvals valid for 2 years where the patient is on a ketogenic diet and the patient is benefiting from the diet.

HIGH FAT LOW CARBOHYDRATE FORMULA - Special	Authority see SA1197 above	 Retail pharmacy
Powder (unflavoured)		g OP 🖌 KetoCal 4:1
		 Ketocal 3:1
Powder (vanilla)		g OP 🖌 KetoCal 4:1

SECTION I: NATIONAL IMMUNISATION SCHEDULE

	Subsidy (Manufacturer's Price) \$	Subsi Per	dised (Brand or Generic Manufacturer
Vaccinations				
ADULT DIPHTHERIA AND TETANUS VACCINE – [Xpharm] Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml Any of the following: 1) For vaccination of patients aged 45 and 65 years of 2) For vaccination of previously unimmunised or parti	old; or ally immunised patient	5 ts; or	✓ <u>AD</u>	<u>T Booster</u>
 For revaccination following immunosuppression; or For boosting of patients with tetanus-prone wound. For use in testing for primary immunodeficiency dis or paediatrician. 	s; or seases, on the recomn			
Note: Please refer to the Immunisation Handbook for ap BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm] For infants at increased risk of tuberculosis. Increased risk i		r catch up	program	mes.
 living in a house or family with a person with current or having one or more household members or carers who equal to 40 per 100,000 for 6 months or longer; or during their first 5 years will be living 3 months or longer 	within the last 5 years		,	
Note a list of countries with high rates of TB are available at www.bcgatlas.org/index.php.	•		•	
Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial with diluent DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – [Xphar		10	✓ BC	G Vaccine
Funded for any of the following criteria:	-			
 A single dose for pregnant women in the second or thir A single dose for parents or primary caregivers of infan Baby Unit for more than 3 days, who had not been exp A course of up to four doses is funded for children from primary immunisation; or 	ts admitted to a Neona osed to maternal vacc	atal Intensi ination at I	ive Care east 14 d	days prior to birth; or
 An additional four doses (as appropriate) are funded fo transplantation or chemotherapy; pre or post splenecto severely immunosuppressive regimens. 				
Notes: Tdap is not registered for patients aged less than 10 appropriate schedule for catch up programmes.	years. Please refer to	the Immu	nisation	Handbook for
Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagluttinin and 2.5 mcg pertactin in 0.5 ml syringe	0.00	10	✓ <u>Boo</u>	<u>ostrix</u>

1 Soostrix

	Subsidy (Manufacturer's Pric \$	e) S Per	Fully ubsidised	Brand or Generic Manufacturer
DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE - Funded for any of the following:	- [Xpharm]			
 A single dose for children up to the age of 7 who have of A course of four vaccines is funded for catch up program primary immunisation; or 	nmes for children	(to the age	e of 10 ye	, ,
 An additional four doses (as appropriate) are funded for pre- or post splenectomy; pre- or post solid organ transp regimens; or 	plant, renal dialysis	s and othe		
 Five doses will be funded for children requiring solid org Note: Please refer to the Immunisation Handbook for approp 	•		orogramm	es
Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagluttinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5ml syringe		10		nfanrix IPV
DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS BAI			_	
Xpharm] Funded for patients meeting any of the following criteria:				
 Up to four doses for children up to and under the age of 2) An additional four doses (as appropriate) are funded for 10 who are patients post haematopoietic stem cell trans post solid organ transplant, renal dialysis and other sev. Up to five doses for children up to and under the age of Note: A course of up-to four vaccines is funded for catch up to complete full primary immunisation. Please refer to the Im 	r (re-)immunisation plantation, or cher erely immunosupp 10 receiving solid programmes for ch	for childr motherapy ressive re organ train hildren (up	en up to a y; pre or po gimens; o nsplantatio to and ur	ost splenectomy; pre- or r on. nder the age of 10 years)
programmes. Inj 30IU diphtheriatoxoid with 40IU tetanustoxoid, 25mcg pertussistoxoid, 25mcg pertussisfilamentoushaemagluttinin, 8 mcgpertactin, 80 D-AgUpoliovirus, 10mcghepatitisBsurfaceantigen in 0.5ml syringe	0.00	10	v 11	nfanrix-hexa
AEMOPHILUS INFLUENZAE TYPE B VACCINE – [Xpharm]		10	• <u>"</u>	<u>namix-nexa</u>
 One dose for patients meeting any of the following: For primary vaccination in children; or An additional dose (as appropriate) is funded for (re-)im transplantation, or chemotherapy; functional asplenic; p or post cochlear implants, renal dialysis and other sevei For use in testing for primary immunodeficiency disease paediatrician. 	re or post splenec rely immunosuppre	tomy; pre- essive reg	or post s imens; or	olid organ transplant, pre
Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcc prefilled syringe plus vial 0.5 ml		1	✓ <u>⊦</u>	<u>liberix</u>
 EPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: 1) Two vaccinations for use in transplant patients; or 2) Two vaccinations for use in children with chronic liver di 3) One dose of vaccine for close contacts of known hepati 	,			
Inj 1440 ELISA units in 1 ml syringe Inj 720 ELISA units in 0.5 ml syringe		1 1		<u>lavrix</u> Iavrix Junior

	Subsidy		Fully	Brand or
	(Manufacturer's Price)	Subs	idised	Generic
	\$	Per	1	Manufacturer
HEPATITIS B RECOMBINANT VACCINE – [Xpharm]				
Inj 5 mcg per 0.5 ml vial	0.00	1	🖌 ні	BvaxPRO
Funded for patients meeting any of the following criteria:	0.00		• …	
 for household or sexual contacts of known acute he 	natitia D nationta ar h	onatitia D	oorriora	n or
,				, or
 for children born to mothers who are hepatitis B sur for children born to mother the surface of 12 				
for children up to and under the age of 18 years inc				achieved a positive
serology and require additional vaccination or requi	re a primary course o	t vaccinat	ion; or	
 for HIV positive patients; or 				
5) for hepatitis C positive patients; or				
for patients following non-consensual sexual interco	ourse; or			
for patients following immunosuppression; or				
8) for solid organ transplant patients; or				
for post-haematopoietic stem cell transplant (HSCT) patients; or			
following needle stick injury.				
			<i>.</i>	
Inj 10 mcg per 1 ml vial	0.00	1	✓ H	BvaxPRO
Funded for patients meeting any of the following criteria:				
 for household or sexual contacts of known acute he 				; or
for children born to mothers who are hepatitis B sur				
for children up to and under the age of 18 years inc				achieved a positive
serology and require additional vaccination or requi	re a primary course o	f vaccinat	ion; or	
for HIV positive patients; or				
5) for hepatitis C positive patients; or				
for patients following non-consensual sexual interco	ourse; or			
for patients following immunosuppression; or				
8) for solid organ transplant patients; or				
 for post-haematopoietic stem cell transplant (HSCT) patients; or			
10) following needle stick injury.				
Ini 00 mag nex 1 ml profilled evringe	0.00	1	./ E.	anavity D
Inj 20 mcg per 1 ml prefilled syringe	0.00	I	♥ E1	ngerix-B
Funded for patients meeting any of the following criteria:	and the Distribution of the			
 for household or sexual contacts of known acute he for household or sexual contacts of known acute he 				; or
 for children born to mothers who are hepatitis B sur for children up to and up doubte and of 10 up are interested. 	0 (0,			
 for children up to and under the age of 18 years inc 				achieved a positive
serology and require additional vaccination or requi	re a primary course o	vaccinal	ion; or	
4) for HIV positive patients; or				
5) for hepatitis C positive patients; or				
 for patients following non-consensual sexual intercontraction of the sexual inte	ourse; or			
 for patients following immunosuppression; or 				
8) for solid organ transplant patients; or	\			
 for post-haematopoietic stem cell transplant (HSCT for post-haematopoietic stem cell transplant (HSCT) patients; or			
10) following needle stick injury; or				
11) for dialysis patients; or				
12) for liver or kidney transplant patients.				
Inj 40 mcg per 1 ml vial	0.00	1	🖌 LII	BvaxPRO
	0.00	I	• 11	
Funded for any of the following criteria:				
1) for dialysis patients; or				
for liver or kidney transplant patient.				

	Subsidy (Manufacturer's Price) \$	Ful Subsidise Per	,
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND Any of the following:	58) VACCINE [HPV] -	- [Xpharm]	
 Maximum of two doses for children aged 14 years and Maximum of three doses for patients meeting any of the 	,		
 People aged 15 to 26 years inclusive; or Either: 			
People aged 9 to 26 years inclusive 1) Confirmed HIV infection; or			
 Transplant (including stem cell) patients: o Maximum of four doses for people aged 9 to 26 years 		nerapy	
Inj 270 mcg in 0.5 ml syringe	·	10 •	Gardasil 9

	Subsidy (Manufacturer's Price)	Sub	Fully sidised	Brand or Generic
	\$	Per	1	Manufacturer
INFLUENZA VACCINE				
Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)	-			
[Xpharm]		1	🗸 F	luarix Tetra
A) INFLUENZA VACCINE – child aged 6 months to	35 months			
is available each year for patients aged 6 months to	o 35 months who mee	et the follo	owing cr	iteria, as set by
PHARMAC:				
 have any of the following cardiovascular diser 	ases			
a) ischaemic heart disease, or				
 b) congestive heart failure, or 				
c) rheumatic heart disease, or				
d) congenital heart disease, or				
e) cerebo-vascular disease; or				
ii) have either of the following chronic respirator				
a) asthma, if on a regular preventative the				
 b) other chronic respiratory disease with in 	npaired lung lunction;	or		
iii) have diabetes; oriv) have chronic renal disease; or				
v) have any cancer, excluding basal and squam	ious skin cancers if n	nt invasiv	a. or	
vi) have any of the following other conditions:		51 11104510	o, oi	
a) autoimmune disease, or				
b) immune suppression or immune deficie	ncv. or			
c) HIV, or	- , , -			
d) transplant recipients, or				
e) neuromuscular and CNS diseases/disor	rders, or			
f) haemoglobinopathies, or				
g) on long term aspirin, or				
h) have a cochlear implant, or	teles Parata a succession and			
 i) errors of metabolism at risk of major me ii) pro and past enlagestermy, or 	etabolic decompensat	ion, or		
j) pre and post splenectomy, ork) down syndrome, or				
vii) have been hospitalised for respiratory illness	or have a history of s	ignificant	rocnirat	on illness:
Unless meeting the criteria set out above, the follow		0		
a) asthma not requiring regular preventative the	0			ing.
b) hypertension and/or dyslipidaemia without ev		disease		
B) INFLUENZA VACCINE – pregnant women	laonoo or ona organi			
a) are pregnant				
C) Doctors are the only Contractors entitled to claim p	avment from the Fun	der for th	a sunnlu	of influenza vaccina ini
60 mcg in 0.5 ml syringe (paediatric quadrivalent v	accine) to patients eli	gible und	er the al	bove criteria for subsidised
immunisation and they may only do so in respect o	i the influenza vaccin	e listed ir	i the Ph	armaceutical Schedule.

Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)45.00	5
90.00	10

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. *Three months or six months, as applicable, dispensed all-at-once

✓ FluQuadri
✓ Afluria Quad
✓ Influvac Tetra

Subsidy		,	Brand or
(Manufacturer's Price)	5	ubsidised	Generic
\$	Per	~	Manufacturer

- a) Only on a prescription
- b) No patient co-payment payable
- C)

A) INFLUENZA VACCINE - people 3 years and over

is available each year for patients aged 3 years and over who meet the following criteria, as set by PHARMAC:

- a) all people 65 years of age and over; or
- b) people under 65 years of age who:
 - i) have any of the following cardiovascular diseases:
 - a) ischaemic heart disease, or
 - b) congestive heart failure, or
 - c) rheumatic heart disease, or
 - d) congenital heart disease, or
 - e) cerebo-vascular disease; or
 - ii) have either of the following chronic respiratory diseases:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function; or
 - iii) have diabetes; or
 - iv) have chronic renal disease; or
 - v) have any cancer, excluding basal and squamous skin cancers if not invasive; or
 - vi) have any of the following other conditions:
 - a) autoimmune disease, or
 - b) immune suppression or immune deficiency, or
 - c) HIV, or
 - d) transplant recipients, or
 - e) neuromuscular and CNS diseases/disorders, or
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
 - h) have a cochlear implant, or
 - i) errors of metabolism at risk of major metabolic decompensation, or
 - j) pre and post splenectomy, or
 - k) down syndrome, or
 - vii) are pregnant; or
- children aged four years or less (but over three years) who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease.
- B) Contractors will be entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria pursuant to their contract with their DHB for subsidised immunisation, and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

MEASLES, MUMPS AND RUBELLA VACCINE - [Xpharm]

A maximum of two doses for any patient meeting the following criteria:

- 1) For primary vaccination in children; or
- 2) For revaccination following immunosuppression; or
- 3) For any individual susceptible to measles, mumps or rubella; or
- 4) A maximum of three doses for children who have had their first dose prior to 12 months.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj, measles virus 1,000 CCID50, mumps virus 5,012 CCID50,

Rubella virus 1,000 CCID50; prefilled syringe/ampoule of

diluent 0.5 ml0.00 10

(Mar	Subsidy ufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONJUGATE V/	ACCINE - [Xph	arm]		
Any of the following:				
 Up to three doses and a booster every five years for patients or anatomic asplenia, HIV, complement deficiency (acquired 2) One dose for close contacts of meningococcal cases; or A maximum of two doses for bone marrow transplant patient A maximum of two doses for patients following immunosupp Note: children under seven years of age require two doses 8 wee series and then five yearly. 	or inherited), or s; or ression*.	pre o	r post solid	organ transplant; or
*Immunosuppression due to steroid or other immunosuppressive	horany must ho	for a	neriod of ar	pater than 28 days
Inj 4 mcg of each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial		1		lenactra
MENINGOCOCCAL C CONJUGATE VACCINE – [Xpharm] Any of the following:			-	
 Up to three doses and a booster every five years for patients or anatomic asplenia, HIV, complement deficiency (acquired One dose for close contacts of meningococcal cases; or A maximum of two doses for bone marrow transplant patient A maximum of two doses for patients following immunosupp 	or inherited), or s; or			
Note: children under seven years of age require two doses 8 wee series and then five yearly.	ks apart, a boos	ster do	ose three ye	ars after the primary
*Immunosuppression due to steroid or other immunosuppressive Inj 10 mcg in 0.5 ml syringe		for a 1		eater than 28 days. leisvac-C
PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – [Xpharm] Either:				
 A primary course of four doses for previously unvaccinated i Up to three doses as appropriate to complete the primary co 59 months who have received one to three doses of PCV13 	urse of immunis			
Note: please refer to the Immunisation Handbook for the appropr	ate schedule fo	r catch	n up prograi	mmes
Inj 1 mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml				
prefilled syringe	0.00	10	✓ <u>s</u>	ynflorix

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Si	ubsidised	Generic	
\$	Per	1	Manufacturer	

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE - [Xpharm]

Any of the following:

- 1) One dose is funded for high risk children (over the age of 17 months and under 18 years) who have previously received four doses of PCV10; or
- 2) Up to an additional four doses (as appropriate) are funded for high risk children aged under 5 years for (re-)immunisation of patients with any of the following:
 - a) on immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
 - b) with primary immune deficiencies; or
 - c) with HIV infection; or
 - d) with renal failure, or nephrotic syndrome; or
 - e) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
 - f) with cochlear implants or intracranial shunts; or
 - g) with cerebrospinal fluid leaks; or
 - receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
 - i) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
 - j) pre term infants, born before 28 weeks gestation; or
 - k) with cardiac disease, with cyanosis or failure; or
 - with diabetes; or
 - m) with Down syndrome; or
 - n) who are pre-or post-splenectomy, or with functional asplenia; or
- 3) Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients 5 years and over with HIV, for patients pre or post haematopoietic stem cell transplantation, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or
- For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.
- Note: please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4,		
5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5ml		
svringe	10	Prevenar 13

Prevenar 13

1

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE Either:	– [Xpharm]		
 Up to three doses (as appropriate) for patients with l chemotherapy; pre- or post-splenectomy or with fun- complement deficiency (acquired or inherited), coch All of the following: 	ctional asplenia, pre- or p	oost-solid organ t	ransplant, renal dialysis,
 a) Patient is a child under 18 years for (re-)immur b) Treatment is for a maximum of two doses; and c) Any of the following: 			
i) on immunosuppressive therapy or radiati immune response; orii) with primary immune deficiencies; or	on therapy, vaccinate wh	nen there is expe	cted to be a sufficient

- iii) with HIV infection; or
- iv) with renal failure, or nephrotic syndrome; or
- v) who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
- vi) with cochlear implants or intracranial shunts; or
- vii) with cerebrospinal fluid leaks; or
- viii) receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
- ix) with chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
- x) pre term infants, born before 28 weeks gestation; or
- xi) with cardiac disease, with cyanosis or failure; or
- xii) with diabetes; or
- xiii) with Down syndrome; or
- xiv) who are pre-or post-splenectomy, or with functional asplenia.

Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each

23 pneumococcal serotype)	0.00	1	Pneumovax 23
POLIOMYELITIS VACCINE – [Xpharm]			
Up to three doses for patients meeting either of the follow	wing:		
1) For partially vaccinated or previously unvaccinated	individuals; or		
For revaccination following immunosuppression.			
Note: Please refer to the Immunisation Handbook for ap	propriate schedule for ca	tch-up prog	rammes.
Inj 80D antigen units in 0.5 ml syringe	0.00	1	✓ IPOL
ROTAVIRUS ORAL VACCINE – [Xpharm]			
Maximum of two doses for patients meeting the following	j :		
 first dose to be administered in infants aged under 	14 weeks of age; and		
no vaccination being administered to children aged	24 weeks or over.		
Oral susp live attenuated human rotavirus			_
1,000,000 CCID50 per dose, prefilled oral applicator	<i>.</i> 0.00	10	Rotarix

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
VARICELLA VACCINE [CHICKENPOX VACCINE] – [Xpharm] Either:				
1) Maximum of one dose for primary vaccination for eith	er:			
 a) Any infant born on or after 1 April 2016; or b) For previously unvaccinated children turning 11 varicella infection (chickenpox), or 	years old on or after 1	July	2017, who ł	nave not previously had a
Maximum of two doses for any of the following:				
a) Any of the following for non-immune patients:				
 i) with chronic liver disease who may in future ii) with deteriorating renal function before transition prior to solid organ transplant; or 		nspla	antation; or	
iv) prior to any elective immunosuppression*,				
v) for post exposure prophylaxis who are imr				
b) For patients at least 2 years after bone marrow				
 c) For patients at least 6 months after completion (d) For HIV positive papiers to vericelle with m 	1.77			'
 d) For HIV positive non immune to varicella with m e) For patients with inborn errors of metabolism at varicella, or 				
 f) For household contacts of paediatric patients wi immune compromise where the household cont g) For household contacts of adult patients who had 	act has no clinical histo	ory of	varicella, or	
immunocompromised, or undergoing a procedu has no clinical history of varicella.	re leading to immune c	ompr	romise wher	e the household contact
* immunosuppression due to steroid or other immunosuppr 28 days		e for a	a treatment	period of greater than
Inj 2000 PFU prefilled syringe plus vial	0.00	1 10		<u>/arilrix</u> /arilrix
VARICELLA ZOSTER VIRUS (OKA STRAIN) LIVE ATTENUAT Funded for patients meeting either of the following criteria:	TED VACCINE [SHING	LES	VACCINE]	– [Xpharm]
1) One dose for all people aged 65 years; or				1 0000
2) One dose for all people aged between 66 and 80 yea	irs inclusive from 1 Apri	1201	8 and 31 Ma	arch 2020.
Inj 19,400 PFU prefilled syringe plus vial	0.00	1 10		Zostavax Zostavax
Diagnostic Agents				
TUBERCULIN PPD [MANTOUX] TEST – [Xpharm]				

- Svm	bols	
- Jyn	inoia	-

3TC106
- A -
A-Scabies
Abacavir sulphate 106
Abacavir sulphate with
lamivudine 106
Abiraterone acetate
Acarbose
Acarbose Mylan
Acarbose Mylan
Accuretic 10
Accuretic 20
Acetazolamide
Acetic acid with 1, 2- propanediol
diacetate and
benzethonium
Acetic acid with hydroxyquinoline and
ricinoleic acid
Acetylcysteine233
Aci-Jel75
Aciclovir
Infection 102
Sensory228
Acidex6
Acipimox52
Acitretin67
Aclasta114
Aclin110
Actemra211
Actinomycin D161
Actrapid 10
Actrapid Penfill10
Acupan 121
Adalat 1050
Adalat Oros50
Adalimumab180
Adapalene59
Adefin
Adefin XL50
Adefovir dipivoxil101
Adenuric
ADR Cartridge 1.823
Adrenaline
ADT Booster
Adult diphtheria and tetanus
vaccine
Advantan
Advate
Adynovate
Afinitor
Aflibercept190
Afluria Quad
AFT Carbimazole

AFT-Pyrazinamide100
Agents Affecting the
Renin-Angiotensin System 45
Agents for Parkinsonism and Related
Disorders 118
Agents Used in the Treatment of
Poisonings233
Agrylin160
Alanase
Albendazole
Albey
Albustix
Aldurazyme
Alendronate sodium
Alendronate sodium with colecalciferol
Alfacalcidol
Alfamino Junior
Alginic acid
Alglucosidase alfa
Alkeran
Allersoothe
Allmercap
Allopurinol
Alpha-Adrenoceptor Blockers45
Alpha-Keri Lotion
Alphamox 125
Alphamox 250
Alprolix
Alu-Tab
Aluminium hydroxide6
Amantadine hydrochloride118
Ambrisentan
Amiloride hydrochloride51
Amiloride hydrochloride with
furosemide51
Amiloride hydrochloride with
hydrochlorothiazide
Aminophylline 226
Amiodarone hydrochloride47
Amisulpride131
Amitriptyline 124
Amlodipine49
Amorolfine
Amoxicillin
Amoxicillin with clavulanic acid92
Amphotericin B
Amsacrine
AmsaLyo
Amsidine
Amzoate
Anaesthetics
Analgesics 121

Anastrozole	
Andriol Testocaps	<mark>80</mark>
Androderm	<mark>80</mark>
Anoro Ellipta	
Antabuse	. 152
Antacids and Antiflatulents	6
Anten	. 124
Anthelmintics	89
Antiacne Preparations	59
Antiallergy Preparations	
Antianaemics	35
Antiandrogen Oral	
Contraceptives	75
Antiarrhythmics	
Antibacterials	
Antibacterials Topical	59
Anticholinergic Agents	223
Anticholinesterases	110
Antidepressants	124
Antidiarrhoeals	
Antiepilepsy Drugs	
Antifibrinolytics, Haemostatics and	
Local Sclerosants	
Antifibrotics	
Antifungals	
Antifungals Topical	
Antihistamines	.221
Antihypotensives	48
Antimalarials	
Antimigraine Preparations	. 129
Antinausea and Vertigo Agents	. 130
Antiparasitics	
Antipruritic Preparations	<mark>61</mark>
Antipsychotics	. 131
Antiretrovirals	. 105
Antirheumatoid Agents	
Antispasmodics and Other Agents	
Altering Gut Motility	8
Antithrombotic Agents	39
Antithymocyte alobulin	
(equine)	. 180
Antitrichomonal Agents	99
Antituberculotics and	
Antileprotics	99
Antiulcerants	<mark>8</mark>
Antivirals	
Anxiolytics	. 134
Anzatax	
Apidra	
Apidra SoloStar	
Apo-Amlodipine	
Apo-Amoxi	92
Apo-Azithromycin	90
Apo-Bromocriptine	. 118

Apo-Ciclopirox60
Apo-Cilazapril45
Apo-Cilazapril/
Hydrochlorothiazide 46
Apo-Clarithromycin
Alimentary
Infection91
Apo-Clomipramine124
Apo-Diclo SR 110
Apo-Diltiazem CD
Apo-Doxazosin
Apo-Folic Acid
Apo-Furosemide
Apo-Gabapentin
Apo-Leflunomide
Apo-Megestrol
Apo-Metoprolol
Apo-Mirtazapine
Apo-Montelukast
Apo-Nadolol
Apo-Nicotinic Acid
Apo-Ondansetron
Apo-Oxybutynin
Apo-Paroxetine
Apo-Perindopril
Apo-Pindolol
Apo-Pravastatin
Apo-Prazosin
Apo-Prednisone
Apo-Primidone
Apo-Propranolol
Apo-Pyridoxine
Apo-Ropinirole
Apo-Selegiline S29118
Apo-Sumatriptan
Apo-Temozolomide
Apo-Terazosin
Apo-Timol
Apomorphine hydrochloride118
Aprepitant 130
Apresoline
Aptamil Gold+ Pepti Junior255
Aqueous cream64
Aratac
Aripiprazole131
Aripiprazole Sandoz 131
Aristocort63
Arrow - Clopid
Arrow-Amitriptyline 124
Arrow-Bendrofluazide
Arrow-Brimonidine
Arrow-Calcium
Arrow-Diazepam134
Arrow-Doxorubicin 162
Arrow-Fluoxetine 125
Arrow-Lamotrigine 127

Arrow-Losartan &
Hydrochlorothiazide
Arrow-Morphine LA
Arrow-Norfloxacin
Arrow-Ornidazole
Arrow-Quinapril 1045
Arrow-Quinapril 2045
Arrow-Quinapril 545
Arrow-Roxithromycin
Arrow Controling 100
Arrow-Sertraline
Arrow-Timolol
Arrow-Tolterodine
Arrow-Topiramate
Arrow-Tramadol124
Arsenic trioxide
Asacol7
Asamax7
Ascorbic acid31
Aspen Adrenaline54
Aspirin
Blood
Nervous121
Asthalin223
Atazanavir sulphate 107
Atenolol48
Atenolol AFT48
ATGAM180
Ativan135
Atomoxetine147
Atorvastatin53
Atropine sulphate
Cardiovascular
Sensory231
Atropt
Atrovent
AU Synacthen80
Aubagio
Augmentin
Aurorix
AutoSoft 30
AutoSoft 90
Avelox
Avonex
Avonex Pen
Azacitidine
Azacitidine Dr Reddy's
Azamun
Azathioprine
Azithromycin
Azol
Azopt
AZT 106–107
- B -
B-D Micro-Fine
B-D Ultra Fine
B-D Ultra Fine II14

Bacillus Calmette-Guerin (BCG)	
vaccine	180
Bacillus Calmette-Guerin	
vaccine	257
Baclofen	
Bactroban	
Barrier Creams and Emollients	00 64
BCG Vaccine	
Beclazone 100	207
Beclazone 250	221
Beclazone 50	221
Beclomethasone dipropionate	007
Bee venom allergy treatment	220
Bendamustine hydrochloride	
Bendrofluazide	52
Bendroflumethiazide	
[Bendrofluazide]	
BeneFIX	
Benzathine benzylpenicillin	
Benzatropine mesylate	119
Benzbromaron AL 100	116
Benzbromarone	
Benzoin	
Benztrop	
Benzydamine hydrochloride	30
Benzylpenicillin sodium [Penicillin	
G]	
Beta Cream	
Beta Ointment	
Beta Scalp	68
Beta-Adrenoceptor Agonists	223
Beta-Adrenoceptor Blockers	. 48
Betadine	. 65
Betadine Skin Prep	
Betaferon	144
Betahistine dihydrochloride	130
Betaine	
Betaloc CR	
Betamethasone dipropionate	. 62
Betamethasone dipropionate with	
calcipotriol	. 67
Betamethasone sodium phosphate	
with betamethasone acetate	
Betamethasone valerate62	, 68
Betamethasone valerate with	
clioquinol	. 63
Betamethasone valerate with sodium	
fusidate [fusidic acid]	. 63
Betaxolol	
Betnovate	
Betnovate-C	
Betoptic	230
Betoptic S	
Bezafibrate	. 52
Bezalip	

Bezalip Retard52
Bicalutamide 172
Bicillin LA
BiCNU156
Bicnu Heritage156
Bile and Liver Therapy9
Biltricide
Bimatoprost231
Bimatoprost Multichem231
Binarex
Binocrit
Biodone 122
Biodone Extra Forte122
Biodone Forte 122
Bisacodyl26
Bisoprolol fumarate48
BK Lotion
Bleomycin sulphate161
Blood Colony-stimulating
Blood Colony-stimulating Factors
Blood glucose diagnostic test
meter 12
Blood glucose diagnostic test
strip
Blood glucose test strips (visually
impaired)13
Blood Ketone Diagnostic Test
Strip
Bonjela
Boostrix
Bortezomib
Bosentan
Bosentan Dr Reddy's55
Bosvate
Bplex
Breo Ellipta
Brevinor 1/21
Brevinor 1/28
Brevinor 21
Bricanyl Turbuhaler
Brilinta
Brimonidine tartrate
Brimonidine tartrate with timolol
maleate
Brinov
Brinzolamide230
Brolene
Bromocriptine mesylate 118
Brufen SR110
BSF Logem
BSE Mylan Efavirenz Emtricithane
BSF Mylan Efavirenz Emtricitbane
BSF Mylan Efavirenz Emtricitbane Tenofov

Budesonide	
Alimentary	6
Respiratory221,	227
Budesonide with eformoterol	222
Bumetanide	
Buprenorphine with naloxone	
Bupropion hydrochloride	
Burinex	
Buscopan	8
Buspirone hydrochloride	134
Busulfan	
- C -	
Cabergoline	88
Cafergot	120
Cafergot S29	120
Caffeine citrate	227
Calamine	
Calcipotriol	
Calcitonin	0/
Calcitriol	
Calcitriol-AFT	32
Calcium carbonate), 33 40
Calcium Disodium Versenate	
Calcium folinate	158
Calcium Folinate Ebewe	
Calcium Folinate Sandoz	
Calcium gluconate	33
Calcium Homeostasis	
Calcium polystyrene sulphonate Calcium Resonium	44
Calcium Sandoz	
Calogen	240
Candesartan cilexetil	
Candestar	
Canesten	60
Capecitabine	
Capoten	45
Capsaicin	
Musculoskeletal	111
Nervous	121
Captopril	
Carafate	9
Carbaccord	156
Carbamazepine	
Carbimazala	
Carbimazole	
Carbomer	232
Carbomer Carboplatin	232
Carbomer Carboplatin Carboplatin Ebewe	232 156 156
Carbomer Carboplatin Carboplatin Ebewe Carbosorb-X	232 156 156 233
Carbomer Carboplatin Carboplatin Ebewe Carbosorb-X Cardinol LA	232 156 156 233 49
Carbomer Carboplatin Carboplatin Ebewe Carbosorb-X Cardinol LA CareSens Dual	232 156 156 233 49 12
Carbomer Carboplatin Carboplatin Ebewe Carbosorb-X Cardinol LA CareSens Dual CareSens N	232 156 156 233 49 12 2–13
Carbomer Carboplatin Carboplatin Ebewe Carbosorb-X Cardinol LA CareSens Dual CareSens N	232 156 156 233 49 12 2–13 12
Carbomer Carboplatin Carboplatin Ebewe Carbosorb-X Cardinol LA CareSens Dual CareSens N	232 156 156 233 49 12 2–13 12 12
Carbomer Carboplatin Carboplatin Ebewe Carbosorb-X Cardinol LA CareSens Dual CareSens N	232 156 156 233 49 12 2–13 12 12

Carmellose sodium with gelatin and	
pectin	. 30
Carmustine	
Carvedilol	.48
Carvedilol Sandoz	
Catapres	.50
Cathejell	120
CeeNU	
Cefaclor monohydrate	.89
Cefalexin	
Cefalexin Sandoz	89
Cefazolin	89
Ceftriaxone	
Ceftriaxone-AFT	90
Cefuroxime axetil	. 00 . an
Celebrex	
Celecoxib	
Celecoxib Pfizer	
Celestone Chronodose	70
Celiprolol	.48
Cellcept	1/4
Celol	.48
Centrally-Acting Agents	
Cephalexin ABM	. 89
Cetirizine hydrochloride	221
Cetomacrogol	.64
Cetomacrogol with glycerol	.64
Cetuximab	
Charcoal	
Chemotherapeutic Agents	
Chickenpox vaccine	266
Chlorafast	228
Chlorambucil	156
Chloramphenicol	228
Chlorhexidine gluconate	
Alimentary	. 30
Dermatological	.63
Chloroform	
Chlorothiazide	.52
Chlorpheniramine maleate	
Chlorpromazine hydrochloride	
Chlorsig	
Chlortalidone [Chlorthalidone]	52
Chlorthalidone	52
Chlorvescent	
Choice Load 375	- 7 1 70
Choice TT380 Short	.72
Choice TT380 Standard	.72
Choline salicylate with cetalkonium	~~
chloride	
Ciclopirox olamine	
Ciclosporin	
Cilazapril	.45
Cilazapril with	
hydrochlorothiazide	
Cilicaine	.93

Cilicaine VK
Cinacalcet78
Cipflox94
Ciprofloxacin
Infection94
Sensory
Ciprofloxacin Teva228
Circadin146
Cisplatin156
Cisplatin Ebewe156
Citalopram hydrobromide 125
Cladribine
Clarithromycin
Alimentary8
Infection91
Clexane
Clindamycin94
Clindamycin ABM
Clinicians Renal Vit
Clobazam 126
Clobetasol propionate
Clobetasone butyrate
Clofazimine
Clomazol
Dermatological60
Genito-Urinary75
Clomifene citrate88
Clomipramine hydrochloride124
Clonazepam 126, 134
Clonidine
Clonidine BNM50
Clonidine hydrochloride50
Clopidogrel
Clopine
Clopixol133–134
Clotrimazole
Dermatological 60
Genito-Urinary75
Clozapine132
Clozaril
Clustran 129
Co-trimoxazole
Coal tar
Coal tar with allantoin, menthol,
phenol and sulphur68
Coal tar with salicylic acid and
sulphur68
Coco-Scalp
Codeine phosphate
Extemporaneous236
Nervous121
Cogentin 119
Colaspase [L-asparaginase]161
Colchicine
Colecalciferol
Colestid

	_
Colestipol hydrochloride	
Colgout	116
Colifoam	7
Colistin sulphomethate	. 94
Colistin-Link	. 94
Collodion flexible	236
Colloidal bismuth subcitrate	9
Colofac	8
Coloxyl	.25
Combigan	231
Compound electrolytes	.44
Compound electrolytes with glucose	
[Dextrose]	. 44
Compound hydroxybenzoate	236
Concerta	
Condoms	.71
Condyline	. 69
Contraceptives - Hormonal	.72
Contraceptives - Non-hormonal	.70
Copaxone	141
Cordarone-X	.47
Corticosteroids and Related Agents	
for Systemic Use	. 79
Corticosteroids Topical	. 62
Cosentyx Cosmegen	209
Cosmegen	161
Coumadin	.42
Creon 10000	
Creon 25000	
Cromal	
Crotamiton	.61
Crystaderm	. 59
Curam	. 92
Cvite	.31
Cyclizine hydrochloride	130
Cyclizine lactate	130
Cyclogyl	231
Cyclopentolate hydrochloride	231
Cyclophosphamide	156
Cyclorin	. 99
Cycloserine	. 99
Cyklokapron	. 39
Cyproterone acetate	
Cyproterone acetate with	
ethinyloestradiol	. 75
Cystadane	.27
Cytarabine	158
Cytotec	8
Cytoxan	
- D -	
D-Penamine	111
Dabigatran	
Dacarbazine	161
Dacarbazine APP	161
Dactinomycin [Actinomycin D]	161
Daivobet	

Daivonex	
Daktarin	<mark>6</mark> 1
Dalacin C	
Dalteparin sodium	
Danazol	
Dantrium	. 117
Dantrium S29	. 117
Dantrolene	. 117
Daonil	
Dapa-Tabs	
Dapsone	
Daraprim	
Darunavir	. 107
Dasatinib	. 166
Daunorubicin	. 162
DBL Acetylcysteine	.233
DBL Aminophylline	
DBL Bleomycin Sulfate	
DBL Carboplatin	. 156
DBL Cisplatin	
DBL Dacarbazine	.161
DBL Desferrioxamine Mesylate for I	nj
BP	. 234
DBL Docetaxel	
DBL Ergometrine	
DBL Gemcitabine	. 158
DBL Gentamicin	94
DBL Leucovorin Calcium	. 158
DBL Methotrexate Onco-Vial	. 159
DBL Morphine Sulphate	. 123
DBL Morphine Tartrate	. 123
DBL Naloxone Hydrochloride	
DBL Octreotide	.172
DBL Pethidine Hydrochloride	. 124
DBL Vincristine Sulfate	
De-Worm	
Decozol	
Deferasirox	.233
Deferiprone	.234
Denosumab	
Deolate	
Deoxycoformycin Depo-Medrol	. 104
Depo-Provera	
Depo-Testosterone	/4
Deprim DermAssist	
Dermol	02
Desferrioxamine mesilate	2,00 ∧00
Desmopressin acetate Desmopressin-PH&T	
Detection of Substances in	0/
Urine	77
Dexamethasone	
Hormone	70
Sensory	

INDEX: Generic C	Chemicals	and	Brands
------------------	-----------	-----	--------

Dexamethasone phosphate79
Dexamethasone with framycetin and
gramicidin 228
Dexamethasone with neomycin
sulphate and polymyxin B
sulphate
Dexamfetamine sulfate
Dexmethsone
Dextrochlorpheniramine
maleate
Dextrose
DHC Continus121
Diabetes
Diabetes Management11
Diacomit128
Diagnostic Agents266
Diamide Relief6
Diamox
Diasip241
Diason RTH241
Diazepam 126, 134
Diazoxide
Dibenzyline
Diclofenac Sandoz
Diclofenac sodium
Musculoskeletal 110
Sensory
Differin
Difflam
Diflucan96
Diflucan S29
Diflucortolone valerate62
Digestives Including Enzymes23
Digoxin
Dihydrocodeine tartrate 121
Dilantin128
Dilantin Infatab128
Diltiazem hydrochloride
Dilzem
Dimethicone
Dimethyl fumarate
Dipentum
Diphtheria, tetanus and pertussis
vaccine 257
Diphtheria, tetanus, pertussis and
polio vaccine 258
Diphtheria, tetanus, pertussis, polio,
hepatitis B and haemophilus
influenzae type B vaccine
Diprosone
Diprosone OV
Dipyridamole
Disinfecting and Cleansing
Agents 63
Disopyramide phosphate47
Disulfiram152

Diuretics51
Diurin 4051
Docetaxel162
Docetaxel Accord 162
Docetaxel Sandoz 162
Docusate sodium25
Docusate sodium with
sennosides25
Dolutegravir 107
Domperidone 130
Donepezil hydrochloride 150
Donepezil-Rex150
Dopress
Dornase alfa 226
Dortimopt230
Dorzolamide hydrochloride230
Dorzolamide with timolol230
Dostinex
Dosulenin (Dothienin)
hydrochloride 124
Dothiepin
Doxazosin
Doxepin hydrochloride
Doxine
Doxorubicin Ebewe
Doxorubicin hydrochloride
Doxy-50
Doxycycline
DP Lotion
DP Lotn HC
DP-Allopurinol
Dr Reddy's Omeprazole
Drugs Affecting Bone
Metabolism 111
Dual blood glucose and blood ketone
diagnostic test meter 12
Duocal Super Soluble Powder
Duolin
Duolin HFA
Durex Confidence
Durex Extra Safe
Duride
- E -
e-chamber La Grande
e-chamber Mask
e-chamber Turbo
E-Mycin
Ear Preparations
Ear/Eye Preparations
Easiphen Liquid
Econazole nitrate
Efavirenz106 Efavirenz with emtricitabine and
tenofovir disoproxil
Effient
Eformoterol fumarate222

Eformoterol fumarate dihydrate	222
Eftrenonacog alfa [Recombinant	
factor IX]	36
Efudix	
Egopsoryl TA	
Elaprase	27
Elecare	
Elecare LCP	254
Elelyso	29
Elemental 028 Extra	
Elocon	63
Elocon Alcohol Free	
Eltrombopag	36
Eltroxin EMB Fatol	
Emend Tri-Pack	
EMLA	
Emtricitabine	
Emtricitabine with tenofovir	100
disoproxil	102
Emtriva	100
Emulsifying ointment	100 64
Enalapril maleate	04
Enbrel	174
Endocrine Therapy	171
Endoxan	156
Enerlyte	44
Engerix-B	259
Enlafax XR	
Enoxaparin sodium	41
Ensure	249
Ensure Plus	249
Ensure Plus HN	248
Ensure Plus RTH	
Entacapone	
Entapone	118
Entecavir	
Entecavir Sandoz	
Entocort CIR	
Entresto 24/26	
Entresto 49/51 Entresto 97/103	46
Epilim	
Epilim Crushable	120
Epilim IV	
Epilim S/F Liquid	120
Epilim Syrup	120
Epirubicin Ebewe	162
Epirubicin hydrochloride	
Eplerenone	
Epoetin alfa	
Epoprostenol	
Eptacog alfa [Recombinant factor	
VIIa]	37
ERA	
Erbitux	

Ergometrine maleate75
Ergotamine tartrate with
caffeine 129
Erlotinib167
Erythrocin IV91
Erythromycin (as lactobionate)91
Erythromycin ethyl succinate
Erythromycin stearate91
Esbriet
Escitalopram125
Escitalopram-Apotex
Eskazole
Estradot
Estradot 50 mcg81
Estrofem
Etanercept
Ethambutol hydrochloride
Ethics Assiste
Ethics Aspirin
Ethics Aspirin EC
Ethics Enalapril45
Ethics Lisinopril45
Ethinyloestradiol81
Ethinyloestradiol with
desogestrel
Ethinyloestradiol with
levonorgestrel 73
Ethinyloestradiol with
norethisterone
Ethosuximide 127
Etopophos162
Etoposide162
Etoposide phosphate162
Etravirine106
Eumovate62
Everet 127
Everolimus218
Evista112
Exelon151
Exemestane173
Exjade
Extemporaneously Compounded
Preparations and
Galenicals
Eye Preparations
Eylea
Ezetimibe
Ezetimibe Sandoz
Ezetimibe with simvastatin
- F -
Factor eight inhibitor bypassing
fraction
Febuxostat117 Feed Thickener Karicare
Aptamil
Apianii
FEIBA NF
Felo 10 FB 50

Felo 5 ER	
Felodipine	50
Femme-Tab ED	73
Fentanyl	
Fentanyl Sandoz	
Ferinject	
Ferodan	
Ferric carboxymaltose	33
Ferriprox	
Ferro-F-Tabs	
Ferro-tab	
Ferrograd	
Ferrosig	 34
Ferrous fumarate	 34
Ferrous fumarate with folic acid	 2/
Ferrous sulfate	
Ferrous sulphate	
Ferrum H	
Fexofenadine hydrochloride	
Fibro-vein	
Filgrastim	42
Finasteride	
Fingolimod	136
Firazyr	
Flagyl	
FlagyI-S	
Flamazine	
Flecainide acetate	
Fleesinide DNM	47
Flecainide BNM	
Flecainide Controlled Release	
Flecainide Controlled Release Teva	47
Flecainide Controlled Release Teva Fleet Phosphate Enema	47 25
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy	47 25 227
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide	47 25 227 222
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Flixotide Accuhaler	47 25 227 222 222
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide	47 25 227 222 222
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Flixotide Accuhaler Floair Florinef	47 25 227 222 222 222 79
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Flixotide Accuhaler Floair	47 25 227 222 222 222 79
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Flixotide Accuhaler Floair Florinef	47 25 227 222 222 222 79 133
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Accuhaler Floair Floainef Fluanxol Fluarix Tetra Flucil	47 25 227 222 222 222 79 133 261 92
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Accuhaler Floair Floainef Fluanxol Fluarix Tetra Flucil	47 25 227 222 222 222 79 133 261 92
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Accuhaler Floair Floair Fluanxol Fluarix Tetra Flucil Flucin	47 25 227 222 222 222 79 133 261 92 92
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Accuhaler Floair Floainef Fluanxol Fluarix Tetra Flucil	47 25 227 222 222 222 79 133 261 92 92 92 92
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Accuhaler Florinef Floair Fluanxol Fluarix Tetra Flucin Flucioxacillin Flucloxan Flucon	47 25 227 222 222 222 222 222 222
Flecainide Controlled Release Teva Fleet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Flixotide Accuhaler Floair Floair Floair Fluanxol Fluanxol Fluarix Tetra Flucioxacillin Flucloxacillin Flucloxain Flucon Fluconazole	47 25 227 222 222 222 222
Flecainide Controlled Release Teva	
Flecainide Controlled Release Teva	
Flecainide Controlled Release Teva	
Flecainide Controlled Release Teva	47 255 227 222 222 222 222 222 222 222 22
Flecainide Controlled Release Teva	47 25 222 222 222 222 222 222 222 222 222
Flecainide Controlled Release Teva	47 25 222 222 222 222 222 222 222 222 222
Flecainide Controlled Release Teva	47 25 222 222 222 222 222 222 222 222 222
Flecainide Controlled Release Teva	

Fluorouracil sodium	6 9
Fluoxetine hydrochloride	. 125
Flupenthixol decanoate	.133
FluQuadri	
Flutamide	
Flutamide Mylan	.172
Flutamin	172
Fluticasone	222
Fluticasone furoate with	
vilanterol	222
Fluticasone propionate	207
Fluticasone with salmeterol	.221
FML	
Foban	00
Folic acid	
Food Thickeners	.251
Foods And Supplements For Inborn	0
Errors Of Metabolism	. 252
Foradil	
Forteo	. 113
Fortini	.243
Fortini Multi Fibre	.243
Fortisip	.249
Fortisip Multi Fibre	.250
Fosamax	.111
Fosamax Plus	.111
Fragmin	40
Framvcetin sulphate	.228
Framycetin sulphate Fresenius Kabi	3–44
Frisium	126
Frumil	
Frusemide	51
Frusemide-Claris	51
Fucicort	
Fucidin	
Fucithalmic	ອິບ ດດດ
Fungilin	
Furosemide [Frusemide]	
fusidic acid	
Dermatological6	0 60
Dermatological	0, 63
Infection	90
- G -	. 228
Gabapentin	407
Gacet	
Galsulfase	27
Galvumet	11
Galvus	
Gardasil 9	. 260
Gastrodenol Gaviscon Double Strength	9
Gaviscon Double Strength	6
Gaviscon Infant	
Gazyva	. 198
Gefitinib	. 167
Gemcitabine Ebewe	.158
Gemcitabine hydrochloride	. 158

Gemfibrozil52
Gemzar158
Genoptic228
Gentamicin sulphate
Infection
Sensory
Gilenya
Ginet
Glatiramer acetate
Glecaprevir with pibrentasvir 103
Glibenclamide11
Gliclazide11
Glipizide11
Glivec167
Glizide11
Glucagen Hypokit9
Glucagon hydrochloride9
Glucerna Select
Glucerna Select RTH241
Glucobay11
Glucose [Dextrose]43
Gluten Free Foods
Glycerin with sodium saccharin 236
Glycerin with sucrose236
Glycerol
Alimentary25
Extemporaneous236
Glyceryl trinitrate
Alimentary
Cardiovascular
Glycopyrronium
Glycopyrronium bromide
Glycopyrronium with
indacaterol
Glytrin
Gold Knight
Goserelin
Gutron
Gynaecological Anti-infectives75
- H -
Habitrol
Haemophilus influenzae type B
vaccine 258
Haldol
Haldol Concentrate133
Haldol Decanoas 133
Haloperidol132
Haloperidol decanoate133
Hamilton Sunscreen69
Harvoni 103
Havrix258
Havrix Junior258
HBvaxPRO259
healthE Calamine Aqueous Cream
BP61
healthE Dimethicone 10%64

healthE Dimethicone 4% Lotion	65
healthE Dimethicone 5%	
healthE Glycerol BP	236
healthE Urea Cream	
Healtheries Simple Baking Mix	251
Hemastix	
Heparin sodium	<i>11</i>
Heparinised saline	
Heparon Junior	42
	242
Hepatitis A vaccine	200
Hepatitis B recombinant	050
vaccine	259
Hepsera	101
Herceptin	214
Hexamine hippurate	
Hiberix	
Hiprex	
Histaclear	221
Histafen	
Holoxan	156
Horleys Bread Mix	251
Horleys Flour	252
Hormone Replacement Therapy -	
Systemic	80
HPV	260
Humalog	10
Humalog Mix 25	10
Humalog Mix 50	
Human papillomavirus (6, 11, 16, 1	
	8.
31 33 45 52 and 58) vaccine	8,
31, 33, 45, 52 and 58) vaccine	
31, 33, 45, 52 and 58) vaccine [HPV]	260
31, 33, 45, 52 and 58) vaccine [HPV] Humatin	260 95
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira	260 95 180
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira HumiraPen	260 95 180 180
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira HumiraPen Humulin 30/70	260 95 180 180 10
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira HumiraPen Humulin 30/70 Humulin NPH	260 95 180 180 10 10
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira HumiraPen Humulin 30/70 Humulin NPH Humulin R	260 95 180 180 10 10 10
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira HumiraPen Humulin 30/70 Humulin NPH Humulin R Hyaluronic acid	260 95 180 180 10 10 10 232
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumuiraPen. Humulin 30/70 Humulin NPH. Hyaluronic acid. Hybloc.	260 95 180 10 10 10 232 48
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumiraPen. Humulin 30/70 Humulin NPH. Humulin R Hyaluronic acid Hybloc. Hydralazine.	260 95 180 10 10 10 232 48 54
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumiraPen. Humulin 30/70 Humulin NPH. Humulin R. Hyaluronic acid Hybloc. Hydralazine. Hydralazine hydrochloride.	260 95 180 10 10 10 10 232 48 54
31, 33, 45, 52 and 58) vaccine [HPV] Humatin HumiraPen. Humulin 30/70 Humulin NPH. Humulin R. Hyaluronic acid Hybloc. Hydralazine Hydralazine hydrochloride	260 95 180 10 10 10 10 232 48 54
31, 33, 45, 52 and 58) vaccine [HPV] Humatin HumiraPen. Humulin 30/70 Humulin NPH. Humulin R. Hyaluronic acid Hydralazine. Hydralazine. Hydracortisone	260 95 180 10 10 10 10 232 54 54 54
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. Humulin 30/70 Humulin NPH. Humulin R. Hyaluronic acid Hydroc Hydralazine. Hydralazine. Hydrochloride Hydracortisone Dermatological.	260 95 180 10 10 10 10 232 48 54 54 54 54
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumiraPen. Humulin 30/70 Humulin NPH. Humulin R. Hyaluronic acid Hydroc Hydralazine. Hydralazine. Hydralazine. Hydrochloride Hydracortisone Dermatological Hormone.	260 95 180 10 10 10 232 232 54 54 54 54 54 54 54 79
31, 33, 45, 52 and 58) vaccine [HPV] Humatin HumiraPen. Humulin 30/70 Humulin NPH. Hyaluronic acid Hybloc Hydralazine. Hydralazine. Hydracortisone Dermatological Hormone.	260 95 180 10 10 10 232 232 54 54 54 54 54 54 54 79
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumiraPen. Humulin 30/70 Humulin NPH. Humulin R. Hyaluronic acid Hydroc Hydralazine. Hydralazine. Hydralazine. Hydrochloride Hydracortisone Dermatological Hormone.	260 95 180 10 10 10 232 232 54 54 54 54 54 54 54 79
31, 33, 45, 52 and 58) vaccine [HPV] Humatin HumiraPen. Humulin 30/70 Humulin NPH. Humulin R. Hyaluronic acid Hydralazine hydrochloride Hydralazine hydrochloride Hydrocortisone Dermatological Hormone Hydrocortisone acetate with pramoxine hydrochloride	260
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumuiraPen. Humulin 30/70 Humulin NPH. Hyaluronic acid Hybloc Hydralazine Hydralazine Hydrocortisone Dermatological Hydrocortisone acetate. Hydrocortisone acetate with pramoxine hydrochloride Hydrocortisone and paraffin liquid	260
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumuiraPen. Humulin 30/70 Humulin NPH. Hyaluronic acid Hybloc. Hydralazine Hydralazine hydrochloride Hydrocortisone Dermatological. Hormone Hydrocortisone acetate. Hydrocortisone acetate with pramoxine hydrochloride Hydrocortisone and paraffin liquid and lanolin	
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumuiraPen. Humulin 30/70 Humulin NPH. Hyaluronic acid Hybloc Hydralazine Hydralazine Hydrocortisone Dermatological Hydrocortisone acetate. Hydrocortisone acetate with pramoxine hydrochloride Hydrocortisone and paraffin liquid	
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumuiraPen. Humulin 30/70 Humulin NPH. Hyaluronic acid Hybloc. Hydralazine Hydralazine hydrochloride Hydrocortisone Dermatological. Hormone Hydrocortisone acetate. Hydrocortisone acetate with pramoxine hydrochloride Hydrocortisone and paraffin liquid and lanolin	260
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumuiraPen. Humulin 30/70 Humulin NPH. Hyaluronic acid Hybloc. Hydralazine Hydralazine hydrochloride Hydrocortisone Dermatological. Hydrocortisone acetate. Hydrocortisone acetate with pramoxine hydrochloride Hydrocortisone and paraffin liquid and lanolin.	260
31, 33, 45, 52 and 58) vaccine [HPV] Humatin HumiraPen. Humulin 30/70 Humulin NPH. Humulin R Hyaluronic acid Hybloc. Hydralazine Hydrocortisone Dermatological. Hydrocortisone acetate. Hydrocortisone acetate with pramoxine hydrochloride Hydrocortisone butyrate Hydrocortisone butyrate Hydrocortisone with cinchocaine	
31, 33, 45, 52 and 58) vaccine [HPV] Humatin Humira. HumiraPen. Humulin 30/70 Humulin NPH. Humulin R. Hyaluronic acid Hybloc. Hydralazine Hydrocortisone Dermatological. Hydrocortisone acetate. Hydrocortisone acetate with pramoxine hydrochloride Hydrocortisone acetate with pramoxine hydrochloride Hydrocortisone and paraffin liquid and lanolin Hydrocortisone butyrate Hydrocortisone with cinchocaine	260

Hydrogen peroxide
Alimentary31
Dermatological 59
Hydroxocobalamin31
Hydroxychloroquine111
Hydroxyurea 162
Hygroton52
Hylo-Fresh232
Hymenoptera220
Hyoscine butylbromide8
Hyoscine hydrobromide130
Hypam147
Hyperuricaemia and Antigout 116
Hypromellose
Hypromellose with dextran
- -
Ibiamox92
Ibuprofen 110
Icatibant
Idarubicin hydrochloride
Idursulfase
Ifosfamide
Ikorel
lloprost
Imatinib mesilate
Imatinib-AFT167
Imipramine hydrochloride 124
Imiguimod
Immune Modulators
Immunosuppressants
Imuran
Incruse Ellipta
Indacaterol
Indapamide
Infanrix IPV
Infanrix-hexa
Infant Formulae
Infatrini
Infliximab
Influenza vaccine
Influvac Tetra
Inhaled Corticosteroids221
Inhaled Long-acting
Beta-adrenoceptor Agonists 222
Inspra51
Insulin aspart 10
Insulin aspart with insulin aspart
protamine10
Insulin glargine10
Insulin glulisine10
Insulin isophane10
Insulin isophane with insulin
neutral 10
Insulin lispro10
Insulin lispro with insulin lispro

protamine10
Insulin neutral 10
Insulin pen needles13
Insulin pump14
Insulin pump cartridge19
Insulin pump infusion set (steel
cannula)19
Insulin pump infusion set (steel
cannula, straight insertion) 20
Insulin pump infusion set (teflon
cannula, angle insertion with
insertion device) 20
Insulin pump infusion set (teflon
cannula, angle insertion) 21
Insulin pump infusion set (teflon
cannula, straight insertion with
insertion device) 22
Insulin pump infusion set (teflon
cannula, straight insertion)
Insulin pump reservoir23
Insulin syringes, disposable with
attached needle 14
Intal Forte CFC Free226
Intelence 106
Interferon alfa-2a 108
Interferon beta-1-alpha142
Interferon beta-1-beta144
Intra-uterine device72
Invega Sustenna133
IPOL
Ipratropium bromide223, 227
Iressa167
Irinotecan Accord159
Irinotecan Actavis 100 159
Irinotecan hydrochloride 159
Irinotecan-Rex159
Iron polymaltose
Isentress107
Isentress HD 107
Ismo 2054
Ismo 40 Retard54
Isoniazid
Isoniazid with rifampicin100
Isoprenaline [Isoproterenol]54
Isoproterenol
Isoptin
Isoptin SR
Isopto Carpine
Isosorbide mononitrate
Isosource Standard
Isotretinoin59
Lease advecter (a scallbourg) ()
Ispaghula (psyllium) husk
Isuprel54
Isuprel
Isuprel54

Ivermectin
- J - Jadelle
Jakavi
Jevity HiCal RTH
Jevity RTH
Juno Pemetrexed 159
- K -
Kaletra
Keflor
Kemadrin 119
Kenacomb
Kenacort-A 1080
Kenacort-A 4080
Kenalog in Orabase30
Ketocal 3:1256
KetoCal 4:1256
Ketoconazole
Dermatological
Infection
Ketogenic Diet256
Ketoprofen110
KetoSens11
Keytruda216
Kindergen
Kivexa
Klacid91
Kliogest81
Kliovance81
Kogenate FS
Konakion MM
Konsyl-D25
Kuvan
-L-
L-asparaginase
Labetalol
Lacosamide127
Lactulose
Laevolac
Lamictal
Lamivudine 101, 106
Lamivudine Alphapharm106
Lamotrigine
Lamprene
Lanoxin
Lanoxin PG47
Lanoxin S2947
Lansoprazole8
Lantus10
Lantus SoloStar10
Lanvis
Lanzol Relief8
Lapatinib ditosylate168
Largactil 131
Laronidase28
Lasix

Latanoprost	<mark>23</mark> 1
Lax-Suppositories	<mark>26</mark>
Lax-Tab	26
Laxatives	
Laxsol	25
Ledipasvir with sofosbuvir	103
Leflunomide	111
Lenalidomide	162
Letrole	174
Letrozole	
Leukeran FC	1 <mark>56</mark>
Leukotriene Receptor	
Antagonists	226
Leunase	161
Leuprorelin	87
Leustatin	1 <mark>58</mark>
Levetiracetam	127
Levetiracetam-AFT	127
Levlen ED	
Levocabastine	230
Levodopa with benserazide	118
Levodopa with carbidopa	118
Levomepromazine hydrochloride	132
Levomepromazine maleate	132
Levonorgestrel	
Genito-Urinary	74
Hormone	
Levothyroxine	
Lidocaine [Lignocaine]	
Lidocaine [Lignocaine]	
hydrochloride	120
Lidocaine [Lignocaine] with	
chlorhexidine	120
Lidocaine [Lignocaine] with	
prilocaine	120
Lidocaine-Claris	120
Lignocaine	
Lioresal Intrathecal	
Lipazil	
Lipid-Modifying Agents	52
Liquigen	
Lisinopril	45
Lithicarb FC	
Lithium carbonate	132
Livostin	
LMX4	
Locacorten-Viaform ED's	228
Local preparations for Anal and	
Rectal Disorders	7
Locasol	
Locoid	
Locoid Crelo	
Locoid Lipocream	
Locorten-Vioform	
Lodi	

Lodoxamide 230
Logem127
Lomide230
Lomustine 156
Loniten55
Loperamide hydrochloride6
Lopinavir with ritonavir107
Loprofin253
Loprofin Mix253
Lorafix221
Loratadine
Lorazepam135
Lorfast
Lorstat53
Losartan Actavis 46
Losartan potassium 46
Losartan potassium with
hydrochlorothiazide 46
Lovir
Loxamine
Lucrin Depot 1-month87
Lucrin Depot 3-month87
Ludiomil
Lyderm
- M -
m-Eslon
Mabthera
Macrogol 3350 with potassium
Macrogol 3350 with potassium chloride, sodium bicarbonate and
chloride, sodium bicarbonate and
chloride, sodium bicarbonate and sodium chloride25
chloride, sodium bicarbonate and sodium chloride

Medrol79
Medroxyprogesterone acetate
Genito-Urinary74
Hormone
Mefenamic acid
Megestrol acetate
Melatonin
Melphalan
Menactra
Meningococcal (groups A, C, Y and W-135) conjugate vaccine
Meningococcal C conjugate
vaccine
Menthol
Mercaptopurine159
Mercilon 28
Mesalazine
Mesna
Mestinon
Metabolic Disorder Agents26
Meterol
Metformin hydrochloride11
Methadone hydrochloride
Extemporaneous236
Nervous122
Methatabs122
Methopt231
Methotrexate159
Methotrexate Ebewe159
Methotrexate Sandoz 159
Methyl hydroxybenzoate236
Methylcellulose236
Methylcellulose with glycerin and
sodium saccharin
Methylcellulose with glycerin and
sucrose
Methyldopa50
Methyldopa Mylan 50
Methyldopa Mylan S2950
Methylnaltrexone bromide
Methylphenidate ER - Teva149
Methylphenidate hydrochloride 148
Methylphenidate hydrochloride
extended-release
Methylprednisolone
Methylprednisolone (as sodium
succinate)
Methylprednisolone aceponate
Methylprednisolone acetate
Metoclopramide Actavis 10
Metoclopramide hydrochloride 130
Metolazone
Metopirone
Metoprolol succinate
Metoprolol tartrate
· · · F · · · · · · · · · · · · · · · ·

Metronidazole	00
Metroprolol IV Mylan	
Metyrapone	88
Mexiletine hydrochloride	48
Mexiletine Hydrochloride USP	
Miacalcic	78
Micolette	
Miconazole	31
Miconazole nitrate	
Dermatological	61
Genito-Urinary	75
Micreme	
Micreme H	
	03
Microgynon 20 ED	73
Microgynon 30	73
Microgynon 50 ED	73
Microlut	74
Midazolam	
Midazolam-Claris	
Midodrine	. 140
	40
Milan Laboratories	
Minerals	33
Mini-Wright AFS Low Range	.227
Mini-Wright Standard	.227
Minidiab	
MiniMed 640G	14
Minims Pilocarpine	021
Minims Prednisolone	.201
Minirin	
Mino-tabs	93
Minocycline hydrochloride	93
Minomycin	93
Minor Skin Infections	65
Minoxidil	
Mirena	
Mirtazapine	106
Misoprostol	
Mitomycin C	
Mitozantrone	
Mitozantrone Ebewe	
Mixtard 30	10
Moclobemide	
Modafinil	
	150
Modoviail	
Modavigil	. 150
Moduretic	.150 52
Moduretic Molaxole	.150 52 25
Moduretic Molaxole Moments	.150 52 25 71
Moduretic Molaxole	.150 52 25 71
Moduretic Molaxole Moments Mometasone furoate	. 150 52 25 71 63
Moduretic Molaxole Moments Mometasone furoate Monogen	.150 52 25 71 63 .242
Moduretic Molaxole Moments Mometasone furoate Monogen Montelukast	. 150 52 25 71 63 . 242 . 226
Moduretic Molaxole Moments Mometasone furoate Monogen Montelukast Montelukast Mylan	. 150 52 25 71 63 .242 .226 .226
Moduretic Molaxole Moments Mometasone furoate Monogen Montelukast Montelukast Mylan Moroctocog alfa [Recombinant factor	. 150 52 25 71 63 . 242 . 226 . 226 or
Moduretic Molaxole Moments Mometasone furoate Monogen Montelukast Montelukast Mylan Moroctocog alfa [Recombinant factor VIII]	. 150 52 25 71 63 . 242 . 226 . 226 or 38
Moduretic Molaxole Moments Mometasone furoate Monogen Montelukast Montelukast Mylan Moroctocog alfa [Recombinant facto VIII] Morphine hydrochloride	. 150 52 25 71 63 .242 .226 .226 or 38 .122
Moduretic Molaxole Moments Mometasone furoate Monogen Montelukast Montelukast Mylan Moroctocog alfa [Recombinant factor VIII]	. 150 52 25 71 63 . 242 . 226 . 226 or 38 . 122 . 123

Motetis	110
Mouth and Throat	
Movapo	
Moxifloxacin	
MSUD Maxamum	252
Mucilaginous laxatives with	
stimulants	. 25
Mucolytics	226
Mucosoothe	
Multiple Sclerosis Treatments	
Multivitamin renal	
Multivitamins	32
Mupirocin	
Muscle Relaxants	117
Mvite	
Myambutol	
Mycobutin	
MycoNail	
Mycophenolate mofetil	
Mycostatin	. 61
Mydriacyl	231
Mylan Atenolol	
Mylan Clomiphen	88
Myleran	
Myocrisin	111
Myometrial and Vaginal Hormone	
Preparations	.75
Myozyme	26
Mysoline S29	
Mysoline S29	
- N -	128
- N - Nadolol	128 49
- N - Nadolol Naglazyme	128 49 27
- N - Nadolol Naglazyme Nalcrom	128 49 27 7
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride	128 49 27 7 233
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord	128 49 27 7 233 152
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride	128 49 7 233 152 152
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Naphazoline hydrochloride	128 49 27 7 233 152 152 232
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Naphazoline hydrochloride Naphcon Forte	128 49 7 233 152 152 232 232
- N - Nadolol Naglazyme Nalcrom Nalcrom Naltraccord Naltrexone hydrochloride Naphazoline hydrochloride Naphoon Forte Naprosyn SR 1000	128 49 27 233 152 152 232 232 110
- N - Nadolol Naglazyme Nalcrom Nalcrom Naltraccord Natrexone hydrochloride Naphazoline hydrochloride Naphoon Forte Naprosyn SR 1000 Naprosyn SR 750	128 49 27 233 152 232 232 232 110 110
- N - Nadolol Naglazyme Nalcrom Nalcrom Naltraccord Natraccord Naphrazoline hydrochloride Naphoon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen	128 49 27 7 233 152 232 232 110 110 110
- N - Nadolol Naglazyme Nalcrom Nalcrom Naltraccord Natrexone hydrochloride Naphazoline hydrochloride Naphoon Forte Naprosyn SR 1000 Naprosyn SR 750	128 49 27 7 233 152 232 232 110 110 110
- N - Nadolol Naglazyme Nalcrom Nalcrom Naltraccord Natraccord Naphrazoline hydrochloride Naphoon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen	128 49 27 7 233 152 232 232 232 110 110 110 125
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord Naltraccord Naphazoline hydrochloride Naphoon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil S29 Nasal Preparations	128 49 27 233 152 232 232 232 110 110 110 125 125 227
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord Nattraccord Naphazoline hydrochloride Naphazoline hydrochloride Naphosp NSR 1000 Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nardil S29 Nasal Preparations Natalizumab.	128 49 27 233 152 232 232 110 110 125 227 138
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord Nattraccord Naphazoline hydrochloride Naphazoline hydrochloride Naphosp NSR 1000 Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nardil S29 Nasal Preparations Natalizumab.	128 49 27 233 152 232 232 110 110 125 227 138
- N - Nadolol Naglazyme Nalcrom Nalcrom Naltraccord Naltraccord Nattexone hydrochloride Naphazoline hydrochloride Naphazoline hydrochloride Naphosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nardil S29 Nasal Preparations Natalizumab Natulan	128 49 27 233 152 232 232 232 110 110 1125 125 227 138 164
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord Nattraccord Naphazoline hydrochloride Naphazoline hydrochloride Naphosp NSR 1000 Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nardil S29 Nasal Preparations Natalizumab.	128 49 27 7 233 152 232 232 232 110 110 110 125 125 227 138 164 131
- N - Nadolol Naglazyme Nalcrom Naloxone hydrochloride Naltraccord Naltraccord Naphazoline hydrochloride Naphazoline hydrochloride Naphazoline hydrochloride Naphoon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil S29 Nasal Preparations Natalizumab Natulan Nausafix Nausicalm	128 49 27 7 233 152 232 232 232 110 110 110 125 227 138 164 131 130
- N - Nadolol Naglazyme Nalcrom Nalcrom Naltraccord Naltraccord Nattraccord Naphazoline hydrochloride Naphazoline hydrochloride Naphozoline hydrochloride Naphozoline hydrochloride Naphozon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil S29 Nasal Preparations Natalizumab Natulan Nausafix Nausicalm Navelbine	128 49 27 7 233 152 232 232 232 110 110 125 227 138 164 131 130 166
- N - Nadolol	128 49 27 7 233 152 232 232 232 110 110 125 227 138 164 131 130 166 226
- N - Nadolol	128 49 7 233 152 232 232 232 110 110 125 227 138 164 131 130 166 226 121
- N - Nadolol	128 49 27 233 152 232 232 232 110 110 125 227 138 164 131 130 166 226 121 263
- N - Nadolol	128 49 27 233 152 232 232 232 110 110 125 227 138 164 131 130 166 226 121 263 31
- N - Nadolol	128 49 27 233 152 232 232 110 110 110 125 227 138 164 131 130 166 226 121 263 31 83
- N - Nadolol	128 49 27 7 233 152 232 232 110 110 125 227 138 164 131 130 166 226 121 263 31 83 254

Neocate Junior Vanilla2	54
Neocate SYNEO2	54
Neoral2	18
Neostigmine metilsulfate1	10
Nepro HP (strawberry)24	
Nepro HP (vanilla)24	14
Nepro HP RTH24	14
Nerisone	32
Neulactil1	
Neulastim	10
NeuroTabs	
Nevirapine10	
	JO 20
Nevirapine Alphapharm 10	0
Nicorandil	55
Nicotine1	53
Nicotinic acid	52
Nifedipine	
Nifuran 10)9
Nilotinib16	68
Nilstat	
Alimentary	31
Genito-Urinary	75
Infection	
Nintedanib22	24
Nipent	
Nitrados14	16
Nitrates	
Nitrazepam14	
Nitroderm TTS	
Nitrofurantoin	19
Nitrolingual Pump Spray	
Nivestim	
Nivolumab2	
Nizoral	
Nodia	
Noflam 250 1	
Noflam 500 1	10
Non-Steroidal Anti-Inflammatory	
Drugs1	10
Nonacog alfa [Recombinant factor	
IX]	38
Nonacog gamma, [Recombinant	
Factor IX]	38
Norethisterone	
Genito-Urinary	74
Hormone	
Norflex	
Norfloxacin	
Noriday 28	
Norimin	13
Normacol Plus	
Normison14	
Norpress 12	
Nortriptyline hydrochloride12	25
Norvir 10	
NovaSource Renal24	44

N
Novatretin
NovoMix 30 FlexPen 10
NovoRapid10
NovoRapid FlexPen10
NovoRapid Penfill 10
NovoSeven RT
Noxafil
Nozinan
Nuelin
Nuelin-SR
Nutilis
Nutrient Modules
Nutrini Energy Multi Fibre
Nutrini Energy Multi Fibre
Nutrini Energy RTH
Nutrini Low Energy Multi Fibre
Nutrini RTH243
Nutrison 800 Complete Multi
Fibre 248
Nutrison Concentrated250
Nutrison Energy248
Nutrison Energy Multi Fibre 248
Nutrison Multi Fibre 248
Nutrison Standard RTH248
Nyefax Retard50
Nystatin
Alimentary3
Dermatological6
Genito-Urinary75
Infection97
NZB Low Gluten Bread Mix25
-0-
O/W Fatty Emulsion Cream
Obinutuzumab
Octocog alfa [Recombinant factor
VIII] (Advate)
Octocog alfa [Recombinant factor
VIII] (Kogenate FS)
Octreotide
Octreotide LAR (somatostatin
analogue) 172
Oestradiol8
Oestradiol valerate8
Oestradiol with norethisterone8
Oestriol
Genito-Urinary75
Hormone82
Oestrogens8
Ofev224
Oil in water emulsion
Olanzapine
Olbetam
Olopatadine
Olsalazine
Omalizumab 199
Omeprazole
Omeprazole actavis 10

Omeprazole actavis 409	Paclitaxel 163
Omnitrope83	Paclitaxel Actavis163
Onbrez Breezhaler	Paclitaxel Ebewe 163
Oncaspar163	Paediatric Seravit
OncoTICE180	Paliperidone133
Ondansetron131	Pamidronate disodium112
Ondansetron ODT-DRLA	Pamisol112
Ondansetron ODT-ORLA	Pancreatic enzyme
One-Alpha	Pantoprazole9
Opdivo	Panzop Relief
Ora-Blend	Panzytrat
Ora-Blend SF	Papaverine hydrochloride
Ora-Plus	Para-amino salicylic acid
Ora-Sweet	Paracare
Ora-Sweet SF	Paracare Double Strength
Orabase	Paracetamol
Oral Supplements/Complete Diet	Paracetamol + Codeine
(Nasogastric/Gastrostomy Tube	(Relieve) 123
Feed) 241	Paracetamol Pharmacare121
Oratane	Paracetamol with codeine 123
Ordine	Paradigm 1.8 Reservoir23
Orgran	Paradigm 3.0 Reservoir23
Orion Temozolomide 164	Paradigm Mio MMT-92122
Ornidazole99	Paradigm Mio MMT-92322
Orphenadrine citrate117	Paradigm Mio MMT-92522
Ortho-tolidine77	Paradigm Mio MMT-94122
Oruvail SR 110	Paradigm Mio MMT-94322
Osmolite RTH248	Paradigm Mio MMT-94522
Other Endocrine Agents88	Paradigm Mio MMT-96522
Other Oestrogen Preparations81	Paradigm Mio MMT-97522
Other Progestogen	Paradigm Quick-Set MMT-38623
Preparations 82	Paradigm Quick-Set MMT-38723
Other Skin Preparations69	Paradigm Quick-Set MMT-39623
Ovestin	Paradigm Quick-Set MMT-39723
Genito-Urinary75	Paradigm Quick-Set MMT-39823
Hormone	Paradigm Quick-Set MMT-39923
Ox-Pam	Paradigm Silhouette MMT-36821
Oxaliccord157	Paradigm Silhouette MMT-37721
Oxaliplatin	Paradigm Silhouette MMT-37821
Oxaliplatin Accord	Paradigm Silhouette MMT-38121
Oxaliplatin Actavis 100	Paradigm Silhouette MMT-38221
Oxaliplatin Ebewe	Paradigm Silhouette MMT-383
Oxazepam	Paradigm Silhouette MMT-384
Oxis Turbuhaler	Paradigm Sure-T MMT-86419
Oxpentifylline	Paradigm Sure-T MMT-86619
	Paradigm Sure-T MMT-800
Oxybutynin	
Oxycodone hydrochloride	Paradigm Sure-T MMT-87619
Oxycodone Sandoz 123	Paradigm Sure-T MMT-88419
OxyNorm	Paradigm Sure-T MMT-88619
Oxytocin	Paraffin
Oxytocin BNM75	Paraffin liquid with wool fat232
Oxytocin with ergometrine	Paraldehyde126
maleate75	Parasidose67
Ozurdex229	Parasiticidal Preparations65
- P -	Parnate 125

Pacifen.....117

Omeprazole actavis 20......9

Parnate S29	.125
Paromomycin	95
Paroxetine	.125
Paser	.100
Patanol	232
Paxam	.134
Pazopanib	
Peak flow meter	227
Pedialyte - Bubblegum	
Pediasure	
Pediasure RTH	
Pegaspargase	
Pegasys	100
Pegfilgrastim	. 100 40
Pegylated interferon alfa-2a	
Pembrolizumab	
Pemetrexed	
Penicillamine	
Penicillin G	
PenMix 30	
PenMix 40	
PenMix 50	
Pentasa	7
Pentostatin [Deoxycoformycin]	.164
Pentoxifylline [Oxpentifylline]	55
Peptamen Junior	.243
Peptisoothe	8
Peptisorb	245
Perhexiline maleate	
Pericyazine	
Perindopril	
Perjeta	200
Permethrin	
Perrigo	07
Pertuzumab	
Peteha	.100
Pethidine hydrochloride	
Pevaryl	
Pexsig	
Pfizer Exemestane	. 173
Pharmacy Health Sorbolene with	
Glycerin	
Pharmacy Services	
Dhahurana	
Pheburane	160
Phenasen	. 100
Phenasen	125
	.125
Phenasen Phenelzine sulphate	.125
Phenasen Phenelzine sulphate Phenobarbitone Phenobarbitone sodium	125 127
Phenasen Phenelzine sulphate Phenobarbitone	.125 .127 .237
Phenasen Phenelzine sulphate Phenobarbitone Phenobarbitone sodium Extemporaneous	125 127 237 147
Phenasen Phenelzine sulphate Phenobarbitone Phenobarbitone sodium Extemporaneous Nervous Phenothrin	125 127 237 147
Phenasen Phenelzine sulphate Phenobarbitone Phenobarbitone sodium Extemporaneous Nervous Phenothrin Phenotybenzamine	. 125 . 127 . 237 . 147 67
Phenasen Phenelzine sulphate Phenobarbitone Phenobarbitone sodium Extemporaneous Nervous Phenothrin Phenotybenzamine hydrochloride	. 125 . 127 . 237 . 147 67
Phenasen Phenelzine sulphate Phenobarbitone sodium Extemporaneous Nervous Phenothrin Phenoxybenzamine hydrochloride Phenoxymethylpenicillin (Penicillin	.125 .127 .237 .147 67 45
Phenasen Phenelzine sulphate Phenobarbitone Phenobarbitone sodium Extemporaneous Nervous Phenothrin Phenotybenzamine hydrochloride	. 125 . 127 . 237 . 147 67 45 93

Phlexy 10253
Phosphate Phebra44
Phosphorus44
Phytomenadione
Pilocarpine hydrochloride231
Pimafucort
Pindolol49
Pine tar with trolamine laurilsulfate
and fluorescein 68
Pinetarsol
Pioglitazone11
Pirfenidone
Pizotifen
PKU Anamix Infant
PKU Anamix Junior
PKU Anamix Junior Chocolate
PKU Anamix Junior LQ
PKU Anamix Junior Vanilla
PKU Lophlex LQ 10253
PKU Lophlex LQ 20253
PKU Lophlex Dourder 050
PKU Lophlex Powder
PKU Lophlex Sensation 20253
Plaquenil
Plendil ER50 Pneumococcal (PCV10) conjugate
vaccine
Pneumococcal (PCV13) conjugate
vaccine
Phoumococcol (PD\/22)
Pneumococcal (PPV23)
polysaccharide vaccine 265
polysaccharide vaccine
polysaccharide vaccine265Pneumovax 23265Podophyllotoxin69Polaramine221Poliomyelitis vaccine265Polyamer25Poly-Gel232Poly-Tears232Poly-Visc232Polycal238Polyvingl alcohol232Ponstan110Posaconazole97
polysaccharide vaccine
polysaccharide vaccine 265 Pneumovax 23 265 Podophyllotoxin 69 Polaramine 221 Poliomyelitis vaccine 265 Poloxamer 225 Poly-Gel 232 Poly-Tears 232 Poly-Visc 232 Polycal 238 Polyvinyl alcohol 232 Ponstan 110 Posaconazole 97 Postium crloride 43-44 Potassium chloride 33 Povidone iodine 33 Povidone iodine 65 Pradaxa 42
polysaccharide vaccine
polysaccharide vaccine 265 Pneumovax 23 265 Podophyllotoxin 69 Polaramine 221 Poliomyelitis vaccine 265 Polyaramine 221 Poliomyelitis vaccine 265 Polyaramine 221 Polyoramer 25 Poly-Gel 232 Poly-Tears 232 Polycal 238 Polyvinyl alcohol 232 Postana 110 Posaconazole 97 Postinor-1 74 Potassium chloride 43 44 Potassium citrate 76 Potassium iodate 33 Povidone iodine 65 Pradaxa 42 Pramipexole hydrochloride 118 Prasugrel 39
polysaccharide vaccine 265 Pneumovax 23 265 Podophyllotoxin 69 Polaramine 221 Poliomyelitis vaccine 265 Polyaramine 221 Poliomyelitis vaccine 265 Polyaramine 221 Polyoramer 25 Poly-Gel 232 Poly-Tears 232 Polycal 238 Polyvinyl alcohol 232 Postana 110 Posaconazole 97 Postinor-1 74 Potassium chloride 43 Potassium citrate 76 Potassium cidate 33 Povidone iodine 65 Pradaxa 42 Pramipexole hydrochloride 118 Prasugrel 39 Pravastatin 53
polysaccharide vaccine 265 Pneumovax 23 265 Podophyllotoxin 69 Polaramine 221 Poliomyelitis vaccine 265 Poloxamer 225 Poly-Gel 232 Poly-Tears 232 Poly-Visc 232 Poly-Visc 232 Polycal 233 Polyval 232 Polyal 232 Postasinor-1 74 Potassium citrate <
polysaccharide vaccine 265 Pneumovax 23 265 Podophyllotoxin 69 Polaramine 221 Poliomyelitis vaccine 265 Polyaramine 221 Poliomyelitis vaccine 265 Polaramine 221 Poliomyelitis vaccine 265 Polavamer 25 Poly-Gel 232 Poly-Tears 232 Poly-Iears 232 Poly-Visc 232 Polyal 238 Polyvinyl alcohol 232 Ponstan 110 Posaconazole 97 Postinor-1 74 Potassium citrate 76 Potassium citrate 76 Pratassium iodate 33 Povidone iodine 65 Pradaxa 42 Pramipexole hydrochloride 118 Prazogrel 39 Prazosin 45
polysaccharide vaccine 265 Pneumovax 23 265 Podophyllotoxin 69 Polaramine 221 Poliomyelitis vaccine 265 Polyaramine 221 Poliomyelitis vaccine 265 Polaramine 221 Poliomyelitis vaccine 265 Polavamer 25 Poly-Gel 232 Poly-Tears 232 Poly-Tears 232 Poly-Iears 232 Polyal 238 Polyvinyl alcohol 232 Postan 110 Posaconazole 97 Postinor-1 74 Potassium citrate 76 Potassium citrate 76 Pratassium cidate 33 Povidone iodine 65 Pradaxa 42 Pramipexole hydrochloride 118 Prazosin 53 Praziquantel 89 Prazosin 45 Pred Forte 230
polysaccharide vaccine 265 Pneumovax 23 265 Podophyllotoxin 69 Polaramine 221 Poliomyelitis vaccine 265 Polyaramine 221 Poliomyelitis vaccine 265 Polaramine 221 Poliomyelitis vaccine 265 Polavamer 25 Poly-Gel 232 Poly-Tears 232 Poly-Iears 232 Poly-Visc 232 Polyal 238 Polyvinyl alcohol 232 Ponstan 110 Posaconazole 97 Postinor-1 74 Potassium citrate 76 Potassium citrate 76 Pratassium iodate 33 Povidone iodine 65 Pradaxa 42 Pramipexole hydrochloride 118 Prazogrel 39 Prazosin 45

Prednisolone sodium
phosphate230
Prednisolone-AFT230
Prednisone80
Pregabalin128
Pregabalin Pfizer 128
Pregnancy Tests - hCG Urine75
Premarin81
Presolol
Prevenar 13264
Prezista107
Priadel
Primacin
Primaquine phosphate99
Primidone
Primolut N82
Priorix
Probenecid117
Probenecid-AFT 117
Procaine penicillin
Procarbazine hydrochloride164
Prochlorperazine
Proctofoam7
Proctosedyl7
Procyclidine hydrochloride119
Procytox156
Progesterone
Proglicem9
Proglycem9
Progynova81
Prolia 111
Promethazine hydrochloride
Propafenone hydrochloride 48
Propamidine isethionate
Propranolol
Propylene glycol237
Propylthiouracil83
Protaphane 10
Protaphane Penfill 10
Protifar240
Protionamide 100
Provera81
Provera HD82
PSM Citalopram 125
Psoriasis and Eczema
Preparations
PTU83
Pulmicort Turbuhaler
Pulmocare
Pulmozyme
Puri-nethol 159
Puria
Pyrazinamide
Pyridostigmine bromide
Pyridoxine hydrochloride
Pyrimethamine95

Pytazen SR	.39
- Q -	
Q 300	99
Quetapel	
Quetiapine	
Quick-Set MMT-390	02
Quick-Set MMT-390	.23
QUICK-Set MINT-391	.23
Quick-Set MMT-392	.23
Quick-Set MMT-393	
Quinapril	. 45
Quinapril with	
hydrochlorothiazide	46
Quinine sulphate	. 99
Qvar	221
- R -	
RA-Morph	122
Raloxifene hydrochloride	112
Raltegravir potassium	107
Ramipex	118
Ranbaxy-Cefaclor	.89
Ranitidine	8
Ranitidine Relief	8
Rapamune	218
Reandron 1000	.80
Recombinant factor IX	38
Recombinant factor VIIa	
Recombinant factor VIII	
Rectogesic	
Redipred	
Relieve	110
Relistor	
Remicade	
Renilon 7.5	
Resonium-A	
Resource Beneprotein	
Resource Diabetic	240
Respigen	24 I 200
Respiratory Devices	220
Respiratory Stimulants	227
Retinol palmitate	227 220
ReTrieve	202
Retrovir	
Revlimid	
Revolade	
Rexacrom	230
RexAir	
Ribomustin	
Ricit	
Rifabutin	
Rifadin	
Rifampicin	
Rifaximin	
Rifinah	
Rilutek	119
Riluzole	119
Riodine	. 65

INDEX:	Generic	Chemicals	and Brands
--------	---------	-----------	------------

Risedronate Sandoz 113
Risedronate sodium 113
Risperdal Consta 134
Risperidone 133-134
Risperon 133
Ritalin148
Ritalin LA149
Ritalin SR148
Ritonavir 107
Rituximab200
Rivaroxaban42
Rivastigmine 151
Rivotril
RIXUBIS
Rizamelt129
Rizatriptan129
Roferon-A108
Rolin
Ropin
Ropinirole hydrochloride118
Rotarix
Rotavirus oral vaccine
Roxane
Alimentary6
Cardiovascular
Roxithromycin
Rubifen
Rubifen SR
Bulide D 91
Rulide D
Rurioctocog alfa pegol [Recombinant
Rurioctocog alfa pegol [Recombinant factor VIII]
Rurioctocog alfa pegol [Recombinant factor VIII]
Rurioctocog alfa pegol [Recombinant factor VIII]
Rurioctocog alfa pegol [Recombinant factor VIII]
Rurioctocog alfa pegol [Recombinant factor VIII]
Rurioctocog alfa pegol [Recombinant factor VIII]
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rytmonorm 48 - S - Sabril Sacubitril with valsartan 46
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rytmonorm 48 - S - 5 Sacubitril with valsartan 46 SalAir 223
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmonorm 48 - S - 5 Sacubitril with valsartan 46 SalAir 225 Salazopyrin 72
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmonorm - S - Sabril 126 Sacubitril with valsartan 48 SalAir 223 Salazopyrin 7 Salazopyrin EN. 7
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmonorm 48 - S - Sabril 128 Sacubitril with valsartan 46 Salazopyrin 7 Salazopyrin EN. 7 Salbutamol 223
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmonorm 48 - S - Sabril 128 Sabril 223 Salazopyrin 7 Salazopyrin FIN. 7 Salbutamol 223 Salbutamol 223
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmonorm 48 - S - 5 Sabril 128 Sacubitril with valsartan 46 Salazopyrin 7 Salazopyrin EN. 7 Salbutamol 223 Salbutamol with ipratropium 5
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmonorm 48 - S - 5 Sabril 128 Sacubitril with valsartan 46 Salazopyrin 7 Salazopyrin EN 7 Salbutamol 223 Salbutamol with ipratropium 5 Salicylic acid 66
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 47 Rythmodan 47 Rythmodan 47 Sabril 128 Sacubitril with valsartan 46 Salazopyrin 7 Salazopyrin EN 7 Salbutamol 223 Salbutamol with ipratropium bromide bromide 223 Salicylic acid 66 Salmeterol 222
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 47 Rythmodan 47 Rythmodan 47 Sabril 128 Sabril 128 Salazopyrin 7 Salazopyrin EN 7 Salbutamol 223 Salbutamol 223 Salbutamol 223 Salicylic acid 68 Salmeterol 222 Sandomigran 130
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 47 Rythmodan 47 Rythmodan 47 Rythmodan 47 Salvil 5 Sabril 126 Sacubitril with valsartan 46 SalAir 223 Salazopyrin 7 Salazopyrin EN 7 Salbutamol 223 Salbutamol 223 Salbutamol 223 Salbutamol 223 Salbutamol 223 Salbutamol with ipratropium 500 bromide 222 Salmeterol 222 Sandostatin LAR 172
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 47 Rythmodan 47 Rythmodan 47 Rythmodan 47 Sabril 128 Sabril 128 Salazopyrin 7 Salazopyrin EN 7 Salbutamol 223 Salbutamol with ipratropium 5 bromide 223 Salicylic acid 66 Salmeterol 222 Sandonstatin LAR 172 Sapropterin dihydrochloride 226
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 48 - S - 5 Sabril 126 Sacubitril with valsartan 48 SalAir 223 Salazopyrin 77 Salazopyrin EN 77 Salbutamol 223 Salbutamol 223 Salbutamol with ipratropium 50 bromide 222 Sandostatin LAR 170 Sandostatin LAR 170 Sacup Preparations 68
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 48 - S - 5 Sabril 126 Sacubitril with valsartan 48 SalAir 223 Salazopyrin 77 Salazopyrin EN 77 Salbutamol 223 Salbutamol with ipratropium 50 bromide 222 Salcylic acid 68 Salmeterol 222 Sandostatin LAR 170 Sapropterin dihydrochloride 28 Scalp Preparations 68 Scopoderm TTS 130
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Sabril 126 Sacubitril with valsartan 46 Salazopyrin 223 Salazopyrin EN 7 Salazopyrin EN 7 Salbutamol 223 Salbutamol 224 Sandomigran
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 48 - S - 5 Sabril 126 Salubitil with valsartan 46 Salazopyrin 77 Salazopyrin EN 77 Salazopyrin EN 77 Salbutamol 223 Salbutamol 222 Salbutamol 222 Salbutamol 222 Salbutamol 222 Salbutamol
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 48 - S - 5 Sabril 220 Salazopyrin 7 Salazopyrin EN 7 Salazopyrin EN 7 Salbutamol 223 Salbutamol with ipratropium 5 bromide 222 Salacopyrin CAR 77 Salacopyria caid 66 Salicylic acid 66 Salpotic acid 66 Scalp Preparations 66 Scopoderm TTS 130 Sedatives and Hypnotics 146
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 47 Rythmodan 47 Rythmonorm 48 - S - 5 Sabril 128 Sacubitril with valsartan 46 Salazopyrin 7 Salazopyrin EN 7 Salbutamol 223 Salproprine EN 7 Salpotation LAR 72 Sandostatin LAR 127 Sapropterin dihydrochloride 28 Scopoderm TTS 130 Sebizole 66 Secukinumab 200 Seedatives and Hypnotics 146 Seebri Breezhaler 223
Rurioctocog alfa pegol [Recombinant factor VIII] 39 Ruxolitinib 170 Rythmodan 47 Rythmodan 48 - S - 5 Sabril 220 Salazopyrin 7 Salazopyrin EN 7 Salazopyrin EN 7 Salbutamol 223 Salbutamol with ipratropium 5 bromide 222 Salacopyrin CAR 77 Salacopyria caid 66 Salicylic acid 66 Salpotic acid 66 Scalp Preparations 66 Scopoderm TTS 130 Sedatives and Hypnotics 146

Senokot	26
Sensipar	78
SensoCard	
Serenace	
Seretide	
Seretide Accuhaler	
Serevent	
Serevent Accuhaler	
Sertraline	
Setrona	
Sevredol	
Sex Hormones Non	120
Contraceptive	80
Shield 49	
Shield Blue	
Shield XL shingles vaccine	12
SII-Onco-BCG	
Sildenafil	
Silhouette MMT-371	
Silhouette MMT-373	21
Siltuximab	
Simvastatin	53
Simvastatin Mylan	
Sinemet	
Sinemet CR	
Sirolimus	
Siterone	
Slow-Lopresor	10
Smith BioMed Rapid Pregnancy	
Smith BioMed Rapid Pregnancy Test	75
Smith BioMed Rapid Pregnancy Test Sodibic	75 44
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate	75 44 25
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate	75 44 25 6
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate	75 44 25 6 111
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate	75 44 25 6 111
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium benzoate Sodium bicarbonate	75 44 25 6 111 28
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium benzoate Sodium benzoate Sodium bicarbonate Blood	75 44 25 6 111 28 43–44
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium benzoate	75 44 25 6 111 28 43–44
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium benzoate Sodium benzoate Sodium bicarbonate Blood	75 44 25 6 111 28 43–44 237
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium alginate Sodium benzoate Sodium benzoate Sodium bicarbonate Blood Extemporaneous Sodium calcium edetate Sodium chloride	75 44 25 6 111 28 43–44 237 234
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium alginate Sodium benzoate Sodium benzoate Sodium bicarbonate Blood Sodium calcium edetate Sodium chloride Blood	75 44 25 6 111 28 43–44 237 234 43
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium alginate Sodium benzoate Sodium benzoate Sodium bicarbonate Blood Sodium calcium edetate Sodium chloride Blood Respiratory	75 44 25 6 111 28 43–44 237 234 43
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium alginate Sodium benzoate Sodium benzoate Sodium bicarbonate Blood Sodium calcium edetate Sodium chloride Blood Respiratory	75 44 25 6 111 28 43–44 237 234 43
Smith BioMed Rapid Pregnancy TestSodibicSodium acid phosphateSodium alginateSodium alginateSodium alginateSodium benzoateSodium benzoateSodium bicarbonate BloodSodium calcium edetateSodium calcium edetateSodium calcium sodium sod	75 44 25 6 111 28 43–44 237 234 43 227
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium benzoate Sodium benzoate Sodium bicarbonate Blood Respiratory Sodium citrate with sodium lauryl sulphoacetate	75 44 25 6 111 28 43–44 237 234 43 43 227
Smith BioMed Rapid Pregnancy TestSodibicSodium acid phosphateSodium alginateSodium alginateSodium alginateSodium benzoateSodium benzoateSodium bicarbonate BloodSodium calcium edetateSodium calcium edetateSodium calcium sodium sod	75 44 25 6 111 28 43–44 237 234 43 43 227
Smith BioMed Rapid Pregnancy TestSodibicSodibicSodium acid phosphateSodium alginateSodium alginateSodium aurothiomalateSodium benzoateSodium benzoateSodium bicarbonate BloodSodium calcium edetateSodium calcium edetateSodium calcium edetateSodium calcium edetateSodium chloride BloodRespiratorySodium citrate with sodium lauryl sulphoacetateSodium citro-tartrateSodium citro-tartrateSodium citro-tartrateSodium cromoglicate	75 44 25 6 111 28 43–44 237 234 43 43 227
Smith BioMed Rapid Pregnancy TestSodibicSodibicSodium acid phosphateSodium alginateSodium alginateSodium aurothiomalateSodium benzoateSodium benzoateSodium bicarbonate BloodSodium calcium edetateSodium calcium edetateSodium calcium edetateSodium calcium edetateSodium chloride BloodRespiratorySodium citrate with sodium lauryl sulphoacetateSodium citro-tartrateSodium citro-tartrateSodium citro-tartrateSodium cromoglicate AlimentarySodium cromoglicate	75 44 25 111 28 43–44 237 234 227 26 76
Smith BioMed Rapid Pregnancy TestSodibic Sodium acid phosphateSodium alginateSodium alginateSodium benzoate Sodium bicarbonate Blood Sodium calcium edetateSodium calcium edetate Sodium chloride Blood Respiratory Sodium citrate with sodium lauryl sulphoacetate Sodium citrate algination algination algination Sodium citrate algination algination algination Sodium citrate algination algination algination Sodium citrate algination algination algination Sodium comoglicate Alimentary Respiratory	75 44 25 6 111 28 43–44 237 234 227 26 76 76
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium bicarbonate Blood Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium chloride Blood Respiratory Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium cromoglicate Alimentary Respiratory Sensory	75 44 25 6 111 28 43–44 237 224 224
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium bicarbonate Blood Extemporaneous Sodium calcium edetate Sodium calcium edetate Sodium chloride Blood Respiratory Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium citro-tartrate Sodium comoglicate Alimentary Respiratory Sensory Sodium fluoride	75 44 25 6 111 28 43–44 237 224 224
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium benzoate Sodium benzoate Biood Extemporaneous Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium cirro-tartrate Sodium cirro-tartrate Sodium cirro-tartrate Sodium cromoglicate Alimentary Respiratory Sensory Sodium fluoride Sodium Fusidate [fusidic acid]	75 44 25 6 111 28 43–44 43 237 224 227 26
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium benzoate Sodium benzoate Biood Extemporaneous Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium citro-tartrate Sodium cirro-tartrate Sodium cromoglicate Alimentary Respiratory Sensory Sodium fluoride Sodium Fusidate [fusidic acid] Dermatological	75
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium alginate Sodium aurothiomalate Sodium benzoate Sodium bicarbonate Biood Extemporaneous Sodium calcium edetate Sodium clarate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium citro-tartrate Sodium citro-tartrate Sodium citro-tartrate Sodium citro-tartrate Sodium citro-tartrate Sodium fuoride Sodium fluoride Sodium fluoride Sodium Fusidate [fusidic acid] Dermatological Infection	75
Smith BioMed Rapid Pregnancy Test Sodibic Sodium acid phosphate Sodium alginate Sodium aurothiomalate Sodium benzoate Sodium benzoate Biood Extemporaneous Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium calcium edetate Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium citro-tartrate Sodium cirro-tartrate Sodium cromoglicate Alimentary Respiratory Sensory Sodium fluoride Sodium Fusidate [fusidic acid] Dermatological	75

acid] 232
Sodium phenylbutyrate29
Sodium polystyrene sulphonate 44
Sodium tetradecyl sulphate
Sodium valproate
Sofradex
Soframycin
Solian
Solifenacin Mylan
Solifenacin succinate
Solu-Cortef
Solu-Medrol
Solu-Medrol-Act-O-Vial
Somatropin (Omnitrope)
Sotalol
Spacer device
Span-K
Spiolto Respimat
Spiractin
Spiriva
Spiriva Respimat
Spironolactone
Sporanox
Sprycel
Stemetil
Stesolid
Stimulanto/ADUD Tractmonto 147
Stimulants/ADHD Treatments 147
Stimulants/ADHD Treatments
Stimulants/ADHD Treatments
Stimulants/ADHD Treatments
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralifate 9
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralifate 9 Sulfadiazine Silver 60
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine 95 Sulfasalazine 7
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfasalazine 7 Sulindac 110
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine 95 Sulfadazine 7 Sulindac 110 Sulphur 68
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfadac 110 Sulphur 68 Sulprix 131
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfacalazine 7 Sulfadac 110 Sulphur 68 Sulprix 131 Sumatriptan 129
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfadazine 71 Sulfadazine 68 Sulprix 131 Sumatriptan 129 Sunitinib 170
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfasalazine 7 Sulindac 110 Sulprix 131 Sumatriptan 129 Sunitinib 170
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfasalazine 7 Sulindac 110 Sulprix 131 Sumatriptan 129 Sunitinib 170
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine Solium 95 Sulfasalazine 7 Sulfadiazine Silver 68 Sulprix 131 Sumatriptan 129 Sunscreens 69 Sunscreens, proprietary 69 Sure-T MMT-863 19
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfasalazine 7 Sulphur 68 Sulprix 131 Sumatriptan 129 Sunscreens 69 Sure-T MMT-863 19 Sure-T MMT-865 19
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfasalazine 7 Sulphur 68 Sulprix 131 Sumatriptan 129 Sunscreens 69 Sure-T MMT-863 19 Sure-T MMT-865 19 Sure-T MMT-873 19
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfadiazine 7 Sulfadiazine 10 Sulfadiazine 110 Sulptix 131 Sumatriptan 129 Sunscreens, proprietary 69
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Storahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfasalazine 7 Sulindac 110 Sulphur 68 Sulprix 131 Sumatriptan 129 Sunscreens, proprietary 69 Sure-T MMT-865 19 Sure-T MMT-873 19 Sure-T MMT-875 19 Sure-T MMT-883 19
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfasalazine 7 Sulphur 68 Sulprix 131 Sumatriptan 129 Suinerens, proprietary 69 Sure-T MMT-863 19 Sure-T MMT-875 19 Sure-T MMT-883 19 Sure-T MMT-885 19
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Storahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfadazine 7 Sulindac 110 Sulphur 68 Sulprix 131 Sumatriptan 129 Sunitinib 170 Sure-T MMT-863 19 Sure-T MMT-875 19 Sure-T MMT-885 19
Stimulants/ADHD Treatments 147 Stiripentol 128 Stocrin 106 Stomahesive 30 Strattera 147 Stromectol 65 Suboxone 151 Sucralfate 9 Sulfadiazine Silver 60 Sulfadiazine sodium 95 Sulfasalazine 7 Sulphur 68 Sulprix 131 Sumatriptan 129 Suinerens, proprietary 69 Sure-T MMT-863 19 Sure-T MMT-875 19 Sure-T MMT-883 19 Sure-T MMT-885 19

Sutent	170
Sylvant	210
Symbicort Turbuhaler 100/6	222
Symbicort Turbuhaler 200/6	
Symbicort Turbuhaler 400/12	
Symmetrel	118
Sympathomimetics	54
Synacthen	
Synacthen Depot	80
Synacthen S29	
Synacthene Retard	.00 .80
Synflorix	
Synthroid	
Syntometrine	
Syrup (pharmaceutical grade)	237
Systane Unit Dose	232
- I - T&R	
Tacrolimus	
Tacrolimus Sandoz	
Taliglucerase alfa	
Tambocor Tambocor CR	.47
Tamoxifen citrate	173
Tamoxifen Sandoz	173
Tamsulosin hydrochloride	
Tamsulosin-Rex	
Tandem Cartridge	.19
Tandem t:slim X2	
Tap water	
Tarceva	
Tasigna	
Tasmar	
Tecfidera	135
Tegretol	126
Tegretol CR	
Telfast	
Temaccord	
Temazepam	
Temizole 20	
Temozolomide	
Tenofovir disoproxil	102
Tenofovir Disoproxil Teva	102
Tenoxicam	
Tepadina	
Terazosin	.45
Terbinafine	
Terbutaline sulphate	223
Teriflunomide	
Teriparatide	113
Testosterone	.80
Testosterone cipionate	.80
Testosterone esters	.80
Testosterone undecanoate	.80
Tetrabenazine	
Tetrabromophenol	

Tetracosactrin	
Tetracyclin Wolff	93
Tetracycline	93
Thalidomide	165
Thalomid	165
Theophylline	226
Thiamine hydrochloride	
THIO-TEPÁ	157
Thioguanine	
Thiotepa	157
Thymol glycerin	31
Thyroid and Antithyroid Agents	
Ticagrelor	
Tilade	
Tilcotil	
Timolol	
Cardiovascular	49
Sensory	
Timoptol XE	
Tiotropium bromide	224
Tiotropium bromide with	
olodaterol	224
Tivicay	
TMP	
ТОВІ	
Tobramycin	
Infection	96
Sensory	229
Tobramycin Mylan	
Tobramycin Mylan Tobrex	<mark>96</mark>
	96 229
Tobrex	96 229 211
Tobrex Tocilizumab	96 229 211 124
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine	96 229 211 124 118 77
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax	96 229 211 124 118 77
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine	96 229 211 124 118 77
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain	96 229 211 124 118 77 128 111
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate	96 229 211 124 118 77 128 111 128
Tobrex Tocilizumab Tofranil. Tolcapone. Tolterodine. Topamax. Topical Products for Joint and Muscular Pain Topiramate Actavis.	96 229 211 124 128 128 111 128 128
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Topiramate Actavis Total parenteral nutrition (TPN)	96 229 211 124 118 77 128 111 128 128 43
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Topiramate Actavis Total parenteral nutrition (TPN) TPN	96 229 211 124 118 77 128 111 128 128 43 43
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride	96 229 211 124 118 77 128 111 128 43 43 43 43
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100	96 229 211 124 118 77 128 111 128 43 43 43 43 43 43 43 43 43
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 150	96 229 211 124 118 77 128 111 128 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 43 424 424 424 444 444 444 444 444 444 444 444
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 150 Tramal SR 200	96 229 211 124 118 77 128 128 128 128 43 43 43 124 124 124
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 150 Tramal SR 200 Tramal SR 200 Trandate	96 229 211 124 118
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 150 Tramal SR 200 Tramal SR 200 Tranal SR 200 Tranal SR 200 Tranal SR 200 Tranal SR 200	
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax. Topical Products for Joint and Muscular Pain Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 150 Tramal SR 200 Tranal SR 200 Tranal SR 200 Tranate Tranexamic acid Tranylcypromine sulphate	
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax. Topical Products for Joint and Muscular Pain Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 150 Tramal SR 150 Tramal SR 200 Tramal SR 200 Tranal SR 200	
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 100 Tramal SR 150 Tramal SR 200 Trandate Tranexamic acid Transtycypromine sulphate Travatan	
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 100 Tramal SR 150 Tramal SR 200 Tranal SR 200 Tranadate Tranadate Tranaylcypromine sulphate Travylcypromine sulphate Travatan Travatan	
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 100 Tramal SR 150 Tramal SR 150 Tramal SR 200 Trandate Trandate Tranexamic acid Tranylcypromine sulphate Travylcypromine sulphate Travycoprost Travoprost	
Tobrex Tocilizumab	
Tobrex Tocilizumab Tofranil Tolcapone Tolterodine Topamax Topical Products for Joint and Muscular Pain Topiramate Actavis Topiramate Actavis Total parenteral nutrition (TPN) TPN Tramadol hydrochloride Tramal SR 100 Tramal SR 100 Tramal SR 150 Tramal SR 200 Trandate Tranexamic acid Tranylcypromine sulphate Travylcypromine sulphate Travatan Travoprost Travopt Treatments for Dementia Treatments for Substance	
Tobrex Tocilizumab	

Tretinoin
Dermatological 59
Oncology165
Trexate
Triamcinolone acetonide
Alimentary
Dermatological63
Hormone80
Triamcinolone acetonide with
gramicidin, neomycin and nystatin
Dermatological
Sensory
Triazolam147
Trichozole
Triclosan63
Trimethoprim
Trimethoprim with
sulphamethoxazole
[Co-trimoxazole]
Trisequens
Trisul
Trophic Hormones
Tropicamide
Trusopt
TruSteel
Tuberculin PPD [Mantoux] test266
Tubersol
Two Cal HN
Two Cal HN RTH
Tykerb
Tysabri
- U -
Ultibro Breezhaler
Ultraproct
Umeclidinium
Umeclidinium with vilanterol
Univent
Ural
Urea
Urex Forte
Urinary Agents
Urinary Tract Infections
Uromitexan
Ursodeoxycholic acid
Ursosan
Utrogestan
- V -
Vaccinations
Vaclovir
Valaciclovir
Valganciclovir
Valganciclovir Mylan102
Valganciciovii iviyiari
Vanconycin
Varinali
Varenicline Filzer

_

Zytiga......171

Varicella vaccine [Chickenpox
vaccine] 266
Varicella zoster virus (Oka strain) live
attenuated vaccine [shingles
vaccine] 266
Varilrix
Various233
Vasodilators54
Vasopressin Agonists
Vedafil
Velcade161
Veletri57
Venlafaxine126
Venomil220
Ventavis58
Ventolin223
Vepesid162
Verapamil hydrochloride50
Vergo 16130
Vermox
Verpamil SR50
Vesanoid165
Vexazone11
Vfend
Viaderm KC63
Vidaza157
Vigabatrin 128
Vildagliptin 11
Vildagliptin with metformin
hydrochloride 11
Vimpat
Vinblastine sulphate
Vincristine sulphate
Vinorelbine
Vinorelbine Ebewe
Viramune Suspension
ViruPOS
Vistil
Vistil Forte
Vit.D3
VitA-POS
Vitabdeck
Vitadol C
Vital
Vitamin A with vitamins D and C 31
Vitamin B complex
Vitamins
Vivonex TEN
Volibris
Voltaren
Voltaren D
Voltaren Ophtha
Volumatic
Voriconazole

Votrient
Vttack98
- W -
Warfarin sodium
Wart Preparations
Wasp venom allergy treatment220
Water
Blood
Extemporaneous237
Wool fat with mineral oil64
- X -
Xarelto
Xifaxan
XMET Maxamum
Xolair
XP Maxamum253
Xylocaine 120
Xylocaine 2% Jelly 120
Xyntha
-Z-
Zantac8
Zapril
Zarontin
Zaroxolyn51
Zavedos162
Zeffix101
Zetlam101
Ziagen106
Zidovudine [AZT] 106
Zidovudine [AZT] with
lamivudine
Zimybe
Zinc and castor oil
Zinc sulphate34
Zincaps34
Zinnat90
Ziprasidone133
Zista
Zithromax90
Zoladex
Zoledronic acid
Hormone
Musculoskeletal 114
Zoledronic acid Mylan78
Zopiclone 147
Zopiclone Actavis 147
Zostavax
Zostrix111
Zostrix HP121
Zuclopenthixol decanoate
Zuclopenthixol hydrochloride
Zusdone
Zyban152
Zypine132
Zypine ODT 132
Zyprexa Relprevv 133







